Abbott, J, 910(ab)
Abdel-Dayem, HM, 1396, 2014, 843(ab), 867(ab)
Abdel-Nabi, HH, 14, 959(ab), 1000(ab)
Abe, K, 1019(ab)
Abe, S, 1019(ab)
Abel, W, 117
Abi-Dargham, A, 911(ab)
Abraham, V, 832(ab)
Abramovici, J, 1005(ab)
Abrams, MJ, 710, 910(ab)
Abrams, PG, 1099
Aburano, T, 2024, 957(ab), 1020(ab)
Acharya, AS, 986(ab)
Achong, DM, 256
Acito, P, 915(ab)
Ackerman, RF, 1819
Ackermann, RF, 908(ab)
Adachi, I, 1023(ab)
Adams, HR, 945(ab)
Adams, M, 974(ab)
Adatepe, MH, 263
Adelstein, SJ, 384
Aden, MD, 1132, 894(ab)
Adler, A, 997(ab), 1044(ab)
Adriaens, PJ, 551, 1032(ab)
Affleck, D, 881(ab)
Afriyie, M, 973(ab)
Aftab, N, 2154
Aggarwal, S, 1548
Agid, Y, 1481, 1019(ab)
Agostini, D, 471
Ahn, CS, 964(ab)
Ahonen, A, 1255
Aigner, TG, 1383, 945(ab), 965(ab)
Akamune, A, 893(ab), 933(ab), 972(ab)
Akansel, G, 2110, 868(ab)
Akiba, A, 1005(ab)
Akiba, H, 958(ab)
Akoun, G, 81
Aktolun, C, 464(le)
Alagona, P, Jr, 1723(le)
Alamos, F, 838(ab)
Alavi, A, 269, 590, 751, 1964, 2036, 848(ab), 849(ab), 857(ab), 858(ab), 896(ab), 897(ab), 898(ab), 902(ab), 929(ab), 940(ab), 954(ab), 965(ab), 992(ab), 999(ab), 1012(ab), 1013(ab), 1588(le)
Albarède, P, 409
Albert, R, 900(ab)
Alderson, PO, 570, 1042(ab)
Alexander, GE, 940(ab)
Alexander, M, 873(ab), 874(ab)
Alexoff, DL, 853(ab)
Aliabadi, P, 643
Alioth, C, 833(ab)
Aikire, AL, 974(ab)
Allada, V, 977(ab)
Allen, EW, 981(ab), 1034(ab)
Allen, LF, 23
Allenberg, JR, 907(ab)
Allie, D, 1269
Allman, KC, 2067
Al-Mohannadi, S, 2014, 867(ab)
Alpert, NM, 908(ab), 924(ab)
Altehoefer, C, 886(ab)
Althouse, L, 972(ab)
Al-Tikriti, MS, 848(ab), 945(ab)
Altman, KI, 1725
Altmann, A, 1982, 1019(ab)
Al-Zaabi, KS, 978(ab)
Amano, M, 1008(ab)
Amarenco, P, 858(ab)
Ambrose, KR, 1028(ab)
Ambrosetti, P, 1766
Aminian, A, 1021(ab)
Amino, S, 1019(ab)
Amis, ES, 1042(ab)
Ammann, W, 157
Ampil, FL, 1047(ab)
Amstutz, HP, 231
Anderson, CJ, 558, 1685, 837(ab)
Anderson, JA, 1003(ab), 1010(ab)
Anderson, PJ, 2090
Anderson, R, 927(ab)
Anderson, T, 839(ab)
Anderson, TL, 990(ab)
Andersson, L, 1654, 954(ab)
Andreassian, B, 835(ab)
Andre-Fouet, X, 953(ab)
Andrews, D, 964(ab)
Andrich, MP, 852(ab), 976(ab)
Angelberger, P, 108
Anker, JP, 903(ab)
Ansari, A, 844(ab)
Ansari, MS, 847(ab)
Antar, MA, 928(ab), 970(ab), 1040(ab), 1041(ab)
Antich, PP, 974(ab), 990(ab), 1003(ab), 1010(ab)
Antico, VF, 2094
Antman, KH, 1594
Antoine, J-M, 956(ab)
Antonino, A, 2222
Antonucci, F, 895(ab)
Aoki, S, 844(ab), 966(ab)
Aoshima, S, 6
Aotsuka, A, 917(ab)
Appelbaum, FR, 863(ab), 941(ab), 960(ab), 987(ab)
Appelbaum, JW, 1099
Appledorn, R, 956(ab)
Arai, H, 1019(ab)
Araki, N, 1029(ab)
Araki, Y, 951(ab)
Aras, T, 1027(ab)
Araujo, LI, 1669
Archer, CM, 850(ab)
Archer, S, 423
Areeda, J, 876(ab)
Argenyi, E, 1917(le)
Aric, I, 1041(ab)
Arimizu, N, 324
Arılkan, O, 1027(ab)
Arntz, IE, 936(ab)
Aronen, HJ, 867(ab)
Arsenault, A, 875(ab)
Asahina, M, 917(ab)
Asano, T, 333
Ascoop, CAPL, 1727
Ashida, K, 246
Ashmore, RF, 995(ab)
Assis, RVC, 995(ab)
Atkins, HI, 305
Atkins, HL, 1717
Atkinson, ER, 423
Atkinson, JB, 826(ab)
Aubert, B, 1006(ab)
Austin, MC, 877(ab), 930(ab)
Avet, P, 1269
Awad, I, 970(ab)
Axworthy, DB, 880(ab), 909(ab), 910(ab), 934(ab)

Babaian, RJ, 1001(ab)
Babich, J, 924(ab), 935(ab)
Babich, JW, 2154, 910(ab), 996(ab), 1024(ab)
Bacharach, SL, 1209, 2058, 2226, 881(ab), 938(ab)
Badger, C, 960(ab)
Badger, CC, 863(ab), 987(ab)
Bading, JR, 1373
Bae, R, 926(ab)
Baer, L, 906(ab)
Bagdades, E, 1022(ab)
Bahrassa, FS, 1047(ab)
Baidoo, KE, 899(ab), 921(ab), 1032(ab)
Bailey, DL, 901(ab)
Baird, AE, 877(ab)
Bakir, MA, 2154
Bakker, WH, 652, 955(ab), 903(ab), 914(ab)
Baldock, C, 1041(ab)
Baldwin, R, 896(ab)
Baldwin, RM, 1836, 1964, 848(ab), 911(ab), 945(ab)
Balériaux, D, 868(ab)
Ballinger, JR, 970(ab)
Balon, HR, 1393, 898(ab)
Balseiro, J, 2059(le)
Balter, HS, 1949
Ban, T, 886(ab)
Banaszczyk, M, 921(ab)
Bander, N, 913(ab)
Bando, M, 1016(ab)
Bankole, A, 849(ab)
Banks, WR, 830(ab), 975(ab), 983(ab)
Banzo, I, 955(ab)
Barbaras, L, 947(ab)
Barbarics, E, 1033(ab)
Barbaro, NM, 967(ab)
Barber, HB, 851(ab), 879(ab), 1002(ab)
Barber, R, 983(ab)
Barbet, J, 912(ab), 1000(ab)
Barbour, MM, 951(ab)
Bares, R, 1001(ab)
Barkan, AL, 1608, 834(ab)
Barker, WW, 1459
Barkovich, AJ, 967(ab)
Barlow, CF, 838(ab)
Barnes, D, 950(ab)
Barnes, WE, 2214
Barness, B, 837(ab)
Barnett, CA, 938(ab)
Barnhart, CS, 951(ab)
Barrett, HH, 851(ab), 879(ab), 891(ab), 1002(ab)
Barrett, JS, 959(ab)
Barrio, JR, 633, 1472
Barron, BJ, 968(ab), 1047(ab)
Bartelsmeier, A, 906(ab)
Bartenstein, P, 915(ab)
Barthelemy, E, 956(ab)
Bartlett, B, 1024(ab)
Bartolozzi, C, 954(ab)
Barton, D, 846(ab)
Barton, H, 2222
Barzen, G, 902(ab), 971(ab), 997(ab), 1018(ab)
Basile, F, 866(ab)
Basmadjian, GP, 981(ab)
Basoglu, T, 906(ab)
Bassano, DA, 150, 901(ab)
Bassingthwaighte, JB, 581
Bataille, G, 832(ab)
Batchelor, S, 1041(ab)
Bateman, TM, 876(ab), 951(ab)
Battisti, C, 1859
Baudhuin, T, 825(ab), 837(ab), 875(ab)
Baudoux, M, 1337
Bauer, A, 865(ab), 993(ab)
Baum, RP, 853(ab), 904(ab), 912(ab)
Baxter, KG, 1039(ab), 1046(ab)
Bayhan, H, 464(le), 866(ab)
Bayouth, JE, 941(ab)
Bazin, JP, 1011(ab)
Beanlands, R, 684, 826(ab), 865(ab), 882(ab)
Beatty, BG, 953(ab)
Beauchamp, HT, 900(ab)
Beaumier, P, 934(ab)
Beaumier, PL, 394, 880(ab), 909(ab), 910(ab), 1028(ab)
Bebin, M, 971(ab)
Beck, P, 972(ab)
Becker, DP, 867(ab)
Becker, JA, 1005(ab), 1043(ab)
Becker, W, 903(ab), 1428(le)
Beckers, C, 73
Bede, JI, 1914(le)
Beetz, R, 1021(ab)
Behrenbeck, T, 2080
Beierwaltes, WH, 2116
Beilin, I, 886(ab)
Bekdik, C, 319
Belinka, BA Jr, 988(ab)
Bellande, E, 989(ab), 1034(ab)
Bellen, J, 1283
Beller, GA, 668, 1732, 864(ab)
Bellina, CR, 1020(ab)
Bellinger, MF, 923(ab), 977(ab)
Belliveau, JW, 867(ab)
Bellon, EM, 1044(ab)
Belzberg, AS, 1468
Benard, JF, 1003(ab)
Bender, H, 942(ab), 1002(ab)
Bendriem, B, 2020, 843(ab), 882(ab), 883(ab), 888(ab), 943(ab)
Ben-Haim, S, 1486
Benhali, H, 1011(ab)
Ben-Harush, M, 1699
Benjamin, C, 855(ab), 866(ab)
Benjamin, RS, 858(ab), 992(ab)
Benkert, O, 887(ab)
Bennett, DV, 849(ab)
Bennett, LR, 827(ab), 1043(ab)
Benoliel, J, 1846
Bensel, K, 835(ab)
Benvenuti, C, 471
Berding, G, 972(ab)
Berg, BO, 918(ab)
Berger, HJ, 144
Berger, KL, 1579, 858(ab), 1003(ab), 1007(ab), 1009(ab)
Berger, MR, 1982, 966(ab), 1019(ab)
Bergh, JR, 1039(ab)
Bergmann, SR, 836(ab), 837(ab), 855(ab), 884(ab), 1426(le)
Berk, MR, 1556
Berkovic, SF, 930(ab)
Berkovitz, DM, N25(10)
Berkowitz, KA, 512
Berlangieri, SU, 1047(ab)
Berlin, JA, 858(ab), 873(ab)
Berman, DS, 1509, 854(ab), 876(ab), 911(ab)
Berná, L, 840(ab), 845(ab), 895(ab), 994(ab)
Bernard, HF, 955(ab)
Bernstein, ID, 863(ab), 941(ab), 960(ab), 987(ab)
Berrah, H, 843(ab), 888(ab)
Berridge, MS, 885(ab), 984(ab)
Berry, J, 2067
Bertoni, JM, 1047(ab)
Bertrand, A, 906(ab), 956(ab)
Besnard, J-C, 981(ab)
Besozzi, MC, 885(ab), 931(ab), 983(ab)
Besser, GM, 1121, 914(ab)
Bessières, M, 906(ab)
Bettinardi, V, 973(ab)
Beuscart, R, 947(ab)
Bex, M, 832(ab)
Bhadkamkar, VA, 858(ab), 1001(ab)
Bhatia, K, 1994
Bhargava, KK, 919(ab), 986(ab)
Bhattacharva, S, 938(ab)
Bianchi, R, 1020(ab)
Bianco, JA, 1586(le)
Biasio, Y, 854(ab)
Bice, AN, 771, 864(ab), 872(ab), 889(ab), 1005(ab), 1251(le),

1429(le)
Bidaut, LM, 868(ab)
Biedler, JL, 1373
Biegel, J, 878(ab)
Biegon, A, 890(ab)
Biemer, E, 859(ab)
Bierman, R, 435
Biersack, H-J, 526, 839(ab), 844(ab), 914(ab), 972(ab), 995(ab), 1028(ab)
Bigard, M-A, 956(ab)
Biggs, T, 676
Bigner, DD, 1535, 881(ab), 934(ab)
Bihl, H, 839(ab)
Bilchik, T, 269
Billings, J, 870(ab), 890(ab), 963(ab), 989(ab)
Billingsley, JL, 2052
Biniakiewicz, D, 993(ab)
Binon, J-P, 1337
Birnbaum, BA, 960(ab)
Bischof Delaloye, A, 1756, 903(ab), 956(ab)
Bischoff, H, 828(ab), 1045(ab)
Bishop, HA, 1040(ab)
Bisson, G, 855(ab), 866(ab)
Bjorn, MJ, 1099
Bjornson, B, 1758
Black, HR, 2045, 906(ab)
Black, KL, 867(ab)
Black, PMcL, 844(ab), 1018(ab)
Bladin, PF, 930(ab)
Blaha, WH, 1017(ab)
Blahd, W, 967(ab)
Blair, DR, 1011(ab), 1018(ab)
Blanche, S, 976(ab)
Blanchot, C, 913(ab)
Blank, EW, 1530
Blankenship, D, 993(ab)
Blankespoor, SC, 1881, 901(ab)
Blanksma, PK, 870(ab)
Blaser, K, 231
Blatchford, G, 975(ab)
Bläuenstein, P, 231
Blaufox, MD, 175, 739, 1723, 907(ab)
Blend, MJ, 853(ab)
Blickman, JG, 2249
Blokland, JAK, 1406
Blomqvist, G, 908(ab)
Bloomfield, PM, 1669, 911(ab), 994(ab), 1008(ab)
Blower, PJ, 469(le)
Blum, R, 912(ab)
Blumenthal, RD, 958(ab), 1000(ab)
Blumhardt, R, 984(ab)
Böck, JC, 971(ab)
Bockisch, A, 887(ab), 1021(ab)
Boelrijk, A, 921(ab)
Boerman, OA, 958(ab)
Bohdiewicz, PJ, 898(ab)
Boisson, N, 1006(ab)
Bok, BD, 380, 835(ab), 1251(le)
Bol, A, 837(ab), 875(ab), 884(ab)
Boles, MA, 2214, 1041(ab)
Boles Ponto, LL, 1008(ab), 1027(ab)
Bolzati, C, 850(ab)
Bomanji, J, 1121, 904(ab), 914(ab), 924(ab)
Bond, HW, 885(ab)
Boni, G, 1020(ab)
Boniface, G, 853(ab)
Bonilla, JJ, 955(ab)
Bonino, C, 999(ab)
Bonnet, AM, 1481, 1019(ab)
Bonow, RO, 815, 1209, 2226, 2057(le), 881(ab), 938(ab)
Bonte, F, 992(ab)
Bonte, FJ, 826(ab)
Booker, FS, 850(ab)
Borbely, K, 1931
Borchert, R, 830(ab), 975(ab), 983(ab)
Bordlee, RP, 1857
Borer, JS, 2057(le), 845(ab)
Borges-Neto, S, 825(ab)
Borkon, AM, 951(ab)
Borm, JJJ, 917(ab)
Bormans, G, 937(ab)
Bormans, GM, 551
Borst, MM, 2138
Bosworth, M, 974(ab)
Bottino, B, 1028(ab)
Bottlaender, M, 883(ab), 973(ab)
Botvinick, EH, 1444, 896(ab), 910(ab), 935(ab), 994(ab)
Boucher, Y, 1801, 894(ab)
Boudreau, RJ, 873(ab)
Bouillon, R, 832(ab)
Boulahdour, H, 919(ab)
Bourekas, EC, 1553
Bourgeois, P, 1427(le)
Bourguignon, M, 696, 896(ab), 1019(ab)
Bourguignon, MH, 471, 1481, 843(ab), 888(ab), 896(ab), 947(ab)
Bourne, D, 981(ab)
Bove, E, 68
Boven, E, 2000
Bowen, WD, 981(ab)
Bowman, BM, 975(ab)
Bowsher, JE, 879(ab), 961(ab)
Boyd, SJ, 1029(ab)
Braat, S, 874(ab), 875(ab)
Braat, SH, 874(ab)
Bracken, RB, 937(ab)
Brady, LW, 942(ab)
Brady, T, 867(ab)
Braegelmann, F, 845(ab)
Brandau, W, 920(ab)
Brandt, J, 848(ab)
Branscheid, D, 828(ab)
Brass, LM, 878(ab)
Brasseur, P, 1337
Braun, A, 2103
Braun, J, 1001(ab)
Brechbiel, MW, 842(ab), 1001(ab), 1031(ab)
Breeman, A, 1727
Breeman, WAP, 652, 955(ab)
Breen, S, 1005(ab)
Breen, SL, 1316
Breithardt, G, 915(ab)
Breitz, HB, 1099
Bremner, JD, 911(ab)
Brennan, KM, 884(ab)
Brenner, N, 900(ab)
Bresnahan, DR Jr, 951(ab)
Briele, B, 526, 839(ab), 844(ab), 914(ab), 995(ab)
Britell, C, 1035(ab)
Britton, KE, 1121, 904(ab), 914(ab), 924(ab)
Broadhurst, P, 938(ab)
Brodack, J, 1025(ab)
Brodack, JW, 850(ab), 937(ab), 980(ab)
Brodie, JD, 192, 287, 1720, 847(ab)
Broich, K, 870(ab), 898(ab), 972(ab)
Brooks, CE, 950(ab)
Brooks, KM, 921(ab)
Brooks, RA, 1931
Broquet, PE, 1766
Brotchi, J, 868(ab)
Brouillet, E, 973(ab)
Broussard, W, 985(ab)
Brown, DW, 1750
Brown, J, 848(ab)
Brown, JA, 985(ab)
Brown, JK, 1881, 901(ab)
Brown, MA, 884(ab)
Brown, MD, 885(ab)
Brown, ML, 1613, 923(ab)
Brown, MT, 966(ab)
Brown, RS, 841(ab), 893(ab), 1021(ab)
Brown, SJ, 2017, 835(ab), 1049(ab)
Brown, T, 949(ab)
Brownell, AL, 946(ab)
Brownell, GL, 946(ab)
Bruchelt, G, 859(ab)
Brun, A, 868(ab)
Brunetti, A, 834(ab)
Brunken, R, 882(ab)
Brunken, RC, 1628, 856(ab), 857(ab), 945(ab), 977(ab)
Bruns, C, 652
Bubeck, B, 629(le)
Buchbinder, B, 867(ab)
Buchbinder, SF, 842(ab), 926(ab)
Buchegger, F, 903(ab)
Buchsbaum, DJ, 1029(ab)
Buchwald, AB, 845(ab)
Buckley, KR, 922(ab)
Buczala, S, 832(ab)
Budihna, NV, 587
Budinger, TF, 2133, 862(ab), 884(ab), 915(ab), 939(ab)
Buell, U, 102, 886(ab), 1001(ab)
Bugaj, JE, 979(ab)
Buijs, WCAM, 1113
Buist, MR, 2000
Bulteau, C, 977(ab)
Bunker, C, 1301
Bunko, H, 441, 1200, 875(ab)
Bunting, RW, 1028(ab)
Buonanno, FS, 908(ab)
Buonocore, E, 885(ab), 923(ab)
Burg, MM, 939(ab)
Burke, TS, 1390
Burkholder, D, 979(ab)
Burn, PR, 998(ab)
Burns, HD, 900(ab)
Burrows, L, 949(ab)
Buscombe, JR, 903(ab)
Bushe, H, 958(ab)
Bushman, MJ, 989(ab), 1033(ab), 1024(ab)
Bushnell, DL, 2214
Busnardo, B, 1478
Bussière-Lapalus, F, 1846
Butchko, G, 912(ab)
Butler, CS, 964(ab)
Butler, RE, 1014(ab)
Butler, SP, 1029(ab), 1252(le)
Buxton, DB, 865(ab), 945(ab), 1425(le)
Bylund, DB, 861(ab)
Byrne, CL, 843(ab)

Cabahug, C, 1015(ab), 1028(ab)
Cacheris, W, 974(ab)
Cacini, W, 2190
Cahill, N, 19N(le)
Caillat-Vigneron, N, 913(ab)
Cain, JW, 838(ab)
Calay, R, 1337
Caldwell, JH, 102, 2144, 2202
Calenoff, E, 934(ab), 936(ab)
Çaliköglu, T, 319
Callahan, AP, 910(ab), 1023(ab), 1028(ab)
Callahan, RJ, 819, 845(ab), 925(ab), 1024(ab), 1028(ab)
Calne, DB, 964(ab)
Caluser, C, 867(ab)
Camargo, EE, 1216, 1004(ab)
Camera, L, 842(ab), 1001(ab)
Camici, PG, 1353
Cammilleri, S, 990(ab)
Campini, R, 846(ab)
Camrud, AR, 845(ab)
Cancro, R, 287
Caner, B, 319
Cann, CE, 1881, 901(ab)
Cantos, E, 1046(ab)
Cao, Q, 905(ab)
Cao, ZJ, 892(ab)
Capelli, L, 68
Caraceni, T, 1014(ab)
Caracò, C, 892(ab), 918(ab), 999(ab)
Caraher, J, 994(ab)
Caraher, JM, 1243, 881(ab)
Carey, D, 865(ab)
Carey, JE, 423
Caride, VJ, 1712, 913(ab)
Carlsen, J, 251
Carlson, KE, 558
Carpenter, RC, 873(ab)
Carpi, A, 954(ab)
Carrasquillo, JA, 842(ab), 986(ab), 1001(ab)
Carretta, R, 939(ab)
Carril, JM, 955(ab)
Carriö, I, 2249, 840(ab), 845(ab), 895(ab), 994(ab)
Carroll, RG, 498, 2249(le)
Carson, GC, 1047(ab)
Carson, RE, 2103, 881(ab), 945(ab), 1010(ab)
Carstens, MC, 992(ab)
Cartner, T, 874(ab)
Carton, EG, 239
Cartwright, PC, 873(ab)
Carvalho, PA, 181, 1516, 970(ab)
Casara, D, 1478
Casciari, JJ, 2202, 1010(ab)
Casey, ME, 861(ab), 1430(le)
Casey, MJ, 829(ab)
Cashman, P, 938(ab)
Casi, M, 863(ab)
Cassel, D, 916(ab), 952(ab)
Castaigne, A, 471, 896(ab)
Castaneda, AR, 838(ab), 930(ab)
Castelli, L, 892(ab), 918(ab), 999(ab)
Cattaruzzi, E, 895(ab)
Cavagnaro, CF, 956(ab)
Cave, V, 186, 2086, 854(ab), 866(ab), 952(ab)
Cerar, A, 587
Ceriani, R, 912(ab)
Ceriani, RL, 1530
Cerino, M, 951(ab)
Cerletty, JM, 869(ab)
Cerqueira, MD, 202, 763, 1324, 1493, 1642, 866(ab), 939(ab)
Cerrito, M, 959(ab)
Césaro, P, 858(ab)
Cestaro, V, 1046(ab)
Chabriat, H, 1481, 1019(ab)
Chabris, CF, 908(ab)
Chaiken, L, 829(ab)
Chaillout, JJ, 1003(ab)
Chaiwanarat, T, 924(ab)
Chalmers, N, 872(ab)
Chalon, S, 981(ab)
Chaly, T, 923(ab), 1027(ab)
Chamberlain, MJ, 516
Chamovitz, DL, 2055
Chan, A, 836(ab), 865(ab)
Chan, H-W, 14
Chan, K, 833(ab)
Chan, SY, 836(ab), 856(ab), 857(ab), 1009(ab)
Chan, YW, 920(ab)
Chandarlapaty, SCK, 1045(ab)
Chang, CJ, 985(ab)
Chang, L, 839(ab), 977(ab)
Chang, PI, 993(ab)
Chang, SL, 1012(ab)
Chang, W, 852(ab)
Chao, BH, 981(ab)
Chaovapong, W, 2006, 880(ab)
Chapnick, J, 960(ab)
Chapuis, A, 1003(ab)
Charkes, ND, 1780
Charney, DS, 1964, 848(ab), 911(ab), 945(ab)
Charron, M, 923(ab), 977(ab), 996(ab), 997(ab)
Chartrand, R, 1550
Chatal, JF, 912(ab), 943(ab), 985(ab), 1030(ab)
Chatterjee, K, 896(ab)
Chatterjee, S, 830(ab)

Chatziioannou, A, 861(ab)
Chaudhuri, TK, 1035(ab)
Chavali, RV, 839(ab), 1005(ab), 1018(ab), 1043(ab)
Chen, BC, 613
Chen, B-S, 282
Chen, C, 848(ab), 964(ab)
Chen, CL, 955(ab)
Chen, C-T, 783, 947(ab), 949(ab), 962(ab), 1012(ab), 1019(ab)
Chen, CY, 955(ab)
Chen, DCP, 844(ab), 937(ab)
Chen, EQ, 888(ab)
Chen, F, 934(ab), 936(ab)
Chen, GH, 997(ab)
Chen, GTY, 1005(ab), 1043(ab)
Chen, K, 944(ab)
Chen, LS, 1132, 894(ab)
Chen, MN, 986(ab)
Chen, MT, 1034(ab)
Chen, TT, 829(ab), 867(ab)
Chen, WL, 1033(ab)
Chen, YK, 1034(ab)
Cheng, H, 871(ab)
Cheres, A, 2017
Cherqui, D, 919(ab)
Cherrick, I, 914(ab)
Cherrier, F, 906(ab)
Cherry, SC, 1045(ab)
Cherry, SR, 595, 862(ab), 879(ab), 922(ab), 1010(ab)
Chetanneau, A, 912(ab)
Cheung, N-KV, 2020
Chevres, A, 2017, 835(ab), 1049(ab)
Chi, SC, 977(ab)
Chiang, J-H, 282
Chiao, P, 933(ab)
Chiariello, M, 505
Chin, HW, 1047(ab)
Chin, J, 988(ab)
Chin, M, 994(ab)
Chinen, LK, 937(ab), 980(ab)
Chinol, M, 900(ab), 942(ab), 985(ab), 1030(ab)
Chiotelis, E, 988(ab)
Chiron, C, 696, 976(ab), 977(ab)
Chiu, ML, 1516, 864(ab), 1033(ab)
Cho, DS, 1146, 1613
Cho, KS, 991(ab)
Choi, BI, 2118
Choi, CW, 877(ab)
Choi, J, 1031(ab)
Choi, Y, 339, 633, 828(ab), 829(ab), 865(ab), 881(ab), 882(ab), 944(ab), 945(ab)
Chon, KS, 1010(ab)
Chong, R, 900(ab), 1025(ab)
Choong, KKL, 2094
Chou, J-S, 1012(ab)
Chou, KT, 1013(ab)
Chow, WK, 997(ab)
Christensen, M, 975(ab)
Christian, BT, 850(ab), 931(ab)
Christian, PE, 467(le), 833(ab), 878(ab), 892(ab), 901(ab), 1003(ab)
Christian, TF, 2080
Christman, DR, 192
Chrumpradit, S, 890(ab)
Chu, LS, 1012(ab)
Chu, TS, 865(ab)
Chua, T, 854(ab), 911(ab)
Chun, SB, 986(ab)
Chung, D-G, 55
Chung, JK, 877(ab), 892(ab), 905(ab)
Chung, Y-H, 919(ab)
Ciarmiello, A, 68
Cini, R, 900(ab)
Cinotti, L, 953(ab), 1011(ab)
Claessens, RAMJ, 388, 1113, 1330, 903(ab), 920(ab), 936(ab), 950(ab), 1031(ab)
Clark, CM, 157
Clarke, LP, 161, 889(ab)
Clarke, SEM, 469(le)
Clavo, A, 841(ab)
Cleeland, R, 924(ab)
Clerc, J, 2162
Cleto, EM, Jr, 435
Cleynhens, B, 1032(ab)
Clinthorne, NH, 831(ab), 842(ab), 878(ab)
Cload, P, 875(ab)
Cloninger, K, 876(ab)
Clorius, JH, 907(ab)
Coade, G, 939(ab)
Coakley, AJ, 313
Cody, R, 1020(ab)
Coenen, HH, 2138
Cohen, AM, 904(ab)
Cohen, C, 973(ab)
Cohen, RC, 2094, 949(ab)
Cohen, RM, 1383, 945(ab), 965(ab)
Cohen, TJ, 910(ab)
Cohen, WA, 1789
Colan, SD, 930(ab)
Colcher, D, 23, 1648
Cole, WC, 974(ab)
Coleman, PS, 905(ab)
Coleman, RE, 532, 575, 922, 825(ab), 834(ab), 838(ab), 872(ab), 879(ab), 891(ab), 901(ab), 961(ab), 966(ab), 1047(ab)
Collier, BD, 2110, 868(ab), 869(ab)
Collier, TL, 890(ab), 1025(ab)
Collins, REC, 313
Colombo, F, 924(ab)
Colsher, JG, 1430(le)
Comazzi, V, 850(ab), 989(ab), 1034(ab)
Combs, MJ, 833(ab)
Comerota, AJ, 952(ab)
Comet, M, 953(ab), 1034(ab)
Conlin, CJ, 1042(ab)
Connett, JM, 1685
Conrad, G, 1046(ab)
Conrady, A, 223
Consigny, PM, 973(ab)
Constantinescu, A, 974(ab), 990(ab), 1003(ab), 1010(ab)
Conversano, A, 855(ab)
Conway, JJ, 2047
Conzo, G, 892(ab)
Cook, SA, 1040(ab), 1041(ab), 1048(ab), 1586(le)
Cooke, CD, 876(ab), 927(ab)
Cooper, DL, 913(ab)
Cooper, JA, 59, 1566, 932(ab)
Cooper, M, 829(ab), 982(ab), 1011(ab), 1012(ab), 1018(ab), 1019(ab)
Cooper, MD, 947(ab), 949(ab)
Cooper, R, 868(ab)
Cooper, S, 964(ab)
Coote, D, 868(ab)
Coppens, A, 875(ab)
Coppola, N, 68
Corbett, JR, 927(ab), 990(ab)
Cordes, M, 922(ab), 964(ab), 971(ab), 1018(ab)
Cordon Cardo, C, 1002(ab)
Cordovilla, JJ, 955(ab)
Corlija, M, 851(ab), 988(ab), 1032(ab), 1048(ab)
Corne, RA, 2061
Corona, JF, 287
Correia, JA, 620, 924(ab)
Corrigan, GE, 1042(ab)
Corrigan, P, 1620, 948(ab)
Corstens, FHM, 388, 1113, 1330, 1958, 903(ab), 920(ab), 936(ab), 950(ab), 1031(ab), N16(4)
Cosgrove, R, 971(ab)
Costa, DC, 1014(ab)
Costello, J, 838(ab), 930(ab)
Coubes, P, 970(ab)
Coughlin, DJ, 988(ab)
Coulange, C, 990(ab)
Countryman, PH, 861(ab)
Countryman, PJ, 862(ab)
Coupal, JJ, 991(ab)
Courtois, M, 836(ab)
Cowan, MJ, 2202
Cowie, AR, 2222
Coxson, PG, 884(ab)
Cradduck, TD, 1005(ab), 1007(ab), 1043(ab)
Crane, J, 992(ab)
Crawford, D, 858(ab)
Crawley, J, 448, 451
Croft, BY, 833(ab)
Cromwell, T, 883(ab)
Cronin, V, 1000(ab)
Crouzel, C, 883(ab), 896(ab)
Crouzel, M, 888(ab)
Csernay, L, 458
Cullom, SJ, 161, 2232, 842(ab)
Culver, CM, 1402
Cumming, MC, 1044(ab)
Cumming, P, 916(ab)
Cummings, D, 1132, 894(ab)
Cunningham, J, 941(ab)
Cunningham, JR, 1001(ab)
Cuocolo, A, 505, 1209, 833(ab), 905(ab), 915(ab), 938(ab)
Curley, T, 859(ab)
Curtet, C, 912(ab)
Curtis, JJ, 924(ab)
Curtis, RL, 1024(ab)
Cutler, C, 899(ab)
Cutler, PD, 595, 1045(ab)
Cyr, J, 920(ab)
Czemin, J, 856(ab)
Czernin, I, 836(ab)
Czernin, J, 1628, 856(ab), 857(ab), 865(ab), 1009(ab)
DaCosta, M, 969(ab)
DaCosta, MC, 969(ab)
Dadparvar, S, 2017, 835(ab), 1049(ab)
Dae, MW, 1444, 896(ab), 910(ab), 935(ab), 994(ab)
Daemen, BJG, 373
Daghighian, F, 2020
Dahlberg, ST, 1783, 846(ab), 864(ab)
Dahlbom, M, 633, 1191, 828(ab), 862(ab), 1045(ab)
Dai, WL, 996(ab)
Dalley, RW, 1789
Dalrymple, G, 978(ab)
Damasio, H, 1008(ab)
Dambro, TJ, 1701
Damjanov, A, 851(ab)
Danchin, N, 906(ab)
Dannals, RF, 847(ab), 848(ab), 860(ab), 883(ab), 885(ab), 929(ab), 964(ab), 968(ab)
Danos, P, 972(ab)
Dao, NH, 1039(ab)
Darbee, J, 835(ab)
Darcourt, J, 1846
Darras, J-C, 409
DaSilva, IN, 983(ab)
DaSilva, JN, 861(ab), 870(ab)
Datz, FL, 260, 467(le), 833(ab), 878(ab), 892(ab), 901(ab), 1003(ab)
Daube-Witherspoon, ME, 1010(ab), 1430(le)
Dave, K, 944(ab)
Davidson, J, 900(ab)
Davidson, M, 856(ab)
Davies, H, 1935
Davis, K, 312
Davison, A, 558, 1357, 1949, 1033(ab)
Dawood, FW, 978(ab)
Day, DE, 1024(ab)
Dean, CJ, 2154
Dean, GW, 1875
Dean, RT, 144, 845(ab)
Deane, CP, 1468
Debrand-Passard, A, 902(ab)
Dec, GW, 477
De Carle, D, 2059(le)
De Chiro, G, 834(ab)
deCosta, BR, 981(ab)
Decoster, P, 905(ab)
Decostre, P, 175
DeDeyn, PP, 972(ab)
De Fabritiis, A, 2040
de Gaudio, C, 954(ab)
De Geeter, F, 1914(le)
DeGrado, TR, 865(ab), 870(ab), 994(ab)
De Groof, M, 825(ab), 836(ab), 1009(ab)
Degrossi, OJ, 999(ab)
DeHaan, CE, 1012(ab)
de Jong, M, 652, 955(ab), 1025(ab)
de Kaski, MC, 756
de Kierk, JMH, 646
DeKock, M, 905(ab)
Delaage, M, 912(ab), 1000(ab)
de la Fourniere, L, 981(ab)
DeLaney, ML, 969(ab)
DeLaPaz, R, 867(ab)
DeLaPena, R, 1014(ab)
Delbeke, D, 826(ab)
Delcourt, E, 1337
deLearie, L, 974(ab)
de Leon, F, 1043(ab)
Delforge, J, 882(ab), 883(ab), 888(ab), 896(ab), 943(ab)
Delgado-Escueta, AV, 1017(ab)
Della Vittoria, G, 915(ab)
Del Rio, P, 999(ab)
del Rosario, RB, 860(ab)
Del Vecchio, S, 1848
De Marco, T, 1444, 896(ab)
Demirel, D, 464(le)
Demonceau, G, 480
DeNardo, GL, 1030, 862(ab), 863(ab), 926(ab), 927(ab), 941(ab), 982(ab), 1031(ab)
DeNardo, S, 912(ab)
DeNardo, SJ, 862(ab), 863(ab), 927(ab), 941(ab), 982(ab), 1030(ab), 1031(ab)
DeNardo, SL, 926(ab)
Denays, R, 485
Dence, CS, 724, 925(ab), 932(ab)
Denis, M, 81
Depas, G, 976(ab), 977(ab)
de Paulis, T, 847(ab), 848(ab)
DePuey, EG, 876(ab), 928(ab), 957(ab)
Derebek, E, 1722
Dereme, T, 875(ab), 905(ab)
Dereniak, EL, 1002(ab)
Derenzo, SE, 862(ab)
de Ridder, LIF, 1167
Derkx, FHM, 990(ab)
DeRogatis, AJ, 957(ab)
De Roo, MJ, 551, 832(ab), 933(ab), 937(ab), 1032(ab)
De Rosch, MA, 850(ab)
Desai, HJ, 1943
Desai, SP, 1704
de Silva, R, 1669
Detry, JM, 825(ab)
Deussen, A, 2138
Deutsch, E, 981, 2190, 850(ab), 899(ab), 900(ab), 924(ab), 937(ab), 980(ab), 988(ab), 1025(ab)
Deutsch, EA, 993(ab)
Deutsch, G, 826(ab)
Deutsch, K, 2190, 900(ab), 981(ab), 1025(ab)
Deutsch, KF, 850(ab), 937(ab), 980(ab)
De Vernejoul, P, 409
DeVito, RP, 889(ab), 932(ab)
Devous, MD, Sr, 1888, 1919, 2030, 826(ab), 827(ab), 838(ab), 1018(ab)
deVries, DJ, 1004(ab)
Dewan, NA, 836(ab)

Dewanjee, MK, 777, 921(ab), 956(ab), 980(ab)
Dewey, SL, 521, 830(ab), 847(ab), 887(ab), 888(ab)
Dewhirst, MW, 958(ab)
DeWoody, K, 848(ab)
Dey, HM, 1964, 878(ab), 886(ab), 896(ab), 906(ab)
De Zwart, F, 1722
Dhawan, V, 923(ab)
D'Hondt, AM, 825(ab)
Dhumeaux, D, 919(ab)
Diamanti, CI, 2006, 931(ab)
Diaz, C, 840(ab)
Di Carli, M, 825(ab), 856(ab)
Di Chiro, G, 1931
Dick, R, 1020(ab)
Diego, I, 992(ab)
Dierckx, R, 972(ab), 1013(ab)
Dieren, EV, 927(ab)
Diethelm, AG, 1178, 924(ab)
Digby, WM, 595
Diggles, L, 835(ab), 846(ab), 876(ab)
Dilizian, V, 1209
Dilsizian, V, 815, 938(ab)
Dimitrakopoulou, A, 1982, 1019(ab)
Ding, XS, 1012(ab)
Ding, Y-S, 830(ab)
Di Palma, E, 999(ab)
Di Paola, R, 1011(ab)
Di Resta, G, 2020
Diril, H, 942(ab), 1031(ab)
DiRocco, RJ, 1152, 865(ab), 993(ab)
Ditlow, C, 934(ab), 936(ab)
Divgi, C, 1002(ab)
Divgi, CR, 904(ab), 913(ab), 941(ab)
DiZio, JP, 558
Dobbeleir, A, 972(ab), 1013(ab), 1021(ab)
Dobovsky, EV, 948(ab)
Dobrinsky, C, 928(ab)
Docter, R, 955(ab)
Dodd, T, 880(ab), 934(ab)
Dodek, PM, 1468
Dodge, RK, 1542
Doerr, RJ, 14, 886(ab), 959(ab)
Dohi, Y, 932(ab)
Dohzono, H, 1033(ab)
Doi, T, 1637
Dökmeci, B, 866(ab)
Doll, J, 1007(ab), 1045(ab)
Donath, A, 1766
Dondi, M, 2040
Donna, GA, 877(ab)
Donohoe, KJ, 947(ab), 1003(ab)
Dörr, U, 839(ab)
Dosio, F, 924(ab)
Doty, R, 858(ab)
Doucet, S, 875(ab)
Doudet, DJ, 1383, 945(ab), 965(ab)
Dougall, NJ, 1623
Douglas, MA, 881(ab)
Dove, P, 471
Dowling, D, 989(ab)
Downey, A, 912(ab)
Drane, WE, 876(ab), 923(ab)
Driedger, AA, 1722
Drozda, SE, 860(ab)
Drüeke, T, 913(ab)
Drum, DE, 643, 849(ab)
Dua, G, 972(ab)
Duara, R, 1459
Duatti, A, 850(ab), 989(ab)
Duboc, D, 471
Dubois-Randé, J-L, 471, 896(ab)
Dubovsky, EV, 1178, 924(ab)
duCret, RP, 873(ab)
Dujić, Ž, 1917(le), 2056(le)
Dulac, O, 696, 977(ab)
Duncker, D, 840(ab), 845(ab), 895(ab), 994(ab)
Dunigan, KA, 975(ab)
Dunn, B, 938(ab)
Dunn, EK, 117, 973(ab), 1035(ab)
Dunn, J, 974(ab)
Dunn, WL, 1039(ab)
Dunning, AJ, 895(ab)
du Plessis, AJ, 838(ab)
Durack, LD, 771, 864(ab), 889(ab), 941(ab)
Durakc, LD, 1005(ab)
Durski, K, 872(ab), 922(ab)
Duus, S, 251
Duval, AM, 471
Dworkin, HJ, 1402
Dwyer, JP, 1594
Dymond, DS, 2124

Eary, JF, 748, 771, 863(ab), 864(ab), 889(ab), 941(ab), 960(ab), 987(ab)
Eberl, S, 901(ab)
Eberling, JL, 939(ab)
Ebmiere, KP, 1623
Eccles, SA, 2154
Eckard, DA, 826(ab)
Edelbroek, M, 1283
Edwards, B, 850(ab)
Edwards, DS, 979(ab)
Efange, SMN, 890(ab), 983(ab)
Egbe, P, 1411, 1994
Egeli, R, 1766
Eggli, DF, 1143, 1854, 947(ab)
Ehrenkaufer, RL, 829(ab), 985(ab)
Ehrhardt, GJ, 558, 1024(ab)
Eichstädt, H, 902(ab), 997(ab)
Eidelberg, D, 923(ab)
Eisenberg, B, 972(ab)
Eisner, RL, 1571, 865(ab)
Elander, N, 1026(ab)
Elder, ST, 829(ab)
Elgazzar, AH, 898(ab), 978(ab), 1047(ab), 1048(ab)
Elias, AD, 1594
Elkowitz, S, 914(ab)
Ell, PJ, 1843, 903(ab), 1014(ab)
Ellis, A, 1040(ab)
Ellis, WG, 939(ab)
Ellison, D, 1121, 904(ab)
Elmaleh, D, 946(ab)
Elmaleh, DR, 946(ab), 1026(ab)
Elmendorf, SL, 59
Elmqvist, D, 868(ab)
Elsinga, PH, 373, 870(ab)
Emrich, D, 223, 845(ab), 957(ab)
Emrich, JG, 942(ab), 1002(ab)
Enas, J, 890(ab)
Enderle, A, 950(ab)
Endo, K, 1181, 853(ab), 905(ab), 1001(ab)
Engel, U, 251
Englaro, EE, 351, 1132, 894(ab)
Enomoto, K, 333
Ensing, G, 1025(ab)
Ensminger, WD, 735
Epstein, A, 987(ab)
Erbas, B, 854(ab), 859(ab)
Erbengi, D, 319
Ercan, MT, 1027(ab)
Erdman, WA, 992(ab)
Eriksson, L, 861(ab), 908(ab), 1011(ab)
Ernest, D, 1468
Errico, D, 855(ab)
Erwin, WD, 927(ab), 932(ab), 938(ab), 941(ab)
Eschima, D, 1029(ab)
Eshbach, J, 851(ab)
Eshima, D, 33, 1620, 921(ab), 990(ab), 1031(ab)
Eskridge, JM, 1789
Essamri, B, 837(ab)
Esser, PD, 1411, 1042(ab)
Essiambre, R, 1091, 855(ab)
Esterbrooks, DJ, 837(ab)
Esterhai, J, 902(ab)
Estorch, M, 840(ab), 845(ab), 895(ab), 994(ab)
Estrada, WN, 898(ab)
Eterović, D, 1917(le), 2056(le)
Evans, D, 902(ab)
Evans, N, 959(ab), 1000(ab)
Evans, NH, 14
Evans-Blumer, M, 1024(ab)
Even-Sapir, E, 950(ab)
Evora, PH, 829(ab), 985(ab)
Eybalin, C, 951(ab)
Eybalin, MC, 951(ab)
Ezekowitz, MD, 777
Ezuddin, S, 839(ab), 1016(ab), 1035(ab)
Ezzeddine, B, 975(ab)

Faber, TL, 927(ab)
Facchetti, L, 846(ab)
Fagret, D, 953(ab), 1034(ab)
Fahey, FH, 537, 1859, 833(ab), 899(ab)
Faivre-Chauvet, A, 943(ab)
Falcone, S, 1016(ab)
Falconer, SJ, 1039(ab)
Falk, P, 975(ab)
Fallone, PS, 904(ab)
Fan, KT, 974(ab)
Fang, LST, 948(ab)
Fang, Y-B, 982(ab)
Fanti, S, 2040
Farber, L, 913(ab)
Farde, L, 860(ab), 931(ab), 1011(ab), 1016(ab)
Farhangi, M, 1451
Farlow, DC, 2094
Farnsworth, RH, 1022(ab)
Farrell, E, 14, 959(ab), 1000(ab)
Fass, J, 1001(ab)
Fawwaz, RA, 570, 988(ab)
Fayad, PB, 878(ab)
Fazio, F, 834(ab), 924(ab), 925(ab), 944(ab), 959(ab), 973(ab), 1014(ab)
Fedio, VA, N15(3), N30(9), N14(12)
Feine, U, 309, 956(ab)
Feinendegen, LE, 2138
Feld, T, 88
Feldman, JM, 834(ab)
Feldman, M, 883(ab)
Feldstein, ML, 849(ab)
Felix, R, 902(ab), 971(ab), 997(ab), 1018(ab)
Feller, AM, 859(ab)
Fer, MF, 1099
Ferguson, DM, 239
Fernandez, G, 854(ab)
Fernandez-Ulloa, M, 1692, 898(ab), 978(ab), 1047(ab)
Fernando, J, 1003(ab), 1010(ab)
Ferremans, W, 1427(le)
Ferrieri, RA, 847(ab)
Fessler, JA, 831(ab), 878(ab), 882(ab)
Fettich, JJ, 873(ab)
Fiasse, R, 976(ab)
Ficken, VJ, 927(ab), 1034(ab)
Ficshman, AJ, 946(ab)
Fig, LM, 1608, 834(ab)
Fink, L, 978(ab)
Fink, S, 1035(ab)
Fink-Bennett, D, 1393, 876(ab), 898(ab), 1017(ab)
Finlay, J, 867(ab)
Finn, RD, 2020, 867(ab), 904(ab)
Fioravanti, C, 900(ab), 979(ab)
Fisch, I, 1766
Fischer, S, 920(ab)
Fischman, AJ, 996, 845(ab), 867(ab), 910(ab), 915(ab), 924(ab), 965(ab), 998(ab), 1024(ab), 1587(le)
Fischman, SJ, 1378
Fisher, DR, 1099, 863(ab), 941(ab)
Fisher, KM, 359
Fisher, RS, 832(ab), 929(ab)
Fisher, SJ, 869(ab), 893(ab), 926(ab), 959(ab), 1021(ab)
Fishman, AJ, 1026(ab)
Fishman, EK, 1042(ab)
Fissekis, JD, 1373
Fitzpatrick, JM, 952(ab)
Fleishman, MJ, 906(ab)
Fleming, E, 1029(ab)
Fleming, WK, 1915(le)
Fletcher, JW, 1046(ab)
Flierdt, Evd, 859(ab)
Floyd, CE, Jr, 879(ab)
Fogarasi, M, 925(ab)
Foged, C, 931(ab)
Fogelman, I, 1589
Foisie, DC, 1099
Foley, K, 859(ab)
Folks, R, 1620, 948(ab)
Folks, RD, 927(ab)
Folli, S, 903(ab)
Fonazzari, I, 970(ab)
Ford, K, 874(ab)
Ford, PV, 127
Forman, D, 1000(ab)
Formiconi, AR, 831(ab)
Forrest, LJ, 1542
Forster, AM, 850(ab)
Forstrom, LA, 840(ab), 845(ab)
Fossella, FV, 992(ab)
Foster, ED, 59
Foster, NL, 887(ab)
Fournier, D, 973(ab)
Fourré, C, 2162
Fowler, JS, 192, 521, 1720, 830(ab), 847(ab), 853(ab), 870(ab), 887(ab), 888(ab), 946(ab)
Fowler, PJ, 516
Fox, J, 966(ab)
Fox, KR, 1588(le)
Fragu, P, 2162
Fraiderik, R, 1006(ab)
Franceschi, G, 863(ab)
Francesconi, LC, 989(ab)
Francis, IR, 1125
Francken, G, 1040(ab)
Frangin, Y, 981(ab)
Frank, AR, 829(ab), 836(ab), 975(ab)
Frankar, G, 884(ab)
Franken, Ph, 1914(le)
Franklin, T, 851(ab)
Franks, W, 55
Franzius, C, 906(ab)
Freedman, N, 1209
Freedman, NMT, 2226, 881(ab), 938(ab)
Freemer, M, 1044(ab)
Frenkel, A, 49, 1774
Freudenberg, N, 1399
Frey, D, 888(ab)
Frey, EC, 2238
Frey, KA, 423, 1836, 858(ab), 882(ab), 887(ab), 929(ab), 1003(ab)
Frick, MP, 829(ab), 836(ab), 837(ab), 861(ab), 975(ab), 1026(ab)
Friden, A, 1304
Fried, M, 956(ab)
Friedland, RP, 2184
Friedlander-Klar, H, 859(ab)
Friedman, J, 854(ab)
Friedman, JD, 1509
Frist, WH, 826(ab)
Fritsch, HW, 906(ab)
Fritz, B, 1810, 934(ab)
Fritzberg, AR, 394, 1099, 880(ab), 909(ab), 910(ab), 934(ab), 979(ab)
Front, D, 1699, 1774
Frost, J, 883(ab)
Frost, JJ, 872(ab), 883(ab), 911(ab), 922(ab), 929(ab)
Frost, MF, 1042(ab)
Frouin, F, 1011(ab)
Frouin, V, 882(ab)
Frover-McKay, M, 1917
Fryer, DG, 972(ab)

Fucello, AJ, 1378
Fujibayashi, Y, 545, 659, 891(ab), 1023(ab), 1026(ab)
Fujii, R, 413, 466(le)
Fujii, T, 893(ab), 933(ab), 969(ab), 972(ab), 1004(ab)
Fujita, H, 135, 272, 1696, 827(ab), 909(ab)
Fujita, T, 897(ab), 966(ab)
Fukuchi, M, 834(ab)
Fukuda, H, 911(ab)
Fukui, H, 997(ab)
Fukumura, T, 877(ab), 945(ab), 1015(ab)
Fukuyama, H, 1637, 897(ab)
Fulham, MJ, 1931, 834(ab)
Fulmer, H, 876(ab)
Fulton, RR, 901(ab)
Funke, M, 950(ab)
Furmanski, P, 912(ab)
Fusamoto, H, 997(ab)
Futami, S, 971(ab)

Gabel, M, 993(ab)
Gabor, FV, 1003(ab)
Gad, MA, 431, 929(ab)
Gaggi, R, 2040
Gagne, GM, 1428(le), 901(ab), 961(ab)
Gagnon, D, 875(ab)
Gajardo, P, 998(ab)
Gal, RA, 2124
Galantowicz, P, 1040(ab)
Galati, MG, 892(ab)
Galen, K, 974(ab)
Gallagher, KP, 1346
Galle, P, 919(ab)
Galli, M, 856(ab)
Gallinger, S, 960(ab)
Galloway, S, 897(ab), 898(ab), 954(ab)
Galt, JR, 2232, 842(ab), 991(ab)
Gambhir, SS, 613, 944(ab), 1045(ab)
Gan, MP, 827(ab), 1043(ab)
Gansow, OA, 842(ab), 1001(ab), 1031(ab)
Ganz, WI, 1304, 921(ab), 1016(ab), 1022(ab), 1035(ab)
Garada, BM, 1312, 839(ab), 887(ab), 970(ab), 1018(ab), 1043(ab), 1432(le)
Garber, CE, 876(ab), 951(ab)
García, A, 403, 2060(le)
Garcia, EV, 2232, 468(le), 842(ab), 876(ab), 927(ab), 948(ab)
García, F, 403, 2060(le)
Garcia, FA, 1949
García del Río, H, 999(ab)
Gardin, D, 380
Gardner, KA, 1045(ab)
Garg, PK, 575, 934(ab)
Garg, S, 934(ab)
Garmestani, K, 842(ab), 1001(ab)
Gascon, P, 904(ab)
Gaskin, G, 491
Gaston, RS, 924(ab)
Gatley, SJ, 830(ab), 853(ab), 870(ab), 995(ab)
Gaul, FE, 710
Gautherot, E, 912(ab), 1000(ab)
Gavin, PR, 1012(ab)
Gazelle, S, 179
Ge, YW, 1032(ab)
Gearhart, JP, 924(ab)
Geatti, O, 895(ab)
Geckle, WJ, 968(ab)
Gee, A, 1041(ab)
Gelfand, MJ, 351, 1048(ab)
Geltman, EM, 855(ab), 1426(le)
Geltofsky, J, 1378
Genç, C, 866(ab)
Genna, S, 852(ab)
Gennaro, O, 999(ab)
Gentili, A, 1044(ab)
Georgiou, M, 1035(ab)
Gerada, B, 181, 1005(ab)
Germano, G, 613, 1509, 854(ab), 911(ab)
Germine, M, 1964
Gerrity, JI, 988(ab)
Gerson, MC, 993(ab)
Gestin, JF, 943(ab)
Geworski, L, 972(ab)
Ghafouripour, AK, 921(ab), 980(ab)
Ghali, A, 978(ab)
Gianolli, L, 924(ab)
Gianuzzi, P, 846(ab)
Gibbons, R, 927(ab)
Gibbons, RJ, 176, 2080
Gibson, RE, 900(ab), 979(ab)
Gibson, T, 1589
Gifford, HC, 891(ab)
Giganti, M, 850(ab)
Gil, M, 998(ab)
Gilardi, MC, 1014(ab)
Gilbert, JC, 2133
Gildersleeve, DL, 860(ab)
Gill, HK, 850(ab)
Gilland, DR, 451, 879(ab), 901(ab), 961(ab)
Gilmore, MP, 846(ab), 864(ab)
Gilroy, J, 1017(ab)
Gindi, G, 963(ab)
Gingold EL, 1881, 901(ab)
Giorgi, MCP, 995(ab)
Girelli, ME, 1478
Girgensohn, S, 1021(ab)
Gitler, MS, 883(ab)
Giubbini, R, 846(ab)
Gjedde, AH, 585, 847(ab), 848(ab), 879(ab), 909(ab), 916(ab)
Gladish, GW, 1044(ab)
Glantz, MJ, 532
Glaspy, JA, 828(ab)
Glass, J, 867(ab)
Glenn, S, 912(ab), 980(ab)
Glennon, P, 942(ab)
Glick, SJ, 605, 843(ab)
Glickman, SL, 910(ab)
Glover, DK, 864(ab)
Glowniak, JV, 431, 716, 935(ab)
Glutowski, TD, 869(ab)
Gmeiner, B, 1028(ab)
Go, A, 827(ab)
Go, RT, 928(ab), 970(ab), 1040(ab), 1041(ab), 1048(ab), 1586(le)
Gobuty, AH, 982(ab)
Goddard, A, 896(ab), 911(ab)
Goddard, AW, 1964
Goedemans, W, 1025(ab)
Goffe, DK, 943(ab)
Gæoğüs, T, 319
Goin, J, 849(ab)
Goins, B, 984(ab), 1027(ab)
Gold, RH, 1039(ab)
Goldberg, IE, 867(ab)
Goldenberg, DM, 803, 1110, 863(ab), 903(ab), 904(ab), 910(ab), 958(ab), 1000(ab), 1002(ab)
Goldenberg, JA, 516
Goldhaber, SZ, 849(ab)
Golding, R, 858(ab), 927(ab)
Goldman, S, 868(ab)
Goldsmith, SJ, 1175, 949(ab), 969(ab), 995(ab), 999(ab), 1031(ab)
Goldstein, I, 46
Gomes, JA, 995(ab)
Gomez-Mont, F, 287
Gona, JM, 1040(ab)
Gonin, R, 1594
Goodman, MM, 885(ab), 890(ab), 931(ab), 983(ab), 1025(ab)
Goodrich, JK, 631(le)
Goodwin, DA, 1816, 2006, 880(ab), 931(ab)
Goodwin, GM, 1623
Goomer, NC, 990(ab), 1010(ab)
Gordon, E, 992(ab)
Gordon, I, 1935, 2090
Gorenberg, M, 1699, 1774
Goris, ML, 1578, 933(ab)
Goris, RJA, 1330, 936(ab), 950(ab)
Gorlin, R, 905(ab)
Gorrie, GH, 974(ab)
Gosfield, E III, 992(ab)
Gottschalk, A, 1422
Gotzens, V, 403, 2060(le)
Gözükara, I, 869(ab), 885(ab), 968(ab)
Grady, C, 2103
Grady, MS, 1789
Grafström, G, 953(ab)
Grafton, SC, 1472
Graham, MC, 2020, 941(ab)
Graham, MM, 581, 2202, 944(ab), 1009(ab), 1010(ab), 1045(ab)
Graham, W, 996(ab)
Grandin, C, 837(ab)
Granowska, M, 904(ab)
Grant, A, 903(ab)
Grassi, F, 973(ab), 1014(ab)
Gratz, KF, 972(ab)
Gray, BD, 921(ab)
Gray, BG, 55
Graziani, LJ, 1943
Greco, A, 1014(ab)
Green, AJ, 1020(ab)
Green, JF, 931(ab)
Green, JM, 989(ab)
Green, MA, 837(ab), 931(ab), 1049(ab)
Green, MV, 2057(le), 852(ab)
Green, SL, 1010(ab)
Greenberg, ID, 2061
Greenberg, J, 985(ab), 1012(ab)
Greene, R, 961(ab)
Greene, RW, 964(ab)
Greenough, R, 438, 828(ab), 858(ab)
Greenspan, RG, 906(ab)
Greer, KL, 901(ab)
Gregoir, C, 1337
Grégoire, J, 875(ab)
Gregory, C, 947(ab)
Grehl, O, 1001(ab)
Greitemann, B, 840(ab)
Grenier, RP, 2124, 846(ab)
Greve, J, 1022(ab)
Grierson, JR, 2202
Griffin, T, 904(ab)
Griffith, J, 1183
Griffith, JL, 905(ab)
Griffiths, GL, 1110, 910(ab)
Grill, V, 908(ab)
Grinspoon, SK, 906(ab)
Gritters, LS, 975(ab)
Groch, MW, 927(ab), 932(ab), 938(ab), 941(ab)
Grochowski, EW, 157
Grond, M, 940(ab)
Grootoonk, S, 861(ab)
Gropler, RJ, 855(ab)
Groshar, D, 49, 1699
Grossman, A, 1121, 914(ab)
Grossman, M, 857(ab), 1012(ab)
Grossman, ZD, 150
Grothaus-King, A, 1789
Grotta, J, 968(ab)
Grover-McKay, M, 1917(le)
Growdon, JH, 704
Gruaz-Guyon, A, 912(ab), 1000(ab)
Gruber, M, 867(ab)
Gruenewald, SM, 2094
Gruenwald, F, 526, 844(ab)
Grummon, GD, 850(ab), 1033(ab)
Grünwald, F, 972(ab)
Guerra, UP, 895(ab)
Guerrero, TM, 1045(ab)
Guibourg, HC, 999(ab)
Guidry, GW, 995(ab)
Guillevin, L, 913(ab)
Guillon JM, 81
Guilloteau, D, 981(ab)
Gullberg, GT, 831(ab), 878(ab), 891(ab), 892(ab), 901(ab), 902(ab), 961(ab), 1003(ab)
Gulyás, B, 908(ab)
Günalp, B, 866(ab)
Gunes, I, 868(ab)
Guo, LW, 1685
Guo, YZ, 870(ab), 871(ab), 982(ab), 989(ab)
Gupta, NC, 829(ab), 836(ab), 837(ab), 975(ab)
Gupta, SM, 919(ab), 1251(le)
Gustavson, LM, 880(ab)
Gutowski, TD, 926(ab)
Gyobu, T, 967(ab)
Haapanen, A, 1255
Haaparanta, M, 1255
Haberkorn, U, 1981, 1019(ab)
Hademenos, GJ, 605, 962(ab)
Hadian, D, 955(ab)
Hagberg, C-E, 860(ab)
Hahn, K, 887(ab), 1021(ab)
Haire, W, 978(ab)
Haka, MS, 1125
Halama, JR, 1043(ab)
Haldemann, A, 231
Haldin, C, 1016(ab)
Halkar, RK, 837(ab), 991(ab)
Hall, H, 860(ab), 931(ab), 1011(ab)
Hall, K, 878(ab)
Hall, LC, 1692
Halldin, C, 860(ab), 931(ab), 1011(ab)
Hallgring, E, 1312, 887(ab)
Halpern, S, 2162
Halpern, SE, 2148
Ham, H, 485
Ham, HR, 174, 175
Hamacher, K, 2138
Hamamoto, K, 135, 893(ab), 909(ab), 912(ab), 919(ab), 933(ab), 969(ab), 972(ab), 1004(ab)
Hamamoto, T, 976(ab)
Hambien, SM, 1047(ab)
Hamilton, SE, 908(ab)
Hamlin, DK, 943(ab)
Hammell, TC, 1006(ab)
Hampel, KE, 997(ab)
Hamvas, A, 1661
Han, MC, 2118
Handa, N, 969(ab), 1014(ab), 1015(ab)
Hanelin, LG, 972(ab)
Hanna, MG, 1031(ab)
Hanrahan, S, 890(ab)
Hanrath, P, 886(ab)
Hansen, CL, 1574, 952(ab)
Hansen, HJ, 863(ab), 904(ab), 910(ab), 1002(ab)
Hansen, L, 900(ab), 921(ab)
Hanson, G, 1008(ab)
Hanson, MW, 532, 838(ab), 966(ab)
Hanson, S, 968(ab)
Hantraye, P, 946(ab)
Hanyu, H, 1019(ab)
Hara, M, 988(ab), 1033(ab)
Harada, K, 988(ab), 1029(ab), 1033(ab)
Harapanhalli, RS, 2196
Harcke, HT, 873(ab), 874(ab)
Hardman, N, 903(ab)
Hardoff, R, 845(ab)
Harker, J, 827(ab)
Harkness, BA, 1859, 833(ab)
Härkonen, R, 1255
Harp, GD, 763
Harrell, CR, 963(ab), 1006(ab)
Harris, CC, 922(ab)
Harris, GC, 867(ab)
Harris, JM, 826(ab)
Harris, RE, 1048(ab)

Harris, TD, 979(ab)
Harrison, K, 978(ab)
Harrison, R, 989(ab)
Hartiala, J, 1255
Hartman, JJ, 836(ab)
Hartman, NG, 1468
Hartoko, Th, 1013(ab)
Hartsough, NE, 1002(ab)
Harwood, SJ, 498, 2249(le)
Hasan, A, 980(ab)
Hasçelik, Z, 1027(ab)
Hasegawa, BH, 1881, 901(ab)
Hasegawa, S, 988(ab)
Hasegawa, Y, 208
Haseman, MK, 1750
Hasfeld, M, 915(ab)
Hashikawa, K, 940(ab), 969(ab), 1014(ab), 1015(ab)
Hashimoto, S, 934(ab)
Hasizume, 958(ab)
Haspel, MV, 1031(ab)
Hasselquist, BE, 852(ab), 873(ab)
Hatano, K, 897(ab)
Hatazawa, J, 1696, 827(ab), 857(ab), 897(ab)
Hattner, RS, 115, 1444, 918(ab)
Hauptmann, St, 1001(ab)
Hauser, MF, 840(ab)
Hauser, MM, 710
Haustein, J, 971(ab)
Hawes, DR, 1486
Hawk, TC, 1472, 1047(ab)
Hawkins, HH, 1044(ab)
Hawkins, R, 856(ab)
Hawkins, RA, 339, 633, 1191, 828(ab), 829(ab), 867(ab), 881(ab), 944(ab), 945(ab), 1039(ab), 1045(ab)
Hawkins, WG, 1007(ab)
Hawman, PC, 852(ab)
Hayashi, H, 333, 1015(ab)
Hayashida, K, 365
Haynie, TP, 828(ab), 858(ab), 992(ab), 1001(ab)
Hayostek, RJ, 1613
Haywood, L, 1000(ab)
Haze, K, 853(ab)
He, XS, 981(ab)
He, Z-X, 1846
Heelan, R, 345
Hefti, F, 890(ab)
Heidner, GL, 1542
Heikkonen, JJ, 913(ab)
Heironimus, JD, 2052
Heiser, RC, 468(le)
Heiss, WD, 861(ab), 940(ab), 1013(ab)
Helfaer, MA, 1004(ab)
Heller, GV, 876(ab), 951(ab)
Helling, D, 1024(ab)
Hellman, RS, 868(ab), 939(ab)
Hellström, I, 2160, 862(ab)
Hellström, KE, 2160, 862(ab)
Helwig, A, 957(ab)
Hendel, RC, 1783
Heninger, GR, 1964
Henkes, H, 971(ab), 1018(ab)
Henkin, RE, 1041(ab)
Henkin, RI, 996(ab)
Henneman, G, 894(ab)
Hennessey, JG, 1042(ab)
Henrich, M, 2138
Henry, TR, 929(ab)
Heo, J, 186, 2086, 854(ab), 866(ab), 916(ab), 952(ab)
Herbst, CP, 888(ab)
Herholz, K, 940(ab)
Herman, SD, 951(ab)
Herman, Z, 992(ab)
Herrero, P, 837(ab), 884(ab)
Herrin, JT, 73
Herrold, EM, 845(ab)
Herscovitch, P, 2103, 1010(ab)
Hertel, A, 853(ab), 904(ab), 912(ab)
Hertzberg, VS, 1132, 894(ab)
Herzog, H, 2138
Herzog, KM, 2190
Hess, H, 853(ab)
Hesse, B, 2106
Heusser, CH, 903(ab)
Heya, T, 957(ab)
Heyman, S, 269, 873(ab)
Heyndrickx, GR, 884(ab)
Hichwa, RD, 1008(ab), 1027(ab), 1430(le)
Hickey, J, 954(ab)
Hickey, P, 838(ab)
Hicks, KW, 1011(ab)
Hierholzer, J, 902(ab), 971(ab), 1018(ab)
Hiesiger, E, 1720
Hiesiger, EM, 192
Higano, S, 911(ab), 963(ab)
Higashi, K, 841(ab)
Higashi, S, 967(ab), 998(ab)
Hildebrand, J, 868(ab)
Hill, TC, 965(ab)
Hilleman, D, 837(ab)
Hilson, AJW, 1020(ab)
Hilton, S, 1002(ab)
Hilton, TC, 847(ab), 876(ab)
Hindmarsh, T, 1016(ab)
Hinge, D, 875(ab)
Hinkin, C, 967(ab)
Hinnefeld, JD, 1132, 894(ab)
Hirano, M, 920(ab)
Hirano, T, 1181
Hirata, K, 886(ab)
Hirayama, K, 917(ab)
Hironaka, FH, 995(ab)
Hirose, Y, 1008(ab)
Hirth, W, 900(ab), 974(ab)
Hisada, K, 179, 441, 1200, 2024, 877(ab), 918(ab), 957(ab), 967(ab), 1020(ab)
Hitchens, RE, 1430(le)
Hitzemann, 521
Hitzemann, R, 887(ab), 888(ab), 1046(ab)
Hixson, DJ, 537
Hnatowich, DJ, 1810, 909(ab), 921(ab), 925(ab), 934(ab), 958(ab), 1030(ab)
Ho, PJ, 1608, 834(ab)
Ho, VB, 1039(ab)
Hobbs, KEF, 1020(ab)
Hoberman, A, 923(ab)
Hoch, DB, 2211
Hochberg, F, 867(ab)
Hodgson, HJ, 756
Hodson, EM, 2094
Hoekstra, OS, 858(ab), 927(ab)
Hoffer, P, 896(ab)
Hoffer, PB, 1964, 848(ab), 878(ab), 906(ab), 911(ab), 913(ab), 945(ab)
Höffken, H, 906(ab)
Hoffman, BJ, 935(ab)
Hoffman, EJ, 595, 613, 1191, 828(ab), 879(ab), 1010(ab), 1045(ab), 1430(le)
Hoffman, JM, 532, 1472, 838(ab), 922(ab), 966(ab), 1047(ab)
Hoffman, TJ, 435, 988(ab), 1032(ab), 1048(ab)
Höflich, G, 972(ab)
Hofstetter, J, 981(ab)
Högberg, T, 860(ab)
Hoh, CK, 339, 633, 1191, 828(ab), 829(ab), 867(ab), 945(ab), 1045(ab)
Højgaard, L, 2106
Holan, V, 949(ab), 969(ab)
Holdeman, K, 978(ab)
Holden, JE, 922(ab)
Holman, BL, 181, 704, 1312, 1357, 1516, 1888, 1949, 839(ab), 852(ab), 887(ab), 970(ab), 1005(ab), 1018(ab), 1033(ab), 1043(ab), 1432(le)
Holmes, DR, 845(ab)
Holmes, GL, 1018(ab)
Holmes, RA, 435, 1451, 851(ab), 988(ab), 1032(ab), 1048(ab)
Holoye, P, 992(ab)
Holsclaw, D, 835(ab)
Holt, SA, 1417
Holthoff, VA, 1013(ab)
Holweg, R, 931(ab)
Hommeyer, SH, 748
Honda, N, 969(ab)
Honeyman, J, 1043(ab)
Honeyman, JC, 1042(ab), 1043(ab)
Hong, CD, 991(ab)
Hong, J, 1035(ab)
Hong, MK, 892(ab)
Hong, SB, 877(ab)
Hong, WH, 962(ab)
Hoogeveen, EK, 990(ab)
Hör, G, 853(ab), 904(ab), 912(ab)
Horai, Y, 891(ab)
Horan, PK, 899(ab), 921(ab)
Hori, M, 952(ab)
Horibe, K, 246
Hörl, W, 859(ab)
Horn, L, 973(ab)
Hornu, CHG, 832(ab)
Horowitz, M, 2027
Horowitz, M, 1283
Horowski, R, 1018(ab)
Hörtnagl, H, 108
Hortobagyi, G, 828(ab)
Hosain, F, 1251(le)
Hoschl, R, 868(ab)
Hoshi, H, 916(ab), 971(ab)
Hosono, M, 853(ab), 893(ab), 1001(ab)
Hotchkiss, RS, 925(ab)
Hotson, G, 117
Hotze, AL, 526, 839(ab), 844(ab), 914(ab)
Houle, S, 960(ab)
Hoverath, H, 828(ab), 1007(ab), 1045(ab)
Hovsepian, D, 1042(ab)
Howell, RW, 277, 2196
Hradilek, P, 982(ab)
Hsieh, J, 852(ab)
Hsu, CY, 997(ab), 1013(ab)
Hsu, TH, 1034(ab)
Hua, T, 878(ab)
Huang, G, 852(ab)
Huang, H, 861(ab), 974(ab), 1026(ab)
Huang, SC, 339, 613, 633, 1235, 1472, 881(ab), 882(ab), 944(ab), 945(ab)
Huberty, JP, 1444
Hubner, KF, 885(ab), 923(ab), 983(ab)
Huck, S, 108
Hudson, HM, 960(ab)
Huesman, 884(ab), RH
Hughes, JA, 1048(ab)
Hughes, JMB, 836(ab), 1022(ab)
Hughey, BJ, 932(ab)
Huijgens, PC, 858(ab), 927(ab)
Hundeshagen, H, 972(ab)
Hung, GL, 844(ab)
Hung, JC, 176, 306, 1613
Hunink, MGM, 1432(le)
Hunter, DW, 1039(ab)
Hupp, T, 907(ab)
Hurwitz, RA, 918(ab)
Hutchins, B, 934(ab)
Hutchins, G, 882(ab), 1008(ab), 1020(ab)
Hutchins, GD, 684, 1243, 826(ab), 870(ab), 878(ab), 881(ab), 933(ab), 994(ab)
Hutchinson, RJ, 1735
Hutson, WR, 833(ab)
Hutton, BF, 901(ab), 960(ab)
Hvid-Jacobsen, K, 251
Hwang, D-R, 830(ab), 975(ab), 983(ab)
Hwang, YC, 830(ab)
Hynes, M, 974(ab)

Ibis, E, 2110
Ichihara, T, 1200, 918(ab)
Ichijo, K, 1851
Ichise, M, 55, 970(ab)
Ichiya, Y, 877(ab), 945(ab), 1015(ab)
Ide, M, 932(ab)
Ido, T, 413, 1972, 840(ab), 897(ab), 984(ab)
Iervasi, G, 1020(ab)
Ii, M, 967(ab)
Iida, H, 1669, 827(ab), 911(ab), 963(ab), 994(ab), 1008(ab)
Iida, Y, 897(ab), 1024(ab)
Iijima, N, 891(ab)
Iio, A, 933(ab)
Ikeda, M, 940(ab)
Ikekubo, K, 659, 885(ab)
Ikeoka, N, 744
Iles, S, 950(ab)
Im, J-G, 2118
Imahori, Y, 413, 466(le)
Imai, K, 951(ab)
Imai, Y, 853(ab)
Imaizumi, M, 246
Imaseki, K, 324
Imbriaco, M, 915(ab)
Immerzeel, DJMJ, 936(ab)
Ingvar, M, 908(ab), 1011(ab)
Innis, RB, 1964, 848(ab), 896(ab), 911(ab), 945(ab), 961(ab)
Inoue, O, 917(ab)
Inoue, T, 1181, 909(ab), 912(ab), 969(ab), 972(ab), 1004(ab)
Inoue, Y, 857(ab), 968(ab), 969(ab)
Inugami, A, 1696
Iravani, A, 923(ab)
Isacson, O, 946(ab)
Isaka, Y, 246
Ishida, Y, 940(ab), 952(ab), 969(ab), 1014(ab), 1015(ab)
Ishii, I, 1020(ab)
Ishii, K, 1016(ab)
Ishii, S, 1016(ab)
Ishimaru, T, 1023(ab)
Ishimura, J, 834(ab)
Ishiwata, K, 1972, 840(ab), 841(ab), 897(ab), 984(ab), 1016(ab), 1025(ab)
Işik, E, 866(ab)
Isitman, AT, 2110
Iskandrian, AS, 186, 2086, 854(ab), 866(ab), 916(ab), 952(ab)
Iskandrian, B, 854(ab), 916(ab), 952(ab)
Iskandrian, BB, 186
Islan, S, 435
Isobe, M, 1000(ab)
Isono, K, 333
Israel, O, 1699, 1774
Itami, J, 324
Itami, M, 324
Itoh, H, 1696, 911(ab), 963(ab)
Itoh, M, 857(ab), 897(ab)
Itoh, T, 917(ab)
Itoi, Y, 246
Itti, R, 874(ab), 875(ab), 1011(ab)
Iuliucci, JD, 978(ab)
Ivanovic, M, 842(ab), 851(ab), 1012(ab), 1015(ab)
Iwasaki, Y, 897(ab), 966(ab)
Iwashita, S, 996(ab)
Iwata, R, 897(ab)
Izaki, M, 995(ab)
Izon, D, 904(ab)

Jabbour, BA, 829(ab)
Jabir, AM, 1044(ab), 1045(ab)
Jabir, R, 1044(ab), 1045(ab)
Jacobs, MP, 830(ab), 975(ab), 983(ab)
Jacobs, W, 1035(ab)
Jacobson, AF, 202, 1642,

849(ab), 866(ab), 1035(ab)
Jaggi, J, 1012(ab)
Jagust, WJ, 890(ab), 939(ab)
Jahan, S, 978(ab)
Jain, D, 874(ab), 938(ab), 939(ab), 993(ab)
Jain, SP, 981(ab)
Jamar, F, 73, 976(ab)
Jang, JJ, 892(ab)
Janicek, MJ, 1758, 970(ab)
Janin, C, 1003(ab)
Jansen, J, 957(ab)
Jansons, D, 947(ab)
Janssen, AGM, 917(ab), 1016(ab)
Jarrousse, B, 913(ab)
Jarry, M, 855(ab)
Jaszcak, RJ, 961(ab)
Jaszczak, RJ, 451, 879(ab), 891(ab), 901(ab), 922(ab)
Jauch, M, 956(ab)
Jay, M, 398, 1915(le)
Jeffery, PJ, 883(ab)
Jehan, A, 835(ab)
Jensen, PF, 251
Jeong, JM, 889(ab), 986(ab), 1001(ab)
Jerushalmi, J, 1774
Jeusset, J, 2162
Jewett, DM, 423, 982(ab)
Jhingran, SG, 974(ab)
Jia, MX, 927(ab)
Jimenez, H, 1304, 987(ab)
Jinnouchi, S, 971(ab)
Jochelson, MS, 1594
Joensuu, H, 691
John, CS, 889(ab)
John, E, 851(ab), 979(ab), 987(ab)
Johnson, DK, 904(ab)
Johnson, JC, 623, 1916(le)
Johnson, K, 1312
Johnson, KA, 181, 704, 887(ab), 1005(ab), 1018(ab), 1043(ab), 1432(le)
Johnson, LL, 229, 1411, 1994, 846(ab)
Johnson, MC, 820
Johnson, SH, 575
Johnson, VE, 879(ab)
Johnston, GS, 966(ab), 970(ab)
Johnston, RE, 842(ab)
Jomura, I, 744
Jones, AG, 1357, 1516, 1949, 937(ab), 1033(ab)
Jones, AL, 1002(ab)
Jones, BE, 676
Jones, FD-L, 827(ab)
Jones, JJ, 1014(ab)
Jones, M, 948(ab)
Jones, RH, 825(ab)
Jones, RML, 1766
Jones, T, 1669
Jones, WT, 41
Jonker, N, 491
Jonkhoff, AR, 927(ab)
Jönsson, B-A, 1654, 1825, 953(ab), 954(ab)
Jørgensen, F, 2106
Jorgenson, MA, 845(ab)
Joseph, JL, 968(ab)
Joseph, K, 906(ab)
Joshua, AV, 841(ab)
Jouve, B, 843(ab)
Joyce, ME, 716
Juillière, Y, 906(ab)
Julian, BA, 924(ab)
Juni, JE, 239, 1206, 1017(ab)
Juweid, M, 873(ab), 893(ab)
Jyawook, S, 996(ab)

Kabalka, GW, 890(ab), 931(ab), 983(ab), 1025(ab)
Kaieda, M, 1016(ab)
Kairemo, KJA, 913(ab)
Kaiser, HJ, 886(ab)
Kalagian, H, 867(ab)
Kalff, V, 1346, 2222
Kalkowski, PJ, 881(ab)
Kallergi, M, 889(ab)
Kalloo, AN, 1216
Kamada, M, 998(ab)
Kamada, T, 940(ab), 952(ab), 969(ab), 997(ab), 1014(ab), 1015(ab)
Kamano, T, 969(ab)
Kamata, R, 951(ab)
Kambara, H, 659, 856(ab), 885(ab), 886(ab), 953(ab)
Kaminski, MS, 893(ab)
Kämmer, M, 1019(ab)
Kammermeier, H, 102
Kanada, H, 1001(ab)
Kanaya, K, 958(ab), 1004(ab), 1005(ab)
Kanaya, S, 958(ab), 1004(ab), 1005(ab)
Kaneko, M, 6
Kang, SB, 905(ab)
Kanke, M, 144
Kanmaz, B, 868(ab)
Kanner, AM, 1014(ab)
Kanno, I, 1696, 827(ab), 857(ab), 911(ab), 1008(ab)
Kanstrup, IL, 251
Kanvinde, MH, 981(ab)
Kao, CH, 254, 955(ab), 977(ab), 986(ab), 997(ab), 1013(ab)
Kao, PF, 1022(ab)
Kapadvanjwala, M, 956(ab), 980(ab)
Kaphan, G, 990(ab)
Kaplan, JD, 1661
Kaplan, WD, 1594
Kappes, R, 1035(ab)
Kapucu, O, 917(ab), 1016(ab)
Karalasingam, L, 1253(le)
Karayalcin, G, 914(ab)
Karcher, G, 906(ab)
Kari, B, 852(ab)
Karl, IE, 925(ab)
Karlsson, P, 860(ab)
Karp, JS, 861(ab), 862(ab), 871(ab), 1430(le)
Karrison, T, 853(ab)
Kasahara, A, 997(ab)
Kashikura, K, 1005(ab)
Kashiwagi, T, 997(ab)
Kasi, LP, 941(ab), 992(ab), 1001(ab)
Kasper, S, 972(ab)
Kassis, AI, 384, 781
Katafuchi, T, 272
Katayama, S, 968(ab)
Katial, R, 266
Kato, H, 659, 885(ab)
Kato, M, 1015(ab)
Kato, N, 1017(ab)
Katona, CE, 1014(ab)
Katsetos, CD, 2017
Katti, KK, 910(ab), 1032(ab)
Katti, KV, 851(ab), 910(ab), 979(ab), 987(ab), 1032(ab), 1048(ab)
Katz, RD, 1039(ab)
Katzenellenbogen, JA, 558, 724
Kaufman, GE, 2214
Kaul, S, 1732
Kavanagh, P, 911(ab)
Kawada, T, 844(ab)
Kawai, C, 659
Kawai, H, 6
Kawai, K, 891(ab)
Kawai, T, 1023(ab)
Kawakami, K, 1004(ab)
Kawamoto, M, 659, 856(ab), 885(ab), 886(ab), 953(ab)
Kawamura, M, 1516
Kawarabayashi, C, 853(ab)
Kawasaki, Y, 967(ab)
Kawasuji, M, 441
Kearfott, KJ, 842(ab)
Keeling, CA, 1750
Keenan, A, 848(ab)
Kegel, J, 186
Keiser, HR, 833(ab)
Keller, F, 1178
Kelley, A, 956(ab)
Kelley, MJ, 2222
Kelly, JD, 850(ab)
Kemler, S, 952(ab)
Kemp, BJ, 1875
Kempf, J, 2014
Kenda, R, 873(ab)
Kenemans, P, 1113, 1958, 2000
Kengen, RAM, 1251(le)
Kennedy, DN, 867(ab)
Kennedy, JW, 939(ab)
Kennedy, RL, 127
Kerr, JM, 1836
Kershaw, G, 907(ab)
Kessler, J, 940(ab), 1013(ab)
Kessler, ML, 926(ab)
Kessler, RM, 826(ab), 847(ab), 848(ab)
Ketring, AR, 623, 1916(le), 851(ab), 910(ab), 979(ab), 987(ab), 1032(ab), 1048(ab)
Kettle, AG, 313
Keyes, JW, Jr, 1859
Khalkhali, I, 835(ab)
Khanna, S, 825(ab), 856(ab), 867(ab), 944(ab), 1009(ab)
Khaw, BA, 144, 1994, 895(ab), 934(ab), 936(ab), 943(ab), 959(ab)
Khazaeli, MB, 23, 1648
Khedkar, N, 258
Khelifa, F, 990(ab)
Khonsari, A, 967(ab)
Kiat, H, 1509, 854(ab), 876(ab), 911(ab)
Kiba, A, 1935
Kiefer, J, 912(ab)
Kijewski, MF, 962(ab)
Kikuchi, H, 893(ab)
Kikuchi, T, 333
Kilbourn, MR, 423, 861(ab), 870(ab), 882(ab), 982(ab), 983(ab)
Kilts, CD, 922(ab)
Kim, A, 836(ab)
Kim, BT, 828(ab)
Kim, CK, 902(ab), 919(ab), 999(ab)
Kim, C-W, 2118
Kim, EE, 828(ab), 858(ab), 985(ab), 992(ab), 1001(ab)
Kim, H, 974(ab)
Kim, H-L, 1225
Kim, KY, 936(ab)
Kim, SB, 991(ab)
Kim, SE, 877(ab)
Kim, SM, 961(ab)
Kim, SY, 902(ab)
Kimball, AW, 869(ab)
Kimball, AW Jr, 883(ab)
Kimura, J, 1637
Kimura, Y, 893(ab), 909(ab), 912(ab), 933(ab)
Kinahan, PE, 871(ab)
King, HF, 963(ab)
King, MA, 161, 605, 842(ab), 843(ab), 962(ab)
King, PT, 847(ab)
Kinoshita, M, 969(ab)
Kinoshita, R, 988(ab), 1029(ab), 1033(ab)
Kinoshita, S, 932(ab)
Kinsey, BM, 983(ab)
Kinuya, K, 967(ab)
Kinuya, S, 842(ab), 889(ab), 957(ab), 986(ab), 1001(ab)
Kippenhan, JS, 1459
Kipper, SL, 902(ab)
Kir, M, 464(le)
Kirchner, PT, 1917(le)
Kirsch, C-M, 832(ab), 897(ab), 917(ab)
Kirsh, C-M, 1291
Kirsh, J, 960(ab)
Kirsh, JC, 55, 970(ab)
Kitamura, S, 1016(ab)
Kitapçi, M, 319
Kiuru, AJ, 913(ab)
Kjøller, E, 251
Klauser, AG, 1291
Klein, BE, 1701
Klein, HA, 996(ab)
Klein, HH, 223, 906(ab)
Klemm, E, 972(ab)
Klingensmith, WC, III, 1417
Klinkowstein, RE, 932(ab)
Klipper, R, 984(ab), 1027(ab)
Klosa, B, 1399
Knapp, FF Jr, 910(ab), 995(ab), 1023(ab), 1024(ab), 1028(ab)
Knecht, R, 912(ab)
Kneeland, B, 992(ab)
Knight, D, 756
Knight, LC, 710, 467(le), 832(ab), 964(ab)
Knobloch, E, 1035(ab)
Knopp, MV, 828(ab), 1007(ab), 1045(ab)
Knusel, B, 890(ab)
Knuuti, MJ, 1255
Kobayashi, A, 6
Kobayashi, H, 853(ab), 893(ab), 1001(ab)
Kobayashi, K, 744
Koch, KT, 895(ab)
Koch, P, 959(ab)
Koenders, EB, 1031(ab)
Koeppe, RA, 423, 1008, 858(ab), 870(ab), 878(ab), 882(ab), 887(ab), 1003(ab), 1007(ab), 1009(ab)
Koga, S, 1741, 965(ab)
Koh, C-S, 2118, 877(ab), 892(ab), 905(ab)
Köhler, U, 995(ab)
Kojima, A, 988(ab), 1029(ab), 1033(ab)
Kojima, H, 998(ab)
Kolbe, H, 972(ab)
Kollman, M, 710
Kollmann, M, 832(ab)
Kolodny, GM, 1699, 1774, 947(ab), 1003(ab)
Kolsky, KL, 900(ab), 980(ab), 985(ab)
Komai, S, 1741
Kondo, S, 893(ab)
Konings, AWT, 373
Konishi, J, 545, 659, 897, 1263, 1501, 1637, 853(ab), 856(ab), 885(ab), 886(ab), 891(ab), 893(ab), 953(ab), 966(ab), 1001(ab), 1023(ab), 1024(ab), 1026(ab)
Konstam, MA, 905(ab)
Kooij, PPM, 652, 894(ab), 914(ab)
Kooji, PPM, 990(ab)
Koon Teoh, S, 1312
Koper, JW, 652
Kopicka, K, 910(ab), 979(ab), 982(ab), 1032(ab)
Koral, KF, 842(ab), 926(ab)
Kosslyn, SM, 908(ab)
Kostakoglu, L, 345, 1396, 843(ab), 1002(ab)
Köster, G, 950(ab)
Kosuda, S, 844(ab), 966(ab)
Kotlyarov, EV, 966(ab), 970(ab)
Kotts, C, 934(ab)
Kousaka, T, 853(ab)
Kovacs, FM, 403, 2060(le)
Kozawa, SM, 581
Kozell, LB, 581
Kozuka, K, 952(ab), 1015(ab)
Kozuka, T, 365, 940(ab), 969(ab), 997(ab), 1014(ab)
Kramer, EL, 912(ab), 926(ab), 960(ab)
Krasnow, AZ, 868(ab)
Krause, B, 885(ab)
Krenning, EP, 652, 894(ab), 903(ab), 914(ab), 955(ab), 990(ab)
Kretschko, J, 859(ab)
Kreuzer, H, 845(ab)
Krevsky, B, 467(ie), 832(ab)
Krishna, L, 2017
Krishnamurthy, GT, 431, 542

Krishnamurthy, S, 542
Krishnan, R, 910(ab), 994(ab)
Krivokapich, J, 856(ab)
Kroger, L, 912(ab)
Kroger, LA, 862(ab)
Krohn, KA, 581, 2202, 987(ab)
Kroll, K, 2202
Krom, RF, 239
Kronauge, JF, 1357, 1516, 1949, 864(ab), 1033(ab)
Kronrad, L, 982(ab)
Kroon, D, 910(ab)
Kroop, S, 898(ab)
Kropp, J, 526, 844(ab), 995(ab), 1028(ab)
Kruezer, H, 223
Krumholtz, A, 966(ab)
Krumholz, H, 1003(ab)
Kuang, L-R, 985(ab)
Kuba, A, 458
Kubo, A, 875(ab), 934(ab)
Kubodera, A, 891(ab)
Kubota, K, 1972, 840(ab), 841(ab), 984(ab)
Kubota, R, 1972, 840(ab), 841(ab), 984(ab)
Kuczynski, BL, 1152, 865(ab), 993(ab)
Kuebler, WK, 1007(ab)
Kuhar, MJ, 964(ab)
Kuhl, DE, 423, 1125, 1836, 858(ab), 882(ab), 887(ab), 929(ab), 1003(ab), 1009(ab)
Kuhle, W, 1628
Kuhle, WG, 1235
Kuhlmann, L, 920(ab), 1030(ab)
Kuijper, AFM, 1727
Kuiper, MA, 917(ab), 1016(ab)
Kuji, I, 1020(ab)
Kukis, DL, 942(ab), 1030(ab), 1031(ab)
Kulkarni, PV, 974(ab), 990(ab), 1003(ab), 1010(ab)
Kumar, A, 1548, 2103, 1013(ab)
Kung, HF, 1964, 848(ab), 870(ab), 871(ab), 890(ab), 896(ab), 945(ab), 954(ab), 982(ab), 989(ab)
Kung, MP, 871(ab), 890(ab), 982(ab), 989(ab)
Kuni, CC, 873(ab)
Kuniyasu, Y, 998(ab)
Kupfer, S, 949(ab)
Kurata, C, 6, 845(ab)
Kurihara, K, 1005(ab)
Kurkoki, T, 744
Kursh, ED, 41
Kurt, AM, 1766
Kusakabe, K, 958(ab), 1004(ab), 1005(ab)
Kuten, A, 1774
Kutom, AH, 951(ab)
Kuwabara, H, 879(ab), 909(ab), 916(ab)
Kuwabara, Y, 877(ab), 945(ab), 1015(ab)
Kuyama, J, 324
Kvols, LJ, 1613
Kwan, A, 844(ab)
Kwekkeboom, DJ, 652, 914(ab)

Labresh, KA, 951(ab)
Ladd, W, 1269
Laflamme, L, 696
LaFrance, N, 878(ab)
LaFrance, ND, 968(ab)
Lahiri, A, 448, 874(ab), 875(ab), 938(ab)
Lai, J, 987(ab)
Laks, H, 977(ab)
Lakshmanan, M, 1848
Lalonde, D, 866(ab)
Lalush, DS, 832(ab)
Lam, C, 888(ab)
Lam, WC, 1007(ab)
Lambert, CR, 980(ab), 1023(ab), 1028(ab), 1029(ab)
Lambert, R, 1091, 1801, 855(ab), 866(ab), 894(ab), 1034(ab)
Lamberts, SWJ, 652, 894(ab), 903(ab), 914(ab), 955(ab)
Lambrecht, RM, 2020
Lamki, L, 968(ab)
Lamki, LM, 1047(ab)
Lammert, G, 1048(ab)
Lammertsma, AA, 1669
Landais, P, 1011(ab)
Landoni, C, 944(ab)
Lang, EV, 1797
Lang, TF, 1881, 901(ab)
Lange, RC, 304
Langer, R, 971(ab)
Langhammer, HR, 854(ab), 859(ab)
Langhorst, SM, 623, 1916(le)
Lanier, L, 1043(ab)
Lanigan, JP, 1024(ab)
Lanspa, S, 975(ab)
Lantto, E, 1253(le)
Lantto, T, 1253(le)
Larar, GN, 2209
Larar, JM, 844(ab)
Larar, JN, 1186
Larcos, G, 1588(le)
Larkin, R, 960(ab)
Larock, MP, 874(ab)
Larson, S, 867(ab)
Larson, SM, 345, 803, 1373, 1396, 2020, 843(ab), 859(ab), 904(ab), 913(ab), 941(ab), 1002(ab)
Larsson, BS, 1825
Laruelle, M, 848(ab), 911(ab), 945(ab)
Lasdun, A, 981(ab)
Lasser, EC, 237
Lastoria, S, 892(ab), 918(ab), 999(ab)
Latham, TB, 355
Latifić-Jasnič, D, 587
Latino, FA, 990(ab)
Lattimer, JC, 1024(ab)
Lau, A, 2059(le)
Lauer, U, 903(ab)
Laurent, R, 868(ab)
Laurie, AJ, 237
Lavender, JP, 491, 756
Lawson, AJ, 886(ab)
Laxer, KD, 967(ab)
Layer, G, 914(ab)
Lazewatsky, J, 989(ab)
Le, N, 889(ab), 957(ab)
Lear, JL, 1819, 463(le), 908(ab), 947(ab)
Le Bars, D, 953(ab), 1011(ab)
LeBlanc, AD, 974(ab)
LeBouthillier, G, 1550
Lechevallier, E, 990(ab)
Leclerq, B, 874(ab)
Leddy, C, 934(ab)
Le Doussal, JM, 912(ab), 1000(ab)
Lee, C, 964(ab)
Lee, DS, 877(ab)
Lee, FA, 939(ab)
Lee, HB, 739, 907(ab)
Lee, HP, 905(ab)
Lee, JD, 1183
Lee, K, 684
Lee, KS, 1579, 981(ab)
Lee, M, 869(ab), 963(ab)
Lee, MC, 877(ab), 892(ab), 905(ab)
Lee, ME, 972(ab)
Lee, MH, 919(ab), 936(ab), 991(ab)
Lee, MK, 919(ab)
Lee, RF, 972(ab)
Lee, SF, 282
Lee, SH, 936(ab)
Lee, TW, 986(ab)
Lee, VW, 463(le)
Lee, YI, 2118
Lees, AM, 845(ab)
Lees, RS, 845(ab)
Lefebvre, B, 1034(ab)
Lefkowitz, D, 1047(ab)
Léger, GC, 879(ab), 916(ab)
Lehikoinen, P, 691
Leichner, PK, 1007(ab)
Leighton, DM, 1022(ab)
Leisure, GP, 885(ab)
Leitha, T, 1028(ab)
Lemlek, J, 2086, 866(ab), 916(ab)
Lemmens, JAM, 1330, 950(ab)
Leners, N, 976(ab)
Lennon, SE, 1797
León, AS, 1949
León, ET, 1949
Leonard JC, 981(ab), 1034(ab)
Leonidas, JC, 914(ab)
Leppo, JA, 120, 1783, 468(le), 846(ab), 864(ab), 993(ab)
Lerner, D, 1022(ab)
Leroy, RF, 1018(ab)
Lesch, MD, 994(ab)
Leskinen-Kallio, S, 691
Lesser, I, 838(ab)
Lesser, RP, 929(ab)
Lette, J, 938(ab), 951(ab)
Leuven, KU, 832(ab)
Levasseur, A, 951(ab)
Levasseur, M, 1481, 1019(ab)
Léveillé, J, 480, 1091, 1034(ab)
Lever, SZ, 899(ab), 921(ab), 1032(ab)
Levina, T, 1022(ab)
Levine, MA, 869(ab)
Levine, R, 1014(ab)
Levivier, M, 868(ab)
Levni, E, 932(ab)
Levy, A, 1046(ab)
Levy, AV, 287
Levy, WC, 763, 1324, 1642
Lewellen, TK, 771, 2202, 889(ab), 1430(le)
Lewis, DH, 1789
Lewis, ML, 512
Leys, D, 1431(le)
Li, J, 842(ab), 891(ab)
Liang, AY, 946(ab)
Liang, C-H, 282
Liang, Z, 872(ab)
Liao, S-C, 282
Liao, SK, 926(ab)
Liao, SQ, 997(ab), 1013(ab)
Libby, D, 880(ab), 1028(ab)
Licho, R, 907(ab)
Lidgi, S, 49
Lie, KI, 870(ab)
Liebes, L, 912(ab)
Liedtke, AJ, 1864
Liew, SC, 1881
Lightfoote, JB, 1039(ab)
Lin, H, 974(ab)
Lin, KN, 1012(ab)
Lin, KP, 882(ab)
Lin, MS, 997(ab)
Lin, S, 1033(ab)
Lin, W, 974(ab)
Lin, WY, 977(ab), 986(ab), 997(ab), 1013(ab)
Linder, KE, 1152, 865(ab), 920(ab)
Lindsley, K, 867(ab)
Line, BR, 1939, 848(ab)
Lingen, AV, 858(ab), 927(ab)
Linhart, NC, 380
Link, JM, 581
Links, JM, 968(ab), 1007(ab), 1430(le)
Linssen, MCJG, 102
Liow, J-S, 871(ab)
Lisbona, R, 1223
Lisic, E, 1024(ab)
Lister-James, J, 845(ab)
Little, JW, 1035(ab)
Littlefield, JL, 1042(ab), 1046(ab)
Litton, J-E, 860(ab), 1011(ab), 1016(ab)
Liu, A, 724
Liu, HC, 1012(ab)
Liu, J, 962(ab)
Liu, RS, 997(ab), 1034(ab)
Liu, S, 1012(ab)
Liu, T, 23, 1648
Liu, XJ, 938(ab)
Liu, Y, 852(ab), 924(ab)
Livni, E, 924(ab)
Ljungberg, M, 962(ab)
Lloyd, T, 1143
LoBuglio, AF, 23, 1648
Loc'h, C, 1481, 883(ab), 1019(ab)
Logan, J, 192, 521, 847(ab), 887(ab), 888(ab), 946(ab)
Logan, KW, 1451
Logemann, TN, 884(ab)
Loisance, D, 471, 896(ab)
Loncaric, S, 842(ab), 851(ab)
Longford, CPD, 890(ab), 931(ab), 1025(ab)
Lopez, M, 914(ab)
Lorenz, CH, 826(ab)
Lorenz, WJ, 828(ab), 1007(ab), 1045(ab)
Losinno, F, 2040
Lötter, MG, 777, 888(ab)
Lovins, K, 991(ab), 1046(ab)
Low, J, 937(ab)
Lowe, J, 860(ab)
Lowe, JL, 1919, 2030, 827(ab)
Löwenberg, B, 903(ab)
Loyalka, SK, 623, 1916(le)
Loyd, D, 1789
Lucignani, G, 944(ab), 973(ab)
Ludbrook, PA, 836(ab)
Lueth, K, 853(ab)
Luh, KE, 1011(ab), 1018(ab)
Lui, D, 903(ab)
Lumbroso, L, 1020(ab)
Luo, J, 926(ab)
Lutterman, JA, 1330, 950(ab)
Luxen, A, 1472, 868(ab)
Lyle, LR, 2184
Lyon, SG, 237
Lyons, EA, 1044(ab)
Lythgoe, MF, 1935, 2090

Ma, GQ, 844(ab), 937(ab)
Maas, K, 874(ab)
Macalintal, S, 867(ab)
Macapinlac, H, 867(ab)
MacEwan, DW, 1044(ab)
Macey, DJ, 926(ab), 927(ab), 941(ab)
MacFall, JR, 922(ab)
MacGregor, R, 521, 887(ab), 888(ab)
MacGregor, RR, 192, 847(ab), 946(ab)
Mach, JP, 1766, 903(ab)
Mach, RH, 829(ab), 985(ab)
Machac, J, 995(ab)
Machecourt, J, 953(ab)
Machida, K, 969(ab)
MacIntyre, WJ, 866(ab), 928(ab), 970(ab), 1040(ab), 1048(ab), 1586(le)
Maclean, JB, 972(ab)
MacNabb, CJ, 870(ab)
Macy, C, 912(ab)
Madani, S, 458
Madar, I, 883(ab)
Maddahi, J, 1509, 825(ab), 828(ab), 829(ab), 854(ab), 856(ab), 867(ab), 876(ab), 1009(ab), 1045(ab)
Maddax, A, 1283
Maddock, EN, 863(ab)
Maddock, SW, 862(ab), 863(ab)
Maden, HA, 464(le)
Madras, B, 946(ab)
Madras, BK, 946(ab)
Madsen, J, 844(ab)
Madsen, MT, 1859, 1917(le)

Maeda, H, 1741, 965(ab), 1023(ab)
Maeda, Y, 967(ab)
Maegdenberg, VVd, 832(ab)
Magata, Y, 856(ab), 886(ab), 897(ab), 953(ab), 966(ab), 1023(ab), 1024(ab)
Magnani, P, 834(ab), 959(ab)
Magné, J, 1846
Magoun, S, 991(ab)
Maguire, GQ Jr, 960(ab)
Mahe, MA, 941(ab)
Mahler, M, 967(ab)
Mahmarian, JJ, 1600, 905(ab), 916(ab), 995(ab)
Mahmood, A, 937(ab)
Mahoney, DK, 1472, 1045(ab)
Mahussain, SA, 978(ab)
Maier-Borst, W, 1366
Mailliard, JA, 975(ab)
Maincent, P, 956(ab)
Maisch, B, 906(ab)
Maizels, M, 2047
Majd, M, 976(ab)
Majocha, RE, 2184
Makay, Á, 458
Maki, M, 958(ab)
Makino, M, 958(ab), 1004(ab), 1005(ab)
Mal, H, 835(ab)
Malarme, M, 1427(le)
Malik, AB, 1023(ab)
Malison, RT, 848(ab), 945(ab), 961(ab)
Maljkovic, V, 908(ab)
Malkin, RD, 876(ab)
Mallin, W, 993(ab)
Malmud, LS, 24N(6), N31(3)
Malveaux, G, 921(ab)
Mamiya, T, 969(ab)
Mand, FF, 167
Mandelkern, M, 967(ab), 1017(ab)
Mandell, GA, 873(ab), 874(ab)
Maneval, DC, 934(ab)
Manglos, SH, 150, 901(ab), 961(ab)
Mangner, T, 684
Mangner, TJ, 860(ab), 861(ab), 870(ab), 882(ab), 982(ab), 983(ab)
Man in 't Veld, AJ, 990(ab)
Mankovich, NJ, 827(ab), 1043(ab)
Manning, RG, 847(ab)
Manno, M, 929(ab)
Mannting, F, 928(ab)
Mantil, JC, 830(ab), 975(ab), 983(ab)
Maquire, GQ Jr, 926(ab)
Maraganore, J, 981(ab)
Marboe, C, 1994
Marciano, DM, 867(ab)
Mardirossian, G, 909(ab), 921(ab), 934(ab), 1030(ab)
Mardirossian, GC, 958(ab)
Marengo, M, 2040
Margouleff, D, 898(ab), 923(ab), 1027(ab)
Mariani, G, 1020(ab)
Mariani, M, 999(ab)
Marie, PY, 906(ab)
Mariën, P, 1013(ab)
Marienhagen, J, 903(ab)
Markham, J, 1661
Markham, JA, 1045(ab)
Markowitz, A, 852(ab)
Marks, PH, 516
Marmion, ME, 850(ab), 1033(ab)
Marmor, A, 938(ab)
Marotta, CA, 2184
Marshall, RC, 938(ab)
Martin, CC, 850(ab), 884(ab), 931(ab)
Martin, GV, 2144, 2202
Martin, M, 912(ab), 1000(ab)
Martin, P, 863(ab), 941(ab), 960(ab)
Martin, SE, 865(ab)
Martinez, C, 258
Maruyama, Y, 920(ab)
Marwick, T, 825(ab), 837(ab), 866(ab), 875(ab), 1040(ab), 1041(ab)
Marzilli, LG, 900(ab), 921(ab)
Marzullo, P, 1925
Masaki, K, 744
Mason, G, 835(ab)
Mason, GR, 836(ab), 1022(ab)
Mason, NS, 847(ab)
Mason, RP, 974(ab)
Mason, WH, 930(ab)
Massuger, LFAG, 1113, 1958
Masters, PR, 1048(ab)
Mastin, ST, 923(ab)
Mastrostamatis, S, 988(ab)
Masuda, K, 877(ab), 945(ab), 998(ab), 1015(ab)
Masure, M-C, 696
Matacchieri, R, 1027(ab)
Matarrese, M, 924(ab), 944(ab), 1014(ab)
Máté, E, 458
Matheja, P, 915(ab)
Mather, S, 1121, 914(ab)
Mather, SJ, 904(ab)
Mathews, D, 826(ab)
Mathias, CJ, 931(ab)
Mathieu, D, 919(ab)
Mathieu, JP, 1034(ab)
Mathis, CA, 2133, 890(ab)
Mathisen, G, 827(ab)
Matoba, N, 966(ab)
Matsouka, DT, 1642
Matsuda, H, 877(ab), 967(ab)
Matsudaira, M, 918(ab)
Matsumori, A, 1501
Matsumoto, K, 413, 545
Matsumoto, M, 940(ab), 969(ab), 1014(ab), 1015(ab)
Matsunaga, T, 1015(ab)
Matsuoka, DT, 763
Matsushita, R, 998(ab)
Mattera, J, 855(ab), 927(ab)
Mattera, JA, 874(ab)
Matteucci, F, 1020(ab)
Matthay, KK, 918(ab)
Matthews, D, 863(ab), 941(ab), 960(ab)
Matthews, KJ, 863(ab)
Mattis, JA, 144
Matzku, S, 1366
Maurea, S, 833(ab), 905(ab), 915(ab), 918(ab)
Maurelli, L, 918(ab)
Maurer, A, 952(ab)
Maurer, AH, 710, 467(le), 832(ab), 964(ab)
Maurer, M, 880(ab)
Mausner, LF, 305, 899(ab), 900(ab), 942(ab), 980(ab), 985(ab), 1030(ab)
Maxon, HR, 1132, 894(ab), 898(ab), 937(ab), 978(ab), 1048(ab)
Mayaud, Ch, 81
Mayberg, HS, 18N(6)
Mayeur, S, 832(ab)
Maynard, C, 939(ab)
Mazière, B, 696, 1481, 973(ab), 977(ab), 1019(ab)
Mazière, M, 883(ab), 973(ab)
Mazzeo, S, 954(ab)
Mazziota, JC, 867(ab)
Mazziotta, JC, 1472, 922(ab), 1010(ab)
McAfee, JG, 889(ab), 1428(le)
McAteer, E, 872(ab)
McBride, BJ, 1836
McCabe, R, 1031(ab)
McCall, MJ, 2006, 880(ab), 1031(ab)
McCallum, RW, 833(ab)
McCandless, BK, 59, 1566, 1023(ab)
McCarthy, G, 961(ab)
McCartney, WH, 831(ab), 842(ab)
McClanahan, TB, 1346
McCord, ME, 1209, 2226
McDermott, K, 904(ab)
McDermott, MP, 1044(ab)
McDevitt, GR, Jr, 2052
McDevitt, MR, 851(ab), 986(ab)
McDevitt, R, 898(ab), 978(ab)
McDonald, KL, 1040(ab)
McEntee, MC, 1542
McEwan, AJ, 841(ab)
McGee, S, 926(ab)
McIlvain, HB, 899(ab)
McIntyre, R, 1028(ab)
McIntyre, WJ, 1041(ab)
McKay, WJ, 877(ab), 930(ab)
McKeever, PE, 735
McKusick, KA, 915(ab), 1254(le)
McLaughlin, AF, 438
McLean, RG, 2059(le)
McLellan, CA, 1383, 945(ab)
McMahan, CA, 1496
McMahon, M, 874(ab), 927(ab)
McMillin, CH, 1046(ab)
McMurry, TJ, 1031(ab)
McNamara, D, 951(ab)
McPartlin, M, 850(ab)
McPherson, DW, 1023(ab), 1028(ab)
McShan, Dl, 735
McSherry, B, 1783
McTigue, M, 2006, 880(ab), 931(ab)
Meares, CE, 2006
Meares, CF, 1685, 880(ab), 942(ab), 1030(ab), 1031(ab)
Mease, RC, 900(ab), 942(ab), 943(ab), 985(ab), 1030(ab)
Medina, LS, 835(ab)
Medrano, R, 905(ab), 916(ab)
Meeder, JG, 870(ab)
Meeuwisse, E, 955(ab)
Megibow, A, 960(ab)
Mehta, BM, 1373
Mehta, VD, 974(ab)
Meignan, M, 81, 919(ab)
Meikle, S, 879(ab)
Meikle, SR, 862(ab), 901(ab), 1045(ab)
Meindl, J, 859(ab)
Meindok, H, 1548
Meinken, GE, 900(ab), 942(ab), 985(ab), 1028(ab), 1030(ab)
Mekkawy, MA, 526
Melega, WP, 1472
Melero, M, 999(ab)
Melin, J, 825(ab)
Melin, JA, 837(ab), 875(ab), 884(ab), 905(ab)
Melis, K, 1021(ab)
Melman, A, 1723
Melon, P, 826(ab)
Melon, PG, 865(ab), 994(ab)
Meltzer, L, 992(ab)
Meltzer, PC, 946(ab)
Mena, I, 835(ab), 838(ab), 839(ab), 846(ab), 876(ab)
Mendelson, J, 1312, 887(ab)
Meneguetti, JC, 995(ab)
Merchant, EB, 14
Meredith, RF, 23, 1648
Merhige, ME, 1040(ab)
Merino, MJ, 1848
Merlet, P, 471, 896(ab)
Merli, G, 999(ab)
Merola, TF, 304
Merrick, MV, 872(ab)
Mertens, H, 102
Mertens, WC, 1437
Messa, C, 339, 945(ab)
Messian, O, 835(ab)
Messinger, DE, 876(ab), 951(ab)
Mestais, C, 1003(ab)
Mester, J, 458
Metherall, JA, 905(ab)
Metz, CE, 451
Metz, JT, 1011(ab), 1018(ab), 1019(ab)
Meuli, R, 956(ab)
Meyer, E, 909(ab)
Meyer, K, 851(ab), 1032(ab)
Meyer, MA, 887(ab), 894(ab)
Meyerrose, GE, 849(ab)
Meyne, NG, 895(ab)
Mezianne, MA, 1048(ab)
Michel, C, 837(ab), 884(ab)
Michelson, RH, 890(ab)
Michigishi, T, 2024, 1020(ab)
Mičinski, M, 587
Middleton, ML, 985(ab)
Mielke, R, 940(ab)
Migneco, O, 1846, 839(ab)
Mikata, A, 324
Miki, H, 969(ab)
Milan, E, 846(ab)
Milius, R, 945(ab)
Milko, D, 996(ab)
Millard, RW, 993(ab)
Miller, B, 838(ab), 839(ab)
Miller, EG, 961(ab)
Miller, FJ, Jr, 260
Miller, J, 1016(ab)
Miller, JH, 930(ab)
Miller, K, 900(ab), 1025(ab)
Miller, MI, 964(ab)
Miller, RF, 903(ab)
Miller, TR, 1678, 1710, 964(ab)
Millet, P, 1011(ab)
Mills, BJA, 398, 1556
Mills, SL, 981(ab), 982(ab)
Milot, A, 1034(ab)
Min, YI, 919(ab)
Minami, C, 835(ab)
Minoshima, S, 1579, 858(ab), 929(ab), 1003(ab), 1007(ab), 1008(ab), 1009(ab)
Mintun, MA, 684, 1579, 1007(ab), 1009(ab)
Miraldi, F, 41
Mirelli, M, 2040
Mirick, GE, 941(ab)
Miron, SD, 1044(ab)
Mirzadeh, S, 1024(ab)
Mita, A, 954(ab)
Mitchell, DS, 973(ab)
Miura, S, 827(ab), 1008(ab)
Miyamae, T, 932(ab)
Miyamoto, C, 1002(ab)
Miyaoka, RS, 1429(le)
Miyatake, S, 893(ab)
Miyauchi, T, 967(ab)
Miyazaki, S, 853(ab)
Mizrachi, H, 912(ab)
Mizukami, Y, 2024
Møller, JT, 251
Mochizuki, T, 1851, 919(ab), 976(ab), 997(ab)
Modell, JG, 826(ab)
Modorati, G, 959(ab)
Mody, F, 856(ab)
Moerlein, SM, 848(ab), 883(ab)
Mohamed, FB, 973(ab)
Molea, N, 845(ab), 1020(ab)
Molina-Murphy, IL, 1558
Molinoff, PB, 982(ab)
Möller, H-J, 972(ab)
Molthoff, CF, 2000
Momose, T, 827(ab), 857(ab), 968(ab), 969(ab), 1006(ab), 1009(ab)
Mone, SM, 930(ab)
Monetti, N, 2040
Monsein, LH, 968(ab)
Moon, DH, 919(ab), 936(ab), 991(ab)
Moon, S, 869(ab), 926(ab)
Moore, D, 974(ab)
Moore, JA, 467(le)

Moore, JG, 833(ab)
Moore, M, 2059(le)
Moore, RH, 948(ab), 998(ab)
Moore, SC, 962(ab), 1004(ab)
Moore, WH, 889(ab), 938(ab)
Morabito, MD, 1002(ab)
Morais, J, 1550
Mordenti, J, 924(ab)
Moresco, RM, 944(ab)
Morgan, HT, 892(ab), 901(ab), 962(ab)
Morgan, MG, 928(ab)
Morgenthaler, JJ, 231
Morguet, AJ, 223
Moriarty, JM, 1758
Morisco, C, 905(ab)
Morishima, S, 1501
Morita, R, 998(ab)
Moriwaki, H, 940(ab), 969(ab), 1014(ab), 1015(ab)
Morozumi, T, 952(ab), 963(ab)
Morrell, NW, 676
Morris, G, 904(ab)
Morris, HH, 928(ab)
Morris, JG, 438
Morris, KDW, N30(9), N15(3), N14(12)
Morrisey, MA, 2249(le)
Morrison, D, 1012(ab)
Morrison, SL, 985(ab)
Morrissey, MA, 498
Mortelmans, L, 933(ab), 937(ab)
Mortensen, T, 992(ab)
Morton, KA, 260, 833(ab), 1003(ab)
Moscatelli, G, 863(ab), 915(ab)
Moser, EA, 1399
Moser, L, 937(ab)
Moses, WW, 862(ab)
Mossberg, KA, 1523
Motomura, N, 1200
Moulton, JS, 937(ab)
Mountz, JM, 826(ab)
Moyes, J, 1121
Moyse, D, 471, 896(ab)
Mozley, D, 870(ab), 871(ab), 897(ab), 898(ab)
Mozley, PD, 954(ab)
Muehllehner, G, 861(ab), 1430(le)
Mueller, SP, 962(ab)
Mueller-Lissner, SA, 1291, 832(ab)
Mufraggi, N, 403, 2060(le)
Mui, F, 1949
Muirhead, KA, 899(ab), 921(ab)
Mukherjee, J, 829(ab), 982(ab)
Mulder, RU, 833(ab)
Müler-Gärtner, HW, 929(ab)
Mulholland, GK, 423, 882(ab), 982(ab), 984(ab)
Mullan, BP, 840(ab)
Muller, D, 826(ab)
Müller, L, 931(ab)
Müller, P, 836(ab), 856(ab), 865(ab)
Müller-Gärtner, HW, 872(ab), 922(ab)
Müller-Schauenburg, W, 956(ab)
Mumper, RJ, 398
Munaka, M, 911(ab), 963(ab)
Munoz, L, 994(ab)
Munson, PR, 988(ab)
Munz, DL, 223, 845(ab), 950(ab), 957(ab)
Murakami, M, 827(ab), 911(ab), 963(ab), 1008(ab)
Muraki, A, 867(ab)
Muramatsu, T, 932(ab)
Muramori, A, 441
Murase, K, 135, 909(ab), 912(ab), 919(ab), 969(ab), 972(ab), 976(ab), 1004(ab)
Murphey, MM, 1039(ab)
Murphy, B, 1040(ab)
Murphy, PH, 889(ab), 938(ab), N38(9), N32(12)
Murray, CL, 1623
Murray, G, 1269
Murray, JL, 941(ab), 1001(ab)
Murthy, S, 863(ab), 904(ab)
Mut, F, 1949
Muzi, M, 944(ab)
Muzic, RF, 885(ab)
Muzik, O, 684, 826(ab), 865(ab), 882(ab)
Muzinic, M, 969(ab)
Myers, MJ, 173

Na, HW, 936(ab)
Naber, AHJ, 920(ab)
Nadel, DM, 1013(ab)
Nagamachi, S, 971(ab)
Nagashima, J, 998(ab)
Nagata, K, 1696
Nagazumi, A, 1016(ab)
Nagel, AA, 830(ab)
Nagel, J, 1459, 998(ab)
Nagel, JS, 704, 2209
Nagle, KR, 850(ab)
Någren, K, 691
Nair, N, 914(ab)
Nair, S, 2017
Nakabeppu, Y, 996(ab)
Nakagawa, I, 1033(ab)
Nakagawa, T, 1741
Nakagawara, J, 1017(ab)
Nakahashi, H, 413
Nakai, T, 853(ab), 893(ab), 1001(ab)
Nakajima, K, 441, 1200, 918(ab)
Nakajo, M, 996(ab)
Nakaki, M, 935(ab), 936(ab)
Nakamura, J, 1017(ab)
Nakamura, K, 934(ab)
Nakamura, M, 1851
Nakamura, O, 844(ab), 966(ab)
Nakamura, S, 893(ab), 933(ab), 972(ab)
Nakane, K, 1741, 965(ab)
Nakano, K, 958(ab)
Nakano, S, 208
Nakata, S, 972(ab)
Nakata, Y, 1023(ab)
Nakatani, N, 920(ab)
Nakatsuka, I, 848(ab)
Nakayama, M, 988(ab), 1029(ab), 1033(ab)
Naldöken, S, 1027(ab)
Namba, Y, 893(ab)
Nanba, R, 1023(ab)
Nappi, A, 905(ab), 915(ab)
Narabayashi, I, 1023(ab)
Narahara, K, 876(ab)
Narahara, KA, 846(ab)
Nariai, T, 413
Narra, RK, 88, 1152, 865(ab), 993(ab)
Narra, VR, 277, 2196
Naruki, Y, 920(ab)
Narula, J, 845(ab), 915(ab), 934(ab), 936(ab), 943(ab), 959(ab)
Nash, R, 924(ab)
Natale, A, 958(ab)
Natale, D, 855(ab)
Natarajan, TK, 968(ab)
Nathan, M, 949(ab)
Nathan, MA, 1011(ab), 1012(ab), 1018(ab)
Nattel, S, 951(ab)
Navia, B, 1312, 887(ab)
Nawaz, K, 978(ab)
Nebandahl, K, 223
Nebeling, B, 1013(ab)
Nebendahl, K, 845(ab)
Nedelman, M, 978(ab)
Nedelman, MA, 144
Neer, RM, 170
Negrin, JA, 898(ab)
Neiman, J, 1016(ab)
Nellis, SN, 1864
Nelp, W, 941(ab), 960(ab)
Nelp, WB, 863(ab), 864(ab), 924(ab), 987(ab), 1005(ab)
Nelson, AD, 41, 885(ab)
Nemetz, ST, 468(le)
Netten, PM, 1330, 950(ab)
Netto, ICV, 1035(ab)
Neumann, DA, 1048(ab)
Neumann, DR, 131, 952(ab), 1040(ab), 1041(ab)
Neumann, PH, 1566, 1023(ab)
Neumann, RD, 833(ab), 852(ab), 889(ab), 893(ab), 957(ab), 986(ab), 1001(ab)
Neumeyer, JL, 945(ab), 964(ab)
Newberg, A, 857(ab), 940(ab), 965(ab)
Newell, DW, 1789
Newman, JS, 256
Newton, MR, 930(ab)
Ney, DR, 1042(ab)
Nguyen, BA, 263
Nguyen, D, 1011(ab)
Nguyen, N, 1346, 865(ab), 994(ab)
Ngyen, A, 865(ab)
Nichols, DC, N30(9), N14(12)
Nichols, K, 928(ab)
Nicholson, RL, 1875
Nickerson, JP, 975(ab)
Nickerson, R, 950(ab)
Nickles, RJ, 850(ab), 884(ab), 931(ab), 1014(ab)
Nicol, PD, 895(ab)
Nicolai, E, 905(ab), 915(ab)
Niedzwiecki, D, 345
Nielsen. SL, 251
Nieman, L, 834(ab)
Niemeyer, MG, 1727
Niesen, A, 904(ab), 912(ab)
Niio, Y, 998(ab)
Nijran, KS, 676
Nikpoor, N, 643
Nimmon, CC, 924(ab)
Nishigori, H, 1025(ab)
Nishihara, M, 1015(ab)
Nishikawa, J, 857(ab), 875(ab), 968(ab), 1006(ab), 1009(ab)
Nishimura, K, 932(ab)
Nishimura, S, 1600
Nishimura, T, 272, 365, 1014, 853(ab), 875(ab), 940(ab), 952(ab), 969(ab), 997(ab), 1015(ab)
Nishiyama, H, 1047(ab)
Nishizaki, Y, 963(ab)
Nishizawa, S, 966(ab)
Nisikawa, J, 827(ab)
Nitzsche, EU, 1399, 828(ab), 865(ab)
Noca, A, 1003(ab)
Nodel, D, 858(ab)
Noël, P, 485
Noguchi, M, 2024
Nohara, R, 659, 856(ab), 884(ab), 885(ab), 886(ab), 953(ab)
Northover, JMA, 904(ab)
Norton, JA, 1848
Nosco, DL, 551, 850(ab), 1033(ab)
Noska, MA, 1357, 958(ab)
Nossiff, ND, 934(ab), 936(ab)
Notghi, A, 872(ab)
Noujaim, AA, 853(ab), 904(ab)
Nourigat, C, 987(ab)
Novak-Hofer, I, 231
Novell, JR, 1020(ab)
Novotney, AC, 1542
Nowak, D, 831(ab)
Nowak, PA, 829(ab), 985(ab)
Nowotnik, DP, 920(ab)
Noz, ME, 912(ab), 926(ab), 960(ab)
Nozaki, T, 1025(ab)
Nunn, AD, 88, 94, 1152, 850(ab), 865(ab), 920(ab), 993(ab)
Nutin, C, 977(ab)
Nuutila, P, 1255
Nuyts, J, 933(ab), 937(ab)

Oates, E, 256, 905(ab), 1041(ab)
Oberdorfer, F, 1982, 828(ab), 1019(ab)
O'Brien, CP, 898(ab)
O'Brien, JP, 1396
O'Carroll, RE, 1623
Ochi, H, 744
O'Connell, JW, 1444, 910(ab), 935(ab)
O'Connor, MK, 239, 1146, 1613, 1006(ab)
Oda, K, 1016(ab)
Odana, I, 1015(ab)
O'Dell, M, 859(ab)
O'Doherty, MJ, 313
O'Donnell, SM, 934(ab), 936(ab), 959(ab)
Odze, R, 960(ab)
Oei, HY, 652, 894(ab), 903(ab), 907(ab), 914(ab), 990(ab)
Oertel, WH, 897(ab), 917(ab)
Offord, RE, 1766
Ogata, Y, 841(ab)
Ogawa, K, 963(ab)
Ogawa, M, 1637
Ogawa, T, 1696
Ogilby, D, 866(ab), 916(ab), 952(ab)
Ogilby, JD, 2086
O'Grady, LF, 862(ab)
Ohashi, K, 1692
Ohnishi, T, 971(ab)
Ohno, T, 918(ab)
Ohta, S, 969(ab)
Ohta, Y, 958(ab)
Ohtake, T, 875(ab), 1006(ab), 1009(ab)
Ohtani, H, 1000(ab)
Ohyama, M, 1016(ab)
Ohyama, Y, 988(ab), 1033(ab)
Oja, P, 1137
Okada, J, 324
Okarvi, S, 1032(ab)
Okazaki, Y, 940(ab), 969(ab), 1014(ab), 1015(ab)
Okazumi, S, 333
O'Keefe, JH, 951(ab)
Oku, N, 940(ab), 969(ab), 1014(ab), 1015(ab)
Oku, S, 1006(ab), 1009(ab)
Okudera, T, 1696
Okumura, A, 969(ab), 972(ab)
Old, LJ, 913(ab)
Oldfield, E, 834(ab)
Olea, E, 998(ab)
Oliveira, MC, 1949
Olivier, P, 906(ab)
Olsen, L, 1016(ab)
Ono, M, 1741
Ono, S, 856(ab), 953(ab)
Ono, Y, 994(ab)
Onsal, I, 1027(ab)
Oosterhuis, WP, 1727
Oosterwijk, E, 913(ab)
Oosterwijk, J, 913(ab)
Opie, LH, 1353
Oratz, R, 912(ab)
Orellana, P, 998(ab)
Oriuch, N, 1181
Orr, RA, 23
Orringer, M, 828(ab)
Orsolon, PG, 895(ab)
Ortega, JC, 990(ab)
Ortiz, M, 999(ab)
Ortiz, V, 998(ab)
Orton, M, 2090
Osaka, G, 934(ab)
Ossenkoppele, GJ, 858(ab), 927(ab)
Oster, ZH, 1028(ab)
Ostertag, H, 828(ab)
Ostertag, HJ, 1007(ab), 1045(ab)

O'Sullivan, F, 944(ab), 1009(ab)
Othmer, P, 1046(ab)
Otsuka, M, 877(ab), 945(ab), 1015(ab)
Otsuka, S, 920(ab)
Ott, RJ, 2154
Otto, CA, 423
O'Tuama, LA, 1758, 2098, 838(ab), 844(ab), 930(ab)
Ouchi, Y, 1637
Overbeck, B, 526, 839(ab), 972(ab)
Owens, ES, 852(ab)
Owunwanne, A, 978(ab)
Oyen, WJG, 388, 1330, 903(ab), 920(ab), 936(ab), 950(ab), 1031(ab)
Ozaki, M, 333
Ozawa, Y, 951(ab)
Ozgüven, M, 866(ab)
Özkilic, H, 1722
Öztürk, E, 866(ab)

Paans, AMJ, 373, 870(ab)
Pabst, HW, 854(ab), 859(ab)
Pace, L, 68, 505, 905(ab), 915(ab)
Padhy, AK, 904(ab), 924(ab)
Padilla, ML, 1175
Paganelli, G, 834(ab), 925(ab), 959(ab)
Page, RL, 1542
Pai, LH, 842(ab)
Paik, CH, 842(ab), 889(ab), 957(ab), 986(ab), 1001(ab)
Pak, KY, 144
Palenker, J, 971(ab)
Palestro, CJ, 1175, 2027, 969(ab), 999(ab), 1031(ab), 1039(ab)
Palevsky, HI, 751, 2036, 849(ab)
Palko, D, 1040(ab)
Palmer, CK, 1042(ab), 1043(ab)
Paltiel, HJ, 351, 1048(ab)
Pan, X, 962(ab)
Pandian, N, 905(ab)
Pang, L, 865(ab)
Pant, KD, 1530
Papadopoulos, SM, 1836
Papapoulos, SE, 1406
Pappas, A, 978(ab)
Parekh, JS, 971(ab)
Parisi, MT, 115, 918(ab)
Park, CH, 1183, 1943, 961(ab)
Park, H, 956(ab)
Park, JH, 2118
Park, JS, 991(ab)
Park, SK, 991(ab)
Parker, A, 930(ab)
Parker, GE, Jr, 1390
Parker, JA, 849(ab), 947(ab), 1003(ab)
Parkes, SL, 1029(ab)
Parkey, RW, 990(ab), 1003(ab), 1010(ab)
Parkinson, D, 848(ab), 883(ab)
Parmentier, C, 1020(ab)
Parodi, O, 1925
Parrot, A, 81
Parsons, JA, 1039(ab)
Parsons, SM, 983(ab), 1011(ab)
Pascal, S, 1459
Pasqualini, R, 850(ab), 989(ab), 1034(ab)
Passeri, A, 831(ab)
Pastan, I, 842(ab)
Patch, GG, 260
Pate, BD, 964(ab)
Patel, K, 923(ab)
Patel, NH, 849(ab)
Patel, RB, 914(ab)
Patterson, RE, 865(ab)
Pauli, S, 1011(ab)
Pauwels, EKJ, 1406, 1727
Pauwels, S, 976(ab)
Pavoni, R, 959(ab)
Pawlik, G, 1013(ab)
Pawlowski, J, 852(ab)
Payne, JK, 1919, 2030, 827(ab)
Payne, SE, 990(ab)
Pearlson, G, 847(ab)
Pelagi, M, 834(ab)
Pèlegrin, A, 1766, 903(ab)
Pelizzari, CA, 922(ab), 1005(ab), 1043(ab), 1047(ab)
Pellegrino-Gensey, JL, 1378
Peller, PH, 1039(ab)
Peller, PJ, 968(ab)
Pellevoisin, C, 981(ab)
Pellikka, PA, 2080
Peltier, P, 912(ab)
Penney, BC, 161, 843(ab), 1004(ab)
Pentlow, KS, 2020
Pepping, M, 972(ab)
Perani, D, 973(ab), 1014(ab)
Perdikaris, N, 2059(le)
Pereszlenyiova, E, 982(ab)
Perez, JE, 855(ab), 884(ab)
Periasamy, M, 974(ab)
Periman, SB, 1014(ab)
Perin, M, 1766
Perlmutter, JS, 848(ab), 883(ab)
Perrone-Filardi, P, 881(ab), 938(ab)
Perry, BD, 829(ab)
Perry, DL, 1002(ab)
Perry, JR, 451, 2238, 831(ab), 842(ab), 961(ab)
Pestika, B, 258
Peters, AM, 65, 173, 491, 756, 836(ab), 1022(ab)
Peters, CA, 2098
Peterson, CD, 830(ab), 975(ab), 983(ab)
Peterson, J, 912(ab)
Peterson, LM, 1010(ab)
Petiet, A, 380
Petrella, G, 999(ab)
Petrick, N, 842(ab)
Petry, N, 684
Petry, NA, 423, 1836, 2067, 865(ab)
Pezzullo, L, 892(ab)
Pfeiffer, N, 871(ab), 963(ab)
Phalen, JJ, 975(ab)
Pham, DH, 1548
Pham, H, 846(ab)
Pham, T, 965(ab)
Phaneuf, DC, 1091, 855(ab)
Phelps, M, 825(ab), 856(ab), 865(ab)
Phelps, ME, 339, 595, 613, 633, 945, 1191, 1235, 1472, 1628, 828(ab), 829(ab), 836(ab), 856(ab), 881(ab), 882(ab), 944(ab), 1045(ab)
Phillips, W, 819, 984(ab), 1027(ab)
Phillips, WT, 1496
Philpott, GW, 1685
Picard, D, 1550
Picard, M, 1550, 951(ab)
Piccolo, M, 1478
Pich, S, 223
Piepenburg, R, 887(ab), 1021(ab)
Piepsz, 175
Piepsz, A, 174, 485
Pierfitte, M, 1003(ab)
Pieri, PL, 915(ab)
Piers, DA, 1251(le)
Pierson, R, 549
Pieterman, H, 990(ab)
Pietrzyk, U, 861(ab), 1013(ab)
Piffanelli, A, 850(ab)
Pike, M, 910(ab)
Pilcher, G, 974(ab)
Pileggi, F, 995(ab)
Pinedo, HM, 2000
Pinsky, CM, 863(ab), 904(ab), 1002(ab)
Pipes, D, 1024(ab)
Pippin, CG, 1031(ab)
Piret, L, 73
Pirro, JP, 1152, 865(ab), 993(ab)
Pisani, T, 870(ab)
Pisani, TL, 861(ab)
Piwnica-Worms, D, 1516, 864(ab), 1033(ab)
Plaizier, MABD, 1915(le)
Platt, DA, 876(ab)
Platts, S, 989(ab)
Platts, SH, 979(ab)
Pleus, RC, 861(ab), 1026(ab)
Plott, G, 1648
Plott, WE, 23
Pochon, S, 1766
Podoloff, D, 992(ab)
Podoloff, DA, 828(ab), 858(ab), 992(ab), 1001(ab)
Poels, LG, 1958
Poewe, W, 1018(ab)
Pohl, J, 981(ab)
Pohost, GM, 915(ab)
Pollard, KR, 771, 864(ab), 889(ab), 1005(ab)
Pomier, G, 1550
Ponto, J, 1027(ab)
Poppe, G, 937(ab)
Porenta, G, 1235, 1628, 836(ab), 856(ab), 857(ab), 1009(ab)
Port, SC, 2124, 846(ab)
Portenoy, R, 859(ab)
Porter, AT, 1316, 1437
Porter, B, 863(ab)
Portlock, C, 345
Posniakoff, TA, 1411
Potchen, EJ, 1807
Potts, MS, 998(ab)
Potvin, C, 1801, 894(ab)
Poublon, RML, 894(ab)
Powe, JE, 1316, 1437
Prados, MD, 2133
Prandi, D, 403, 2060(le)
Prat, L, 845(ab)
Prato, FS, 355, 1875
Pratt, JP, 947(ab)
Preslar, J, 1917(le)
Press, O, 941(ab)
Press, OW, 863(ab), 960(ab)
Preston, DF, 1039(ab), 1046(ab)
Pretorius, PH, 888(ab)
Price, DC, 967(ab), 974(ab)
Price, JC, 883(ab), 911(ab)
Prieto, I, 866(ab)
Prigent, F, 1509
Prince, JR, 927(ab)
Prior, J, 1003(ab), 1010(ab)
Prohovnik, I, 940(ab)
Proto, G, 895(ab)
Provenzale, J, 248
Prummel, MF, 894(ab)
Przedborski, S, 868(ab)
Puma, J, 825(ab)
Purdy, PD, 826(ab)
Purnell, G, 978(ab)
Pusey, CD, 491
Puskás, C, 840(ab), 920(ab)
Pütter, D, 1030(ab)
Pyzalski, R, 1014(ab)

Qian, J, 932(ab), 938(ab)
Qian, W, 889(ab)
Quadri, SF, 853(ab)
Quadri, SM, 987(ab)
Quaife, RA, 927(ab)
Queloz, J, 956(ab)
Quesenberry, J, 1024(ab)
Quick, C, 954(ab)
Quinn, RJ, 1029(ab), 1252(le)
Quinones, N, 967(ab), 1017(ab)
Quint, L, 828(ab)
Quintana, C, 998(ab)
Quirce, JM, 955(ab)

Rabito, CA, 948(ab)
Rabushka, LS, 1042(ab)
Rackover, M, 1002(ab)
Radcliffe, R, 988(ab)
Radensky, P, 19N(l)
Raisys, V, 866(ab)
Raja, S, 996(ab), 997(ab)
Raju, N, 920(ab)
Ram, S, 1029(ab)
Ramalingam, K, 920(ab)
Ramanathan, P, 914(ab)
Ramanna, L, 843(ab), 869(ab)
Ramos, J, 957(ab)
Rampal, M, 990(ab)
Ramsay, SC, 438
Rangarajan, A, 963(ab)
Rangarajan, V, 914(ab)
Ransone, C, 2006, 880(ab), 931(ab)
Rao, DV, 277, 2196
Rasey, JS, 2202, 1010(ab)
Rath, P, 859(ab)
Rathe, R, 1043(ab)
Ratib, O, 1628
Ratliff, BA, 1099
Rattner, Z, 878(ab), 911(ab)
Rauh DA, 710
Raval, U, 875(ab)
Ravert, HT, 847(ab), 848(ab), 860(ab), 883(ab), 885(ab), 929(ab), 968(ab)
Ray, S, 924(ab)
Raylman, RR, 1243, 881(ab)
Raynaud, C, 696, 1481, 976(ab), 977(ab), 1019(ab)
Reba, RC, 1225, 883(ab), 889(ab), 996(ab)
Reba, RS, 966(ab)
Redepenning, L, 836(ab)
Reece, C, 161
Reed, BR, 939(ab)
Reed, J, 1366
Reed, NL, 1750
Reekers, JA, 907(ab)
Reese, L, 355, 1875
Rege, S, 828(ab), 829(ab)
Rehncrona, S, 868(ab)
Reiche, W, 886(ab)
Reid, R, 1437
Reijs, AEM, 652
Reilly, RM, 2248(le), 960(ab)
Reilly, SM, 1881
Reiman, RE, 834(ab)
Reinartz, R, 1001(ab)
Reinbold, F, 907(ab)
Reinhardt, CP, 993(ab)
Reinhardt, M, 1981, 1019(ab)
Reiser, M, 914(ab)
Reist, H, 884(ab)
Reither, H, 108
Reitz, R, 1032(ab)
Reivich, M, 857(ab), 929(ab), 940(ab), 965(ab), 985(ab), 1012(ab), 1013(ab)
Remy, Ph., 858(ab)
Renn, O, 880(ab)
Reno, JM, 2184, 880(ab), 1028(ab)
Renstrom, B, 1864
Reubi, JC, 652, 903(ab)
Reuland, P, 309
Revkin, J, 939(ab)
Reyes, P, 961(ab)
Reynolds, JC, 1848, 833(ab), 986(ab)
Rhodes, BA, 1028(ab), 1029(ab), 1031(ab)
Rhodes, CG, 1669
Riambau, V, 845(ab)
Ricard, M, 1006(ab), 1020(ab)
Ricaurte, GA, 964(ab)
Ricciardelli, B, 505
Rice, KC, 981(ab)
Richmond, JC, 1027(ab)
Richmond, JCW, 1008(ab)
Richter, W, 902(ab), 997(ab)
Riddell, C, 843(ab), 888(ab)
Rieker, O, 839(ab), 844(ab), 914(ab)
Riesinger, U, 854(ab)
Rifkin, CK, 896(ab)
Rigo, P, 874(ab), 875(ab)
Riley, R, 964(ab)
Rios, L, 998(ab)
Risler, LJ, 987(ab)
Ritchie, JL, 939(ab)
Riva, N, 863(ab)
Riva, P, 863(ab)

Rivera-Luna, H, 1004(ab)
Rivitz, SM, 470, 1905
Robbins, J, 1848
Roberson, PL, 735, 1833
Roberts, CM, 676
Roberts, R, 1024(ab)
Robertson, JS, 777, 1726
Robeson, W, 923(ab)
Robinson, RG, 1046(ab)
Roca, M, 845(ab)
Rocca, C, 953(ab)
Rockett, J, 1269
Rocque, PA, 1685
Rodney, RA, 1411, 846(ab)
Roessner, J, 841(ab)
Rogers, GA, 1011(ab)
Rogers, KD, 923(ab)
Rogers, WL, 1836, 831(ab), 842(ab), 878(ab), 933(ab)
Rogulski, MM, 851(ab), 1002(ab)
Roh, JK, 877(ab)
Rojas-Burke, J, 13N(6), 17N(6), 24N(5), N19(9), N22(9), N24(9), N34(9), N9(2), N13(4), N13(7), N15(1), N15(7), N16(10), N18(1), N23(11), N25(1), N27(3), N28(8), N35(11), N25(12), N30(12), N31(12)
Rokhsar, S, 856(ab)
Roman, R, 2017, 1049(ab)
Romano, J, 832(ab)
Romoio, G, 846(ab)
Roodt, A, 899(ab)
Rooholamini, SA, 1486
Roos, JC, 1915(le)
Ropchan, JR, 1017(ab)
Roque, C, 1046(ab)
Ros, P, 1043(ab)
Rosa, E, 1373
Rose, A, 1021(ab)
Rose, EA, 1994
Rose, K, 1766
Rosebrough, SF, 880(ab)
Rosen, BR, 867(ab)
Rosen, G, 843(ab), 869(ab)
Rosen, I, 868(ab)
Rosen, T, 830(ab)
Rosenblate, H, 258
Rosenfeld, SS, 532
Rosenkranz, K, 971(ab)
Rosenpire, KC, 1125
Rosenquist, G, 836(ab), 1009(ab), 1045(ab)
Rosenqvist, G, 1191, 856(ab)
Rosenson, AS, 1022(ab)
Rosenspire, KC, 94
Rosenthall, L, 950(ab)
Rossi, MA, 952(ab)
Rossini, P, 846(ab)
Rossleigh, MA, 1022(ab)
Rössler, B, 839(ab)
Rosso, J, 81
Roszell, N, 993(ab)
Roth, CA, 988(ab)
Rothberg, ML, 836(ab)
Rothpearl, A, 1042(ab)
Rothstein, RD, 1707
Rottenberg, DA, 200
Roussel, P, 947(ab)
Rowe, CC, 930(ab)
Royal, HD, 330, 835(ab), 849(ab)
Rozanski, A, 2074, 928(ab)
Rubello, D, 1478
Rubin, RH, 1378, 910(ab), 924(ab)
Rubinstein, M, 1005(ab)
Ruck, P, 309
Ruhrmann, S, 972(ab)
Ruiz, M, 864(ab)
Rumsey, WL, 94, 1152
Ruotsalainen, U, 691, 1255
Rusckowski, 921(ab)
Rusckowski, M, 1810, 925(ab), 934(ab)
Rush, AJ, 838(ab)
Russell, C, 1648
Russell, CD, 23, 1178, 924(ab), 948(ab)
Ruth, TJ, 922(ab), 964(ab)
Ryan, JR, 898(ab), 978(ab)
Ryan, PJ, 1589
Ryo, UY, 398, 1915(le)
Rysavy, J, 829(ab), 975(ab)
Rysavy, JA, 861(ab), 1026(ab)
Ryser, JE, 1766
Ryu, M, 333

Sabbe, J, 827(ab)
Sacker, D, 851(ab)
Sacker, DF, 1028(ab)
Sadato, N, 886(ab), 897(ab), 966(ab)
Sadatoh, N, 1637
Saerens, J, 1013(ab)
Saffer, JR, 879(ab)
Saga, T, 853(ab), 889(ab), 957(ab), 986(ab), 1001(ab)
Sager, LH, 1001(ab)
Saha, GB, 928(ab), 1040(ab), 1041(ab)
Sahajwalla, M, 996(ab)
Saika, Y, 1023(ab)
Sai-Maurel, C, 943(ab)
Saing, H, 899(ab)
Saini, S, 1344
Saito, JM, 1042(ab)
Saito, N, 967(ab)
Saito, S, 951(ab)
Saji, H, 848(ab), 891(ab), 897(ab), 1023(ab), 1024(ab)
Sakahara, H, 853(ab), 893(ab), 905(ab), 1001(ab)
Sakai, S, 1015(ab)
Sakaki, S, 135, 909(ab), 912(ab), 969(ab)
Sakakibara, E, 1741, 965(ab)
Sakowski, R, 878(ab)
Sakurai, Y, 827(ab)
Salako, QA, 982(ab), 1030(ab)
Saleh, MN, 23
Salford, L, 868(ab)
Sallan, SE, 844(ab)
Salmon, Y, 175
Saltzberg, MT, 993(ab)
Salvatore, M, 68, 505, 892(ab), 905(ab), 915(ab), 918(ab), 999(ab)
Samaratunga, R, 937(ab)
Samaratunga, RC, 783
Sambuceti, G, 1925
Sampathkumaran, KS, 855(ab)
Sampathkumaran, R, 912(ab)
Samson, Y, 1481, 858(ab), 1019(ab)
Sanchez, J, 2014
Sanchez, JA, 1994
Sanchez-Urdazpal, L, 239
Sander, B, 971(ab)
Sanderson, JA, 880(ab)
Sandler, ED, 115, 918(ab)
Sandler, MP, 826(ab)
Sandrock, D, 845(ab), 950(ab), 957(ab)
Sands, H, 29
Sanger, J, 912(ab)
Sanger, JJ, 926(ab), 960(ab)
Sano, I, 968(ab)
San Roman, F, 403
Santini, L, 892(ab)
Santos, O, 1530
Santos-Ocampo, C, 951(ab)
Sarangarajan, R, 2190
Saraste, M, 1255
Sarkar, S, 1035(ab)
Sarkar, SD, 1551
Sarkar, SS, 117
Sasaki, H, 857(ab)
Sasaki, M, 877(ab), 1015(ab)
Sasaki, T, 1016(ab), 1017(ab), 1025(ab)
Sasaki, W, 945(ab)
Sasaki, Y, 827(ab), 857(ab), 875(ab), 968(ab), 1006(ab)
Sasner, JJ, 998(ab)
Sassaman, MB, 981(ab)
Sastry, KSR, 2196
Satake, R, 2024
Satin, A, 181
Satlin, A, 1432(le)
Sato, J, 893(ab), 957(ab)
Sato, K, 1017(ab)
Sato, S, 958(ab)
Sato, T, 841(ab)
Satyamurthy, N, 633
Sauter, MK, 970(ab)
Savi, A, 924(ab)
Sawamura, H, 988(ab)
Sayman, HB, 629(le)
Schaab, K, 899(ab)
Schad, N, 1269
Schäfers, M, 915(ab)
Schaible, T, 848(ab)
Schaible, TF, 978(ab)
Schalekamp, MADH, 990(ab)
Schapiro, M, 2103
Scharf, S, 992(ab)
Scharff, MD, 985(ab)
Scheffel, U, 860(ab), 883(ab), 885(ab), 964(ab)
Scheinberg, DA, 941(ab)
Scheipers, C, 1191
Schelbert, H, 825(ab), 856(ab), 865(ab), 882(ab), 1009(ab)
Schelbert, HR, 1235, 1263, 1628, 836(ab), 856(ab), 857(ab), 881(ab), 945(ab), 977(ab)
Schelosky, L, 1018(ab)
Schelstaete, KHG, 1167
Schembri, GP, 840(ab)
Scher, H, 859(ab)
Scherrer, M, 81
Schiepers, C, 633, 827(ab), 933(ab), 937(ab)
Schiff, RG, 914(ab), 1042(ab)
Schifter, T, 838(ab), 966(ab), 1047(ab)
Schlegel, S, 887(ab)
Schleicher, W, 950(ab)
Schlom, J, 23, 1648
Schlumberger, M, 172
Schlyer, D, 995(ab)
Schmarkey, LS, 865(ab)
Schmidt, DE, 847(ab)
Schmidt, DH, 2124
Schmidt, K, 944(ab)
Schneider, J, 956(ab)
Schneider, RF, 1428(le)
Schnobrich, KE, 904(ab)
Schnur, W, 1
Schnyder, P, 956(ab)
Schober, O, 840(ab), 915(ab), 920(ab), 1428(le)
Schochat, D, 23
Schofer, O, 1021(ab)
Schold, SC, 532, 966(ab)
Schörner, W, 971(ab)
Schrader, J, 2138
Schroder, LE, 937(ab)
Schroettle W, 1291
Schroff, RW, 1099
Schubiger, PA, 231
Schuhmacher, J, 1366
Schulmberger, M, 1020(ab)
Schultz, B, 2027
Schulzer, M, 964(ab)
Schumpelick, V, 1001(ab)
Schuster, DP, 1661
Schuster, JM, 958(ab)
Schwaiger, M, 684, 1125, 1346, 2067, 826(ab), 834(ab), 865(ab), 870(ab), 882(ab), 933(ab), 994(ab), 1008(ab)
Schwartz, D, 910(ab)
Schwartz, DA, 710
Schwartz, JG, 1496
Schwartz, RB, 839(ab), 970(ab)
Schwartz, RS, 845(ab)
Schwarz, J, 897(ab), 917(ab)
Schwarz, SW, 1685
Schwarzer, A, 868(ab)
Schweighardt, S, 14, 959(ab)
Schwimmer, JJ, 926(ab)
Schwizer, W, 956(ab)
Schyler, D, 521
Sciuk, J, 840(ab), 920(ab), 1428(le)
Sclafani, S, 117
Scott, A, 867(ab)
Scott, AM, 1396, 868(ab), 904(ab)
Scott, JA, 407, 470, 820, 1918, 2061, 2249, 2250, 1254(le)
Scott, JR, 841(ab)
Scott, RM, 844(ab)
Seabold, JE, 1486
Sedvall, G, 860(ab), 1016(ab)
Seed, WA, 676
Seeger, LL, 1399, 1039(ab)
Seftel, AD, 46
Segall, GM, 1797, 629(le)
Segers, MFG, 1958
Sehgal, VJ, 895(ab)
Seibyl, JP, 1964, 896(ab), 911(ab)
Seiler, CA, 1099
Seki, C, 885(ab), 968(ab)
Seldin, DW, 1411, 1994
Selikson, MH, 954(ab)
Selin, CE, 1045(ab)
Sen, C, 969(ab)
Senda, M, 1016(ab), 1025(ab)
Senekowitsch, R, 859(ab)
Senneff, MJ, 836(ab), 1426(le)
Senoh, M, 1017(ab)
Seo, S, 857(ab)
Serafini, A, 1016(ab), 1022(ab), 1035(ab)
Serafini, AN, 1304, 921(ab), 956(ab), 980(ab), 1045(ab)
Serra, R, 994(ab)
Serrano, J, 955(ab)
Setaro, JF, 906(ab)
Setoain, J, 403
Seymour, J, 1043(ab)
Sfakianakis, G, 1022(ab)
Sfakianakis, GN, 1304, 921(ab), 956(ab), 980(ab), 1016(ab), 1035(ab), 1045(ab)
Sgouros, G, 2167, 941(ab)
Shah, A, 977(ab)
Shalaby, K, 934(ab)
Shani, J, 1031(ab)
Shanker, R, 977(ab)
Shao, L, 870(ab), 963(ab), 985(ab)
Shapiro, B, 1125, 1608, 1735, 834(ab), 895(ab)
Sharkey, RM, 863(ab), 904(ab), 958(ab), 1000(ab), 1002(ab)
Shattuc, S, 866(ab)
Shaw, R, 161
Shaw, SM, 1049(ab)
Shaya, E, 847(ab), 848(ab)
Shaya, EK, 964(ab)
Shea, C, 830(ab), 853(ab)
Shea, NL, 905(ab)
Sheehan, FH, 763, 1642
Shefer, RE, 932(ab)
Shelton, ME, 836(ab)
Shen, LH, 986(ab)
Shen, S, 926(ab)
Shepard, HM, 934(ab)
Sheperd, JH, 904(ab)
Sherman, P, 870(ab)
Sherman, PS, 423, 861(ab)
Sherman, T, 856(ab)
Sherwood, DF, 359
Shi, QX, 993(ab)
Shibasaki, H, 897(ab)
Shibata, N, 208
Shidara, N, 844(ab), 966(ab)
Shieh, CB, 1022(ab)
Shields, AF, 581, 1009(ab)
Shields, AT, 115, 967(ab)
Shields, S, 847(ab), 876(ab)
Shigesawa, T, 919(ab), 976(ab)
Shigeta, A, 958(ab)
Shih, W-J, 1556, 991(ab), 1046(ab)
Shimizu, M, 1023(ab)
Shimosegawa, E, 1696, 827(ab)
Shinotoh, H, 917(ab)
Shiomi, S, 744
Shirato, M, 853(ab), 893(ab)
Shiue, CY, 861(ab), 975(ab), 1026(ab)
Shiue, GG, 861(ab), 1026(ab)

Shochat, D, 1648
Shoemaker, RL, 851(ab)
Shortkroff, S, 937(ab)
Shoup, TM, 946(ab), 1026(ab)
Shreve, PD, 860(ab)
Shuke, N, 1200, 2024, 877(ab), 957(ab), 1020(ab)
Shulkin, BL, 1125, 1735
Siccardi, AG, 834(ab)
Siegel, A, 269
Siegel, BA, 855(ab)
Siegel, J, 904(ab)
Siegel, JA, 1574
Siegel, ME, 844(ab), 937(ab)
Sievanen, H, 1137
Silagan, GT, 1509, 854(ab), 876(ab)
Silberstein, EB, 1, 2190, 1025(ab)
Silberzweig, J, 973(ab)
Silbiger, M, 161
Siles, S, 990(ab)
Silveira, ST, 826(ab)
Silverman, C, 1780
Silverman, CL, 964(ab)
Silverstein, EA, 946(ab)
Silzofski, WJ, 2017
Simanis, JP, 864(ab)
Simmons, G, 1046(ab)
Simons, ME, 1548
Simpson, N, 938(ab)
Sinclair, I, 924(ab)
Singer, H, 848(ab)
Singh, A, 435, 1451
Singh, J, 469(le)
Singh, M, 974(ab)
Singh, PR, 851(ab), 910(ab), 9387(ab), 1032(ab), 1048(ab)
Singletary, S, 828(ab)
Sinusas, A, 874(ab), 927(ab)
Sinusas, AJ, 855(ab), 993(ab)
Sisson, JC, 1125, 894(ab), 1021(ab)
Sitbon, R, 973(ab)
Sitomer, J, 1008(ab)
Sjöholm, H, 868(ab)
Skagen, K, 251
Skamel, HJ, 906(ab)
Skaug, I, 912(ab)
Sketch, M, 825(ab)
Sledge, CB, 937(ab)
Sleiman, C, 835(ab)
Slichter, SJ, 924(ab)
Slinkin, MA, 943(ab)
Slizofski, WJ, 2017, 835(ab), 1049(ab)
Slowikowski, J, 928(ab)
Smart, RC, 2059(le)
Smekal, AV, 914(ah)
Smekal, Av, 995(ab)
Smith, AM, 878(ab)
Smith, AP, 852(ab)
Smith, CA, 1049(ab)
Smith, E, 896(ab)
Smith, EO, 1964, 848(ab), 911(ab), 945(ab)
Smith, G, 847(ab)
Smith, GT, 172, 885(ab), 923(ab), 983(ab)
Smith, H, 1132, 894(ab)
Smith, RH, 1042(ab)
Smith, RJ, 861(ab), 862(ab), 1013(ab)
Smith, RL, 512
Smith, WH, 668, 864(ab)
Snelling, LK, 1004(ab)
Snider, RM, 860(ab)
Snitcowski, R, 995(ab)
Snook, D, 1022(ab)
Snow, BJ, 922(ab), 964(ab)
Snyder, DL, 964(ab)
Soares, J Jr, 995(ab)
Sobel, BE, 836(ab), 855(ab)
Sobus, KS, 873(ab)
Sokoloff, L, 944(ab)
Solanki, K, 924(ab)
Som, P, 1028(ab)
Song, JH, 991(ab)
Song, S-K, 925(ab)
Songini, C, 834(ab), 959(ab)
Soobramoney, S, 904(ab)
Sood, VK, 986(ab)
Sorandes, T, 966(ab), 970(ab)
Soroa, VE, 999(ab)
Sorrentino, S, 68
Sossi, V, 922(ab)
Sostre, S, 1216, 869(ab), 924(ab), 968(ab), 1004(ab)
Soto, R, 1035(ab)
Souder, E, 857(ab), 858(ab), 940(ab), 965(ab)
Soufer, R, 886(ab)
Southee, AE, 1594
Southern, JF, 1558
Spaulding, MB, 14
Specker, B, 898(ab), 978(ab)
Speelman, JD, 917(ab), 1016(ab)
Spence, A, 944(ab)
Spence, AM, 581
Spencer, RP, 1701, 999(ab), 1251(le)
Sperling, M, 930(ab)
Sperling, RA, 704
Spetsieris, P, 923(ab)
Speyer, J, 912(ab)
Spicer, K, 888(ab)
Spiegelhoff, D, 839(ab)
Spiegler, EJ, 1216
Spies, SM, 946(ab)
Spies, WG, 946(ab)
Spinelli, A, 915(ab)
Spitzer, AR, 1943
Sridhara, BS, 875(ab), 938(ab)
Srinivasan, A, 880(ab)
Srivastava, PC, 980(ab)
Srivastava, SC, 305, 307, 989, 899(ab), 900(ab), 942(ab), 943(ab), 980(ab), 985(ab), 1030(ab)
Staab, EV, 1042(ab), 1043(ab)
Stabin, M, 33
Stabin, MG, 783
Stack, R, 825(ab)
Stafford, KA, 2067
Stanus, E, 868(ab)
Starren, JB, 1042(ab)
Staudenherz, A, 1028(ab)
Stecker, MM, 929(ab)
Steelhammer, LC, 1001(ab)
Steinert, H, 887(ab)
Steinling, M, 1431(le)
Stella, A, 2040
Stephens, TS, 923(ab)
Steplewski, Z, 900(ab), 942(ab), 985(ab), 1002(ab), 1030(ab)
Stepniak-Biniakiewicz, D, 924(ab), 988(ab)
Stern, H, 960(ab)
Stern, R, 898(ab)
Stern, S, 2061
Stern, Y, 940(ab)
Stevick, CD, 1797
Stewart, CA, 844(ab)
St. Gibson, W, 2080
Stöcklin, G, 2138, 1013(ab)
Stocks, G, 865(ab)
Stoffer, SS, 1393
Stone, CK, 850(ab), 884(ab), 931(ab)
Stone-Elander, S, 908(ab), 1011(ab)
Stone-Elander, SA, 1026(ab)
Storb, R, 924(ab)
Storey, AE, 850(ab)
Stoub, EW, 1430(le)
Stowers, SA, 847(ab), 876(ab)
Strand, S-E, 1654, 1825, 953(ab), 954(ab), 962(ab)
Strashun, A, 117, 215, 973(ab), 1021(ab), 1035(ab)
Stratton, JR, 763, 1324, 1642
Straub, R, 900(ab)
Straub, RF, 307, 900(ab), 989(ab)
Strauss, DJ, 1396
Strauss, HE, 3A(7)
Strauss, HW, 3A, 144, 935, 1378, 2246, 3A(5), 3A(6), 3A(1), 3A(2), 845(ab), 910(ab), 915(ab), 924(ab), 934(ab), 936(ab), 946(ab), 959(ab), 996(ab), 998(ab), 1000(ab), 1026(ab), 1028(ab), 1587(le)
Strauss, LG, 1981, 1019(ab)
Stray, JE, 943(ab)
Strelkov, AB, 841(ab)
Striano, G, 973(ab), 1014(ab)
Stritzke, P, 969(ab)
Stritzke, PH, 949(ab)
Ström, P, 860(ab)
Strother, SC, 871(ab)
Stubgaard, M, 2106
Studer, M, 880(ab), 942(ab)
Stuttle, AWJ, 756
Styles, JM, 2154
Su, F-M, 880(ab), 909(ab), 910(ab), 934(ab), 979(ab)
Subramanian, G, 1428(le)
Subramanian, R, 1031(ab)
Sucharski, LA, 2067
Sudati, F, 959(ab)
Suehiro, M, 860(ab)
Suematsu, K, 1017(ab)
Suess, E, 108
Suey, C, 912(ab)
Sueyoshi, K, 1023(ab)
Sufka, B, 970(ab)
Sugawara, T, 972(ab)
Sugawara, Y, 909(ab), 912(ab), 969(ab), 1004(ab)
Sugii, A, 988(ab), 1029(ab), 1033(ab)
Suhara, T, 917(ab)
Sulavic, SB, 999(ab)
Sultzer, D, 967(ab)
Sumida, R, 865(ab)
Sumiya, H, 877(ab), 967(ab)
Summers, B, 1035(ab)
Sumrani, N, 1035(ab)
Sun, B, 957(ab)
Sun, K, 865(ab)
Sunderland, J, 829(ab), 975(ab)
Sung, KB, 919(ab)
Susaki, Y, 1009(ab)
Susskind, H, 1717, 1012(ab)
Sutor, R, 826(ab)
Suzuki, K, 844(ab), 917(ab), 966(ab)
Suzuki, S, 932(ab), 998(ab)
Suzuki, T, 932(ab), 998(ab), 1019(ab)
Swartz, BE, 1017(ab)
Sweeney, DC, 996(ab)
Swenson, ER, 581
Swyer, AF, 1175
Swyer, AJ, 2027, 999(ab)
Sybirska, EH, 848(ab), 945(ab)
Syrota, A, 471, 696, 976, 1481, 843(ab), 858(ab), 882(ab), 883(ab), 888(ab), 896(ab), 943(ab), 977(ab), 1019(ab)
Szabo, Z, 869(ab), 885(ab), 968(ab), 1004(ab)
Szlaczky, LA, 990(ab)

Tabuchi, K, 1023(ab)
Taegtmeyer, H, 1523
Taguchi, T, 6
Taillefer, R, 668, 1091, 1801, 855(ab), 866(ab), 894(ab), 1034(ab)
Tainturier, C, 991(ab)
Takahashi, 885(ab)
Takahashi, A, 994(ab)
Takahashi, M, 930(ab), 1029(ab), 1033(ab), 988(ab), 017(ab)
Takahashi, N, 659, 856(ab), 886(ab), 953(ab), 1015(ab)
Takahashi, T, 897(ab), 969(ab)
Takamori, M, 1020(ab)
Takano, M, 920(ab)
Takasaki, M, 1019(ab)
Takashima, Y, 744
Takasiro, K, 857(ab)
Takechi, T, 919(ab), 976(ab)
Takeda, R, 1017(ab)
Takeda, T, 1023(ab)
Takehara, Y, 1851
Takemoto, K, 854(ab)
Takemura, Y, 545
Takeshita, G, 1741, 965(ab)
Takeuchi, A, 1741, 965(ab)
Taki, J, 441, 1200, 918(ab), 1020(ab)
Taki, S, 1020(ab)
Takikawa, H, 998(ab)
Takikawa, S, 923(ab)
Takizawa, K, 998(ab)
Tamahashi, N, 1972
Tamaki, N, 659, 1263, 1501, 1637, 856(ab), 875(ab), 885(ab), 886(ab), 897(ab), 953(ab), 966(ab), 1026(ab)
Tamburro, F, 992(ab)
Tamura, Y, 994(ab)
Tan, J, 935(ab)
Tan, P, 901(ab)
Tanabe, H, 940(ab)
Tanada, S, 135, 893(ab), 909(ab), 912(ab), 969(ab), 972(ab), 1004(ab)
Tanaka, K, 1008(ab)
Tange, S, 1004(ab), 1005(ab)
Taniuchi, H, 1026(ab)
Tansey, W, 985(ab)
Tararine, M, 1003(ab)
Tarbell, NJ, 844(ab)
Tarburton, JP, 2148
Tardieu, M, 976(ab)
Tarry, CT, 2059(le)
Tateno, M, 1181
Tateno, Y, 917(ab)
Tatsch, K, 1291, 832(ab), 897(ab), 917(ab)
Tatum, WO, 929(ab)
Tauxe, N, 997(ab)
Tawarahara, K, 6
Taylor, A, Jr, 33, 296, 1620, 2055(le), 900(ab), 921(ab), 948(ab), 991(ab)
Taylor, LP, 972(ab)
Taylor, S, 890(ab)
Taylor, SF, 1836, 1007(ab), 1008(ab)
Teates, CD, 833(ab), 971(ab)
Tedder, TE, 852(ab)
Teixeira, JP, III, 59
Tenenbaum, F, 1020(ab)
ten Haken, RK, 735
Teoh, SK, 887(ab)
Ter, S-E, 999(ab)
Terada, K, 966(ab)
Teräs, M, 691, 1255
Terashi, A, 1016(ab)
Tercilla, OF, 2059(le)
Ter-Pogossian, MM, 1214
Terry, JA, 961(ab)
Terry, JD, 829(ab)
Testa, D, 1014(ab)
Teule, GJJ, 1915(le), 858(ab), 927(ab)
Tewson, TJ, 983(ab)
Thakur, ML, 851(ab), 973(ab), 979(ab), 986(ab), 987(ab)
Thaler, H, 859(ab)
Thedrez, Ph, 943(ab)
Théroux, P, 875(ab)
Thie, JA, 923(ab)
Thierens, HMA, 1167
Thies, P, 997(ab)
Thiessen, JJ, 2248(le)
Thoams, SR, 937(ab)
Thomas, CMG, 1958
Thomas, FD, 150, 961(ab)
Thomas, JR, 890(ab)
Thomas, SR, 783, 1132, 1717, 894(ab)
Thompson, NW, 1125
Thompson, RB, 2059(le)
Thompson, RC, 847(ab), 876(ab)
Thompson, S, 41
Thompson, W, 908(ab)
Thoolen, MJ, 989(ab)
Thorson, A, 975(ab)
Thorson, LL, 1006(ab)
Thouvenot, P, 956(ab)
Thrall, DE, 1542
Tiel-van Buul, MMC, 907(ab)
Tien, R, 1047(ab)
Tikofsky, RS, 939(ab)
Tilbury, R, 985(ab), 992(ab)

Tilbury, RS, 828(ab)
Ting, G, 986(ab)
Tison, V, 863(ab)
Tisselli, A, 915(ab)
Tobin, M, 1073(ab)
Todde, S, 973(ab)
Todd-Pokropek, A, 1007(ab)
Tomiguchi, S, 988(ab), 1029(ab), 1033(ab)
Tomita, J, 998(ab)
Tomiyoshi, K, 1181
Tonami, N, 441, 2024, 877(ab), 957(ab), 967(ab), 1020(ab)
Tondeur, M, 485
Toney, MO, 2052
Toni, MG, 954(ab)
Toorongian, SA, 870(ab), 982(ab), 983(ab), 994(ab)
Topchik, S, 1304
Torchilin, VP, 943(ab), 959(ab)
Torelli, J, 866(ab)
Torizuka, T, 886(ab)
Torres, G, 840(ab), 845(ab), 895(ab), 994(ab)
Toth-Abonyi, M, 1935
Tournier, E, 1003(ab)
Tow, DE, 964(ab)
Toyama, H, 1741, 965(ab), 970(ab), 1016(ab)
Tran, H, 968(ab)
Tran, HD, 1047(ab)
Tranel, D, 1008(ab)
Travagli, JP, 1020(ab)
Travin, MI, 876(ab)
Treffert, JD, 932(ab), 947(ab), 949(ab)
Trehan, J, 825(ab)
Treves, ST, 1758, 2098, 838(ab), 844(ab), 930(ab), 1018(ab)
Trimarco, B, 505, 905(ab), 915(ab)
Trivedi, MH, 838(ab)
Tromholt, N, 2106
Troutner, DE, 899(ab), 921(ab)
Trubetskoy, V, 959(ab)
Trubetskoy, VS, 943(ab)
Trulock, EP, 835(ab)
Tsang, BW, 931(ab)
Tse, N, 828(ab)
Tselentakis, M, 886(ab)
Tselfes, J, 1003(ab)
Tsuchida, T, 897(ab), 966(ab)
Tsuda, T, 912(ab), 1004(ab)
Tsui, BMW, 451, 2238, 831(ab), 832(ab), 842(ab), 892(ab), 961(ab)
Tsuji, S, 877(ab), 967(ab)
Tsutsumi, K, 969(ab)
Tuama, LAO, 1018(ab)
Tulchinsky, M, 1854, 947(ab)
Tuli, M, 978(ab)
Tumeh, SS, 1186
Tune, L, 847(ab)
Tung, C-H, 901(ab), 902(ab)
Tupler, RH, 1553
Turbiner, EH, 1553
Turkheimer, F, 944(ab)
Turkington, TG, 901(ab), 922(ab), 1047(ab)
Turner, FE, 716, 935(ab)
Turner, M, 1045(ab)
Turpin, S, 1034(ab)
Twiford, TW, 1047(ab)
Tzen, KY, 1022(ab)

Ucar, N, 859(ab)
Uccelli, L, 850(ab)
Udelson, JE, 905(ab)
Uebis, R, 886(ab)
Ueda, S, 413, 466(le)
Ueda, T, 744, 971(ab)
Uehara, T, 272, 365
Uemura, K, 1696, 827(ab), 857(ab), 911(ab), 963(ab), 1008(ab)
Ueno, A, 1023(ab)
Underwood, D, 866(ab)
Unlü, M, 319
Uno, K, 324
Unsworth, C, 982(ab)
Untereker, WJ, 2086, 866(ab)
Ur, E, 1121, 914(ab)
Urbain, JL, 832(ab)
Urion, DK, 1758
Urita, Y, 920(ab)
Utsunomiya, H, 575
Uyan, C, 866(ab)
Uygur, G, 868(ab), 869(ab)
Uzum, F, 868(ab)

Vaalburg, W, 373, 870(ab)
Vaccarino, RA, 1411, 1994, 846(ab)
Vaghaiwalla-Mody, F, 856(ab), 857(ab)
Vaghi, M, 924(ab)
Vahjen, GA, 304
Vaidyanathan, G, 1535, 881(ab)
Valette, H, 471, 843(ab), 888(ab), 896(ab)
Valk, PE, 2133
Valkow, ND, 287
Vallabhajosula, S, 969(ab), 995(ab), 1031(ab)
van Aswegen, A, 888(ab)
Van Cauteren, J, 832(ab)
van den Mieracker, AH, 990(ab)
Vanderheyden, J-L, 1099, 900(ab), 934(ab), 979(ab), 981(ab), 1025(ab)
van der Meer, JWM, 388, 1330, 903(ab), 920(ab), 936(ab), 950(ab), 1031(ab)
van der Pluijm, M, 955(ab)
van der Vliet, JA, 1330, 950(ab)
Vandervoot, PM, 1558
van der Vusse, GJ, 102
van der Wall, EE, 1727
Vander Zwagg, R, 1269
Vandevivere, J, 972(ab), 1013(ab), 1021(ab)
Van de Wiele, C, 1167
Vandewoude, M, 1013(ab)
van Dieren, EB, 1915(le)
van Dijk, A, 646
van Dongen, A, 907(ab)
Van Frank, R, 1427(le)
Van Haelst, JP, 1167
van Hagen, PM, 652
Vanhagen, PM, 903(ab)
Van Haight, C, 2184
Vanhaverbeek, M, 1337
van Heerden, BB, 883(ab)
Van Heertum, R, 939(ab)
Van Heertum, RL, 906(ab), 988(ab)
van het Schip, AD, 646
van Kaick, G, 1982, 828(ab), 907(ab), 1019(ab), 1045(ab)
van Lingen, A, 1915(le)
van Montfrans, GA, 907(ab)
Van Nerom, C, 1032(ab)
Van Nerom, CG, 551
Vanoverschelde, JL, 837(ab), 884(ab)
van Rensburg, AA, 888(ab)
van Rijk, PP, 646
van Royen, EA, 894(ab), 895(ab), 907(ab), 917(ab), 1016(ab)
Van Train, K, 854(ab), 876(ab)
Van Train, KF, 1509
van Vlies, B, 895(ab)
van Waarde, A, 870(ab)
Varastet, M, 883(ab), 973(ab)
Vardi, Y, 49
Vargas, K, 985(ab)
Varma, VM, 996(ab)
Varney, DM, 748
Vavouraki, H, 988(ab)
Veilleux, M, 951(ab)
Veith R, 1324
Vekemans, MC, 832(ab)
Velasquez-Rocha, S, 935(ab)
Vellet, AD, 516
Vemon, P, 831(ab)
Vemuru, RP, 919(ab)
Venkatesan, P, 979(ab)
Venkatesan, PP, 987(ab)
Vera, DR, 1160
Verani, M, 927(ab)
Verani, MS, 1600, 905(ab), 916(ab), 995(ab)
Verbruggen, A, 1032(ab)
Verbruggen, AM, 551
Verdera, ES, 1949
Verdy, M, 894(ab)
Vergara, E, 892(ab), 918(ab), 999(ab)
Vergnes, R, 947(ab)
Verheggen, R, 957(ab)
Verheij, LF, 1406
Verheijin, RHM, 1958
Verhoeff, NPLG, 916(ab), 917(ab), 1016(ab)
Verma, RC, 827(ab), 1043(ab)
Vernick, J, 1183
Vervaet, A, 1013(ab)
Verzijlbergen, FJ, 1727
Vespie, A, 937(ab)
Vessella, RL, 943(ab)
Vetter, RJ, 1613
Vetterlein, D, 934(ab)
Vezina, WC, 516
Vidaihet, M, 1019(ab)
Vidailhet, M, 1481
Viereggе, P, 1013(ab)
Vijayakumar, S, 853(ab)
Vijayakumar, V, 853(ab)
Villanueva-Meyer, J, 838(ab), 839(ab), 846(ab), 876(ab)
Villela, MA, 942(ab), 1030(ab)
Vining, DJ, 1044(ab)
Vinitski, S, 973(ab)
Vinson, EL, 668
Virzi, F, 921(ab), 925(ab), 934(ab)
Visser, G, 858(ab)
Visser, GM, 870(ab)
Visser, TJ, 652, 955(ab)
Vitols, PJ, 993(ab)
Vleugels, S, 937(ab)
Voderholzer, A, 1291
Voderholzer, W, 832(ab)
Vogel, JM, 127
Voipio-Pulki, L-M, 1255
Volkert, EW, 1024(ab)
Volkert, WA, 623, 1451, 1916(le), 851(ab), 910(ab), 979(ab), 987(ab), 988(ab), 1032(ab), 1048(ab)
Volkow, N, 995(ab)
Volkow, ND, 521, 1720, 2020, 830(ab), 847(ab), 887(ab), 888(ab), 946(ab), 1046(ab)
vom Dahl, J, 886(ab)
von Smekal, A, 536
Vorne, M, 1253(le)
Votaw, JR, 826(ab), 847(ab)
Vral, AM, 1167
Vuori, I, 1137

Wackers, FJTh, 855(ab), 874(ab), 886(ab), 927(ab), 938(ab), 939(ab), 993(ab)
Wada, A, 208
Wada, K, 545, 1026(ab)
Wada, M, 1029(ab)
Wadas, MA, 2214
Wagner, HN, Jr, 1216, 847(ab), 848(ab), 860(ab), 869(ab), 885(ab), 929(ab), 964(ab), 968(ab), 1004(ab), N10(8)
Wagner, R, 1013(ab)
Wagner, RH, 1041(ab)
Wahl, RL, 975, 828(ab), 841(ab), 869(ab), 893(ab), 894(ab), 926(ab), 959(ab), 1020(ab), 1021(ab)
Wahner, HW, 1039(ab)
Waite, SD, 1006(ab)
Wakasugi, S, 208, 935(ab), 936(ab)
Wakisaka, S, 971(ab)
Wakita, K, 413
Walker, B, 992(ab)
Walker, BS, 826(ab)
Walker, WJ, Jr, 20N(6)
Wallace, R, 974(ab)
Wallace, S, 985(ab)
Wallich, R, 1982, 1019(ab)
Wallis, JW, 1678, 1710, 964(ab)
Walovitch, RC, 480, 878(ab), 968(ab)
Walsh, C, 912(ab)
Walsh, J, 438
Walsh, RA, 993(ab)
Waltman, AC, 948(ab)
Wanet, P, 1005(ab)
Wang, AK, 1039(ab)
Wang, F, 854(ab)
Wang, FP, 1509
Wang, GJ, 521, 2020, 887(ab), 888(ab), 946(ab), 1028(ab), 1046(ab)
Wang, H, 891(ab)
Wang, KY, 955(ab)
Wang, MF, 1044(ab)
Wang, PY, 1013(ab)
Wang, R, 991(ab)
Wang, S, 868(ab)
Wang, S-J, 254, 955(ab), 977(ab), 986(ab), 997(ab), 1012(ab), 1013(ab)
Wang, TST, 570, 1994, 988(ab)
Wang, X, 842(ab)
Ward, R, 898(ab)
Ware, RW, 1857
Warhoe, KA, 862(ab)
Wartski, M, 843(ab), 888(ab), 947(ab)
Washburn, LC, 937(ab), 993(ab), 1048(ab)
Waskin, HA, 838(ab)
Wasserman, L, 1411
Watabe, K, 897(ab)
Watanabe, E, 857(ab)
Watanabe, K, 971(ab)
Watanabe, N, 1181
Watanabe, R, 1033(ab)
Watanabe, T, 1001(ab), 1006(ab), 1009(ab), 827(ab), 68(ab)
Watanabe, Y, 919(ab), 976(ab), 1020(ab)
Watanuki, S, 857(ab)
Waters, D, 951(ab)
Watkins, GL, 1008(ab), 1027(ab)
Watson, DD, 668, 864(ab)
Watson, E, 777
Watson, EE, 819
Wauters, E, 1427(le)
Waxman, AD, 843(ab), 869(ab)
Webb, D, 925(ab)
Webber, D, 1041(ab)
Weber, DA, 1717, 842(ab), 851(ab), 1012(ab), 1015(ab)
Weber, W, 859(ab)
Webster, WB, 498, 2249(le)
Wegelius, U, 1255
Weiden, PL, 1099
Weiland, DM, 1125
Weinberger, DR, 981(ab)
Weindling, SN, 930(ab)
Weiner, RE, 1701
Weinheimer, CJ, 884(ab)
Weinreich, R, 884(ab)
Weinstein, H, 1783, 993(ab)
Weinstein, J, 957(ab), 1022(ab)
Weinstein, JN, 893(ab)
Weise, SB, 908(ab)
Weisman, H, 848(ab)
Weisman, HF, 978(ab)
Weiss, A, 843(ab)
Weiss, MJ, 1291
Welch, MJ, 558, 724, 1685, 837(ab), 925(ab), 932(ab)
Welcke, U, 906(ab)
Wellman, H, 918(ab)
Wells, P, 313
Welt, S, 913(ab)
Wernovsky, G, 930(ab)
Wernz, J, 912(ab)
Wese, F-X, 73
Wessel, D, 838(ab)
Wetzel, H, 887(ab)
Wetzel, LH, 1039(ab)

Wheeler, RH, 23, 1648
White, D, 974(ab)
White, DL, 974(ab)
Whiting, JH, Jr, 260
Widén, L, 908(ab), 1011(ab)
Widman, J, 2116
Wiebe, LI, 841(ab)
Wiegand, V, 845(ab)
Wieland, DM, 860(ab), 870(ab)
Wielopolski, L, 1278
Wienhard, K, 861(ab), 1013(ab)
Wieringa, AR, 373
Wiersinga, WM, 894(ab)
Wiesner, RF, 239
Wiesnewski, G, 911(ab)
Wijngaarde, R, 894(ab)
Wijns, W, 825(ab), 837(ab), 875(ab), 884(ab), 905(ab)
Wikander, R, 832(ab)
Wilbur, DS, 465(le), 943(ab)
Wilder, S, 851(ab), 979(ab), 987(ab)
Wilkinson, G, 872(ab)
Wilkinson, R, 936(ab), 996(ab)
Wilkinson, RA, 845(ab), 1024(ab)
Wilkinson, RW, 1028(ab)
Willemart, B, 825(ab), 875(ab), 905(ab)
Williams, CC, 1048(ab)
Williams, HJ, 847(ab), 876(ab)
Williams, JR, 987(ab)
Williams, KA, 359
Williams, LE, 953(ab)
Williams, RG, 977(ab)
Wilson, A, 834(ab)
Wilson, AA, 847(ab), 848(ab), 883(ab), 929(ab)
Wilson, CR, 2110, 869(ab)
Wilson, IK, 830(ab)
Wilson, LA, 953(ab)
Wilson, ME, 306
Wilson, RA, 716
Wilson, SD, 869(ab)
Winn, HR, 1789
Winnard, P, 909(ab)
Wironen, J, 993(ab)
Wiseman, JC, 868(ab)
Wisenberg, S, 355
Wisniewski, G, 848(ab), 945(ab)
Wittry, MD, 1046(ab)
Woda, A, 897(ab)
Wolber, G, 828(ab)
Wolf, A, 995(ab)
Wolf, AP, 192, 521, 1720, 830(ab), 847(ab), 853(ab), 870(ab), 887(ab), 888(ab), 946(ab)
Wolf, F, 903(ab)
Wolf, JE, 953(ab)
Wolf, SB, 1099
Wolf, W, 830(ab)
Wolfangel, R, 1024(ab)
Wolfangel, RG, 308, 989(ab), 1033(ab)
Wolfe, E, 882(ab)
Wolfe, ER, 1008(ab)
Wolk, AP, 2020
Wolters, EC, 917(ab)
Wolters, ECMJ, 1016(ab)
Wong, A, 1045(ab)
Wong, C, 851(ab)
Wong, CTC, 1012(ab), 1015(ab), 1028(ab)
Wong, DF, 847(ab), 848(ab), 964(ab), 968(ab)
Wong, GY, 904(ab)
Wong, S, 945(ab)
Wong, WH, 828(ab), 985(ab), 992(ab), 1011(ab), 1430(le)
Woodin, M, 878(ab)
Woodle, DR, 880(ab)
Woods, RP, 922(ab), 1010(ab)
Woods, S, 896(ab)
Woods, SW, 1964
Woolfenden, JM, 851(ab), 879(ab), 1002(ab)
Wooter, W, 33
Worth, J, 1312, 887(ab)
Worthy, M, 865(ab)
Wszolek, Z, 964(ab)
Wu, AM, 953(ab)
Wu, C, 1030(ab), 1031(ab)
Wu, KH, 977(ab)
Wyatt, RJ, 1383, 965(ab)
Wysor, W, 2067

Xu, X-L, 871(ab)

Yaghmai, I, 827(ab), 1043(ab)
Yamada, J, 1024(ab)
Yamada, S, 1972, 840(ab), 841(ab), 984(ab)
Yamada, T, 1501
Yamagami, H, 952(ab)
Yamaguchi, N, 967(ab)
Yamaguchi, S, 1637
Yamamoto, H, 333
Yamamoto, I, 998(ab)
Yamamoto, Y, 1008(ab)
Yamanaka, M, 998(ab)
Yamasaki, T, 917(ab)
Yamashita, J, 967(ab)
Yamashita, S, 932(ab)
Yamauchi, H, 1637
Yamazaki, N, 6
Yang, D, 985(ab)
Yang, DJ, 828(ab), 992(ab)
Yang, KTA, 282
Yang, SH, 1008(ab)
Yang, SK, 919(ab)
Yang, S-O, 2118
Yang, WJ, 924(ab)
Yang, Y, 989(ab)
Yang, Z-Y, 829(ab), 982(ab)
Yao, T-J, 345
Yap, JT, 947(ab), 949(ab)
Yarmush, ML, 1378
Yasuda, T, 1558, 1905
Yasugi, T, 951(ab)
Ye, J, 842(ab)
Yeh, S, 867(ab)
Yeh, SDJ, 345, 2020, 843(ab), 859(ab)
Yeh, SH, 955(ab), 977(ab), 997(ab), 1012(ab), 1013(ab), 1034(ab)
Yeo, E, 937(ab)
Yeung, DW, 899(ab), 954(ab)
Yokoi, T, 911(ab)
Yokota, A, 1025(ab)
Yokoyama, A, 545, 891(ab), 897(ab), 1023(ab), 1024(ab), 1026(ab)
Yokoyama, K, 957(ab), 1020(ab)
Yonekura, R, 996(ab)
Yonekura, Y, 545, 659, 1023, 1263, 1637, 856(ab), 885(ab), 886(ab), 891(ab), 897(ab), 953(ab), 966(ab), 1024(ab), 1026(ab)
Yoon, B-W, 877(ab)
Yoshida, A, 1501
Yoshikawa, K, 324
Yoss, RG, 2110
Yost, RW, 1046(ab)
You, DL, 1022(ab)
Young, ET, 1002(ab)
Young, P, 1789
Yu, CC, 964(ab)
Yu, DC, 1045(ab)
Yu, L, 868(ab)
Yu, S, 926(ab)
Yu, SL, 997(ab)
Yuen-Green, MS, 1444
Yuille, D, 839(ab)
Yuille, DL, 1704
Yung, B, 847(ab), 964(ab)
Yung, BCK, 924(ab)

Zaidel, M, 947(ab)
Zaino, EC, 1278
Zalutsky, MR, 575, 1535, 881(ab), 934(ab), 958(ab)
Zambuto, G, 989(ab)
Zamora, PO, 1029(ab), 1031(ab)
Zang, Y, 1010(ab)
Zanzi, I, 898(ab), 923(ab)
Zanzonico, P, 2180, 845(ab)
Zaret, B, 927(ab)
Zaret, BL, 855(ab), 874(ab), 886(ab), 938(ab), 939(ab), 993(ab)
Zasadny, K, 1020(ab)
Zasadny, KR, 926(ab)
Zea-Ponce, Y, 1964, 848(ab), 896(ab), 911(ab), 945(ab)
Zeeberg, BR, 883(ab)
Zeeburg, BR, 1225
Zeiter, PC, 863(ab)
Zeng, GL, 831(ab), 891(ab), 892(ab), 901(ab)
Zhang, JJ, 1943, 961(ab)
Zhang, XX, 989(ab)
Zhang, Y, 831(ab)
Zhao, XD, 831(ab)
Zheng, J, 984(ab)
Zhu, X, 954(ab)
Ziegler, SI, 1007(ab)
Zierz, St, 995(ab)
Ziessman, HA, 266, 537, 833(ab), 899(ab)
Ziffer, J, 876(ab)
Ziffer, JA, 927(ab)
Zilbovicius, M, 696, 1481, 858(ab), 1019(ab)
Zilleruelo, GE, 956(ab)
Zimmer, AM, 946(ab)
Zimmerman, RE, 839(ab), 852(ab), 1005(ab), 1018(ab), 1043(ab)
Zingraff, J, 913(ab)
Zinn, KR, 1685
Zito, F, 959(ab)
Zito, V, 1859
Zloty, M, 886(ab), 913(ab)
Zoccarato, O, 846(ab)
Zoghbi, SS, 1964, 848(ab), 896(ab), 911(ab), 945(ab)
Zöller, M, 1366
Zonnenberg, BA, 646
Zubal, G, 1964, 906(ab)
Zubal, IG, 1712, 963(ab), 1006(ab)
Zubieta, JA, 882(ab)
Zuccala, A, 2040
Zuckier, LS, 1723, 985(ab)
Zuñiga, EH, 1047(ab)
Zwas, ST, 859(ab)
Zwinderman, AH, 1406, 1727

A

Abdomen
diffuse uptake of Tc-99m MDP, continuous ambulatory dialysis, bone scintigraphy, 2052
fast diagnosis of infections, Tc-99m HMPAO lymphocytes, 1253(le)
Abscess
focal infection, radiolabeled proteins, biodistribution and kinetics, 388
intracranial, differential diagnosis, Tc-99m antigranulocyte antibody, 957(ab)
odontogenic, spread of infectious complications, Tc-99m HMPAO white blood cells, 254
Absorptiometry
dual energy X-ray
bone mineral and body composition, fan-beam design, 1063(ab)
bone mineral density, skeletal sites, 1137
dual photon absorptiometry
single-photon, utility of, 170
Acetate, cellulose-, hemodialyzer, comparative thrombogenicity, 956(ab)
Acetazolamide
cerebrovascular response, Tc-99m DTPA-HSA, new method for monitoring, 969(ab)
effect on vascular response, diaschisis, Tc-99m HMPAO SPECT, 967(ab)
Tc-99m HMPAO SPECT, PET and, cerebrovascular disease, 877(ab)
Acetylcholine, release and endogenous dopamine, GABAergic modulation, PET, 847(ab)
Achalasis, esophageal scintigraphy, 590
Acquired immunodeficiency syndrome (AIDS)
cerebral perfusion imaging, 827(ab)
dementia complex, cocaine abuse, brain perfusion SPECT, 887(ab), 1312
differentiation of infectious from malignant CNS lesions, FDG-PET, 838(ab)
gastric uptake of Ga-67, 643
infectious diseases and, Annual Meeting highlights, 24N(8)
noninvasive monitoring of drug targeting, 3′-fluoro-3′-deoxythymidine, 830(ab)
Pneumocystis pneumonia, pulmonary disposition, Ga-67, 512
Acromegaly
active, rest and exercise radionuclide ventriculography, 834(ab)
bone mineral density, axial skeleton, 1608
Actomyosin, contraction/relaxation, T2 relaxation behavior, 974(ab)
Acupuncture
anatomic divisions, 407
message transmission, nuclear medicine, 409
ADAC Laboratories, lawsuit filed by Trionix, gamma camera technology, 18N(2)
Adenocarcinoma, CEA concentration measurement, quantitative autoradiography, 892(ab)
Adenoma
parathyroid
hyperparathyroidism, Tc-99m sestamibi, 1801
Tc-99m sestamibi double-phase study, primary hyperparathyroidism, 894(ab)
parathyroid imaging, 1807
Adenosine
choice of stress for diagnostic perfusion, wall motion imaging, MIBI-SPECT and stress echocardiography, 825(ab)
detection of total ischemic myocardium at jeopardy, combination of flow reserve with metabolic assessment, 837(ab)
extent and location of CAD, patients without prior myocardial infarction, 2067
-induced coronary hyperemia, early thallium imaging after PTCA, 2086
infusion, myocardial ischemia, hemodynamic-scintigraphic study, 952(ab)
myocardial perfusion imaging, serum caffeine levels, 24-hour abstention, 866(ab)
regional cardiac, noninvasive assessment, PET, 2138
stress N-13 ammonia myocardial perfusion PET, coronary artery disease, 825(ab)
teboroxime myocardial perfusion imaging, accuracy, optimal imaging time, 854(ab)
thallium scintigraphy, high cardiac risk, patients referred for vascular surgery, 952(ab)
Tl-201 compared to Tc-99m teboroxime, coronary stenosis, 864(ab)
Tl-201 scintigraphy, lung thallium uptake, 1600
***S*-Adenosyl-L-homocysteine hydrolase,** potential inhibitor, synthesis and metabolism, I-125 iodocycloadenosin-4′-ene, 980(ab)
Adhesion molecules, intercellular, lung neutrophil sequestration, endotoxemia, 1023(ab)
Adrenal gland
adrenocortical scintigraphy, unilateral incidentally discovered adrenal or juxtaadrenal masses, 996(ab)
C-11 cocaine, distribution and kinetics, 521
C-11 HED PET, localization, pheochromocytoma, 1125
SPECT, without dexamethasone suppression, primary aldosteronism, 834(ab)
Adrenoceptors
alpha-2, ligands, C-11 MK-912 and C-11 WY 26703, 861(ab)
beta, use of CGP-12177 and CGP-26505, 870(ab)
Adriamycin
acute cardiotoxicity, Tc-99m sestamibi, chick heart cells, 864(ab)
cardiomyopathy
abnormal cardiac adrenergic neuron activity, I-125 MIBG, 208
disturbed neuronal energy metabolism, 935(ab)
myocardial damage, In-111 antimyosin antibody, 936(ab)
prediction of congestive heart failure, I-125 MIBG, 935(ab)
congestive cardiomyopathy, I-125 MIBG, 215
risk of congestive heart failure, In-111 antimyosin studies, 895(ab)
Aging
central dopamine D2 receptors, specific and non-specific binding, C-11 YM-09151-2, 897(ab)
decline of L-6-[F-18]fluorodopa rate constant K_1, 964(ab)
declining myocardial flow reserve, higher cardiac work at rest, 836(ab)
dopamine receptors, SPECT and IBZM, 897(ab)
older adults, blunted response of myocardial perfusion, dipyridamole, 1425(le)
Air pollution, exposed persons, burning oil wells in Kuwait, lung imaging studies, 978(ab)
Alcohol
acute and chronic, antral processing, solid meal, 832(ab)
-dependent men, C-11 flumazenil binding, benzodiazepine receptors, 1016(ab)
diffuse liver disease, emission tomography, 1337
intoxication, cocaine distribution and kinetics, human brain and heart, 946(ab)
young alcoholics, brain deficits, PET and MRI, 1070(ab)
Aldosteronism, primary, adrenal SPECT, without dexamethasone suppression, 834(ab)
Algorithms
accelerated reconstruction, ordered subsets, 960(ab)
cone beam reconstruction, displaced center-of-rotation, 891(ab)
estimation of slope in PATLAK analysis, dynamic PET data, 944(ab)
fan beam convolution reconstruction, variable focal length collimators, 891(ab)
FFT interpolation, 1007(ab)
generalized Gibbs prior, maximum *a posteriori*-EM SPECT reconstruction, 832(ab)
image reconstruction, brain phantom design, computer simulation studies, 1012(ab)
improved signal-to-noise, 3D ML-EM reconstruction, 961(ab)
issues in quantitation, reoriented cardiac PET images, 1235
iterative linear, filtered back-projection, image reconstruction, 871(ab)
iterative reconstruction, SPECT grey matter imaging, 1225
knowledge-based boundary detector, clinical verification, 938(ab)
least squares, region-of-interest evaluation, emission tomography, 831(ab)
linearization, cerebral blood flow, Tc-99m HMPAO SPECT, 912(ab)
lung scan interpretation, 1417, 1422
mathematical modeling and dosimetry, plasmapheresis, radioimmunotherapy of micrometastases, 941(ab)
multi-energy maximum-likelihood reconstruction, SPECT and PET, 831(ab)
reconstruction
fast interactive method, functional regions, 831(ab)
singular value decomposition, attenuation in SPECT, 831(ab)
restoration and correction, improved quantitation of small objects, PET, 872(ab)
subtraction, parathyroid scintigraphy, 996(ab)
three-dimensional functional brain images, automated method, rotational correction, 1579
Alkylamine, conjugation chemistry for labeling antibodies, 986(ab)
Allied health, Title VII appropriations, 26N(3)
Allograft, cardiac, rejection detection, I-123 anti-ICAM-1 imaging, 1000(ab)
Alzheimer's disease
absolute whole brain glucose metabolism, sensitive marker, 940(ab)
atypical dementia and comparison, FDG PET and MRI data, 965(ab)
cerebral perfusion abnormalities, SPECT, 973(ab)
cognitive and pharmacological challenges, brain disease detection, 1019(ab)
cortical perfusion deficit, demographic and cognitive variables, 940(ab)
delayed SPECT and regional cerebral blood

flow, I-123 IMP, 1015(ab)
diagnostic accuracy of SPECT, 1019(ab)
differential diagnosis of dementia, cerebral blood flow, SPECT and MRI, 1014(ab)
evaluation of neural-network classifier, PET scans, 1459
functional brain SPECT, powerful clinical method, 1888
hippocampal blood flow, SPECT, 940(ab)
hypometabolic parietal cortex, unaltered benzodiazepine receptors, 887(ab)
monoclonal antibody specific for β/A4 amyloid, angiopathy, brain, 2184
patterns of dementia, 1431(le)
scintigraphic appearance, Tc-99m HMPAO SPECT, 181, 312
American College of Cardiology (ACC), standardization, cardiac tomographic imaging, 1434
American College of Nuclear Medicine (ACNM), petition would ease strictures, outpatient nuclear medicine therapy, 13N(7)
American College of Nuclear Physicians (ACNP)
budget testimony, 13N(6)
government relations update, 30N(9)
licensing decision, California radioactive waste site, 40N(9)
SNM and, Medicare fee schedule, 18N(1)
American Heart Association (AHA), standardization, cardiac tomographic imaging, 1434
American Medical Association (AMA), revisions to RVU update, 36N(9)
γ-Aminobutyric acid, modulation of endogenous dopamine, acetylcholine release, PET, 847(ab)
1-Aminocyclobutane[C-11]carboxylic acid, dynamic PET, 2-compartment model, brain tumors, 922(ab)
Amino-dextran, poly-lysine and, In-111 labeled MAB, 988(ab)
Amygdala, quantitation in PET, two-dimensional restoration filter, 921(ab)
Amyloid
angiopathy, monoclonal antibody specific for β/A4 amyloid, Alzheimer's disease, 2184
P-component, radiolabeling, kinetic and scintigraphic studies, 913(ab)
Anatomy
cross-sectional, Macintosh tutorial, 1063(ab)
radiologic, 1067(ab)
Aneurysm
bleeding mycotic iliac, Tc-99m renal scan, 1548
inflammatory abdominal aortic, In-111 imaging, 1553
mycotic, diagnosis, leukocyte scintigraphy, 1486
Angina
-like chest pain, abnormal esophageal motility, gastroesophageal reflux, 955(ab)
unstable, In-111 antimyosin uptake, acute and remote myocardial infarction, 587
Angiography
comparative study of Tl-201, CT/MRI, bone and soft tissue sarcoma, 843(ab)
first-pass radionuclide
exercise-induced myocardial ischemia, upright bicycle ergometry, 359
ordinary gamma camera, computer program, 1064(ab)
moyamoya disease, before and after external-to-internal carotid artery bypass, 1692
planar myocardial perfusion imaging, Tc-99m tebo, 1783
pulmonary, intermediate probability/indeterminate lung scans, 849(ab)
Tc-99m HMPAO, quantitative approach, brain, 877(ab)
Angiography, radionuclide
first-pass, count-based ratio method, left ventricular volume, 2124
left ventricular diastolic function, systemic sclerosis, 68
SPECT myocardial perfusion and, Tc-99m MIBI, dipyridamole, 846(ab)
Tc-99m in thrombosis detection, left atrial appendage, 365
Angioplasty, cerebral, delayed ischemia due to vasospasm, brain SPECT, 1789
Angioplasty, percutaneous transluminal coronary
early thallium imaging, 866(ab)
utility of Tc-99m SPECT, spontaneous chest pain, prediction of clinical improvement, 875(ab)
Angiotensin converting enzyme, renal functional response, captopril, diuretic therapy, 739
Angiotensin II, receptor ligand, distribution, imaging potential, 900(ab)
Animal research
campaign against animal activists, engaging physicians, 24N(5)
design feature and performance, PET system, 595
thwarting attacks, 19N(2)
Animals, small
scintillating fiber detector module, Cu-64 radiopharmaceuticals, PET, 1010(ab)
SPECT imaging, 852(ab)
Anti-antibody, prospects and problems, radioimmunotherapy, 958(ab)
Antibodies, radioimmunodetection and cancer identification, 803
Anticoagulants
platelet/fibrin deposition, coronary stents, minipig model, 845(ab)
UltraTag RBC kit, 989(ab)
Antimyosin
cardiac transplantation rejection, primates, 1994
imaging to detect tumor invasion, muscle layer, 841(ab)
negatively charged-polymer-modified, infarct imaging, different cross-linkers, 959(ab)
Antisense oligonucleotide, In-111, direct method of cell-labeling, whole blood, 980(ab)
Anti-thyroglobulin antibodies, circulating, clinical meaning, differentiated thyroid neoplasms, 1478
Aorta
abdominal, arterial input function determination, hepatic and renal PET studies, 613
injured tissue, radioiodinated endothelin-1, cholesterol-fed rabbits, 845(ab)
Aphasia
acute, Tc-99m HMPAO brain perfusion SPECT, 970(ab)
childhood, regional cerebral perfusion, Landau-Kleffner syndrome, 1758
progressive
pathophysiological evaluation, PET, 1016(ab)
PET and MRI, 857(ab)
Arteriography, contrast, peripheral vascular disease, 1797
Arteriovenous malformations, hepatic, embolization, hereditary hemorrhagic telangiectasia, 260
Artery
carotid
stenosis, cerebrovascular reserve capacity, 971(ab)
Tc-99m HMPAO injection, recurrent glioma, 966(ab)
carotid, external-to-internal, SPECT/MRI/angiography, moyamoya disease, 1692
carotid, internal, occlusion, Tc-99m HMPAO evaluation of cerebral perfusion, 969(ab)
cerebral, unilateral occlusive disorders, crossed cerebellar hypoperfusion, 1637
changing the level of partial pressure, photic stimulation, carbon dioxide, 827(ab)
coronary
acute onset, cardiogenic shock, 1558
bypass graft, C-VEST, 1914(le)
bypass grafting, continuous ventricular function monitor with miniature cadmium telluride detector, 441
cardiac perfusion abnormalities, Kawasaki syndrome, 929(ab)
fibrin deposition following injury, I-125 fibrinogen, 845(ab)
myocardial viability, status of collateral flow, 856(ab)
occlusion, myocardial perfusion and ventricular function, 825(ab)
coronary LAD
imaging regional hypoxia, Tc-99m 2-nitroimidazole, 865(ab)
misonidazole retention after occlusion, myocardial metabolism and blood flow, 993(ab)
experimental wall injury, uptake, In-111 polyclonal IgG and I-125 LDL, 845(ab)
iliac, stenosis, renal transplant hypertension, 1178
patency, serial tomographic imaging, Tc-99m sestamibi, 2080
renal
segmental branch stenosis, captopril renography, 266
stenosis, captopril renal scintigraphy, 2045
stenosis, captopril-stimulated PRA, 907(ab)
stenosis, cortical residual activity on captopril renography, 906(ab)
stenosis, en-bloc pediatric renal transplant, 263
stenosis, renal kinetics in transplants, 923(ab)
stenosis, Tc-99m MAG_3 scintigraphy with captopril, 990(ab)
Artifacts
nuclear medicine, 1068(ab)
PET image reconstruction, 1069(ab)
Ascites, bile extravasation, hepatic transplantation, scintigraphy, 115
Asphyxia, perinatal, cerebral palsy, Tc-99m HMPAO SPECT, 977(ab)
Assays, robotic solid phase extraction, C-11 raclopride, plasma, 853(ab)
Astrocytoma, low grade and anaplastic, FDG PET brain imaging, 966(ab)
Atelectasis, infrequent chest X-ray finding, pulmonary embolism, 849(ab)
Atherosclerosis
imaging lesions with monoclonal antibody Z2D3, antibody-avidin-biotin interactions, 934(ab)
imaging with I-123 SP4, 845(ab)
localization of lesions, class-switched monoclonal antibody Z2D3, 936(ab)
Athletes, myocyte damage, pathologic cardiac hypertrophy, In-111 antimyosin antibody, 994(ab)
Atomic Energy of Canada, Ltd. (AECL), threatened reactor worker strike, 19N(9)

Atrophy, multi-system, I-123 IBZM SPECT, 1018(ab)
Attenuation correction
accuracy of, PET, transmission processing, 862(ab)
breast tissue, myocardial imaging, 961(ab)
cardiac PET, three-dimensional registration, 881(ab)
comparison of left anterior oblique, geometric mean method, gastric emptying, 833(ab)
Cramer-Rao bound analysis of effects, feature size and activity estimation, SPECT, 962(ab)
effect on brain SPECT, 961(ab)
factors, Bremsstrahlung imaging, gamma camera, 161
non-uniform, emission and transmission noise propagation, cardiac SPECT, 902(ab)
of theoretical derivations, empirical evidence, 1578
scanning line source, simultaneous emission/transmission SPECT, 901(ab)
scatter and depth-dependent resolution, 180° myocardial SPECT, 842(ab)
scatter correction and, SPECT quantification, cardiac imaging, 2232
simultaneous transmission and emission, three-detector SPECT, 901(ab)
SPECT
dual-energy X-ray CT, 901(ab)
iterative methods, 962(ab)
use of map, simple method, 843(ab)
Tc-99m HMPAO SPECT brain imaging, 1875
Tl-201 SPECT, differential attenuation, thallium photons, 1574
volume imaging PET scanner, 862(ab)
whole body PET, 862(ab)
Autopsy, -diagnosed dementia, SPECT perfusion imaging, 939(ab)
Autoradiography
dual-isotope
computed radiography, 1005(ab)
Tc-99m sestamibi and Tl-201, uptake in rabbits, 993(ab)
electron microscopic, intracellular distribution of I-125 MIBG, neuroblastoma xenografts, 1021(ab)
heterogeneous activity distribution, In-111 radiopharmaceuticals, rat tissues, 1825
quantitative
CEA concentration measurement, adenocarcinoma, 892(ab)
radiopharmaceutical uptake, dose heterogeneity, 1833
Avidin
-biotin, localization of infection, 1816
-biotin immunoscintigraphy, pharmacokinetics, biotin-chelate conjugates, 880(ab)
imaging atherosclerotic lesions, monoclonal antibody Z2D3, 934(ab)
kidney uptake, isoelectric point, 986(ab)

B

4-BACE, 4-ICE and, chelating agents, 985(ab)
Back
low pain
180° SPECT of the spine, 950(ab)
SPECT *vs.* planar bone scintigraphy, 868(ab)
zygopophyseal joint injection, SPECT and planar bone scintigraphy, 868(ab)
Barre-Liou syndrome, Tc-99m HMPAO SPECT, cervical manipulation, 972(ab)
Basal ganglia
quantification, reiterative reconstruction, 878(ab)
uptake, quantitation with SPECT, monkey brain phantom, 963(ab)
B-cells, anti-pan B-cell antibodies, I-131 radioimmunotherapy, B-cell lymphoma, 863(ab)
Behavior, obsessive-compulsive disorder, cerebral blood flow, defects demonstrated by three-dimensional SPECT, 838(ab)
Benperidol analogs, D-2 receptor-specific PET tracers, 848(ab)
Benzamides, substituted, superior PET ligand, cerebral dopamine D2 receptors, 847(ab)
Benzodiazepine
central type receptors in baboons, triazolam, PET, 973(ab)
medication, benzodiazepine receptor occupancy, SPECT, 887(ab)
Berson-Yalow Award, FDG uptake in tumors, 15N(7)
Bicycle ergometry, first-pass radionuclide angiography, exercise-induced myocardial ischemia, 359
Bile
extravasation in presence of ascites, hepatic transplantation, scintigraphy, 115
lakes in liver transplant infarcts, hepatobiliary scintigraphy, 997(ab)
Bile duct, clearance measured by radionuclide injection, endoscopic nasobiliary drainage tube, gallbladder stone, 997(ab)
Biliary atresia, diagnostic criteria, neonatal jaundice, Tc-99m EHIDA hepatobiliary scintigraphy, 899(ab)
Biopsy, -confirmed residual Hodgkin's disease, mediastinum, Ga-67 SPECT, 345
Biotin
-avidin, localization of infection, 1816
-chelate conjugates, pharmacokinetics, pretargeted avidin-biotin immunoscintigraphy, 880(ab)
conjugates, anti-pan-carcinoma NR-LU-10 monoclonal antibody, radioimmunotherapy, 880(ab)
conjugation of human immunoglobulin, dendrimers as linker molecules, inflammation detection, 986(ab)
-deferoxamine derivatives, plasma stability, pharmacokinetics, 880(ab)
derivatives, evaluation, Tc-99m, 920(ab)
imaging atherosclerotic lesions, monoclonal antibody Z2D3, 934(ab)
radiolabeled, imaging infection/inflammation, streptavidin, 924(ab)
streptavidin
localization of infection, 1810
and tumor localization, substitute for antibody, 934(ab)
Bis(dithiocarbamato)nitrido Tc(V), subcellular distribution, myocardium cells, male rats, 850(ab)
Blood
clot imaging, preparation and evaluation, I-123 hirulog, 981(ab)
continuous withdrawal and counting systems, factors affecting dispersion correction, 1010(ab)
myocardial extraction of teboroxime, 94
reinfusion, infection-control problems, nuclear medicine departments, 13N(4)
whole, direct method of cell-labeling, In-111 antisense oligonucleotide, 980(ab)
Blood-brain barrier
regional transport, glucose and fluorodeoxyglucose, 1819
transport of glucose and fluorodeoxyglucose, regional variations, 908(ab)
Blood flow
bone, influx rate, F-18 PET, 937(ab)
brain
high-resolution I-125 imaging, plastic scintillation detectors, 1003(ab)
interventional neuroradiology, SPECT, 826(ab)
cerebral
brain maturation, children and adolescents, 696
brain perfusion Tc-99m ECD SPECT, PET comparison, 966(ab)
brain tumors and strokes, HMPAO-SPECT and MRI technique, 971(ab)
brain tumors and strokes, Tc-99m HMPAO SPECT, 971(ab)
dementia, differential diagosis, 1014(ab)
dementia, Parkinson's disease, 1012(ab)
Down's syndrome, Tc-99m HMPAO brain SPECT, 1013(ab)
glucose metabolism, patient surviving after CO intoxication, 1696
hyperventilation, temporal lobe epilepsy, 968(ab)
I-123 IMP SPECT, no arterial sampling, 969(ab)
impairment in myotonic dystrophy, 839(ab)
improvement with treatment, chronic cocaine polydrug users, 887(ab)
infantile spasms, 1018(ab)
linearization algorithm, Tc-99m HMPAO SPECT, 912(ab)
mapping of, 1843
mean transit time, index of organ perfusion, 1004(ab)
N-isopropyl[I-123]IMP SPECT, 1741
N-isopropyl-(I-123) p-iodoamphetamine, SPECT, 965(ab)
obsessive-compulsive disorder, defects demonstrated by three-dimensional SPECT, 838(ab)
partition coefficient, I-123 IMP SPECT and O-15 water PET, 911(ab)
partition coefficient, I-123 IMP SPECT, 911(ab)
photic stimulation study, arterial partial pressure of carbon dioxide, 827(ab)
predetermined ROIs, Xe-133 SPECT in children, 977(ab)
regional variation in statistical maps, 1008(ab)
rotating gamma camera, I-123 IMP, 963(ab)
simultaneous SPECT acquisitions, glucose metabolism, 965(ab)
Tc-99m HMPAO and I-123 IMP, SPECT and MRI, 1012(ab)
Tc-99m HMPAO brain SPECT, choreo-athetoid syndrome, 838(ab)
Tc-99m HMPAO brain SPECT, variability, 826(ab)
Tc-99m HMPAO SPECT, chronic subdural hematoma, 246
Tc-99m HMPAO SPECT, Wisconsin card sorting test, 967(ab)
coronary, uptake of tetrofosmin, rabbit heart, 846(ab)
flow reserve measurements and, viable and non-viable myocardium, 856(ab)
global cerebral, Tc-99m ECD and planar imaging, Rhesus monkeys, 979(ab)
hepatic arterial-to-portal venous, ratio, radionuclide techniques in an animal

model, 239
hippocampal, diagnosis of Alzheimer's disease, SPECT, 940(ab)
MIBG heart and lung extraction fraction, first-pass analysis, 716
myocardial
co-injection technique, 1152
deoxyglucose uptake, myocyte viability in ischemia, 1353
expected variability, anesthetized canine, 884(ab)
glucose uptake in ischemic myocardium, F-18 deoxyglucose, 1346
methods for quantification, N-13 ammonia PET, 881(ab)
misonidazole retention, occlusion of LAD coronary artery, 993(ab)
perfusion, Tc-99m tetrofosmin, 993(ab)
polar map displays, cardiac PET, 1628
quantification, 172(le)
Tc-99m Q12 activity, canine heart, 993(ab)
penile, tumescence, dual-radioisotopic technique, 41
portal venous, pulsed Doppler and per-jejunum scintigraphy, liver cirrhosis, 997(ab)
pulmonary, protein flux measurements, PET, 1661
regional cerebral, 14N(8)
renal, convection-diffusion model, 949(ab)
stroke, clinical prognosis, SPECT, 878(ab)
tumor, breast cancer, before and after treatment, 1020(ab)
unilateral major cerebral artery occlusive disorders, crossed cerebellar hypoperfusion, 1637
variations, N-13 ammonia, lack of correlation with other methods, 837(ab)

Blood pool imaging, spillover, method for correction, dynamic cardiac FDG PET, 882(ab)

Blue Cross/Blue Shield, approval of neurological indications for PET, 40N(11)

Bone
benign and malignant lesions, Tc-99m MIBI uptake, Tc-99m MDP, 319
blood flow and influx rate, F-18 PET, 937(ab)
diagnosis of femoral head avascular necrosis, triple-head high-resolution SPECT, 936(ab)
dual bone and WBC scan imaging, osteomyelitis and cellulitis, planar and SPECT imaging, 839(ab)
extraosseous Tc-MDP uptake, pathophysiologic approach, 1063(ab)
formation, radiotherapy and, 1780
fracture, accumulation of F-18 FDG, Tc-99m MDP, 869(ab)
joint inflammation
Tc-99m HIG, 839(ab)
Tc-99m HIG, rheumatoid arthritis, 840(ab)
lesions, Tl-201 uptake pattern, 869(ab)
mass, optimization, follow-up measurements, 1406
metabolism, local and systemic effects of radiation, quantitative SPECT, 1774
metastases, pharmacokinetics, Re-186 after Re-186-HEDP, 646
metastases of prostate carcinoma, strontium-89, low-dose infusion cisplatin, 1437
metastatic cancer, escalating dose schedule, Sm-153 EDTMP, 1451
metastatic disease, multidose Sm-153 EDTMP, pain palliation, 992(ab)
mineral and body composition, dual energy X-ray absorptiometry, fan-beam design, 1063(ab)
mineral assessment, forearm, 1251(le)
mineral content and density, healthy twelve-year-old white females, 1143
mineral density
axial skeleton, acromegaly, 1608
dual-energy X-ray absorptiometry, skeletal sites, 1137
influence of parathyroidectomy, 869(ab)
predictor for osteoporosis, risk factor assessment, 869(ab)
mineral density and spine fracture, cyclic oral phosphate, etidronate, 1
pain, prostate carcinoma, Re-186 HEDP, 859(ab)
pain from metastases, different therapeutic doses, Sr-89, 937(ab)
planar scintigraphy and SPECT, zygapophyseal joint injection, chronic low back pain, 868(ab)
radionuclide scan
MRI imaging, detection of spinal metastases, 992(ab)
osteoid osteoma, 269
scan
chest X-rays and I-131 scans, well-differentiated thyroid cancer, 894(ab)
skeletal nonvisualization, intravenous etidronate therapy, 748
scintigraphy
intravenous pamidronate, Paget's disease, 1589
SPECT, low back pain, 868(ab)
Tc-99m MDP abdominal uptake, continuous ambulatory dialysis, 2052
scintigraphy and I-131 MIBG, detection of neuroblastoma, 1735
scintigraphy in preschool children, lower extremity pain of unknown origin, 351
-seeking agents, comparision, mechanistic implications, 899(ab)
skeletal kinetics, F-18 fluoride ion PET, 633
soft tissue sarcoma and, Tl-201 scan patterns, 843(ab)
180° SPECT of the spine, patients with LBP, 950(ab)
stress fractures, osteosarcoma, lower limb, 1699
subchrondral infractions, acute ligamentous knee injuries, scintigraphy and MRI, 516
suspected infections, Tc-99m anti-granulocyte antibodies, 526
-to-marrow interface
calulation of radiation dose, 1915(le)
radiation dose calculation, Monte Carlo modeling, 623

Bone marrow
body and blood clearance, I-131 Lym-1, B-cell malignancies, 941(ab)
hypermetabolic, Tl-201-chloride uptake, granulocyte stimulating factor, 2014
macro- and microscopic biodistribution, In-111, rats, 954(ab)
MRI and scintigraphy, staging, breast cancer, 914(ab)
radiation absorbed dose estimation, I-131 radioimmunotherapy, leukemia, 941(ab)
scintigraphic changes, hormonal changes, 1427(le)
suppression induced by I-131 monoclonal antibody therapy, recombinant G-CSF, 933(ab)
toxicity of I-131 monoclonal antibody fragments, 941(ab)
value of scanning, possible orthopedic infections, 840(ab)

Book reviews
Biochemistry of Ionizing Radiation, 1725
Computed Tomography and Magnetic Resonance of the Thorax, 470
Future of Human Radiation Research, The, 821
Guidelines for the Evaluation of Radiologic Technologies, BIR Working Party Report, 819
Handbook of Nuclear Medicine: Volume 2: Heart, 1918
ICRP Publication 60, 1990 Recommendations of the International Commission on Radiological Protection, 821
Imaging of the Thyroid and Parathyroid Glands, 820
Interventional Computed Tomography, 179
Medical Radiation Protection Practice Within the EEC, 820
Musculoskeletal Imaging: MRI, CT, Nuclear Medicine and Ultrasound in Clinical Practice, 1254
NCRP REPORT No. 110, Some Aspects of Strontium Radiobiology, 819
Nuclear Hepatology, 1254
Nuclear Medicine: A Teaching File, 1918
Nuclear Medicine in Gastroenterology, 470
Radiation and Thyroid, 179
Safe Use of Diagnostic Ultrasound, The, 820
Selected Atlases of Gastrointestinal Scintigraphy, 1254
Textbook of Radiopharmacy: Theory and Practice, 819

Brain
accuracy of perfusion SPECT, differential diagnosis, dementia, 1017(ab)
adult mouse, activity-related plasticity, benzodiazepine receptors, 883(ab)
alcohol intoxication, cocaine distribution and kinetics, 946(ab)
altered tritiated nicotine accumulation, senescence accelerated mouse, 1023(ab)
arrival delay of O-15 tracers, intravascular radioactivity, 909(ab)
auditory cognitive task, event-related potentials, O-15 water PET, 1016(ab)
benzodiazepine receptors, C-11 flumazenil PET, 1011(ab)
biodistribution and monkey PET imaging, C-11 tetrabenazine, monoaminergic neurons, 870(ab)
blood flow, interventional neuroradiology, SPECT, 826(ab)
blood flow and high-resolution I-125 imaging, plastic scintillation detectors, position-sensitive photomultipliers, 1003(ab)
C-11 cocaine, distribution and kinetics, 521
cerebral blood flow, glucose metabolism, patient surviving after CO intoxication, 1696
cerebral cortical activity, Tc-99m HMPAO, scintigraphy, 117
cerebral dopamine D2 receptors, superior PET ligand, 847(ab)
cerebral glucose uptake, hyperglycemia, 1-(C-11) D-glucose, 908(ab)
cerebral language area, O-15 water PET, 2D brain surface map, 857(ab)
cerebral metabolism
epilepsy and disease duration, PET, 1018(ab)
standardized approach, controlled behavioral conditions, 1011(ab)
cerebral perfusion
abnormalities, SPECT and Alzheimer's disease, 973(ab)

imaging in AIDS, 827(ab)
progressive supranuclear palsy, 704
Tc-99m HMPAO, internal carotid artery occlusion, 969(ab)
cerebrovascular reserve capacity, stenosis of carotid artery, thrombendarteriectomy, 971(ab)
cerebrovascular response to acetazolamide, Tc-99m DTPA-HSA, new method for monitoring, 969(ab)
cerebrum and cerebellum, carbon dioxide reactivity, Tc-99m HMPAO SPECT, 1014(ab)
chronic subdural hematoma, cerebral blood flow, Tc-99m HMPAO SPECT, 246
clinical neurological PET, interactive computer-based atlas, 1071(ab)
cortical areas, visual imagery of reading, PET study with O-15 butanol, 908(ab)
crossed cerebellar diaschisis, cerebral infarction, 877(ab)
crossed cerebellar hypoperfusion, unilateral major cerebral artery occlusive disorders, 1637
cylindrical SPECT system, McSPECT prototype, 852(ab)
death
assessment, Tc-99m CEROTEC scan, 970(ab)
comparative study, TcGH and TcHMPAO, 1016(ab)
diagnostic dilemma, 2211
timely declaration, Tc-99m HMPAO cerebral perfusion scintigraphy, 2209
decreased binding of C-11 cocaine, cocaine addicts, 888(ab)
decreased glucose metabolism, Cushing disease, FDG PET, 834(ab)
developmental cognitive disorders, F-18 FDG PET, 973(ab)
disease detection, cognitive and pharmacological challenges, 1019(ab)
dopamine changes in cocaine abusers, 887(ab)
dual-isotope brain SPECT, Tc-99m and I-123, 2030
dual-isotope imaging in normal volunteers, Tc-99m HMPAO, I-123 IMP, 827(ab)
dual-isotope SPECT, headtome set 031, phantom study, 1017(ab)
examination of visual mental imagery with PET, 908(ab)
F-18 DOPA uptake, delayed L-phenylalanine infusion, 1383
F-18 FDG PET and MRI anatomy, registered atlas, 1071(ab)
F-18 4-fluoro-4-deoxy-D-glucose imaging agent, 983(ab)
feasibility of cortical activation study, sequential Tc-99m HMPAO SPECT, subtraction method, 1015(ab)
functional, SPECT, powerful clinical method, 1888
functional and structural deficits, young alcoholics, PET and MRI, 1070(ab)
functional scans, evidence in criminal court, 18N(6)
glucose metabolic rates, 30- and 45-minute acquisitions, 2103
glucose metabolism, sensitive marker, Alzheimer's disease, 940(ab)
grammatical and semantic components, sentence comprehension, PET activation study, 1012(ab)
hippocampal blood flow, diagnosis of Alzheimer's disease, SPECT, 940(ab)
hypometabolic parietal cortex, unaltered benzodiazepine receptors, Alzheimer's disease, 887(ab)
imaging of subdural hematoma, current role of SPECT, 248
I-131 MIBG approval, 33N(9)
immature third ventricle teratoma, radiographic and neuro-SPECT imaging, 435
improved SPECT, maximum-likelihood reconstruction, 964(ab)
independent aura/ictal/interictal cerebral perfusion, 438
interictal cerebral glucose metabolism, spontaneously epileptic rat, 1024(ab)
intracranial abscess, differential diagnosis, Tc-99m antigranulocyte antibody, 957(ab)
kinetic behavior, Tc-99m HMPAO SPECT, 135
left premotor cortex specialization, finger movements, FDG PET, 857(ab)
living human; C-11 WIN 35,428; dopamine transporter site, 964(ab)
low grade and anaplastic astrocytomas, FDG PET, 966(ab)
maturation in children and adolescents, changes, regional cerebral blood flow, 696
model-based quantitation, knowledge-based factor analysis, 947(ab)
monoclonal antibody specific for β/A4 amyloid, Alzheimer's disease, angiopathy, 2184
neoplasms, *see* Brain neoplasms
neural crest tumors, I-123 MIBG, 1072(ab)
neuroma, PET-fluorodeoxyglucose, 1931
nigrostriatal function in FDOPA PET studies, ratio method and graphical analyses, 945(ab)
non-human primate, monoamine transporter sites, I-123 CIT SPECT, 945(ab)
perfusion pattern in late life depression, 838(ab)
perfusion SPECT, cocaine abuse, AIDS dementia complex, 887(ab), 1312
perfusion SPECT with Tc-99m ECD, regional cerebral blood flow, PET comparison, 966(ab)
PET
automated stereotactic transformation, 1007(ab)
MR images and, accuracy of surface fit registration, 921(ab)
use of linear programming, glucose utilization, 944(ab)
phantom design for computer simulation, image reconstruction algorithms, physiologic models, 1012(ab)
quantification of human basal ganglia, iterative reconstruction, 878(ab)
quantitation of basal ganglia uptake, SPECT, monkey brain phantom, 963(ab)
rapid registration and review, MR, CT and SPECT, 1067(ab)
regional cerebral perfusion
Landau-Kleffner syndrome, related childhood aphasias, 1758
preclinical studies, Tc-99m T691, 1836
regional cerebral uptake, Tc-99m exametazine, unilateral voluntary hand movement, 1623
retention of Tc-99m bicisate, effect of radiolabeled impurities, dosimetry, 989(ab)
same living human, dopamine receptor density, C-11 raclopride and NMSP, 847(ab)
somatosensory stimulation in thalamic lesions, O-15 water PET, 858(ab)
SPECT
attenuation effect, 961(ab)
cerebral angioplasty, delayed ischemia due to vasospasm, 1789
D-2 dopamine receptors, 2′-iodospiperone, 897(ab)
dual radionuclide data acquisition, Tc-99m and I-123, 972(ab)
extracorporeal membrane oxygenation, neonates, 1943
multimedia multimodality interactive computer tutorial, 1071(ab)
relative error-estimation, regional analysis, 969(ab)
transcranial Doppler, acute ischemic stroke therapy, 968(ab)
SPECT grey matter imaging, iterative reconstruction algorithm, 1225
stereotactic biopsy, PET-defined targets, 868(ab)
stereotactic metabolic atlas, functional brain imaging, 858(ab)
stimulated auditory cortex, proton NMR spectroscopy, 974(ab)
striatal FDOPA uptake, cerebral glucose metabolism, patients with chorea, 1015(ab)
surgery and irradiation, Tl-201 imaging, quantification using an animal model, 964(ab)
synthesis, isomers of Tc-99m ECD, monkeys, 979(ab)
Tc-99m, elimination of chiral centers, coordination sphere, 920(ab)
Tc-99m HMPAO
angiography, quantitative approach, 877(ab)
high-resolution SPECT, neurofocal imaging, 1070(ab)
Tc-99m HMPAO SPECT
bilateral and symmetrical anomalies, 485
cerebral blood flow, choreo-athetoid syndrome, 838(ab)
rCBF variability, 826(ab)
regional cerebral blood flow, Down's syndrome, 1013(ab)
temporal lobe metabolism, refractory epilepsy, asymmetry in FDG PET scans, 928(ab)
three-dimensional functional images, automated method, rotational correction, 1579
three-dimensional images, automated method, anatomical standardization, 1003(ab)
Tl-201 SPECT, re-evaluation for brain tumor, 844(ab)
traumatic injury
remote history of, Tc-99m HMPAO SPECT, 52
skeletal screening, children, 873(ab)
tumor marker, [1-^{11}C]putrescine, 192, 200
uptake of 6-[F-18] FDOPA, 916(ab)

Brain neoplasms
childhood, Tc-99m MIBI/Tl-201 SPECT, 844(ab)
comparison of kinetics, Tc-99m ECD and Tc-99m HMPAO, SPECT and compartment model, 969(ab)
dynamic PET, 1-aminocyclobutanc[C-11] carboxylic acid, 2-compartment model, 922(ab)
FDG studies, PET resolution, visual interpretation, 872(ab)
primary, MRI and PET studies, 867(ab)
recurrence
Tl-201 and Tc-99m MIBI MRI, 867(ab)
Tl-201 SPECT studies, 867(ab)
recurrent primary, Tl-201 SPECT, 1071(ab)
recurrent supratentorial and infratentorial, Tl-201 SPECT and F-18 FDG PET, MRI, 867(ab)
strokes and, cerebral blood flow, HMPAO-

SPECT and MRI technique, 971(ab)
therapy, F-18 FDG PET, 1071(ab)
Breast, tissue attenuation, myocardial imaging, 961(ab)
Breast neoplasms
autogenous reconstruction, transverse rectus abdominus myocutaneous flap, Tc-99m dextran lymphoscintigraphy, 859(ab)
before and after treatment, tumor blood flow, 1020(ab)
c-*erb*B2 protein overexpression, I-124 monoclonal antibodies, PET, 2154
labeled BC-2 monoclonal antibody, 999(ab)
locoregionally advanced, preoperative chemotherapy, F-18 FDG-PET, 828(ab)
metastatic
clinical value, CA 15-3 plasma levels, 854(ab)
radioimmunotherapy, 862(ab)
prognosis, internal mammary lymphoscintigraphy, 859(ab)
quantitative dynamic and whole body FDG PET, 828(ab)
radioimmunolocalization, In-111 BrE-3 antibody, Phase I study, 912(ab)
radiolabeled antibodies, oncogene-encoded molecules, tumor imaging and therapy, 2160
staging, MRI and scintigraphy, bone marrow, 914(ab)
Bremsstrahlung, imaging using gamma camera, factors affecting attenuation, 161
Bronchoalveolar lavage, pulmonary disposition of Ga-67, *Pneumocystis* pneumonia, 512
Budd-Chiari syndrome
hepatic necrosis, Tc-99m medronate, 1390
monitoring by I-123 iodoamphetamine scintigraphy, *per os* and *per rectum*, 744

C

CA 15-3, clinical value of plasma levels, follow-up, metastatic breast cancer, 854(ab)
CA 125
human/mouse chimeric monoclonal antibody, ovarian cancer radioimmunoimaging, 1001(ab)
Tc-99m monoclonal antibody, early detection, ovarian cancer recurrences, 904(ab)
Caffeine, serum levels following 24-hr abstention, myocardial perfusion, dipyridamole or adenosine, 866(ab)
Calcium carbonate, cyclic oral phosphate and etidronate, bone mineral density, spine fracture, 1
California, radioactive waste site, licensing decision, 40N(9)
Camera: *see also* Gamma camera
-based method, calculation, Tc-99m MAG_3 clearance, 948(ab)
major changes in nuclear cardiovascular codes, 19N(1)
multicrystal scintillation, single radiopharmaceutical, left ventricular perfusion and performance, 1411
Cancer
CEA-producing, radioimmunodetection, 1750
clinical applications of PET, 330
imaging with two diasteromers, octreoscan-111, 900(ab)
methods and performance characteristics, whole-body PET, 1191
radioimmunotherapy, 1110
therapy, absorbed dose calculations, rapidly growing tumors, 277
Captopril
diuretic therapy, renal functional response, 739
-enhanced scintigraphy, renal artery stenosis, en-bloc pediatric renal transplant, 263
-mediated hemodynamic changes, renal ischemia, 907(ab)
renal scintigraphy
distinguishing functional from anatomic renal artery stenosis, 2045
prognostic value, renovascular hypertension, 2040
unexpected pressor responses, 906(ab)
vs. captopril test, renovascular hypertension, 907(ab)
renography
cortical residual activity, renal artery stenosis, 906(ab)
segmental branch renal artery stenosis, 266
-stimulated PRA, bilateral renal artery stenosis, 907(ab)
Tc-99m MAG_3 scintigraphy, renal artery stenosis, 990(ab)
CARBIDOPA
FDOPA PET studies, nigrostriatal function, ratio method and graphical analyses, 945(ab)
6-[^{18}F]fluoro-L-dopa kinetics, PET, 1472
Carbohydrate, modification, localization of human polyclonal IgG, sites of bacterial infection, 1378
Carbon-11
alkylations, radiochemistry, microwave fields, 1026(ab)
contribution to PET imaging, labeled carbon dioxide, 581
incorrectly labeled reagent, 465(le)
Carbon-11 1,2-diacylglycerols, membrane trapping, phosphatidylinositol turnover, neurotransmission process, 413
Carbon-11 acetate
accelerated clearance, PET ischemic segments, 856(ab)
PET
compared with F-18 FDG, recovery after revascularization, 855(ab)
oxidative metabolism, infarcted and periinfarcted myocardium, 953(ab)
Carbon-11 carazolol, PET, evaluation in pigs, 885(ab)
Carbon-11 carfentanil, PET, effect of nitrous oxide, endogenous opiate system, 883(ab)
Carbon-11 CFT, dopamine fiber loss in Parkinsonism, 946(ab)
Carbon-11 CGP 12177, PET, mechanisms of down-regulation, idiopathic cardiomyopathy, 896(ab)
Carbon-11 cocaine
decreased binding in brain, cocaine addicts, 888(ab)
distribution and kinetics, PET, human body, 521
Carbon-11 doxepin, C-11 pyrilamine and, imaging of H1 histamine receptors, heart, 885(ab)
Carbon-11 FLB 457, preparation of, 860(ab)
Carbon-11 flumazenil
binding to benzodiazepine receptors, chronic alcohol-dependent men, PET and MRI, 1016(ab)
PET, benzodiazepine receptors, human brain homogenates, 1011(ab)
Carbon-11 forskolin, potentiality for imaging, cAMP-related second messenger system, 1025(ab)
Carbon-11 D-glucose, cerebral glucose uptake, hyperglycemia, 908(ab)
Carbon-11 HED
kinetics in rat heart, 870(ab)
PET, localization of pheochromocytoma, 1125
trans-Carbon-11 McN-5652, PET, serotonin uptake sites, 860(ab)
Carbon-11 methionine, PET, effective method, imaging of head and neck cancer, 691
Carbon-11 methylaltanserin, C-11 methylketanserin and, mapping serotonin receptors, 1026(ab)
2-Carbon-11 methyl-amino-2-methyl-3-phenyl-1-propanol, PET, serotonin uptake sites, 861(ab)
Carbon-11 MK-912, compared to C-11 WY 26703, *alpha*-2 adrenoceptor ligands, 861(ab)
Carbon-11 monoxide, ECG gated PET, "background" question, planar Tc-99m gated blood-pool imaging, 938(ab)
Carbon-11 NMPB, tracer kinetic analysis, binding, muscarinic cholinergic receptors, 882(ab)
Carbon-11 NMSP, PET, D-2 dopamine receptor densities, 848(ab)
Carbon-11 NNC 722, potential radioligand, dopamine uptake system, 931(ab)
Carbon-11 putrescine
brain tumor, 200
usefulness as brain tumor marker, 192
Carbon-11 pyrilamine
C-11 doxepin and, imaging of H1 histamine receptors, heart, 885(ab)
distribution, H1 receptor blocking drugs, 968(ab)
Carbon-11 raclopride
NMSP and, dopamine receptor density, same living human brain, 847(ab)
plasma, robotic solid phase extraction assay, 853(ab)
Carbon-11 RO 15-4513, visualization of benzodiazepine receptor binding, 860(ab)
Carbon-11 SAH
PET
myocardial energy balance, 2144
regional cardiac adenosine, 2138
Carbon-11 tetrabenazine
PET
brain biodistribution, monoaminergic neurons, 870(ab)
monoamine terminals, 983(ab)
synthesis, PET imaging, monoamine terminals, 983(ab)
Carbon-11 thymidine, PET, kinetic modeling, DNA synthesis, 1009(ab)
Carbon-11 2α-tropanyl benzilate, synthesis and biodistribution, muscarinic receptor imaging agent, 423
Carbon-11 tyrosine, PET, radiation-induced inhibition, tumor growth, 373
Carbon-11 WIN 35,428, imaging of dopamine transporter site, living human brain, 964(ab)
Carbon-11 YM-09151-2, specific and non-specific binding, age dependency, dopamine D-2 receptors, 897(ab)
Carbon dioxide
arterial partial pressure, photic stimulation study, 827(ab)
labeled
contribution to PET imaging, C-11 labeled compounds, 581
transient metabolite, 585
reactivity in cerebrum and cerebellum, Tc-99m HMPAO SPECT, 1014(ab)

Carbon monoxide, intoxication, cerebral blood flow and glucose metabolism, 1696
2β-Carboxymethoxy-3β-(4-chlorophenyl)-8-(3E- and 3Z-iodopropen-2-yl)nortropanes, radioiodinated, cocaine receptor site mapping, SPECT, 890(ab)
Carcinoembryonic antigen
clinical value of CA 15-3 plasma levels, metastatic breast cancer, 854(ab)
concentration measurement, adenocarcinoma, quantitative autoradiography, 892(ab)
content, role in gastrointestinal tumor targeting, Tc-99m F023C5 anti-CEA IgG1, 892(ab)
In-111 anti-CEA-F(ab')$_2$ fragments, radiation dosimetry, tissue distribution in rats, 1654
monoclonal anti-CEA antibody, Ga-67 anti-CEA 35, colon carcinoma immunoscintigraphy, 1766
-producing cancer, radioimmunodetection, 1750
second generation high-affinity anti-CEA monoclonal antibody, 904(ab)
Carcinoid neoplasms
metastatic, scintigraphic comparison, I-123 MIBG and I-123 TOCT, 1121
somatostatin analog, 914(ab)
Carcinoid syndrome, I-131 MIBG therapy, 834(ab)
Carcinoma, breast, radioimmunodetection, 803
Carcinoma, colonic, immunoscintigraphy, monoclonal anti-CEA antibody, Ga-67 anti-CEA 35, 1766
Carcinoma, colorectal
efficacy and safety, In-111 IVP ZCE 025 monoclonal antibody, 959(ab)
immunoscintigraphy, Loch Ness monster and, 1756
improved demarcation of tumors, dual isotope SPECT immunoscintigraphy, 1000(ab)
metastases detection, In-111 C110 anti-CEA monoclonal antibody, CT, 904(ab)
metastatic, Phase I trial, I-131 chimeric B72.3, 23
pharmacokinetics of In-111 B72.3 monoclonal antibody, 498
pre-operative staging, F-18 FDG PET, 975(ab)
radioimmunodetection, 803
safety and role, In-111 anti-CEA monoclonal antibody ZCE 025, 14
Carcinoma, epidermoid, xenografts, biodistribution, In-111 B3 monoclonal antibody, 842(ab)
Carcinoma, hepatocellular, high-dose targeted irradiation, I-131 lipiodol, 1020(ab)
Carcinoma, ovarian
immunoscintigraphy, I-131 labeled 145-9 monoclonal antibody, 905(ab)
radioimmunodetection, 803
Carcinoma, papillary, thyroidectomy, pelvic radioiodine uptake, rectal wall teratoma, 1848
Carcinoma, prostatic
marrow scintigraphic changes, hormonal therapy, 1427(le)
metastatic
preoperative identification, In-111 CYT-356, 1001(ab)
Sr-89 radiotherapy, 1316
metastatic to bone, strontium-89, low-dose infusion cisplatin, 1437
Re-186 HEDP, bone pain treatment, 859(ab)
Carcinoma, renal cell, radioimmunoscintigraphy, I-131 monoclonal antibody, 913(ab)
Carcinoma, squamous cell, head and neck, radiation-induced response, FDG PET, 829(ab)
Carcinoma, thyroid
autonomously functioning, euthyroid Graves' disease, 2024
detection of metastases, Tc-99m TBI scintigraphy, 914(ab)
differentiated
contribution of Tl-201 scan, 955(ab)
follow-up, Tc-99m MIBI and Tl-201 chloride, 844(ab)
I-123, scintigraphic follow-up, 1020(ab)
Hurthle cell, Tc-99m sestamibi uptake, 1393
I-131 therapy, complications, sequela and dosimetry, 2214
I-131 whole-body scan, replacement with thyroglobulin measurement, 172(le)
two-step immunoscintigraphy, anti-CEA/anti-DTPA bispecific monoclonal antibody, In-111 DTPA dimers, 912(ab)
Carcinoma, thyroid medullary, facile synthesis of Re-188-labeled Rc(V)-DMSA, triphenylphosphine reduction, perrhenate at room temperature, 1024(ab)
Cardiolite, vials and microwave boiling procedure, 468(le)
Cardiology
nuclear probes, 448
second Sino-American nuclear medicine conference, 16N(4)
Cardiomyopathy
Adriamycin
disturbed neuronal energy metabolism, 935(ab)
myocardial damage, In-111 antimyosin antibody, 936(ab)
prediction of congestive heart failure, I-125 MIBG, 935(ab)
Adriamycin-induced, abnormal cardiac adrenergic neuron activity, I-125 MIBG, 208
congestive, Adriamycin, I-125 MIBG, 215
hypertrophic
BMIPP, 1914(le)
myocardial emission computed tomography, 6
idiopathic, mechanisms of down-regulation, C-11 CGP 12177 PET and MIBG imaging, 896(ab)
Cardiotoxicity, Adriamycin, Tc-99m sestamibi, chick heart cells, 864(ab)
Cardiovascular system, major changes in CPT code, 19N(1)
Carditis, rheumatic fever, importance, scintigraphic diagnosis, 995(ab)
Catecholamines
C-11 cocaine, distribution and kinetics, human body, 521
serial measurements of cardiac volumes, count-based methods, 1324
Cations, organic, labeling with Tc-99m, synthesis and renal excretion, 2190
Cellulitis, osteomyelitis and, dual bone and WBC scan imaging, planar and SPECT imaging, 839(ab)
Cellulose, -acetate hemodialyzer, comparative thrombogenicity, 956(ab)
Central nervous system
infectious or malignant lesions, differentiation with FDG PET, AIDS, 838(ab)
primary, lymphoma, F-18 fluorodeoxyglucose PET, 532
Cerebellum, dissociated postnatal rat, uptake mechanisms, Tc-99m D,L-HMPAO, 108
Cerebral palsy, children, quantitative perfusion-defect indexes, Tc-99m HMPAO SPECT, 977(ab)
Cerebrovascular disease, acetazolamide Tc-99m HMPAO SPECT study with PET, 877(ab)
Cesium-137, myth-making at Hanford, 19N(7)
CGP-12177, CGP-26505 and, characterization, β-adrenergic receptors, 870(ab)
Chelating agents
alkylamine conjugation chemistry, labeling of antibodies, 986(ab)
bifunctional, copper-67, 942(ab)
-biotin conjugates, pharmacokinetics, pretargeted avidin-biotin immunoscintigraphy, 880(ab)
comparison of Tc-99m direct *vs.* N2S2 chelate, labeled NR-LU-10 Fab', tumored nude mice, 909(ab)
4-ICE and 4-BACE, 985(ab)
In-111 BAD-Lym-1, radiochemistry and pharmacokinetics, 1030(ab)
In-111 cyclohexl EDTA, anti-CEA F(ab')$_2$ monoclonal antibody, human tumor xenografted nude mice, 943(ab)
methylene bridged phosphineoxide-phosphine, Re-188, 979(ab)
Pd-109, bioconjugates and, 987(ab)
phosphorus hydrazide, bifunctional frameworks, Tc-99m and Re-188, 910(ab)
radiolabeling, antibody-macrocyclic chelate conjugates, 1031(ab)
Re-186 direct *vs.* chelate labeled NR-LU-10 MAb, tumored nude mice, 910(ab)
rigidity and denticity, biodistribution, Y-88 and Pb-203 labeled immunoconjugates, 1030(ab)
structure, In-111 labeled Ab-chelator, liver, 1001(ab)
Chemistry, targeted proteins for diagnostic imaging, 394
Chemotactic peptides, Tc-99m hydrazino nicotinamide, imaging focal sites of infection, 910(ab)
Chemotherapy
early detection of impact, F-18 FDG scintigraphy, malignant lymphoma, 858(ab)
enhanced fluorodeoxyglucose uptake, metabolic design, combination therapy, 1981
-induced kidney disorder, antimyosin antibody uptake, 309(le)
intrarterial carotid artery injection, Tc-99m HMPAO, recurrent glioma, 966(ab)
preoperative, F-18 FDG PET evaluation, locoregionally advanced breast cancer, 828(ab)
Chernobyl, surprise findings of thyroid cancer, 23N(11)
Chest, FDG PET imaging, 975(ab)
Chest pain
acute, myocardial reperfusion imaging, Tc-99m sestamibi, 876(ab)
angina-like, abnormal esophageal motility, gastroesophageal reflux, 955(ab)
spontaneous, coronary intervention, Tc-99m sestamibi SPECT, 875(ab)
Chimera, radiolabeled monoclonal antibodies, 29
Chloramine-T, TCB radioiodinated monomeric antibody P-67, improved tumor retention, 987(ab)
Cholecystectomy, laparoscopic, utility of cholescintigraphy, 898(ab)
Cholecystitis
acute, significance, duodenogastric reflux, 898(ab)
chronic acalculous, specificity, gallbladder ejection fraction, 899(ab)

grading of hyperperfusion and rim sign, biliary scintigraphy, 898(ab)
Cholecystokinin, calculation of gallbladder ejection fraction, continuous sincalide infusion, 3-min infusion method, 537
Cholescintigraphy
morphine-augmented
false-negative, subacute gallbladder perforation, 256
potential pitfalls, 898(ab)
Tc-99m IDA, differentiation, congenital gallbladder abnormality, 431
Cholestasis, intrahepatic *vs.* extrahepatic, hepatobiliary scintigraphy, 1186
Cholesterol, -fed rabbits, radioiodinated endothelin-1, injured aortic tissue, 845(ab)
Chorea, cerebral glucose metabolism, striatal F-DOPA uptake, PET, 1015(ab)
Choreo-athetoid syndrome, cerebral blood flow, brain Tc-99m HMPAO SPECT, 838(ab)
Chromaffin cells
C-11 cocaine, distribution and kinetics, human body, 521
MIBG heart and lung extraction fraction, first-pass analysis, 716
Chromatofocusing, monoclonal Fab′, 2148
Cintichem Corporation, government molybdenum-99 plan, 11N(2)
Cirrhosis, liver, portal venous blood flow, pulsed Doppler and per-jejunum scintigraphy, 997(ab)
Cisplatin, low-dose infusion and strontium-89, hormone refractory prostate carcinoma metastatic to bone, 1437
Citrate dextrose, heparin and, preparation, Tc-99m red blood cells with UltraTag RBC kit, 306(le)
Clean Air Act, amendments, 29N(10)
Cocaine
abuse and AIDS dementia complex, brain perfusion SPECT, 1312, 887(ab)
abusers
brain dopamine changes, 887(ab)
decreased binding, C-11 cocaine, 888(ab)
distribution and kinetics, alcohol intoxication, human brain and heart, 946(ab)
intravenous injection, myocardial sympathetic neuronal function, dogs, 994(ab)
no-carrier added radioiodinated analogs, ligand binding, animal biodistribution, 981(ab)
polydrug users, regional cerebral blood flow, improvement with treatment, 887(ab)
radiolabeled analogs, receptor imaging agent, PET, 1025(ab)
receptors, PET imaging probes, non-human primate model, 946(ab)
receptor site mapping, radioligands, SPECT, 890(ab)
Tc-99m D,L-HMPAO, uptake and respiration, rat brain slices, 964(ab)
Cole, Donald W., Jr., *In memoriam,* 1726
Collimator
cardiofocal, cardiac SPECT, 852(ab)
collimatorless coincidence imaging, computer simulations, 879(ab)
detector interactions and, In-111 imaging, 1004(ab)
distance-dependent blur in SPECT, restoration filter approach, 843(ab)
fan-beam, myocardial SPECT, newborn period and early infancy, 930(ab)
multi-head SPECT camera, sensitivity, resolution and image quality, 1859
penetration, camera-induced scatter, I-131 imaging, 889(ab)
rotating slit, planar scintigraphy, SPECT, 1005(ab)
SPECT collimation, spatially variant focusing, 891(ab)
structure, 1006(ab)
ultra high resolution, unitary construction, cylindrical gamma camera, 852(ab)
variable focal length, fan beam reconstruction algorithms, 891(ab)
Colon, improved transit procedure, easily prepared marker, SPECT, 833(ab)
Colonic neoplasms, metastatic, dose fractionation, radiolabeled antibodies, 1648
Colony-stimulating factor
granulocyte, bone marrow suppression, I-131 monoclonal antibody therapy, 933(ab)
granulocyte-macrophage, thrombocytopenia, hepatic sequestration of In-111 platelets, 923(ab)
Colorectal neoplasms
advanced, radioimmunotherapy I-131 CC49 SPECT, CT, 1002(ab)
Cu-64 antibodies for PET imaging, 1685
imaging considerations, I-131 labeled CC49 monoclonal antibody, 1001(ab)
management with Tc-99m monoclonal antibodies, 904(ab)
two-step targeting of iodinated bivalent haptens, dosimetry, nude mice hosts, 1000(ab)
Commentary
Lines from the President, 31N(3)
radiation safety for beginners, 167
utility of single-photon absorptiometry, dual-energy X-ray absorptiometry, 170
value of "the putrescine experience", 1720
Computed tomography (CT)
brain images, rapid registration, 1005(ab)
comparative study of Tl-201, MRI/angiography, bone and soft tissue sarcoma, 843(ab)
cone beam, image truncation, SPECT gamma camera, 901(ab)
cone beam transmission, imaging of human torso, gamma camera, 150
dual-energy X-ray, attenuation correction, SPECT images, 901(ab)
emission-transmission, prototype imaging system, 1881
fusion with SPECT images, radiolabeled monoclonal antibodies, 960(ab)
Ga-67 scan and, extrapulmonary tuberculosis, 2118
In-111 C110 anti-CEA monoclonal antibody, metastases detection, colorectal carcinoma, 904(ab)
I-131 QSPECT, manual alignment-error compensation, 925(ab)
osteoid osteoma, 269
radioimmunotherapy I-131 CC49 SPECT and, advanced colorectal cancer, 1002(ab)
rapid registration and review, brain, 1073(ab)
standardization, cardiac tomographic imaging, 1434
Tc-99m HMPAO SPECT, remote history, traumatic brain injury, 52
Tc-99m HMPAO SPECT and MR, diagnosis of dementia, 972(ab)
Tc-99m MIBI and Tl-201 scintigraphy, localization, parathyroid enlargement, 895(ab)
Computer and Instrumentation Council, sponsor of first Young Investigators Symposium, 32N(10)
Computers
-aided instruction
nuclear medicine, 1073(ab)
slide presentations, image acquisition, 1066(ab)
system for radiology, 1066(ab)
-assisted diagnosis
artificial neural network, coronary artery disease, 272
pulmonary embolism, ventilation-perfusion lung scanning, 1003(ab)
-based atlas, clinical neurologic PET, 1071(ab)
-based radiology teaching files, 1066(ab)
-based renal nuclear medicine teaching file, 1073(ab)
clinical validation of program, ordinary gamma camera first pass radionuclide angiography, 1064(ab)
-directed coregistration, multislice functional and anatomic images, external fiducials, 961(ab)
graphics for radiologic images, 1068(ab)
high-resolution plain-paper laser printers, hardcopy, nuclear medicine images, 947(ab)
instrumentation and, SNM Mid-Winter Meeting, 23N(1)
interfile file format, transfer of nuclear medicine images, 1007(ab)
Macintosh programs for PET, 1069(ab)
Macintosh tutorial, cross-sectional anatomy, 1063(ab)
major changes in nuclear cardiovascular codes, 19N(1)
model-based quantitation, knowledge-based factor analysis, 947(ab)
multifunctional image-containing database, 947(ab)
multimedia multimodality interactive tutorial, brain SPECT, 1071(ab)
nuclear medicine
efficient management, imaging and non-imaging information, 1006(ab)
multi-media workstation, 947(ab)
workstation, all digital department, 947(ab)
radiologic anatomy, 1067(ab)
simulations
brain phantom design, image reconstruction algorithms, 1012(ab)
collimatorless coincidence imaging, 879(ab)
teaching file for nuclear medicine, 1066(ab)
use of Internet, communications to world community, nuclear medicine, 1067(ab)
use of linear programming, glucose utilization and receptor binding, PET studies of heart and brain, 944(ab)
use of local area networks, intradepartmental distribution, nuclear medicine imaging data, 946(ab)
Congress
government will respond to those who seek influence, 25N(10)
report of disturbing findings, Secretary of Energy, 22N(10)
subcommittee, U.S. radioisotope supply crisis, 16N(10)
support of National Biomedical Tracer Facility, 35N(11)
Contamination
management of exposed or contaminated patient, 1065(ab)
prevention of, I.V. administration, radiopharmaceuticals, 1027(ab)
Contrast material, iodides, potential effects, radioactive thyroid uptake, 237

Copper-61 pyruvaldehyde thiosemicarbazone, quantification of regional canine myocardial perfusion, 884(ab)
Copper-62 PTSM
kinetics in the non-human heart, 684
regional myocardial perfusion, 837(ab)
Copper-64, PET, scintillating fiber detector module, small animals, 1010(ab)
Copper-64 antibodies, PET imaging, 1685
Copper-67
bifunctional chelating agents, 942(ab)
Sm-153 immunoconjugates, tumor therapy, 942(ab)
Copper-PTSM, retention of, complete ischemia-reperfusion, 1026(ab)
Coronary artery disease (CAD)
adenosine stress, N-13 ammonia myocardial perfusion PET, 825(ab)
adenosine thallium scintigraphy, high cardiac risk, patients referred for vascular surgery, 952(ab)
areas of reverse redistribution, planar thallium imaging, viability with PET, 886(ab)
chronic
identification of viable myocardium, 505
rest-redistribution Tl-201, relation to Tc-99m MIBI, 905(ab)
clinical validation of computer program, ordinary gamma camera, first pass radionuclide angiography, 1064(ab)
comparison of rest-redistribution Tl-201 uptake, resting sestamibi uptake, 905(ab)
computer-aided diagnosis, artificial neural network, 272
continuous SPECT imaging protocol, Tc-99m tebo and Tl-201, 1304
detection of total ischemic myocardium at jeopardy, combination of flow reserve with metabolic assessment, 837(ab)
dobutamine and exercise, Tc-99m sestamibi, 951(ab)
dobutamine Tc-99m sestamibi SPECT, 866(ab)
early and delayed myocardial Tc-99m sestamibi SPECT, 855(ab)
echocardiography, 866(ab)
effect of patient motion, tomographic perfusion imaging, 1566
exercise-induced myccardial ischemia, first-pass radionuclide angiography, bicycle ergometry, 359
extent and location, Tl-201 tomography with pharmacologic stress, 2067
incremental diagnostic value and impact, patient treatment, thallium scintigraphy, 1727
incremental value of diagnostic test, cost consciousness, 1732
integration of wall kinetic and perfusion data, tomographic myocardial perfusion scintigraphy, 933(ab)
lung thallium uptake, adenosine Tl-201 scintigraphy, 1600
metabolic cardiac imaging, I-123 IPPA, multicrystal gamma camera, 1269
myocardial imaging, Tc-99m tetrofosmin, 875(ab)
myocardial ischemia, hemodynamic-scintigraphic study, adenosine infusion, 952(ab)
myocardial viability, Tl-201 SPECT *vs.* F-18 FDG PET, 886(ab)
nuclear probes in cardiology, 448
planar gated imaging, 866(ab)
planar myocardial perfusion imaging, Tl-201, Tc-99m sestamibi and Tc-99m teboroxime, 1091
predictive value of dipyridamole thallium imaging, myocardial bridging, 1905
regional glucose metabolism, relation to perfusion, 856(ab)
regional perfusion reserve, noninvasive determination, N-13 ammonia PET, 826(ab)
retrospective post therapy evaluation, cardiac function, PET, 885(ab)
Tc-99m sestamibi myocardial SPECT imaging, comparison, short and standard data acquisition, 855(ab)
Tc-99m sestamibi perfusion, left ventricular ejection fraction, 847(ab)
teboroxime resting washout, stress thallium SPECT, 876(ab)
Coronary stents, platelet/fibrin deposition, anticoagulation, minipig model, 845(ab)
Corticotropin-releasing factor, radioiodinated, potential tracer, CRF-receptor imaging, 996(ab)
Cortisol, adrenocortical scintigraphy, unilateral incidentally discovered adrenal or juxtaadrenal masses, 996(ab)
Court system, criminal, functional brain scans, 18N(6)
Crossed cerebellar diaschisis, hypoperfusion, unilateral major cerebral artery occlusive disorders, 1637
Curshmann-Steinert, myocardial involvement, I-123 IPPA SPECT, 995(ab)
Cushing's disease, decreased cerebral glucose metabolism, FDG-PET, 834(ab)
Cyclic AMP, -related second messenger system, potentiality, C-11 forskolin, 1025(ab)
Cyclotron, industry split over approval, PET tracers, 24N(9)
Cyst, epidermoid inclusion, Tl-201 accumulation, 1857
Cystic fibrosis, effectiveness of PEP mask, Tc-99m DTPA aerosol ventilation, 835(ab)
Cystography
cyclic voiding, vesicoureteral, asymptomatic siblings, 873(ab)
radionuclide, vesicoureteral reflux, children and adolescents, 1022(ab)
Cytomegalovirus, accuracy of early gallium imaging, pulmonary infection, immunocompromised patients, 957(ab)

D

Deferoxamine, -biotin derivatives, plasma stability, pharmacokinetics, 880(ab)
Dementia
accuracy in diagnosis, PET imaging, 967(ab)
atypical, comparison, FDG PET and MRI data, 965(ab)
autopsy-diagnosed, SPECT perfusion imaging, 939(ab)
delayed SPECT and regional cerebral blood flow, I-123 IMP, 1015(ab)
differential diagnosis
brain perfusion SPECT accuracy, 1017(ab)
rCBF/SPECT and MRI, 1014(ab)
Tc-99m HMPAO, 939(ab)
functional brain SPECT, powerful clinical method, 1888
HIV, qualitative approach, SPECT, 1018(ab)
multiinfarct and degenerative, impairment of cognitive functions, extent of disturbance, 940(ab)
patterns of, Alzheimer's disease, 1431(le)
sensitivity and specificity, Tc-99m HMPAO SPECT, 1013(ab)
Deoxyglucose, hexadecylphosphocholine and, design of combination therapy, FDG uptake measurements, 1019(ab)
Department of Energy (DOE)
competition for research dollars, 15N(2)
GAO probe of U.S. isotope troubles, 22N(9)
government molybdenum-99 plan, slow advancement, 11N(2)
government relations update, 16N(3)
isotope problems, 34N(10)
myth-making at Hanford, 19N(7)
National Biomedical Tracer Facility, 33N(9)
panel to reconsider advanced neutron source, 32N(10)
questions about future, isotope production and research, 13N(6)
research appropriations, 30N(12)
Depression
late life
brain perfusion pattern, 838(ab)
F-18 FDG PET, 1013(ab)
schizophrenia and, Tc-99m HMPAO SPECT, 972(ab)
Dexamethasone, lack of suppression, adrenal SPECT, primary aldosteronism, 834(ab)
Diabetes
gastric motility disturbances, scintigraphy, 832(ab)
gastroparesis, gastric emptying rate, variable oral erythromycin, 833(ab)
infectious foot complications, In-111 human nonspecific IgG, 950(ab), 1330
insulin-dependent, secondary gastroparesis, 1707
type 2 patients, oral glucose solution, rapid gastric emptying, 1496
Dialysis, continuous ambulatory, diffuse abdominal uptake of Tc-99m MDP, bone scintigraphy, 2052
Diaminedithiol, ligand system, labeling with Re-186, 1032(ab)
Diaschisis
cross cerebellar, neurolite imaging, stroke, 968(ab)
vascular response to acetazolamide, Tc-99m HMPAO SPECT, 967(ab)
Digoxin
possible imaging agent, 549
radioiodinated derivative, myocardial accumulation, possible Na,K-ATPase imaging agent, 545
α-Dihydrotetrabenazine, C-11 tetrabenazine and C-11 methoxy derivative, PET, monoamine terminals, 983(ab)
Dipyridamole
blunted response of myocardial perfusion, older adults, 1425(le)
effects on renal function, Tc-99m DTPA, 355
-induced left ventricular cavitary dilatation, exercise, thallium imaging, 951(ab)
lack of thallium redistribution, postoperative and long-term outcome, 951(ab)
myocardial perfusion imaging, serum caffeine levels, 24-hour abstention, 866(ab)
stress, metabolic evidence of ischemia, 866(ab)
Tc-99m MIBI radionuclide angiography, SPECT myocardial perfusion, 846(ab)
Tl-201 imaging
dose comparisons, coronary artery disease, 866(ab)
improvement of image quality, walking exercise, 2061

predictive value, myocardial bridging, 1905
Diuresis
captopril, renal functional response, 739
renogram, functional assessment, pre- and post-pyeloplasty, 977(ab)
renography, gravity-assisted drainage view, 1022(ab)
Tc-99m DTPA renography, ureteral status in children, kidney washout, 73
DNA, synthesis, kinetic modeling, C-11 thymidine PET, 1009(ab)
Dobutamine
choice of stress for diagnostic perfusion, wall motion imaging, MIBI-SPECT and stress echocardiography, 825(ab)
exercise and, Tc-99m sestamibi, coronary artery disease, 951(ab)
stress thallium scintigraphy, usefulness and safety, 951(ab)
Tc-99m sestamibi SPECT, detection, coronary artery disease, 866(ab)
Dopamine
acetylcholine release and, GABAergic modulation, PET, 847(ab)
changes in brain, cocaine abusers, 887(ab)
D1 ligand, synthesis and *in vivo* evaluation, F-18 BT-SCH PET, 829(ab)
D2 receptors, chemical family of ligands, 981(ab)
fiber loss in Parkinsonism, C-11 CFT, 946(ab)
"internalization" of F-18 N-methyl-spiroperidol, 870(ab)
striatal F-DOPA uptake, cerebral glucose metabolism, patients with chorea, 1015(ab)
transporter site; C-11 WIN 35,428; living human brain, 964(ab)
uptake system, C-11 NNC 722, 931(ab)
Doppler: *see* Ultrasonography
Dosimetry
absorbed dose and contamination risk, In-111 oxine, 953(ab)
absorbed dose calculations, rapidly growing tumors, 277
cellular level of Kupffer cells, Tc-99m sulphur colloid injection, 380
C-11 2α-tropanyl benzilate, synthesis, biodistribution, 423
effect of radiolabeled impurities, brain retention, Tc-99m bicisate in monkeys, 989(ab)
immunoscintigraphy, In-111 monoclonal antibody fragments, ovarian cancer, 1113
I-131 QSPECT of phantom, transfer of CT vols, manual alignment, 925(ab)
I-123 somatostatin analog, neuroendocrine tumors, 1613
I-131 therapy for thyroid carcinoma, complications, sequela, 2214
I-123 TISCH, 954(ab)
management of exposed or contaminated patient, 1065(ab)
mathematical modeling, plasmapheresis, radioimmunotherapy of micrometastases, 941(ab)
MIRD dose estimate Report No. 16, 1717
MIRDOSE software protocol, monoclonal antibody radioimmunotherapy, 926(ab)
modeling, anti-CD33 monoclonal antibody M195, acute myelogenous leukemia, 941(ab)
nuclear quantitation of tumor size and I-131 amount, planar imaging, 925(ab)
plasmapheresis in radioimmunotherapy, micrometastases, 2167
quantitative approach, I-131 therapy, thyroid cancer, 894(ab)
radioimmunotherapy in a child with neuroblastoma, I-124 3F9 PET, 2020
regional dose distribution to hands, staff formulating/dispensing/administering radiopharmaceuticals, 1065(ab)
Sr-89 radiotherapy, metastatic prostatic carcinoma, 1316
Tc-99m MAG_3, Tc-99m DTPA and I-131 OIH, human biodistribution studies, 33
Tc-99m mapping of leukocytes, secondary ion mass spectrometry microscopy, 2162
three-dimensional tumor, hepatic Y-90 microsphere therapy, 735
two-step targeting of iodinated bivalent haptens, colorectal tumors hosted in nude mice, 1000(ab)
Down's syndrome
nondemented old patients, I-123 IMP SPECT, 967(ab)
regional cerebral blood flow, Tc-99m HMPAO brain SPECT, 1013(ab)
Drug abuse, comparative uptake, Tc-99m HMPAO, I-123 IMP rCBF, 1015(ab)
Dual-photopeak window, method for scatter correction, 605
Dysphagia, esophageal disorders and scintigraphy, 1301
Dystonia, I-123 IBZM SPECT, 1018(ab)

E

Ebstein's deformity, radionuclide evaluation, symptomatic infants and children, 930(ab)
Echocardiography
detection of coronary artery disease, 866(ab)
stress and MIBI SPECT, choice of stress for diagnostic perfusion, wall motion imaging, 825(ab)
Editorials
Adriamycin and congestive cardiomyopathy, I-125 MIBG, 215
anatomic divisions, 407
bloody future for clinical PET, 620
brain death, diagnostic dilemma, 2211
captopril renal scintigraphy, distinguishing functional from anatomic renal artery stenosis, 2045
carbon-11 putrescine, 200
clinical applications of PET in cancer, 330
C-11 SAH PET, myocardial energy balance, 2144
current role of SPECT, imaging of subdural hematoma, 248
detection of cardiovascular infections, radiolabeled leukocytes, 1493
diagnostic imaging of liver, 1344
esophageal disorders and scintigraphy, 1301
euglycemic hyperinsulinemic clamp, myocardial glucose utilization, PET, 1263
gallbladder ejection fraction, decade of progress, future promise, 542
go with the flow—but how far?, 1939
hepatic clearance of Tc-99m HIDA derivatives, hyperbilirubinemic states, 1551
how magic is the bullet, what will it do?, 549
imaging inflammation, current role, labeled autologous leukocytes, 65
immunoscintigraphy of colorectal carcinoma, Loch Ness monster and, 1756
incremental value of diagnostic test, cost consciousness, 1732
labeled carbon dioxide, transient metabolite, 585
lung scan interpretation, 1422
mapping cerebral blood flow, 1843
MIRD approach and limitations, 781
misalignment between PET transmission and emission scans, myocardial imaging, 1214
myocardial blood flow, deoxyglucose uptake, myocyte viability in ischemia, 1353
myocardial FDG PET studies, oral glucose loading or insulin clamp methods, 1263
natural history of infantile hydronephrosis, diuretic renography, 2098
new methods for localizing infection, avidin-biotin, 1816
nonuniformity of dose, implications, radiation protection, 384
nuclear medicine, acupuncture message transmission, 409
nuclear probes in cardiology, 448
of theoretical derivations, empirical evidence, 1578
parathyroid imaging, 1807
prognosis in congestive heart failure, 477
quantitating tumor glucose metabolism, FDG and PET, 339
quantitative autoradiography, radiopharmaceutical uptake, dose heterogeneity, 1833
radioimmunotherapy of cancer, 1110
continuing evolution, 2180
radiolabeled antibodies, oncogene-encoded molecules, tumor imaging and therapy, 2160
radiolabeled monoclonal antibodies, cancer therapy and diagnosis, chimera, 29
radiotherapy and regional bone formation, 1780
referral bias, efficacy, radionuclide stress tests, 2074
risk to others, I-131-treated patients, 2116
scintigraphic appearance, Alzheimer's disease, Tc-99m HMPAO SPECT, 312
scintigraphic evaluation, Sphincter of Oddi dysfunction, 1223
sensitivity of SPECT Tl-201 myocardial perfusion, patient motion, 1571
SPECT, rapidly cleared tracers, 1206
targeted proteins for diagnostic imaging, does chemistry make a difference, 394
Tl-201 and Tc-99m sestamibi, viable myocardium, 815
transmural uptake of perfusion tracers, infarct-specific tracers, 229
ureteral function, assessment of hydronephrosis, 78
vascular testing for impotence, 46
Ejection fraction
gallbladder, specificity, chronic acalculous cholecystitis, 899(ab)
left ventricular
correlation with lung uptake, Tc-99m sestamibi, 846(ab)
gated blood-pool studies, 932(ab)
gated Tc-99m sestamibi SPECT, 927(ab)
Tc-99m sestamibi perfusion, coronary artery disease, 847(ab)
radionuclide evaluation of Ebstein's deformity, symptomatic infants and children, 930(ab)
reduced exercise capacity, Starling effect, cardiac transplantation, 939(ab)
Electric Power Research Institute (EPRI), vote on epidemiology study, 26N(1)
Electrocardiography
response and perfusion images, thallium stress test, 1723(le)
thallium scan, court litigation, 120
Electron microscopy, autoradiography,

intracellular distribution of I-125 MIBG, neuroblastoma xenografts, 1021(ab)
Emission tomography
diffuse alcoholic liver disease, 1337
I-123 beta-methyl-branched fatty acid, hypertrophic cardiomyopathy, 6
iodinated branched fatty acid analog, regional metabolic abnormality, relation to perfusion and wall motion, 659
region-of-interest evaluation, least squares algorithm, 831(ab)
Encephalopathy, opsoclonus-myoclonus, location of neuroblastoma, MIBG usage, 930(ab)
Endocrine neoplasms, gastro-entero-pancreatic, In-111 pentatreotide scintigraphy, 976(ab)
Endocrinology, second Sino-American nuclear medicine conference, 16N(4)
Endoprostheses, septic loosening, WBC scintigraphy with monoclonal antibodies, 840(ab)
Endothelial cells, uptake kinetics, Tc-99m sestamibi, Tl-201, 102
Endothelin-1, radioiodinated, injured aortic tissue, cholesterol-fed rabbits, 845(ab)
Endotoxemia, lung neutrophil sequestration, intercellular adhesion molecules, 1023(ab)
Environmental Protection Agency (EPA)
costs of dual regulation, 29N(10)
mixed waste petition, 33N(9)
national emission standards, 33N(9)
National Emission Standards for Hazardous Air Pollutants, 24N(3)
Epigastric impedancemetry, gastric emptying of liquids, 956(ab)
Epilepsy
Annual Meeting highlights, 22N(8)
cerebral metabolism, effect of disease duration, PET, 1018(ab)
functional brain SPECT, powerful clinical method, 1888
interictal localization of foci, Tc-99m CEROTEC SPECT, 966(ab)
intractable temporal lobe, 3-D semiquantitative method, F-18 FDG PET and Tc-99m HMPAO SPECT, 970(ab)
parietal lobe, F-18 FDG PET, 1017(ab)
presurgical localization of zones, F-18 FDG PET, 928(ab)
refractory, temporal lobe metabolism, asymmetry in FDG PET scans, 928(ab)
simple and partial complex seizures, foci localization, Tc-99m HMPAO SPECT, 971(ab)
spontaneously epileptic rat, interictal cerebral glucose metabolism, 1024(ab)
status epilepticus, Tc-99m HMPAO SPECT, 928(ab)
temporal lobe
decreased binding of I-123 IDEX, muscarinic cholinergic receptors, 928(ab)
hyperventilation, cerebral blood flow, 968(ab)
mesial temporal origin, PET scan findings, 1014(ab)
presurgical evaluation, ictal Tc-99m HMPAO SPECT, 929(ab)
surgical outcome, Xe-133 SPECT, 1018(ab)
temporal lobe surgery, prognostic implications, FDG PET, 929(ab)
Erythrocytes, modification of Tc-99m labeling method, effectiveness, 2222
Erythromycin, oral, gastric emptying rate, diabetic gastroparesis, 833(ab)
Esophagus
abnormal motility, gastroesophageal reflux, angina-like chest pain, 955(ab)
bolus transport and contraction parameters, multiple-swallow investigations, 1291
disorders and scintigraphy, 1301
motility after reconstructive operation, 955(ab)
scintigraphy
achalasia and achalasia-like disorders, 590
reproducibility, normal ranges, 2106
ROC-analysis, 832(ab)
Estradiol, -stimulated rat liver, binding of Tc-99m LDL and I-125 LDL, 1028(ab)
Estrogen, receptor imaging and PET, F-18 fluoro analog, tamoxifen, 985(ab)
Ethanol, percutaneous injection, autonomous thyroid nodule, 954(ab)
Ethics, knowing what is right, 296
(*S*)-*N*-[(1-Ethyl-2-pyrrolidinyl)methyl]-5-(3-[18F] fluoropropy l)2,3-dimethoxy-6-hydroxy-benzamide, superior PET ligand, cerebral dopamine D2 receptors, 847(ab)
Etidronate
cyclic oral phosphate and, bone mineral density, spine fracture, 1
intravenous, skeletal nonvisualization, bone scan, 748
Exercise
dipyridamole-induced left ventricular cavitary dilatation, thallium imaging, 951(ab)
dobutamine and, Tc-99m sestamibi, coronary artery disease, 951(ab)
-induced perfusion defects, delay of image acquisition, Tc-99m TEBO SPECT, 952(ab)
left ventricular function, coronary jeopardy score, 938(ab)
reduced capacity, cardiac transplantation, Starling effect, 939(ab)
serial measurements of cardiac volumes, count-based methods, 1324
walking, improvement, dipyridamole Tl-201 image quality, 2061
Extracellular fluid, volume measurements, reproducibility, critically ill patients, 1468
Extracorporeal membrane oxygenation, brain SPECT, neonates, 1943
Extremity
lower
bone scintigraphy, preschool children, 351
site of fracture or surgery, chronic osteomyelitis, 902(ab)

F

Fab fragments
cross-linking, synthesis and radioiodination, ETAC reagent, 943(ab)
linker-conjugated, monoclonal antiferritin antibody, nude mouse model, 987(ab)
monoclonal antibody $F(ab')_2$ uptake in tumor, hyperthermia, 958(ab)
negatively charged-polymer-modified antimyosin, infarct imaging, 959(ab)
NR-LU-10, CH2 domain deletion mutant, radioimmunotherapy potential, 1028(ab)
transferrin and IgG, preparation, characterization, 986(ab)
Fast Flux Test Facility, halt of activities, 16N(6)
Fatty acid analog, iodinated branched, regional metabolic abnormality, relation to perfusion and wall motion, 659
Fatty acids
iodo-labeled methyl fatty acid, myocardial viability, FDG PET, 953(ab)
kinetics in aerobic myocardium, 1864
FDOPA
OMFD and, combined modeling analysis, non-human primates, 945(ab)
PET, nigrostriatal function, ratio method and graphical analyses, 945(ab)
Fe-PDGF, potential new hepatobiliary MR contrast agent, 974(ab)
Ferrum, evaluation as MR contrast agent, 973(ab)
Fever, unknown origin, Tc-99m antigranulocyte monoclonal antibody, 902(ab)
Fibrin
deposition following coronary artery injury, I-125 fibrinogen, porcine restenosis model, 845(ab)
deposition on coronary stents, anticoagulation, minipig model, 845(ab)
D-dimer plasma concentration, suspected pulmonary embolus, 978(ab)
Fibroblast, -like cells and uptake kinetics, Tc-99m sestamibi, Tl-201, 102
Filters
gamma camera images, *beta*-emitters, neural network restoration, 889(ab)
restoration
defect detection, cardiac SPECT, 842(ab)
distance-dependent collimator blur, SPECT, 843(ab)
two-dimensional restoration, quantitation of amygdala, PET, 921(ab)
Flumazenil, ligand, quantification of benzodiazepine receptors, PET, 883(ab)
Fluorine-18
acyclic analogues of vesamicol, potential cholinergic neuron markers, 983(ab)
labeling of monoclonal antibodies, *N*-succinimidyl 4-[F-18]fluorobenzoate, 881(ab)
PET
bone blood flow and influx rate, 937(ab)
derivatives of SCH 38548, dopamine D1 receptors, 829(ab)
ligands, benzodiazepine receptor studies, 883(ab)
production of, cryogenic O-18 water target, 932(ab)
Fluorine-18 androgens, potential imaging agents, prostatic cancer, 724
Fluorine-18 antimyosin monoclonal antibody fragments, preliminary investigations, canine myocardial infarct model, 575
Fluorine-18 biotin, tumor localization with PET, 1026(ab)
Fluorine-18 BMY 14802, synthesis and resolution, PET studies, baboons, 830(ab)
Fluorine-18 BT-SCH, synthesis and *in vivo* evaluation, dopamine D1 ligand, PET, 829(ab)
Fluorine-18 2-deoxy-2-fluoro-D-glucose, time course of skeletal muscle glucose uptake, euglycemic hyperinsulinemia, 1523
Fluorine-18 deoxyglucose
myocardial blood flow, glucose uptake, ischemic canine myocardium, 1346
PET, mediastinal lymph node mapping, 828(ab)
Fluorine-18 DOPA, uptake in brain, delayed L-phenylalanine infusion, 1383
6-Fluorine-18 DOPA, parametric Dopa-decarboxylase imaging, 879(ab)
Fluorine-18 FDG
accumulation in bone fracture, correlation, Tc-99m MDP, 869(ab)
infection and reactive lymph nodes, 925(ab)
method for comparing different procedures, regional glucose metabolism, 157
microautoradiography, granulation tissues and

phagocytes, mouse tumor tissue, 840(ab)
PET
accuracy, dementia diagnosis, 967(ab)
brain, registered atlas, 1071(ab)
brain tumor therapy, 1071(ab)
compared with C-11 acetate, recovery after revascularization, 855(ab)
developmental cognitive disorders, 973(ab)
3-D semiquantitative method, intractable temporal lobe epilepsy, 970(ab)
evaluation of liver tumors, 333
glucose loading or insulin clamp methods, myocardium, 1263
hibernating myocardium, irreversible perfusion defects, 105(ab)
insulin clamp, myocardial glucose utilization, 1255, 1263
late-life depression, 1013(ab)
lymphoma, 532
malignant lymphoma, proliferative activity, 325
malignant melanoma, 975(ab)
multiple systemic atrophy, selective metabolic involvement, 1014(ab)
myocardial viability, coronary artery disease, 886(ab)
parietal lobe epilepsy, 1017(ab)
preoperative chemotherapy, locoregionally advanced breast cancer, 828(ab)
pre-operative staging, colorectal carcinoma, 975(ab)
presurgical localization, epileptogenic zones, 928(ab)
quantitation, tumor glucose metabolism, 339
radiation-induced inhibition, tumor growth, 373
recurrent brain tumors, 867(ab)
residual or recurrent musculoskeletal sarcoma, 992(ab)
SPECT and, myocardial viability, 1064(ab)
treatment planning and monitoring, lung tumors, 975(ab)
scintigraphy, chemotherapeutic impact, malignant lymphoma, 858(ab)
synthesis, simple procedural change, recovery of O-18 enriched water, 1027(ab)
Tc-99m sestamibi SPECT and, malignancy, 858(ab)
thermally stable ion exchange, heterogeneous nucleophilic radiofluorination, 984(ab)
2-Fluorine-18 FDOPA, high accumulation in non-S phase melanocytes, B16 melanoma, microautoradiography, 984(ab)
6-Fluorine-18 FDOPA
decline of rate constant K_1 *vs.* age, 964(ab)
loss of metabolites in striatum, 916(ab)
OMFD and, combined modeling analysis, non-human primates, 945(ab)
uptake in human brain, 916(ab)
Fluorine-18 fleroxacin, PET, pharmacokinetics, rabbits, 924(ab)
Fluorine-18 fluconazole, PET, pharmacokinetics, humans, 924(ab)
Fluorine-18 fluoride ion, PET, evaluation, skeletal kinetics, 633
Fluorine-18 fluorocarazolol
β-adrenergic radiotracer for PET, 984(ab)
synthesis, ligand for β-adrenergic receptors, 983(ab)
Fluorine-18 fluorodeoxyglucose, PET, cranial and spinal neuromas, 1931
Fluorine-18 4-fluoro-4-deoxy-D-glucose, potential brain/heart/tumor imaging agent, 983(ab)
6-Fluorine-18 fluoro-L-dopa, kinetics, carbidopa administration, PET, 1472
3-*O*-methyl-6-Fluorine-18 fluoro-L-dopa, FDOPA and, combined modeling analysis, non-human primates, 945(ab)
Fluorine-18 fluoromisonidazole
cellular hypoxia in sepsis, 924(ab)
PET, hypoxia in human gliomas, 2133
4-(4-[Fluorine-18]fluorophenyl)-2-[4(5)-methyl-5(4)-imidazolylmet hyl]thiazole, synthesis and biodistribution, imaging 5-HT_3 receptors, 830(ab)
Fluorine-18 FMISO
PET
noninvasive detection, hypoxic myocardium, 2202
quantification, tumor oxygenation status, 1010(ab)
Fluorine-18 MABN, F-18 MBP and F-18 NMSP PET, comparative imaging studies, 985(ab)
Fluorine-18 monoclonal antibody fragments
combination of radioimmunoscintigraphy and PET, 1535
PET, 934(ab)
Fluorine-18 NCQ 616, preparation of, 860(ab)
Fluorine-18 N-methyl-spiroperidol, "internalization", 870(ab)
Fluorine-18 NMSP
PET
benzamide analogs and, 985(ab)
F-18 MABN and F-18 MBP, comparative imaging studies, 985(ab)
Fluorine-18 N-(2-(pyrrolidinyl)-1-phenylethyl)acetamide analog, synthesis, *kappa* opiate receptor, 830(ab)
Fluorodeoxyglucose
areas of reverse redistribution, planar thallium imaging, viability with PET, 886(ab)
blood-brain transport, regional variations, 908(ab)
brain tumor studies, PET resolution, visual interpretation, 872(ab)
enhanced uptake caused by chemotherapy, metabolic design, combination therapy, 1981
glucose and, regional blood-brain transport, 1819
increased uptake as prognostic indicator, myocardial infarction, 886(ab)
PET
Bayesian regression, metabolic rate of glucose utilization, 944(ab)
decreased cerebral glucose metabolism, Cushing's disease, 834(ab)
differential diagnosis, solitary pulmonary nodule, 836(ab)
differentiaton of infectious from malignant CNS lesions, AIDS, 838(ab)
fully quantitative neurological studies, without arterial blood sampling, 922(ab)
HIV-1-infected children, seropositive mothers, 976(ab)
investigation of olfactory system, 858(ab)
left premotor cortex specialization, finger movements, 857(ab)
low grade and anaplastic astrocytomas, brain imaging, 966(ab)
mediastinum, lung cancer, 828(ab)
method for correcting myocardium to blood pool spillover, 882(ab)
MIHA, myocardial viability, 953(ab)
MRI data and, atypical dementia and Alzheimer's disease, 965(ab)
post-treatment evaluation, genitourinary malignancies, 829(ab)
prognostic implications, temporal lobe surgery, 929(ab)
quantitative dynamic and whole body, breast cancer, 828(ab)
radiation-induced response, head and neck carcinoma, 829(ab)
temporal lobe metabolism, refractory epilepsy, 928(ab)
TSH stimulation of thyroid cancer, T4 replacement therapy, 894(ab)
PET imaging of the chest, 975(ab)
purification of used O-18 target water, photochemical combustion, 982(ab)
uptake in tumors, Berson-Yalow Award winners, 15N(7)
uptake into human cancer cells, hypoxia, 841(ab)
uptake kinetics in liver, impact of glucose ingestion, dynamic PET, 945(ab)
uptake measurements, design of combination therapy, hexadecylphosphocholine and deoxyglucose, 1019(ab)
3′-Fluoro-3′-deoxythymidine, noninvasive monitoring of targeting of drugs, AIDS, 830(ab)
Food and Drug Administration (FDA)
approval of drug master file, PET, 33N(9)
government relations update, 15N(3)
PET tracers, industry split over approval, 24N(9)
Foot
diabetic complications, In-111 human nonspecific IgG, 950(ab)
infectious diabetic complications, In-111 human nonspecific immunoglobulin G, 1330
Forearm, bone mineral assessment, 1251(le)
Fourier
amplitude and phase, three-dimensional presentation, gated cardiac blood-pool SPECT, 458
approach to gastric motility, 956(ab)
Fracture
bone, accumulation of F-18 FDG, Tc-99m MDP, 869(ab)
stress, osteosarcoma, lower limb, 1699

G

Gadolinium-DTPA, MRI, recurrent brain tumors, 867(ab)
Gadolinium (III) DTPA-bisamide complexes, nonionic, MRI contrast agents, 974(ab)
Gallbladder
biliary scintigraphy, grading of hyperperfusion, rim sign, 898(ab)
calculation of ejection fraction, continuous sincalide infusion, 3-minute infusion method, 537
differentiation of congenital abnormality, quantitative Tc-99m IDA cholescintigraphy, 431
ejection fraction
decade of progress, future promise, 542
specificity, chronic acalculous cholecystitis, 899(ab)
hepatobiliary scintigraphy, intrahepatic *vs.* extrahepatic cholestasis, 1186
perforation, false-negative, morphine-augmented cholescintigraphy, 256
stone, common bile duct clearance, radionuclide injection, 997(ab)
Gallium, octahedral gallium chelate, monoclonal antibodies, immunoscintigraphy with PET, 1366
Gallium-67

accuracy of early imaging, pulmonary infection, immunocompromised patients, 957(ab)
aminooxyacetyldeferroxamine, monoclonal anti-CEA antibody, colon carcinoma immunoscintigraphy, 1766
chest X-ray patterns in HIV-positive patients, 999(ab)
clinical experience with Tc-99m nanocolloid, 999(ab)
computed tomography and, extrapulmonary tuberculosis, 2118
distribution in man, decrease in both transferrin and hepatic Ga-67 concentration, 1701
gastric uptake, AIDS, 643
In-111 leukocyte and, acute sarcoidosis, 2027
kinetics and therapeutic potential, malignant lymphoma, 926(ab)
limitations in usefulness, prediction of recurrences, Hodgkin's disease, 913(ab)
metastatic and recurrent soft-tissue sarcoma, 1594
pulmonary disposition, *Pneumocystis* pneumonia, 512
role in staging lymphoma, 1588(le)
scanning and MRI, effect of therapy, Hodgkin's lymphoma, 914(ab)
scintiscan, primary plenic non-Hodgkin's lymphoma, treatment of Hodgkin's disease, 1183
Tc-99m DTPA aserosol, pulmonary complications, HIV infection, 81
Tc-99m MDP and, scintigraphic differentiation, osteogenic and Ewing's sarcoma, 1063(ab)

Gallium-67 citrate
disease activity in sarcoidosis, 751
scanning in patients with sarcoid uveitis, 1851
SPECT, biopsy-confirmed residual Hodgkin's disease, mediastinum, 345

Gallium-68, radiopharmaceuticals that are retained in myocardium, 931(ab)

Gallium-68 DF-NGA, regional measurement, hepatic receptor biochemistry, 1160

Gallium-68 platelets, PET imaging, 931(ab)

Gallium-67 polyclonal IgG, In-111 leukocytes and, acute focal inflammatory lesions, 1428(le)

Gamma camera
Bremsstrahlung imaging, factors affecting attenuation, 161
clinical, imaging therapeutic doses, I-131, 771
collimator structure, 1006(ab)
cone-beam transmission CT, imaging, human torso, 150
cylindrical, unitary construction, ultra high resolution collimator, 852(ab)
event loss estimation, radioimmunotherapy, 1005(ab)
experimental myocardial infarction in rabbits, antimyosin Fab conjugation, N-terminal modified DTPA-succinylated polylysine, 943(ab)
first pass radionuclide angiography, clinical validation, computer program, 1064(ab)
gamma-ray
miniature CsI photodiode detectors, 1004(ab)
multiplexer and semiconductor detectors, 1002(ab)
gamma variate fit, camera-based method, Tc-99m MAG_3 clearance, 991(ab)
high-resolution plain-paper laser printers, hardcopy, nuclear medicine images, 947(ab)
images of *beta*-emitters, neural network restoration, 889(ab)
-induced Compton scatter, collimator penetration, I-131 imaging, 889(ab)
multicrystal, metabolic cardiac imaging, severe coronary disease, 1269
piled-up events, digital processing, signal deconvolution, 1003(ab)
rotating, cerebral blood flow, I-123 IMP, 963(ab)
sensitivity per unit area, true characteristic, 1068(ab)
single-headed, rapid radiotracer washout from the heart, SPECT, 1146
SPECT, image truncation, cone beam CT, 901(ab)
technology, lawsuit filed by Trionix against ADAC Laboratories, 18N(2)
three-head rotating, Tc-99m DMSA SPECT, renal scan, 1021(ab)

Gastric emptying
attenuation correction, left anterior oblique, geometric mean method, 833(ab)
determination of time, different views, 127
gastric motility disturbances, diabetes, scintigraphy, 832(ab)
intragastric distribution and, oil, presence of liquid or solid meal, 1283
measurement of liquids, 956(ab)
normal and pathological, magnetic resonance imaging, nuclear medicine techniques, 956(ab)
oral glucose solution, type 2 diabetic patients, 1496
radionuclide, correlation, anterior-only and geometric mean method, 956(ab)
rate, variable oral erythromycin, diabetic gastroparesis, 833(ab)
secondary gastroparesis, insulin-dependent diabetes mellitus, 1707
solid foods, proper definitions, lag phase, 466(le)

Gastroenterology, nuclear, Annual Meeting highlights, 26N(8)

Gastro-entero-pancreatic neoplasms, In-111 pentatreotide scintigraphy, 976(ab)

Gastrointestinal neoplasms, metastatic, radioimmunotherapy, 863(ab)

Gastrointestinal tract
advanced ulcer avid agent, new procedure, Tc-99 phytate sucralfate, 1033(ab)
bleeding studies, Tc-99m red blood cells, early negative images, 202
gastric bleed studies, applications of amplitude images, 1006(ab)
tumor targeting with Tc-99m F023C5 anti-CEA IgG1, role of CEA content, 892(ab)

Gastroparesis, secondary to insulin-dependent diabetes mellitus, 1707

Gated blood-pool imaging
cardiac scintigraphy, Tc-99m liposomes, 984(ab)
clinical verification, knowledge-based boundary detector, 938(ab)
heart, three-dimensional presentation, Fourier amplitude and phase, 458
knowledge-based LV detection, automatic EF calculation, 932(ab)
left ventricular regions of interest, simulated annealing, 932(ab)
SPECT
parametric display, 3-D biventricular function. 952(ab)
potential added clinical value, 910(ab)
Tc-99m, ECG gated PET C-11 monoxide, "background" question, 938(ab)

Gene, models of mental disease, 22N(8)

General Accounting Office (GAO)
probe details U.S. isotope troubles, 22N(9)
scrutiny of federal isotope supply effort, 16N(2)

Genitourinary system, malignancy, post-treatment evaluation, FDG PET, 829(ab)

Glioma
biodistribution of I-125 monoclonal antibody, hand-held NaI-crystal detector, 1002(ab)
distinction of high-grade from low-grade, Tl-201 SPECT, 868(ab)
human, hypoxia, F-18 fluoromisonidazole PET, 2133
microdosimetry estimations, I-125 labeled monoclonal antibody 425, 942(ab)
recurrent, intraarterial carotid artery injection, Tc-99m HMPAO, 966(ab)

Glomerular filtration rate (GFR)
measurement in children, adequacy of one blood sample, 873(ab)
quantitative analysis, dynamic renal studies, factor analysis, 949(ab)
renal plasma flow and, spinal cord injury, 1035(ab)
single plasma, children, 173(le)
Tc-99m DTPA renal uptake, plasma volume product, 1712

Glucose
absolute whole brain, sensitive marker, Alzheimer's disease, 940(ab)
blood-brain transport, regional variations, 908(ab)
cerebral metabolism in patients with chorea, striatal F-DOPA uptake, PET, 1015(ab)
deoxyglucose uptake and myocardial blood flow, ischemia, myocyte viability, 1353
fluorodeoxyglucose and, regional blood-brain transport, 1819
ingestion, hepatic FDG uptake kinetics, dynamic PET, 945(ab)
interictal cerebral metabolism, spontaneously epileptic rat, 1024(ab)
metabolic rates, 30- and 45-minute acquisitions, cerebrum, 2103
metabolism
method for comparing different procedures, F-18 FDG, 157
MPTP-primate model, Parkinson's disease, 965(ab)
metabolism and cerebral blood flow, patient surviving after CO intoxication, 1696
metabolism and rCBF, simultaneous SPECT acquisitions, 965(ab)
metabolism in tumor, quantitation, FDG and PET, 339
myocardial utilization, insulin clamp, F-18 FDG PET, 1255, 1263
oral solution, rapid gastric emptying, type 2 diabetic patients, 1496
regional metabolism in relation to perfusion, coronary artery disease, fasting and loading states, 856(ab)
time course of uptake in skeletal muscle, euglycemic hyperinsulinemia, F-18 2-deoxy-2-fluoro-D-glucose study, 1523
uptake and myocardial blood flow, ischemic myocardium, F-18 deoxyglucose, 1346
utilization, Bayesian regression, estimation of metabolic rate, 944(ab)
utilization and receptor binding, use of linear programming, PET studies of heart and brain, 944(ab)

Glutathione, -mediated decomposition, propylene amine oxime derivatives, ligand structure, 988(ab)

Gold-199, no-carrier-added, production of, 980(ab)

Granulation tissue, microautoradiographic study of F-18 FDG, mouse tumor tissue, 840(ab)
Granulocytes, radiolabeled, kinetics, systemic vasculitis, 491
Granulocyte stimulating factor, hypermetabolic bone marrow, Tl-201-chloride uptake, 2014
Graves' disease
euthyroid, autonomously functioning thyroid carcinoma, 2024
thyroid and orbital radiolabelled somatostatin accumulation, 894(ab)
Gravity, -assisted drainage view, diuresis renography, 1022(ab)

H

Haloperidol, SPECT imaging of dopamine D2 receptors, I-123 IBZM SPECT, 898(ab)
Hand
reflex sympathetic dystrophy, excessive inflammatory response, 936(ab)
regional dose distribution, staff formulating/dispensing/administering radiopharmaceuticals, 1065(ab)
unilateral voluntary movement, regional cerebral uptake, Tc-99m exametazine, 1623
Hapten, valency, pretargeted immunoscintigraphy, murine tumor uptake, 2006
Head, trauma, remote history of, Tc-99m HMPAO SPECT, 52
Head and neck cancer
C-11 methionine PET, 691
staging, Tc-99m monoclonal antibody 174H.64 SPECT, 912(ab)
Health and Human Services (HHS)
CLIA-88, 24N(3)
Medicare reimbursement, 19N(3)
new physicians, 19N(3)
nuclear medicine comments on RVUs and interim values, 19N(3)
outpatient hospital reimbursement, 23N(3)
rebundling of CPT-4 codes, 23N(3)
relative value unit update committee, 19N(3)
SPECT reimbursement, 19N(3)
Heart
abnormal adrenergic neuron activity, Adriamycin-induced cardiomyopathy, I-125 MIBG, 208
acute Adriamycin cardiotoxicity, Tc-99m sestamibi, chick heart cells, 864(ab)
acute onset of cardiogenic shock, normal coronary arteries, 1558
alcohol intoxication, cocaine distribution and kinetics, 946(ab)
allograft rejection, detection with I-123 anti-ICAM-1 imaging, rats, 1000(ab)
Annual Meeting highlights, 24N(8)
blood-pool scintigraphy, Tc-99m liposomes, 984(ab)
cardiac peak power, severely impaired left ventricular ejection fraction, good effort tolerance, 938(ab)
cardiovascular training requirements, 23N(4)
C-11 cocaine, distribution and kinetics, 521
C-11 HED kinetics, 870(ab)
complete ischemia-reperfusion, retention of Cu-PTSM, 1026(ab)
congestive heart failure prediction
Adriamycin cardiomyopathy, I-125 MIBG, 935(ab)
Adriamycin therapy, In-111 antimyosin studies, 895(ab)
congestive heart failure, prognosis, 477
coronary blood flow, tetrofosmin uptake, 846(ab)
deep hypothermic cardiac surgery, choreoathetoid syndrome, brain Tc-99m HMPAO SPECT, 838(ab)
detection of cardiovascular infections, radiolabeled leukocytes, 1493
F-18 4-fluoro-4-deoxy-D-glucose imaging agent, 983(ab)
functional recovery after revascularization, C-11 acetate compared to F-18 FDG, PET, 855(ab)
function in neonates and children, arterial switch operation, PET, 977(ab)
globally denervated human and canine, scintigraphic assessment, MIBG uptake, 1444
high cardiac risk, patients referred for vascular surgery, adenosine thallium scintigraphy, 952(ab)
high count rate PET, spatially dependent deadtime losses, 2226
imaging of H1 histamine receptors, C-11 pyrilamine and C-11 doxepin, 885(ab)
immune mechanisms in disease, Mallinckrodt Fellow, 17N(6)
incomplete right bundle branch block, normal coronary angiogram, reversible Tl-201 perfusion defects, 1556
intracoronary Doppler probes and PET, concordant quantification, flow reserve, 836(ab)
iron, noninvasive in-vivo measurement, 1278
isolated perfused rat, subcellular distribution, Tc-99m MIBI, 1516
left ventricular mass and infarct size, N-13 ammonia PET, explanted human hearts for validation, 826(ab)
major upward creep, exercise Tl-201 myocardial SPECT, chronic obstructive pulmonary disease, 1846
measurement of receptor concentration, instrumental errors, PET, 882(ab)
metabolic imaging in severe coronary disease, I-123 IPPA, multicrystal gamma camera, 1269
MIBG extraction fraction, first-pass analysis, 716
MIBG imaging
patients with heart failure, 471
prognostic guide, heart failure, 896(ab)
MIBG uptake at 1-year post-cardiac transplant, partial reinnervation in man, 896(ab)
PET
reorientation, issues in quantitation, 1235
use of linear programming, glucose utilization, 944(ab)
postoperative and long-term outcome, lack of thallium redistribution, dipyridamole imaging, 951(ab)
radionuclide cardiac volumes, correction for Compton scatter, buildup factor, 1642
rapid radiotracer washout, single-headed gamma camera SPECT system, 1146
retrospective post-therapy evaluation, coronary artery disease patients, PET, 885(ab)
serial measurements of volumes, count-based methods, 1324
simultaneous estimation, myocardial perfusion, chamber volume, 933(ab)
SPECT
attenuation scans, three-dimensional registration, 881(ab)
cardiofocal collimator, 852(ab)
defect detection, cone beam geometry, 961(ab)
defect detection, restoration filters, 842(ab)
emission and transmission noise propagation, non-uniform attenuation correction, 902(ab)
reconstructions, truncated projections, 831(ab)
three-detector, simultaneous transmission and emission, 901(ab)
standardization of cardiac tomographic imaging, 1434
standardized imaging, actions of the Board of Trustees, SNM, 23N(4)
static PET studies, automated three-dimensional analysis, 1008(ab)
Tl-201 SPECT, Tc-99m transmission source, simultaneous acquisition of emission/transmission data, 2238
transplantation, coronary arteriopathy, SPECT Tl-201 *vs.* sestamibi, 951(ab)
transplantation rejection in primates, antimyosin agents, 1994
uncomplicated valvular replacement, significance, In-111 antimyosin scintigraphy, 895
volumes, delineation of myocardium, PET and SPECT, 933(ab)
Hemangioma, hepatic, diagnosis, triple-head high-resolution SPECT, 918(ab)
Hematoma
chronic subdural, cerebral blood flow, Tc-99m HMPAO SPECT, 246
subdural, current role of SPECT, 248
Hematopoietic neoplasia, soft-shell clam, 998(ab)
Hemiplegia, alternating, childhood, Tc-99m HMPAO SPECT, 1021(ab)
Hemodialyzer, cellulose-acetate, comparative thrombogenicity, 956(ab)
Hemodynamics, captopril-mediated changes, renal ischemia, 907(ab)
Heparin
anticoagulant citrate dextrose and, preparation, Tc-99m red blood cells with UltraTag RBC kit, 306(le)
anticoagulation, Tc-99m antifibrin Fab' localization, acute venous thrombosis, 978(ab)
In-111 DTPA-heparin, radiolabeling, protamine, 1028(ab)
Hepatobiliary tract
excretion of Tc-99m MAG_3, 990(ab)
Fe-PDGF as MR contrast agent, 974(ab)
scintigraphy
bile lakes, liver transplant infarcts, 997(ab)
hepatic transport function, 998(ab)
Hepatocytes
evaluation of local reduced mass, Tc-99m NGA, chronic liver diseases, 998(ab)
In-111, distribution of transplanted cells, 918(ab)
primary rat culture model, inhibition of hepatic uptake, radiolabeled monoclonal antibodies, 893(ab)
Hevesy Nuclear Medicine Pioneer Award, Michael J. Welch, 16N(7)
Hexadecylphosphocholine, deoxyglucose and, design of combination therapy, FDG uptake measurements, 1019(ab)
Hip
prosthesis loosening, combined roentgenological contrast/radionuclide arthrography, 950(ab)
S-ROM prosthesis, perioperative uptake of MDP, 950(ab)
Hippocampus
blood flow, diagnosis of Alzheimer's disease,

SPECT, 940(ab)
temporal lobe epilepsy, decreased binding of I-123 IDEX, muscarinic cholinergic receptors, 928(ab)
Hippuric acid, ligands, Tc-99m renal function agents, 988(ab)
Hirulog, I-123, preparation and evaluation, blood clot imaging, 981(ab)
Histidine, second Tc-99m binding site in IgG, 1029(ab)
HIV-1: *see also* Human immunodeficiency virus
-infected children, seropositive mothers, FDG PET, 976(ab)
Hodgkin's disease
biopsy-confirmed residual, Ga-67 SPECT, 345
effect of therapy on Hodgkin's lymphoma, Ga-67 scans and MRI, 914(ab)
limitations in usefulness, gallium imaging, prediction of recurrences, 913(ab)
primary splenic non-Hodgkin's lymphoma, Ga-67 scintiscan, 1183
Holmium-166, neuron-activated, polymeric microspheres, radionuclide synovectomy, 398
Holmium-166 hydroxyapatite, radiation synovectomy, 937(ab)
HPLC, Tc-99m monoclonal antibody, recovery and calibration, 1030(ab)
Human anti-mouse antibody
novel HAMA radioimmunoassay, ovarian cancer patients, 852(ab)
patient response, ImmuRAID-CEA, 1002(ab)
response after immunoscintigraphy, chimeric anti-CEA monoclonal antibodies, 903(ab)
Human immunodeficiency virus (HIV): *see also* HIV-1
dementia, qualitative approach, SPECT, 1018(ab)
noninvasive monitoring of targeting of drugs, 3′-fluoro-3′-deoxythymidine, AIDS, 830(ab)
-positive patients
acute infection detection, In-111 human immunoglobulin, 903(ab)
Ga-67 chest X-ray patterns, 999(ab)
pulmonary complications, Tc-99m DTPA aerosol, Ga-67 scanning, 81
-related incidents, infection-control problems, nuclear medicine departments, 13N(4)
Hunter, Oscar B. Jr., *In Memoriam,* 631
Huntington's disease, subjects with and at risk for, I-123 IBZM and Tc-99m HMPAO SPECT, 970(ab)
Hydronephrosis
antenatal, surgery *vs.* conservative management, impaired renal function, 873(ab)
assessment, ureteral function, 78
infantile, natural history of, diuretic renography, 2098
suspected uretero-pelvic junction obstruction, postnatal assessment, volume expanded diuretic renography, 2094
ureteral status in children, kidney washout, Tc-99m DTPA diuresis renography, 73
"well tempered" diuretic renogram, asymptomatic neonate, 2047
Hydroureteronephrosis, "well tempered" diuretic renogram, asymptomatic neonate, 2047
Hydroxyapatite, radiolabeling of particles, use, radiation synovectomy agents, 980(ab)
Hyperemia, adenosine-induced coronary, early thallium imaging after PTCA, 2086
Hyperglycemia, cerebral glucose uptake, 1-(C-11) D-glucose, 908(ab)
Hyperinsulinemia, time course of skeletal muscle glucose uptake, F-18 2-deoxy-2-fluoro-D-glucose study, 1523
Hyperparathyroidism
localization of parathyroid adenoma, Tc-99m sestamibi, 1801
parathyroid imaging, 1807
parathyroid scintigraphy, subtraction algorithm, 996(ab)
primary, localization of adenomas, Tc-99m sestamibi dual-phase study, 894(ab)
Hyperplasia, focal nodular, hot spots, TBIDA liver scan, 918(ab)
Hypertension
localization of pheochromocytoma, C-11 HED PET, 1125
non-Goldblatt renovascular, distinctive pathophysiology, 907(ab)
renal functional response, captopril, diuretic therapy, 739
renovascular
captopril renal scintigraphy *vs.* captopril test, 907(ab)
prognostic value, captopril renal scintigraphy, 2040
triple radiopharmaceutical renal study, DTPA renogram, 1034(ab)
Hyperthermia, monoclonal antibody $F(ab')_2$ uptake in tumor, 958(ab)
Hyperthyroidism, lithium carbonate therapy, psychiatric disorders, 996(ab)
Hyperventilation, cerebral blood flow, temporal lobe epilepsy, 968(ab)
Hypoxia
cellular, sepsis, marker F-18 fluoromisonidazole, 924(ab)
chemistry of Tc-PnAO-nitroimidazole complex, 919(ab)
2-fluoro-2-deoxy-D-glucose uptake, human cancer cells, 841(ab)
human gliomas, F-18 fluoromisonidazole PET, 2133
myocardium, detection using F-18 FMISO PET, 2202
quantification of tumor oxygenation status, F-18 FMISO PET, 1010(ab)
Tc-labeled imaging agent, occlusion of LAD coronary artery, rabbit myocardium, 865(ab)
viable tissue, radioiodinated 2-nitroimidazole derivatives, SPECT, 891(ab)
Hysterosalpingography, radionuclide, Tc-99m pertechnetate, radiation dose to ovaries, 282

I

4-ICE, 4-BACE and, chelating agents, 985(ab)
Immunoconjugates
Cu-67 and Sm-157, tumor therapy, 942(ab)
In-111 cyclohexl EDTA, anti-CEA $F(ab')_2$ monoclonal antibody, human tumor xenografted nude mice, 943(ab)
Re-186, effective stabilization, 979(ab)
simple synthesis and activation, 1,4,7,10-tetraazacyclododecane, 942(ab)
Immunoglobulin G
localization of infection, streptavidin and biotin, 1810
polyclonal, detection of inflammation, 1031(ab)
second Tc-99m binding site, relation to histidine groups, 1029(ab)
transferrin and $F(ab')_2$ conjugates, preparation, characterization, 986(ab)
vs. IgM antibodies, infection imaging, In-111 immunoglobulins, 1031(ab)
Immunoglobulin G4, I-131 chimeric B72.3, Phase I trial, metastatic colorectal cancer, 23
Immunoglobulins
conjugation with biotin, dendrimers as linker molecules, inflammation detection, 986(ab)
humanized, use of SCID mice for *in vivo* testing, 985(ab)
Tc-99m labeling, dendrimers as linker molecules, 986(ab)
Immunophoresis, efficacy, reduction of myelosuppression, radioimmunotherapy, 863(ab)
Immunoscintigraphy
avidin-biotin, pharmacokinetics, biotin-chelate conjugates, 880(ab)
colon carcinoma, monoclonal anti-CEA antibody, Ga-67 anti-CEA 35, 1766
colorectal carcinoma, Loch Ness monster and, 1756
dosimetric evaluation, In-111 monoclonal antibody fragments, ovarian cancer, 1113
dual isotope SPECT, improved demarcation of tumors, occult colorectal carcinoma, 1000(ab)
gamma imaging, experimental myocardial infarction, rabbits, 943(ab)
human anti-mouse response, chimeric anti-CEA monoclonal antibodies, 903(ab)
immune mechanisms in heart disease, Mallinckrodt Fellow, 17N(6)
octahedral gallium chelate, monoclonal antibodies, PET, 1366
ovarian carcinoma, I-131 labeled 145-9 monoclonal antibody, 905(ab)
pretargeted, hapten valency, murine tumor uptake, 2006
technical limitations, Tc-99m anti-CEA antibodies, 1001(ab)
two-step, medullary carcinoma of thyroid, anti-CEA/anti-DTPA bispecific mAb and In-111 DTPA dimers, 912(ab)
Impotence
paraplegics, treatment choice, nuclear penogram, 1035(ab)
penile blood flow, tumescence, dual-radioisotopic technique, 41
quantitative dynamic parameters, 1723(le)
vascular testing, 46
Indium, radioindium-labeled autologous platelets, MIRD dose estimate No. 15, 777
Indium-111
antisense oligonucleotide, direct method of cell-labeling, whole blood, 980(ab)
attachment to antibody via popular chelators, liver homogenates, 1030(ab)
collimator and detector interactions, 1004(ab)
hepatocytes, distribution of transplanted cells, 918(ab)
human immunoglobulin, acute infection detection, HIV-positive patients, 903(ab)
imaging of inflammatory abdominal aortic aneurysm, 1553
labeled Ab-chelator, chelator structure, liver, 1001(ab)
labeled human nonspecific IgG, evaluation, inflammatory bowel disease, 919(ab)
labeled radiopharmaceuticals, quantitative autoradiographic study, heterogeneous activity distribution, 1825
macro- and microscopic biodistribution, bone marrow and testes, rats, 954(ab)
octreoscan-111, two diasteromers, cancer imaging, 900(ab)

targeted proteins, diagnostic imaging, 394
whole-body retention, inflammatory bowel disease, 756
Indium-111 anti-carcinoembryonic antigen, monoclonal antibody ZCE 025, safety and role, colorectal carcinoma, 14
Indium-111 anti-CEA-F(ab')$_2$ fragments, radiation dosimetry, tissue distribution, rats, 1654
Indium-111 antimyosin
detection of tumor invasion of muscle layer, 841(ab)
myocardial damage in Adriamycin cardiomyopathy, 936(ab)
pathologic cardiac hypertrophy, myocyte damage, athletes, 994(ab)
risk of congestive heart failure, Adriamycin therapy, 895(ab)
scintigraphy, significance, uncomplicated valvular replacement, 895(ab)
uptake, chemotherapy-induced kidney disorder, 309(le)
uptake in acute and remote myocardial infarction, comparison with pathologic findings, 587
Indium-111 antimyosin Fab, myocardial distribution, nontransmural infarction, 223
Indium-111 antimyosin monoclonal antibody, scintigraphy, time course, myocardial infarction, 1501
Indium-111 BAD-Lym-1, radiochemistry and pharmacokinetics, 1030(ab)
Indium-111 B3 monoclonal antibody, biodistribution in athymic nude mice, human epidermoid carcinoma xenografts, 842(ab)
Indium-111 B72.3 monoclonal antibody, pharmacokinetics in colorectal cancer, 498
Indium-111 BrE-3 antibody, radioimmunolocalization of breast cancer, Phase I study, 912(ab)
Indium-111 C110 anti-CEA monoclonal antibody, CT and, metastases detection, colorectal carcinoma, 904(ab)
Indium-111 cyclohexyl EDTA, anti-CEA F(ab')$_2$ monoclonal antibody and, human tumor xenografted nude mice, 943(ab)
Indium-111 CYT-356, preoperative identification, metastatic prostate carcinoma, 1001(ab)
Indium-111 DOCT, I-123 TOCT somatostatin analogues and, somatostatin receptor-positive neoplasms, 914(ab)
Indium-111 DTPA-D-Phe-1-octreotide
handling by isolated perfused rat liver, 955(ab)
somatostatin receptor scintigraphy, 652
Indium-111 DTPA-heparin, radiolabeling and pharmacokinetics, protamine, biodistribution, 1028(ab)
Indium-111 IgG
infectious diabetic foot complications, 950(ab), 1330
reflex sympathetic dystrophy of the hand, excessive inflammatory response, 936(ab)
Indium-111 immunoglobulins, infection imaging, IgM *vs.* IgG antibodies, 1031(ab)
Indium-111 leukocytes
diffuse pulmonary uptake, drug-induced pneumonitis, 1175
Ga-67 and, acute sarcoidosis, 2027
Ga-67 polyclonal IgG and, acute focal inflammatory lesions, 1428(le)
infection mishaps, 27N(4)
Indium-111 monoclonal antibody
chimeric cT84.66, radiation dose estimates, 953(ab)
enhanced tumor targeting, metabolizable chemical spacer, 957(ab)
IVP ZCE 025, efficacy and safety, colorectal carcinoma, 959(ab)
preparation of high specific activity, amino-dextran and poly-lysine, 988(ab)
Indium-111 monoclonal antibody fragments, dosimetric evaluation, immunoscintigraphy, ovarian cancer, 1113
Indium-111 monoclonal antimyosin Fab, cardiac transplantation rejection, primates, 1994
Indium-111 octreoscan, kit development for cancer detection, 1025(ab)
Indium-111 oxine
absorbed dose and contamination risk, 953(ab)
Tc-99m HMPAO leukocytes, Tc-99m antigranulocyte Fab′ fragments, infectious diseases, 903(ab)
Tc-99m leukocyte imaging and, simultaneous imaging, community hospital, 902(ab)
Indium-111 pentatreotide, scintigraphy, gastro-entero-pancreatic endocrine tumors, 976(ab)
Indium-111 platelets, thrombocytopenia and hepatic sequestration, GM-CSF, 923(ab)
Indium-111 polyclonal IgG
carbohydrate modification, sites of bacterial infection, 1378
I-125 LDL and, uptake, experimental arterial wall injury, 845(ab)
single radiopharmaceutical kit, 1024(ab)
Indium-111 somatostatin analogue
scintigraphy, visualization, malignant lymphoma, 903(ab)
Tc-99m somatostatin analogue and, preparation, preliminary evaluation, 851(ab)
Indium-111 transferrin, quantitation of intestinal protein loss, inflammatory bowel disease, 919(ab)
Indium-111 white blood cells
chronic osteomyelitis, site of fracture or surgery, lower extremity, 902(ab)
necrotizing tracheobronchitis, 1704
Infants: *see also* Pediatric patients
Tc-99m MAG$_3$ clearance, preliminary "normal" values, 1021(ab)
Infection
acute, In-111 human immunoglobulin, HIV-positive patients, 903(ab)
AIDS and infectious disease, Annual Meeting highlights, 24N(8)
assessment of infectious conditions, musculoskeletal system, Tc-99m HIG, 839(ab)
bacterial, effects of carbohydrate modification, polyclonal IgG, 1378
bone, Tc-99m anti-granulocyte antibodies, 526
detection in rats, Tc-99m liposome labeling procedure, 1027(ab)
diagnosis of mycotic aneurysm, leukocyte scintigraphy, 1486
differentiation from malignant CNS lesions, FDG PET, AIDS, 838(ab)
F-18 FDG, 925(ab)
focal, radiolabeled proteins, biodistribution and kinetics, 388
imaging focal sites, Tc-99m hydrazino nicotinamide conjugated chemotactic peptides, 910(ab)
imaging in patients with streptavidin, radiolabeled biotin, 924(ab)
localization, role for avidin-biotin, 1816
orthopedic, value of bone marrow scanning, 840(ab)
second Sino-American nuclear medicine conference, 16N(4)
sternal wound, diagnosis, Tc-99m leukocyte imaging, 59
targeted proteins, diagnostic imaging, 394
Tc-99m antigranulocyte Fab′ fragments, scintigraphy, In-111 oxine/Tc-99m HMPAO leukocytes, 903(ab)
Inflammation
abdominal aortic aneurysm, In-111 imaging, 1553
accumulation in inflammatory focus, Tc-99m anti-fibrin monoclonal antibody, 1181
acute focal lesions, In-111 leukocytes, Ga-67 polyclonal IgG, 1428(le)
antimyosin imaging, detection of tumor invasion of muscle layer, 841(ab)
conjugation of human immunoglobulin, dendrimers as linker molecules, 986(ab)
imaging
current role, labeled autologous leukocytes, 65
Tc-99m dexamethasone phosphate, 1027(ab)
radiolabeled polyclonal IgG, 1031(ab)
reflex sympathetic dystrophy of the hand, excessive inflammatory response, 936(ab)
tumor and, one-step labeling kit, Tc-99m HIG, 1028(ab)
Inflammatory bowel disease
In-111 labeled human nonspecific immunoglobulin G, 919(ab)
In-111 whole-body retention, 756
quantitation of intestinal protein loss, In-111 transferrin, 919(ab)
Tc-99m glucoheptonate white blood cells, 998(ab)
In memoriam
Donald W. Cole, Jr., 1726
Oscar B. Hunter, Jr., 631
Insulin
clamp, myocardial glucose utilization, F-18 FDG PET, 1255, 1263
-dependent diabetes mellitus, secondary gastroparesis, 1707
Interleukin 2, tumor uptake of monoclonal antibody, 934(ab)
Intestine, quantitation of protein loss, In-111 transferrin, inflammatory bowel disease, 919(ab)
Iodides, contrast material, potential effects, radioactive thyroid uptake, 237
Iodine-123
I-125 and I-131 labeled compounds, radiotoxicity, mouse testes, 2196
myocardial viability after infarction, exercise-redistribution SPECT Tl-201, 906(ab)
scintigraphic follow-up, differentiated thyroid carcinoma, 1020(ab)
Tc-99m and
dual radionuclide data acquisition, quantitative brain SPECT, 972(ab)
SPECT, brain, 2030
Iodine-123 BMIPP
hypertrophic cardiomyopathy, 1914(le)
TL-201 and, assessment, ischemic but viable myocardium, 885(ab)
Iodine-123 CIT, SPECT, monoamine transporter sites, non-human primate brain, 945(ab)
Iodine-123 ERC 9, potential new pancreatic imaging agent, 841(ab)
Iodine-123 β-methyl-branched fatty acid, myocardial emission computed tomography, hypertrophic cardiomyopathy,

6
Iodine-123 HIDPM, portal systemic shunt fraction quantification, liver diseases, 997(ab)
Iodine-123 hirulog, preparation and evaluation, blood clot imaging, 981(ab)
Iodine-123 IBF, SPECT, preclinical study, D2 dopamine receptor, 870(ab)
Iodine-123 IBZM
dopamine D2 receptors, dynamic SPECT and whole body imaging, 896(ab)
quantitation in human plasma, 871(ab)
SPECT
differential diagnosis of Parkinsonism, 917(ab)
dopamine D2 receptors, 1964
dopamine D2 receptors, effects of age, 897(ab)
dopamine D2 receptors, haloperidol, 898(ab)
dopamine D2 receptors, Parkinson's disease, 917(ab)
dopamine D2 receptors, Parkinson syndromes, 917(ab)
dopamine D2 receptors, unilateral Parkinson's disease, 1016(ab)
dopamine D2 receptors, Wilson's disease, 897(ab)
Parkinson's disease, multi-system atrophy and dystonia, 1018(ab)
semiquantification, scatter correction, 972(ab)
subjects with and at risk for Huntington's disease, 970(ab)
Iodine-123 IDEX, decreased binding to muscarinic cholinergic receptors, hippocampus, temporal lobe epilepsy, 928(ab)
Iodine-123 ILIS, SPECT, dopamine D2 receptors, supranuclear palsy, 1019(ab)
Iodine-123 IMP
cerebral blood flow
rotating gamma camera, 963(ab)
Tc-99m HMPAO and, uptake in drug abuse, 1015(ab)
SPECT
cerebral blood flow, no arterial sampling, 969(ab)
cerebral perfusion, progressive supranuclear palsy, 704
dementia, 1015(ab)
nondemented older patients, Down's syndrome, 967(ab)
partition coefficient, regional cerebral blood flow, 911(ab)
Tc-99m HMPAO and
dual-isotope brain imaging, normal volunteers, 827(ab)
regional cerebral blood flow, SPECT and MRI, 1012(ab)
***N*-isopropyl-Iodine-123 IMP,** SPECT, regional cerebral blood flow, 965(ab), 1741
Iodine-123 iodoamphetamine, scintigraphy, Budd-Chiari syndrome, 744
Iodine-123 IPPA
metabolic cardiac imaging, multicrystal gamma camera, severe coronary disease, 1269
SPECT, myocardial involvement, systemic myopathies, 995(ab)
Iodine-123 2′-ISP, SPECT, D2 dopamine receptors, 897(ab)
Iodine-123 LSD, improved preparation, 982(ab)
Iodine-123 MIBG
cardiac imaging
prognostic guide, heart failure, 896(ab)
prognostic value, heart failure, 471
increased lung uptake, ischemic heart disease, 955(ab)
mechanisms of down-regulation, idiopathic cardiomyopathy, 896(ab)
neural crest tumors, 1072(ab)
prognosis in congestive heart failure, 477
scintigraphy, metastatic carcinoid tumors, 1121
uptake at 1-year post-cardiac transplant, partial reinnervation in man, 896(ab)
Iodine-123 MIHA, myocardial viability, FDG PET, 953(ab)
Iodine-123 somatostatin analog, dosimetry and biodistribution, neuroendocrine tumors, 1613
Iodine-123 SP4, imaging atherosclerosis, 845(ab)
Iodine-123 TISCH, dosimetry, 954(ab)
Iodine-123 TOCT
In-111 DOCT somatostatin analogues and, somatostatin receptor-positive neoplasms, 914(ab)
scintigraphy, metastatic carcinoid tumors, 1121
Iodine-123 Tyr-3-octreotide, compared to In-111 DTPA-D-Phe-1-octreotide, somatostatin receptor scintigraphy, 652
Iodine-124 3F9, PET, tumor dosimetry, radioimmunotherapy in a child with neuroblastoma, 2020
Iodine-124 monoclonal antibodies, PET, c-*erb*B-2 protein overexpression, breast cancer, 2154
Iodine-125
anti-P185HER2 monoclonal antibody, animal tumor model, 934(ab)
I-123 and I-131 labeled compounds, radiotoxicity, mouse testes, 2196
rat brain blood flow, plastic scintillation detectors, position-sensitive photomultipliers, 1003(ab)
Iodine-125 altanserine, synthesis, potential ligand, SPECT and serotonin S_2 receptors, 1023(ab)
Iodine-125 antimyosin, interference of myosin heavy chain fragments, myocardial infarction, 895(ab)
Iodine-125 digoxin, high myocardial accumulation, 545
Iodine-125 epidepride, I-125 ioxipride and, alternate syntheses, 982(ab)
Iodine-125 epidermal growth factor, handling by isolated perfused rat liver, 955(ab)
Iodine-125 fibrinogen, fibrin deposition, coronary artery injury, 845(ab)
Iodine-125 iodoacylcycloadenosin-4′-ene, synthesis and metabolism, potential inhibitor, *S*-adenosyl-L-homocysteine hydrolase, 980(ab)
Iodine-125 5-iodo-6-nitroquipazine, synthesis and evaluation, presynaptic serotonin ligand, 890(ab)
Iodine-125 ioxipride, I-125 epidepride and, alternate syntheses, 982(ab)
Iodine-125 LDL
binding to parenchymal and non-parenchymal cells, normal and estradiol-stimulated rat liver, 1028(ab)
In-111 polyclonal IgG and, uptake, experimental arterial wall injury, 845(ab)
Iodine-125 LSD, improved preparation, 982(ab)
Iodine-125 MIBG
abnormal cardiac adrenergic neuron activity, Adriamycin-induced cardiomyopathy, 208
Adriamycin and congestive cardiomyopathy, 215
intracellular distribution, electron microscopic autoradiography, neuroblastoma xenografts, 1021(ab)
intraoperative detection, pheochromocytoma, 1020(ab)
uptake by serotonin transporter, 935(ab)
Iodine-125 monoclonal antibody
biodistribution, hand-held NaI-crystal detector, 1002(ab)
microdosimetry estimations, internalization, human glioma cells, 942(ab)
Iodine-125 PAB, preparation and characterization, potential malignant melanoma imaging radiopharmaceutical, 889(ab)
Iodine-125 QNB, muscarinic receptor binding, pharmacokinetic sensitivity, rat brain, 883(ab)
Iodine-125 Tyr-3-octreotride, handling by isolated perfused rat liver, 955(ab)
Iodine-131
amount and tumor size, Alderson phantom, planar imaging, 925(ab)
anti-pan B-cell antibodies, radioimmunotherapy, B-cell lymphoma, 863(ab)
B1 and BC8 antibodies, trace and therapeutic amounts, 864(ab)
camera-induced scatter, collimator penetration, 889(ab)
contamination, thyroid cancer patients, 2110
I-123 and I-125 labeled compounds, radiotoxicity, mouse testes, 2196
imaging therapeutic doses, clinical gamma camera, 771
outpatient nuclear medicine therapy, petition would ease strictures, 13N(7)
pan-B-cell monoclonal antibody, B-cell lymphoma, radioimmunotherapy, 893(ab)
post-thyroid cancer therapy, radiation safety considerations, 1402
QSPECT of phantom, transfer of CT cols, manual alignment, 925(ab)
radioimmunotherapy of leukemia, bone marrow radiation absorbed dose estimation, 941(ab)
taste dysfunction, thyroid cancer, 996(ab)
therapeutic amounts, iodination of monoclonal antibodies, 982(ab)
therapy for thyroid cancer, quantitative dosimetric approach, 894(ab)
therapy for thyroid carcinoma, complications, sequela and dosimetry, 2214
-treated patients, risk to others, 2116
utility in well-differentiated thyroid cancer, chest X-rays, bone scans, 894(ab)
whole-body scan, replacement with thyroglobulin measurement, 172(le)
Iodine-131 chimeric B72.3, Phase I trial, metastatic colorectal cancer, 23
Iodine-131 hippurate, Tc-99m MAG_3 or, functional and anatomic evaluation, renal transplants, 1035(ab)
Iodine-131 lipiodol, high-dose targeted irradiation, liver tumors, 1020(ab)
Iodine-131 LL2 monoclonal antibody, repeated low-dose radioimmunotherapy, lymphoma, 863(ab)
Iodine-131 Lym-1, body and blood clearance and marrow radiation dose, B-cell malignancies, 941(ab)
Iodine-131 MIBG
bone scintigraphy and, detection of neuroblastoma, 1735
brain imaging, 33N(9)
diagnosis of pheochromocytoma, 833(ab)
scintigraphic assessment of uptake, globally denervated human and canine hearts, 1444

scintigraphy
diagnostic value, kindred with MEN-II, 1065(ab)
pitfalls, diagnosis of neuroblastoma, 930(ab)
therapy for carcinoid syndrome, 834(ab)
Iodine-131 monoclonal antibody
bone marrow suppression, recombinant G-CSF, 933(ab)
CC49
imaging considerations, 1001(ab)
radioimmunotherapy SPECT images, CT and advanced colorectal cancer, 1002(ab)
immunoscintigraphy of ovarian carcinoma, 905(ab)
radioimmunoscintigraphy, renal cell carcinoma, 913(ab)
Iodine-131 monoclonal antibody fragments, bone marrow toxicity, 941(ab)
Iodine-131 Mu-9 IgG, Re-188 and, therapeutic potential, single and fractionated doses, 1000(ab)
Iodine-131 octreotide, dosimetry and biodistribution, I-123 somatostatin analog, neuroendocrine tumors, 1613
Iodine-131 OIH
radiation dosimetry, human biodistribution studies, 33
single-injection multi-sample renal clearance methods
comparison, 948(ab)
optimum sample times, 948(ab)
Iodine-131 1,2-Pal-3-IPPA, site specific/stable radioiodination, pancreatic lipase, urine analysis, 1028(ab)
Iodocholesterol, radiation injury after interstitial injection, 1722(le)
5-Iododeoxyuridine, efficacy of radioimmunotherapy, human tumors growing in nude mice, 1530
3-Iodophenylisothiocyanate, radiodinated, coupling to monoclonal antibodies, 1029(ab)
Iomazenil, binding to human benzodiazepine receptor, dynamic SPECT, 911(ab)
Ion mass spectrometry microscopy, secondary, Tc-99m mapping, leukocytes, 2162
Iron
hepatic and cardiac, noninvasive *in vivo* measurement, 1278
transferrin and hepatic Ga-67 concentration, Ga-67 distribution, 1701
Irradiation
high-dose targeted, primary liver tumors, I-131 lipiodol, 1020(ab)
total body, toxicity, non-Hodgkin's lymphoma, 960(ab)
Ischemia
delayed, cerebral angioplasty and vasospasm, brain SPECT, 1789
renal, captopril-mediated hemodynamic changes, 907(ab)
Isoelectric focusing, chromatofocusing studies, monoclonal Fab′, 2148
Isotec, Inc., rejection of petition, 14N(6)
Isotopes
DOE's problems, 34N(10)
medical use of, Nuclear Regulatory Commission, 30N(9)
trouble in U.S., GAO probe, 22N(9)

J

Jaundice, neonatal, diagnostic criteria for biliary atresia, Tc-99m EHIDA hepatobiliary scintigraphy, 899(ab)
Joint
inflammation
Tc-99m HIG, 839(ab)
Tc-99m HIG and bone scans, rheumatoid arthritis, 840(ab)
Journal of Nuclear Medicine (JNM), seeking new editor, 20N(7)

K

Kanji-Kana reading process, analysis by PET, 827(ab)
Kawasaki syndrome, cardiac perfusion abnormalities, long-term follow-up, 929(ab)
Kidney
blood flow, convection-diffusion model, 949(ab)
cancer, pre-operative sterilization, intra-arterial Sm-153 microspheres, 1024(ab)
cationic renal tubular agent, Tc-99m DACH, normal human volunteers, 923(ab)
chemotherapy-induced disorder, antimyosin antibody uptake, 309(le)
clearance, single-injection multisample methods, 948(ab)
comparison of Tc-99m direct *vs.* N2S2 chelate, labeled NR-LU-10 Fab′, tumored nude mice, 909(ab)
computer-based nuclear medicine teaching file, 1073(ab)
-depth correction in renal uptake rate, Tc-99m DMSA, compartment modeling, 1004(ab)
direct and indirect Tc-99m labeled antibody, comparison in mice, 909(ab)
diuretic MAG_3 renal scintigraphy, routine protocol, congenital and acquired renal disorders, 1035(ab)
DMSA renal scans, variability, standardized rating scale, 922(ab)
dynamic studies, quantitative analysis, factor analysis, 949(ab)
effects of dipyridamole on function, Tc-99m DTPA, 355
excretion of Tc-99m-labeled organic cations, 2190
functional clearance, captopril, diuretic therapy, 739
imaging with Tc-99m 2GAM, 923(ab)
impaired renal function, antenatal hydronephrosis, surgery *vs.* conservative management, 873(ab)
model-based quantitation, knowledge-based factor analysis, 947(ab)
normalized diuretic renogram parameters, diagnosis, obstructive uropathy, 923(ab)
parenchymal renal lesion after ESWL, Tc-99m DMSA, 990(ab)
PET studies, use of abdominal aorta, arterial input function determination, 613
plasma flow and glomerular filtration rate, spinal cord injury, 1035(ab)
post-transplanted patients, radioangioscintigraphy, 991(ab)
potential imaging agents, Tc-99m MAG_3, 919(ab)
potential of camera-based method, MAG_3 clearance, gamma variate fit, 991(ab)
pre- and post-pyeloplasty, functional assessment, diuretic renogram, 977(ab)
procedures of choice in renal nuclear medicine, 175(le)
prospective validation, single sample technique, Tc-99m MAG_3 clearance, 1620
rapid tubular transport, structural requirements, Re and Tc-99m complexes, 900(ab)
real time monitoring, risk of radiocontrast-induced acute renal failure, 948(ab)
renal artery stenosis, cortical residual activity, captopril renography, 906(ab)
renal tubular transport, Tc-99m complexes, 920(ab)
suspected uretero-pelvic junction obstruction, postnatal assessment, volume expanded diuretic renography, 2094
Tc-99m, ligands related to MAG_3 and hippuric acid, 988(ab)
Tc-99m DMSA high-resolution SPECT, three-head rotating gamma camera, 1021(ab)
Tc-99m DTPA uptake-plasma volume product, glomerular filtration rate, 1712
Tc-99m L,L-EC imaging agent, 551
Tc-99m MAG_3
hepatic activity, 992(ab)
simplified ERPF determination, 1034(ab)
Tc-99m scan, diagnosis, bleeding mycotic iliac aneurysm, 1548
transplantation
functional and anatomic evaluation, Tc-99m MAG_3 *vs.* I-131 hippurate, 1035(ab)
kinetics and chronic rejection, renal artery stenosis, 923(ab)
renal artery stenosis, captopril-enhanced scintigraphy, 263
Tc-99m mertiatide, atlas, 1073(ab)
transplant hypertension, iliac artery stenosis, 1178
triple radiopharmaceutical renal study, standard DTPA renogram, renovascular hypertension, 1034(ab)
unexpected pressor responses, captopril renal scintigraphy, 906(ab)
uptake of avidin, isoelectric point, 986(ab)
washout during Tc-99m DTPA diuresis renography, ureteral status, children, 73
Knee, acute ligamentous injuries, subchrondral bone infractions, scintigraphy and MRI, 516
Krypton-81m
anatomy of radioisotope lung scanning, 676
go with the flow—but how far?, 1939
multiple-gated imaging, right ventricular volume determination, 932(ab)
separation of regional ventilation and volume, 1935
Kupffer cells, dosimetry at cellular level, Tc-99m sulphur colloid injection, 380
Kuwait, burning oil wells and air pollution, lung imaging studies, 978(ab)

L

Laminin, platelet-binding, direct Tc-99m labeling, 1031(ab)
Landau-Kleffner syndrome, regional cerebral perfusion, related childhood aphasias, 1758
Language, analysis of Kanji-Kana reading process by PET, 827(ab)
Lead-203 immunoconjugates, biodistribution, chelate rigidity and denticity, 1030(ab)
Leukemia, bone marrow radiation absorbed dose estimation, I-131 radioimmunotherapy, 941(ab)
Leukemia, myelogenous, acute, modeling and dosimetry, anti-CD33 monoclonal antibody M195, 941(ab)
Leukocytes
labeled autologous, current role, imaging inflammation, 65
radiolabeled, detection, cardiovascular infections, 1493
scintigraphy, diagnosis of mycotic aneurysm,

1486
Tc-99m mapping, secondary ion mass spectrometry microscopy, 2162
Ligands
angiotensin II, distribution, imaging potential, 900(ab)
binding and animal biodistribution, no-carrier-added radioiodinated cocaine analogs, 981(ab)
chemical family of, dopamine D2 receptors, 981(ab)
diaminedithiol, labeling with Re-186, 1932(ab)
flumazenil, quantification of benzodiazepine receptors, PET, 883(ab)
macrocyclic, bifunctional DTPA and, serum stability studies with Y-88, 1031(ab)
PET, cerebral dopamine D2 receptors, 847(ab)
phosphorus-nitrogen backbone, formulation, new radiopharmaceuticals, 1072(ab)
radioiodinated high-affinity dopamine D2 receptor, *in vivo* comparison, 848(ab)
-receptor modeling, PET, multi-injection approach, 943(ab)
relation to MAG_3 and hippuric acid, Tc-99m renal function agents, 988(ab)
structure, glutathione-mediated decomposition, propylene amine oxime derivatives, 988(ab)
synthesis of I-125 altanserine, SPECT, serotonin S_2 receptors, 1023(ab)
Tc and Re complexes, unsymmetrical BAT ligand, 989(ab)
Light, photic stimulation study, arterial partial pressure, carbon dioxide, 827(ab)
Liposomes, Tc-99m, new labeling procedure, infection detection in rats, 1027(ab)
Lithium carbonate, therapy for psychiatric disorders, hyperthyroidism, 996(ab)
Lithotripsy, extracorporeal shockwave, parenchymal renal lesion, Tc-99m DMSA, 990(ab)
Liver
activity in Tc-99m MAG_3 renal scans, 992(ab)
arteriovenous malformations, embolization, hereditary hemorrhagic telangiectasia, 260
chelator structure, In-111 labeled Ab-chelator, 1001(ab)
chronic disease, evaluation of local reduced mass, Tc-99m NGA, 998(ab)
cirrhosis, portal venous blood flow, pulsed Doppler and per-jejunum scintigraphy, 997(ab)
clearance of Tc-99m HIDA derivatives, hyperbilirubinemic states, 1551
diagnosis of hepatic hemangioma, triple-head high-resolution SPECT, 918(ab)
diagnostic imaging, 1344
enhanced tumor targeting, metabolizable chemical spacer, In-111 monoclonal antibody, 957(ab)
FDG uptake kinetics, impact of glucose ingestion, dynamic PET, 945(ab)
hepatic arterial-to-portal venous blood flow, validation, radionuclide techniques in an animal model, 239
hepatic sequestration of In-111 platelets, thrombocytopenia, GM-CSF, 923(ab)
hepatobiliary scintigraphy, intrahepatic *vs.* extrahepatic cholestasis, 1186
homogenates of In-111 and Y-90, attachment to antibody via popular chelators, 1030(ab)
inhibition of hepatic uptake, radiolabeled monoclonal antibody, primary rat hepatocyte culture model, 893(ab)
iron, noninvasive *in vivo* measurement, 1278
isolated perfused, I-125 Tyr-3-octreotide, In-111 DTPA-D-Phe-1-octreotide and I-125 epidermal growth factor, 955(ab)
lesions, Tc-99m monoclonal antibodies and Tc-99m colloid, image subtraction analysis, 913(ab)
model-based quantitation, knowledge-based factor analysis, 947(ab)
necrosis, Tc-99m medronate, Budd-Chiari syndrome, 1390
normal and estradiol-stimulated, binding of Tc-99m LDL and I-125 LDL, 1028(ab)
PET studies, use of abdominal aorta, arterial input function determination, 613
portal systemic shunt fraction quantification, I-123 HIDPM, 997(ab)
reduced accumulation, radiolabeled monoclonal antibodies, In-111 thioether-poly-L-lysine-DTPA monoclonal antibody-$TP41.2F(ab')_2$, 570
-spleen scan, fatty liver, masquerade as neoplasm, 258
TBIDA scan hot spots, focal nodular hyperplasia, 918(ab)
transplantation, bile extravasation, scintigraphy, 115
transplant infarcts, bile lakes, hepatobiliary scintigraphy, 997(ab)
transport function, hepatobiliary scintigraphy, 998(ab)
volume measurement with SPECT, autopsy and NMR imaging, 1066(ab)
Y-90 microsphere therapy, three-dimensional tumor dosimetry, 735
Liver disease, diffuse alcoholic, emission tomography, 1337
Liver neoplasms
dual energy acquisition, Tl-201 and Tc-99m phytate, high-resolution three head SPECT, 976(ab)
evaluation with F-18 FDG PET, 333
high-dose targeted irradiation, I-131 lipiodol, 1020(ab)
imaging by Tl-201 and Tc-99m phytate, high-resolution three-head SPECT, 918(ab)
Low-level radioactive waste (LLRW)
California radioactive waste site, licensing decision, 40N(9)
disposal of, 30N(10)
federal deadline, activists and politicians, 15N(1)
federal policy, challenged, 25N(12)
gauging the effect of court ruling, 28N(8)
repository closures, 34N(9)
shouldering burden of, 20N(6)
waste network, 34N(9)
Low-Level Radioactive Waste Policy Amendments Act (LLRWPA)
shouldering burden, 20N(6)
Supreme Court to hear case, 33N(3)
Lung
blood flow, protein flux measurements, PET, 1661
chronic obstructive pulmonary disease, major upward creep of heart, exercise Tl-201 myocardial SPECT, 1846
complications of HIV infection, Tc-99m DTPA aerosol, Ga-67 scanning, 81
diffuse pulmonary uptake, In-111 leukocytes, drug-induced pneumonitis, 1175
diseases, V/Q ratio frequency distribution, 1023(a)
disposition of gallium-67, *Pneumocystis* pneumonia, 512
enhanced V/Q mismatch sign, pulmonary embolism, 1072(ab)
imaging studies of persons exposed to air pollution, burning oil wells in Kuwait, 978(ab)
increased uptake of I-123 MIBG, ischemic heart disease, 995(ab)
indeterminate probability scan, decision analysis, 1251(le)
infection, accuracy of early gallium imaging, immunocompromised patients, 957(ab)
intermediate probability/indeterminate scans, pulmonary angiography, 849(ab)
mean transit times of teboroxime, compared to Tc-99m pertechnetate, 846(ab)
metastases, microdistribution, monoclonal antibodies, 957(ab)
MIBG extraction fraction, first-pass analysis, 716
model-based quantitation, knowledge-based factor analysis, 947(ab)
neutrophil sequestration, intercellular adhesion molecules, endotoxemia, 1023(ab)
perfusion and ventilation scans, severe diffuse obstructive airway disease, 1072(ab)
radioaerosol clearance, effect of molecular size, 1022(ab)
radioisotope scanning, anatomy of, 676
radiolabeled granulocyte kinetics, systemic vasculitis, 491
radiopulmonary clearance, appropriate background subtraction, 836(ab)
scan and pulmonary arteriogram improvement, urokinase, 849(ab)
scan interpretation, 1417, 1422
interobserver variation, 978(ab)
scintigraphy, follow-up, transplantation, 835(ab)
single transplant, quantitative exercise-rest ventilation-perfusion imaging, 835(ab)
solitary pulmonary nodule, differential diagnosis, FDG PET, 836(ab)
thallium uptake, adenosine Tl-201 scintigraphy, 1600
uptake of Tc-99m sestamibi, correlation with LV ejection fraction, 846(ab)
ventilation, Tc-99m DTPA and Tc-99m desferoxamine aerosols, SPECT, 835(ab)
ventilation-perfusion scans
computer-assisted diagnosis, pulmonary embolism, 1003(ab)
number of segmental mismatches, likelihood of pulmonary embolism, 849(ab)
Lung neoplasms
mediastinum, FDG PET staging, 828(ab)
radioimmunodetection, human monoclonal antibody, 958(ab)
treatment planning and monitoring, F-18 FDG PET, 975(ab)
Lymphedema
lymphoscintigraphy, 999(ab)
multiscintigraphic imaging approach, 874(ab)
Lymph nodes
mediastinal, mapping, F-18 deoxyglucose PET, 828(ab)
reactive, infection and, F-18 FDG, 925(ab)
Lymphocytes, Tc-99m HMPAO, radiotoxicity study, micronucleus assay, 1167
Lymphoma
F-18 FDG PET, 532
Hodgkin's, effect of therapy, Ga-67 scans and MRI, 914(ab)
malignant
F-18 FDG scintigraphy, chemotherapeutic impact, 858(ab)

In-111 somatostatin analogue scintigraphy, 903(ab)
kinetics and therapeutic potential, Ga-67, 926(ab)
proliferative activity, PET F-18 FDG, 325
non-Hodgkin's
Ga-67 scintiscan, 1183
toxicity, total body irradiation, 960(ab)
optimal imaging time for thallium, tumor agent, 844(ab)
repeated low-dose radioimmunotherapy, I-131 LL2 monoclonal antibody, 863(ab)
staging, role of gallium scanning, 1588(le)
thryoid, uptake, Tc-99m MIBI and Tl-201 chloride, 1396
Lymphoma, B-cell, I-131 anti-pan B-cell antibodies, radioimmunotherapy, 863(ab), 893(ab)
Lymphoscintigraphy
diagnosis of lymphedema, 999(ab)
internal mammary, breast cancer prognosis, 859(ab)
Tc-99m dextran, transverse rectus abdominus myocutaneous flap, autogenous breast reconstruction, 859(ab)

M

Magnetic resonance spectroscopy, fluorinated polymeric molecular probes, non-invasive assessment, pH, 974(ab)
Malformations, intracranial arteriovenous, sequential high resolution SPECT, Tc-99m RBC and Tc-99m HMPAO, 839(ab)
Malignancy
bone lesions, Tl-201 uptake pattern, 869(ab)
genitourinary, post-treatment evaluation, FDG PET, 829(ab)
Tc-99m sestamibi SPECT, F-18 FDG glucose, 858(ab)
Malignancy, B-cell, body and blood clearance, marrow radiation dose, I-131 Lym-1, 941(ab)
Manometry, esophageal disorders and scintigraphy, 1301
Manpower Survey, 1992, 51N(11)
MDP, perioperative uptake, S-ROM hip prosthesis, 950(ab)
Mediastinum
biopsy-confirmed residual Hodgkin's disease, Ga-67 SPECT, 345
FDG PET staging, lung cancer, 828(ab)
lymph node mapping, F-18 deoxyglucose PET, 828(ab)
Medical Internal Radiation Dose (MIRD), radiopharmaceutical uptake, dose heterogeneity, quantitative autoradiography, 1833
Medicare
fee schedule, 34N(9)
SNM and ACNP response, 18N(1)
Office of Payment Policy, 36N(9)
reform, charting the impact, 18N(2)
statement by physician payment review commission, 24N(3)
volume performance standard, 24N(3)
Melanoma
malignant
F-18 FDG PET, 975(ab)
preparation of I-125 PAB, 889(ab)
uveal, radioimmunoscintigraphy, 3-step monoclonal antibody pretargeting technique, 959(ab)
Melanoma, B16, non-S phase melanocytes, accumulation of 2-[F-18]FDOPA, microautoradiography, 984(ab)
MEN-II, kindred with, diagnostic value, I-131 MIBG scintigraphy, 1065(ab)
Meningioma, prediction of histological type, Tl-201 SPECT, 971(ab)
Mental disease, genetic models, 22N(8)
Metaiodobenzylguanidine, heart and lung extraction fraction, first-pass analysis, 716
Metastasis
bone, pharmacokinetics, Re-186 after Re-186-HEDP, 646
bone cancer, escalating dose schedule, Sm-153 EDTMP, 1451
bone disease, multidose Sm-153 EDTMP, pain palliation, 992(ab)
bone pain, different therapeutic doses, Sr-89, 937(ab)
breast cancer
clinical value, CA 15-3 plasma levels, 854(ab)
radioimmunotherapy, 862(ab)
carcinoid tumors, scintigraphic comparison, I-123 MIBG and I-123 TOCT, 1121
colon cancer, dose fractionation, radiolabeled antibodies, 1648
detection in colorectal carcinoma, In-111 C110 anti-CEA monoclonal antibody, CT, 904(ab)
gastro-entero-pancreatic endocrine tumors, In-111 pentatreotide scintigraphy, 976(ab)
gastrointestinal cancer, radioimmunotherapy, 863(ab)
lung, microdistribution, monoclonal antibodies, 957(ab)
prostate carcinoma, preoperative identification, In-111 CYT-356, 1001(ab)
prostate carcinoma to bone, strontium-89, low-dose infusion cisplatin, 1437
quantitative tumor scintigraphy, dogs with osteosarcoma, 1542
recurrent soft-tissue sarcoma and, gallium imaging, 1594
spinal, radionuclide bone scan, MRI imaging, 992(ab)
thyroid carcinoma, Tc-99m TBI scintigraphy, 914(ab)
Methionine, thymidine or, location in cell, radiation-induced alterations, 841(ab)
Methylene, bridged phosphineoxide-phosphine, versatile chelating agent, Re-188, 979(ab)
MIBI, -SPECT and stress echocardiography, choice of stress for diagnostic perfusion, wall motion imaging, 825(ab)
Microautoradiography
F-18 FDG, granulation tissues and phagocytes, mouse tumor tissue, 840(ab)
high accumulation of 2-[F-18]FDOPA, non-S phase melanocytes, B16 melanoma, 984(ab)
Microdosimetry, estimations of I-125 monoclonal antibody 425, internalization, human glioma cells, 942(ab)
Micrometastases
continuing evolution, 2180
neuroblastoma, radioiodinated MIBG, multicellular tumor spheroids, 859(ab)
plasmapheresis in radioimmunotherapy, mathematical model, dosimetry, 2167
Micronucleus assay, lymphocyte labeling, Tc-99m HMPAO, radiotoxicity, 1167
Microspheres
intra-arterial Sm-153, pre-operative sterilization, kidney cancer, 1024(ab)
polymeric, radionuclide synovectomy, neuron-activated holmium-166, 398
Y-90 therapy, three-dimensional tumor dosimetry, 735
Microwave
boiling procedure for Cardiolite vials, 468(le)
breakage of Tc-99m sestamibi vial, 176(le)
MIRD dose
approach and limitations, 781
estimate No. 15, radioindium-labeled autologous platelets, 777
pamphlet No. 14, urinary bladder model, radiation dose calculations, 783
Misonidazole, retention after occlusion of LAD coronary artery, regional myocardial metabolism, blood flow, 993(ab)
Mitral valve disease, Tc-99m radionuclide angiography, thrombosis detection, left atrial appendage, 365
Molybdenum-99
DOE actions, 14N(6)
doubts about U.S. production, 21N(10)
government plan, slow advancement, 11N(2)
threatened reactor worker strike, 19N(9)
Monoamine, transporter sites, I-123 CIT SPECT, non-human primate brain, 945(ab)
Monoclonal antibodies
A11, diagnosis, neuroendocrine tumors, 834(ab)
β/A4 amyloid, Alzheimer's disease, angiopathy, 2184
Annual Meeting highlights, 13N(8)
anti-CEA/anti-DTPA bispecific, two-step immunoscintigraphy, medullary carcinoma of thyroid, 912(ab)
antiferritin, linker-conjugated $F(ab')_2$ fragments, 987(ab)
anti-fibrin, Tc-99m labeling, accumulation in inflammatory focus, 1181
anti-pan-carcinoma NR-LU-10, biotin conjugates, radioimmunotherapy, 880(ab)
attachment of monofunctional DTPA analogs, 988(ab)
BC-2, detection of breast tumors, 999(ab)
B72.3/CC49/CC83, radioiodination, pharmacokinetics, 960(ab)
CEA-producing cancer, radioimmunodetection, 1750
chimeric antibody chCE7, radioimmunolocalization, neuroblastoma xenografts, 231
chimeric anti-CEA, HAMA response after immunoscintigraphy, 903(ab)
chimeric cT84.66, In-111 labeling, radiation dose estimates, 953(ab)
chimeric MOv18, reactive with ovarian cancer-associated antigen, 2000
coupling, radioiodinated 3-iodophenylisocyanate, 1029(ab)
Cu-64-labeled, PET imaging, 1685
direct and indirect Tc-99m labeled antibody, comparison in mice, 909(ab)
dose fractionation of radiolabeled antibodies, metastatic colon cancer, 1648
ethics, 296
$F(ab')_2$ fragments, c-kit protooncogene overexpression, scintigraphic detection, 893(ab)
$F(ab')_2$ tumor uptake, hyperthermia, 958(ab)
F-18 antimyosin monoclonal antibody fragments, preliminary investigations, canine myocardial infarct model, 575
human/mouse chimeric, recognition of CA125, ovarian cancer radioimmunoimaging, 1001(ab)
I-131 chimeric B72.3, Phase I trial, metastatic colorectal cancer, 23

In-111 B72.3, pharmacokinetics, colorectal carcinoma, 498
In-111 labeled IVP ZCE 025, efficacy and safety, colorectal carcinoma, 959(ab)
In-111 thioether-poly-L-lysine-DTPA monoclonal antibody-TP41.2F(ab′)$_2$, reduced hepatic accumulation, 570
iodination, therapeutic amounts of I-131, 982(ab)
labeling of white blood cells, 34N(5)
labeling with F-18, *N*-succinimidyl 4-[F-18] fluorobenzoate, 881(ab)
M195, modeling and dosimetry, acute myelogenous leukemia, 941(ab)
microdistribution, experimental lung metastases, 957(ab)
monoclonal Fab′, chromatofocusing studies, 2148
NR-LU-10
  CH2 domain deletion mutant, radioimmunotherapy potential, 1028(ab)
  Re-186 direct *vs.* chelate labeling, tumored nude mice, 910(ab)
octahedral gallium chelate, immunoscintigraphy, PET, 1366
optimizing intraperitoneal radioimmunotherapy, 959(ab)
radioimmunodetection of lung cancer, 958(ab)
radioimmunotherapy, MIRDOSE dosimetry software protocol, 926(ab)
radiolabeled
  antibody-macrocyclic chelate conjugates, 1031(ab)
  chimeras, 29
  fusion of SPECT images with CT/MRI images, 960(ab)
  heterogeneous distribution, binding site barrier, 893(ab)
  inhibition of hepatic uptake, primary rat hepatocyte culture model, 893(ab)
  oncogene-encoded molecules, tumor imaging and therapy, 2160
  radiation absorbed dose, planar scintigraphic views, 925(ab)
second generation high-affinity anti-CEA, 904(ab)
3-step pretargeting technique, radioimmunoscintigraphy, uveal melanoma, 959(ab)
TNT-1 and TNT-1-F(ab′)$_2$, Re-186, radioimmunotherapy, 987(ab)
tumor-associated antigens, similarity and co-expression, 853(ab)
tumor uptake, effect of interleukin 2, 934(ab)
ZCE 025, In-111 anti-CEA, colorectal carcinoma, 14
Z2D3
  imaging atherosclerotic lesions, antibody-avidin-biotin interactions, 934(ab)
  localization, atherosclerotic lesions, 936(ab)
Monte Carlo, modeling techniques, radiation dose calculation, bone-to-marrow interface, 623
Morphine
-augmented cholescintigraphy
  false-negative, subacute gallbladder perforation, 256
  potential pitfalls, 898(ab)
Moyamoya disease, SPECT/MRI/angiography, before and after external-to-internal carotid artery bypass, 1692
Multidrug resistance, tumor, *in vivo* identification, tritium-3-colchicine, 1373
Multiple systemic atrophy, selective metabolic involvement, 1014(ab)
Muscle, skeletal, time course of glucose uptake, euglycemic hyperinsulinemia, F-18 2-deoxy-2-fluoro-D-glucose study, 1523
Muscular dystrophy, myocardial involvement, I-123 IPPA SPECT, 995(ab)
Musculoskeletal system, assessment of infectious conditions, Tc-99m HIG, 839(ab)
Myasthenia gravis, Tl-201 SPECT, 1020(ab)
Mycobacterium avium-intracellulare, accuracy of early gallium imaging, pulmonary infection, immunocompromised patients, 957(ab)
Myelosuppression, reduction of, efficacy of immunophoresis, radioimmunotherapy, 863(ab)
Myocardial infarction
  acute, Tc-99m glucarate and Tl-201, rats, 1988
  acute and remote, In-111 antimyosin uptake, pathologic findings, 587
  artifact or, gated Tc-99m sestamibi SPECT, 927(ab)
  canine model, preliminary investigations, F-18 antimyosin monoclonal antibody fragments, 575
  consequences of ventricular tachycardia, scintigraphic phase analysis, 994(ab)
  experimental, gamma imaging, rabbits, 943(ab)
  increase in FDG uptake, prognostic indicator, 886(ab)
  infarct-specific tracers, transmural uptake, perfusion tracers, 229
  inferior, right ventricular ischemia, low-level exercise Tc-99m sestamibi SPECT, 876(ab)
  instant kit method, labeling antimyosin Fab′, Tc-99m, 144
  interference in antimyosin imaging, circulating myosin heavy chain fragments, 895(ab)
  interval between reinjection and imaging, Tl-201 image, 915(ab)
  late infarct size and ejection fraction, thrombolytic therapy, 939(ab)
  left ventricular mass and, N-13 ammonia PET, explanted human hearts for validation, 826(ab)
  necessity of thallium reinjection, 916(ab)
  negatively charged-polymer-modified antimyosin, 959(ab)
  patients without, pharmacologic stress, extent and location of CAD, 2067
  regional metabolic abnormality, relation to perfusion, wall motion, 659
  -related arterial patency, serial tomographic imaging, Tc-99m sestamibi, 2080
  size determination, cardiac myosin heavy chain, 853(ab)
  time course, In-111 antimyosin monoclonal antibody scintigraphy, 1501
  Tl-201 compared to Tc-99m sestamibi, 865(ab)
  viability, iodo-labeled methyl fatty acid, FDG PET, 953(ab)
Myocardial ischemia
  adenosine infusion, hemodynamic-scintigraphic study, 952(ab)
  assessment of viable myocardium, combined imaging, I-123 BMIPP and Tl-201, 885(ab)
  blood flow and deoxyglucose uptake, myocyte viability, 1353
  blood flow and glucose uptake, F-18 deoxyglucose, 1346
  detection by combining flow reserve with metabolic assessment, coronary artery disease, 837(ab)
  early or delayed reperfusion, myocardial oxidative metabolism, mechanical function, 884(ab)
  ECG response and perfusion images, thallium stress test, 1723(le)
  enhanced detection after thallium reinjection, quantitative reversibility maps, visual analysis, 916(ab)
  exercise-induced, first-pass radionuclide angiography, upright bicycle ergometry, 359
  extent and severity, PET, predictor of prognosis following thrombolytic therapy, 837(ab)
  general thallium redistribution model, 915(ab)
  increased lung uptake in I-123 MIBG, 955(ab)
  metabolic evidence, dipyridamole stress, 866(ab)
  myocardial energy balance, C-11 SAH PET, 2144
  PET ischemic segments, accelerated clearance, C-11 acetate, 856(ab)
  regional cardiac adenosine, PET, 2138
  -reperfusion, retention of Cu-PTSM, Langendorff perfused rat heart, 1026(ab)
  right ventricular, inferior myocardial infarction, low-level exercise Tc-99m sestamibi SPECT, 876(ab)
  Tl-201 defect reversibility and severity, quantitative *vs.* visual analysis, 905(ab)
Myocarditis, immune mechanisms in heart disease, Mallinckrodt Fellow, 17N(6)
Myocardium
  accumulation of radioiodinated digoxin derivative, possible Na,K-ATPase imaging agent, 545
  aerobic, fatty acid kinetics, 1864
  biokinetics of Tc-99m tetrofosmin, one-day imaging, 874(ab)
  blood flow
    co-injection technique, 1152
    expected variability, anesthetized canine, 884(ab)
    methods for quantification, N-13 ammonia PET, 881(ab)
    polar map displays, cardiac PET images, 1628
  Tc-99m Q12 activity, dogs, 993(ab)
  blood flow and glucose uptake, ischemia, F-18 deoxyglucose, 1346
  blood pool spillover, method for correction, dynamic cardiac FDG PET, 882(ab)
  bridging, predictive value, dipyridamole thallium imaging, 1905
  characteristics of Tc-99m tetrofosmin, coronary heart disease, 875(ab)
  clinical efficacy of tetrofosmin, 874(ab)
  comparison of defect size, Tc-99m tetrofosmin, peak exercise, 874(ab)
  computer-aided diagnosis, coronary artery disease, artifical neural network, 272
  continuous monitoring, left ventricular function during exercise, coronary jeopardy score, 938(ab)
  damage in Adriamycin cardiomyopathy, In-111 antimyosin antibody, 936(ab)
  defect size and severity, correlation, Tc-99m sestamibi and N-13 ammonia PET, 875(ab)
  delineation of, heart volumes, PET and SPECT, 933(ab)
  diffuse necrosis, acute onset, cardiogenic shock, 1558
  distribution of In-111 antimyosin Fab, Tc-99m sestamibi and, nontransmural infarction, 223
  emission computed tomography, I-123 beta-methyl-branched fatty acid, hypertrophic cardiomyopathy, 6
  extraction of teboroxime, interaction with

blood, 94
FDG PET studies, oral glucose loading or insulin clamp methods, 1263
flow reserve decline with age, higher cardiac work at rest, 836(ab)
glucose utilization, insulin clamp, F-18 FDG PET, 1255, 1263
hibernating, irreversible perfusion defects, Rb-82 and F-18 FDG PET, 1065(ab)
human pharmacokinetics and radiopharmacological studies, Tc-99m CPI, 1949
hypoxic, detection using F-18 FMISO PET, 2202
imaging, breast tissue attenuation, 961(ab)
imaging regional hypoxia, Tc-99m 2-nitroimidazole, occlusion of LAD coronary artery, 865(ab)
infarcted and periinfarcted, oxidative metabolism, C-11 acetate PET, 953(ab)
iodo-labeled methyl fatty acid, viability, FDG PET, 953(ab)
kinetics of Cu-62 PTSM, non-human heart, 684
left ventricular time-activity curve, O-15 water PET, 1669
MIBG heart and lung extraction fraction, first-pass analysis, 716
misalignment between PET transmission and emission scans, 1209, 1214
N-13 ammonia stress perfusion imaging in PET, objective computerized quantitative method, 1009(ab)
oxidative metabolism, early or delayed reperfusion, mechanical function, 884(ab)
perfusion
adenosine stress, N-13 ammonia PET, 825(ab)
blood flow and, Tc-99m tetrofosmin, 993(ab)
blunted response to dipyridamole, older adults, 1425(le)
long-term follow-up, Kawasaki syndrome, 929(ab)
quantification, O-15 water and Rb-82 PET, 884(ab)
quantitative evaluation, gated or non-gated Cardiolite SPECT, 927(ab)
radial slices, SPECT, 1070(ab)
Tc-99m MIBI radionuclide angiography and SPECT, dipyridamole, 846(ab)
thallium uptake after reinjection, 915(ab)
tissue viability, hypoperfused regions, 857(ab)
Tl-201 SPECT *vs.* Rb-82 PET, 1064(ab)
wall thickness, simultaneous estimation, 933(ab)
perfusion and ventricular function, simultaneous assessment, total coronary artery occlusion, 825(ab)
perfusion and viability, 3-D SPECT, Tc-99m sestamibi stress perfusion, 926(ab)
perfusion at fatal infarction, location and size, scintigraphic defects, 251
perfusion imaging with dipyridamole or adenosine, serum caffeine levels, 24-hour abstention, 866(ab)
perfusion scintigraphy, integration of wall kinetic and perfusion data, 933(ab)
perfusion studies, blinded evaluation, planar Tc-99m sestamibi, 668
perfusion with PET correction for patient motion, automated region definition, 882(ab)
PET, region-of-interest strategy, 1243
planar perfusion imaging, Tc-99m tebo, Tl-201 and coronary angiography, 1783
quantification of blood flow, 172(le)
rapid synthesis of no-carrier-added N-13 dopamine, 931(ab)
regional metabolism and blood flow, misonidazole retention, occlusion of LAD coronary artery, 993(ab)
regional perfusion
Cu-62 PTSM, 837(ab)
Cu-61 pyruvaldehyde thiosemicarbazone, 884(ab)
reinjection studies, Tl-201 SPECT, collateralization, 915(ab)
reperfusion imaging with Tc-99m sestamibi, acute chest pain, non-diagnostic EKG, 876(ab)
resting and exercise imaging in children, Tc-99m MIBI SPECT, 929(ab)
retained Ga-68 radiopharmaceuticals, 931(ab)
retention characteristics, Tl-201, Tc-99m sestamibi and Tc-99m teboroxime, 865(ab)
simultaneous rest Tl-201/stress Tc-99m sestamibi, perfusion SPECT, 854(ab)
180° SPECT, scatter, attenuation and depth-dependent resolution, 842(ab)
SPECT study with fan-beam collimators, newborn period and early infancy, 930(ab)
structural characterization, Tc-99m tetrofosmin, 850(ab)
subcellular distribution, bis(dithiocarbamato)nitrido Tc(V), male rats, 850(ab)
sympathetic nerves, postnatal maturation, high-resolution scintigraphy, 935(ab)
sympathetic neuronal function, intravenous cocaine injection, dogs, 994(ab)
systemic myopathies, I-123 IPPA SPECT, 995(ab)
Tc-99m imaging agent, kit development, Technecard, 850(ab)
Tc-99m nitrido dithiocarbamate, improved synthesis, 989(ab)
Tc-99m perfusion agents, 22N(1)
Tc-99m PPN.1011 SPECT, clinical evaluation, 875(ab)
Tc-99m sestamibi, comparison, same-day protocols, 186
Tc-99m sestamibi SPECT
comparison, short and standard data acquisition, 855(ab)
early and delayed imaging, coronary artery disease, 855(ab)
same day, 876(ab)
Tc-99m tebo SPECT, delay of image acquisition, 952(ab)
teboroxime, adenosine, accuracy and optimal imaging time, 854(ab)
thickening and phase analysis, Tc-99m sestamibi multiple gated SPECT, 926(ab)
tissue fraction, rapid imaging technique, 994(ab)
tissue uptake, cationic technetium complexes, 1033(ab)
tomographic perfusion imaging, effect of patient motion, 1566
uptake in dogs, side chain modifications, bis(dithiocarbamato) nitrido technetium(V), 1034(ab)
viability
chronic coronary artery disease, TL-201 SPECT *vs.* F-18 DG PET, 886(ab)
delayed post-reinjection Tl-201 imaging, 1064(ab)
F-18 FDG, PET and SPECT, 1064(ab)
radioisotopic assessment, sestamibi scintigraphy, 1925
status of collateral flow, 856(ab)
Tc-99m MIBI scintigraphy, thallous chloride injection, 906(ab)
Tc-99m sestamibi SPECT *vs.* F-18 FDG PET, 886(ab)
Tl-201 and Tc-99m sestamibi SPECT, 905(ab)
viability after infarction, exercise-redistribution SPECT Tl-201, 906(ab)
viable
chronic coronary artery disease, 505
Tl-201 and Tc-99m sestamibi, 815
viable and non-viable, blood flow and flow reserve measurements, 856(ab)

Myocytes
damage in pathologic cardiac hypertrophy, athletes, In-111 antimyosin antibody studies, 994(ab)
endothelial and fibroblast-like cells, Tc-99m sestamibi, Tl-201, 102

Myopathy, systemic, myocardial involvement, I-123 IPPA SPECT, 995(ab)

Myosin
antimyosin imaging, detection of tumor invasion of muscle layer, 841(ab)
heavy chain, determination of infarct size, 853(ab)
heavy chain fragments, interference in antimyosin imaging, myocardial infarction, 895(ab)

Myotonic dystrophy, regional cerebral blood flow impairment, 839(ab)

N

Na,K-ATPase, possible imaging agent, myocardial accumulation, radioiodinated digoxin derivative, 545

National Biomedical Tracer Facility
Congressional subcommittee, U.S. radioisotope supply crisis, 16N(10)
Congressional support, 35N(11)
government relations update, 16N(3)

National Emission Standards for Hazardous Air Pollutants (NESHAP), Environmental Protection Agency, 24N(3)

National Institutes of Health (NIH), educating lawmakers, 30N(10)

Neonates: *see also* Pediatric patients
asymptomatic, hydronephrosis or hydroureteronephrosis, "well tempered" diuretic renogram, 2047
brain SPECT, extracorporeal membrane oxygenation, 1943
cardiac function, arterial switch operation, PET, 977(ab)
jaundice, diagnostic criteria for biliary atresia, Tc-99m EHIDA hepatobiliary scintigraphy, 899(ab)

Neoplasms: *see also* specific type
somatostatin receptor-positive, I-123 TOCT and In-111 DOCT somatostatin analogues, 914(ab)

Nerve, central cholinergic terminals, PET studies, 1011(ab)

Neural crest neoplasms, I-123 MIBG, 1072(ab)

Neural-network, classifier, PET scans, normal and Alzheimer's disease subjects, 1459

Neuroblastoma
I-131 MIBG and bone scintigraphy, 1735
I-131 MIBG approval, 33N(9)
location of, opsoclonus-myoclonus, MIBG usage, 930(ab)
micrometastases, radioiodinated MIBG, multicellular tumor spheroids, 859(ab)

pitfalls in diagnosis, I-131 MIBG scintigraphy, 930(ab)
radioimmunotherapy in a child, tumor dosimetry, I-124 3F9 PET, 2020
xenografts
distribution of I-125 MIBG, electron microscopic autoradiography, 1021(ab)
radioimmunolocalization, chimeric antibody chCE7, 231
Neuroendocrine neoplasms
diagnosis with A11 monoclonal antibody, 834(ab)
dosimetry and biodistribution, I-123 somatostatin analog, 1613
Neurolite
aid in diagnosis and localization of stroke, 878(ab)
imaging of cross cerebellar diaschisis in stroke, 968(ab)
Neurology, second Sino-American nuclear medicine conference, 16N(4)
Neuroma, cranial and spinal, PET-fluorodeoxyglucose, 1931
Neurons
-activated holmium-166, polymeric microspheres, radionuclide synovectomy, 398
cholinergic, F-18 labeled acyclic analogues, vesamicol, 983(ab)
monoaminergic, C-11 tetrabenazine PET, brain biodistribution, 870(ab)
myocardial sympathetic neuronal function, intravenous cocaine injection, dogs, 994(ab)
Neuropsychological test, cerebral blood flow, Tc-99m HMPAO SPECT, chronic subdural hematoma, 246
Neuroradiology, interventional, brain blood flow, SPECT, 826(ab)
Neurotransmission, membrane trapping of C-11 1, 2-diacylglycerols, phosphatidylinositol turnover, 413
Neutron, source, Department of Energy, 32N(10)
Neutrophils, sequestration in lung, intercellular adhesion molecules, endotoxemia, 1023(ab)
Newsline
Commentary
functional brain scans, evidence in criminal court, 18N(6)
government will respond to those who seek influence, 25N(10)
Lines from the President, 24N(6), 38N(9), 32N(12)
second Sino-American nuclear medicine conference, 16N(4)
shouldering burden of low-level radioactive waste, 20N(6)
Forum: The Future of Nuclear Medicine, 15N(5)
Newspapers, citations in medical journals, 27N(1)
Nicotine, tritiated, altered accumulation in brain, senescence accelerated mouse, 1023(ab)
Nitrogen-13 ammonia
logistics, flow-through trapping, 931(ab)
myocardial perfusion PET images, adenosine stress, coronary artery disease, 825(ab)
PET
defect size and severity, 875(ab)
left ventricular mass and infarct size, explanted human hearts for validation, 826(ab)
methods for quantification, myocardial blood flow, 881(ab)
regional perfusion reserve, coronary artery disease, 826(ab)
regional uptake and blood flow variations, lack of correlation with other methods, 837(ab)
stress perfusion imaging in PET, objective computerized quantitative method, heart, 1009(ab)
Nitrogen-13 dopamine, no-carrier-added, rapid synthesis, myocardial imaging, 931(ab)
2-Nitroimidazole, radioiodinated derivatives, viable hypoxic tissue, SPECT, 891(ab)
Nitroimidazoles, chemistry of Tc-PnAO-nitroimidazole complex, localization in hypoxic tissue, 919(ab)
Nitrous oxide, endogenous opiate system, C-11 carfentanil PET, 883(ab)
Nordion, privatization, 19N(2)
Norepinephrine, disturbed neuronal energy metabolism, Adriamycin cardiomyopathy, 935(ab)
Nuclear energy
history 16N(12)
Nuclear magnetic resonance
anatomy-oriented 3-D ROI definition system, 1006(ab)
brain functional and structural deficits, young alcoholics, 1070(ab)
brain images, rapid registration, 1005(ab)
cerebral blood flow and SPECT, differential diagnosis, dementia, 1014(ab)
C-11 flumazenil, benzodiazepine receptor binding, alcohol-dependent men, 1016(ab)
chronic osteomyelitis, site of fracture or surgery, lower extremity, 902(ab)
comparative study of Tl-201, CT/angiography, bone and soft tissue sarcoma, 843(ab)
3D PET and, image registration, simple device, 1008(ab)
FDG PET and, atypical dementia, Alzheimer's disease, 965(ab)
Fe-PDGF as hepatobiliary contrast agent, 974(ab)
ferrum as a contrast agent, 973(ab)
fusion with SPECT images, radiolabeled monoclonal antibodies, 960(ab)
Ga-67 scans and, effect of therapy, Hodgkin's lymphoma, 914(ab)
moyamoya disease, before and after external-to-internal carotid artery bypass, 1692
MRI contrast agents, nonionic gadolinium (III) DTPA-bisamide complexes, 974(ab)
normal and pathological gastric emptying, 956(ab)
PET and
accuracy of surface fit registration, brain, 921(ab)
fully automated and robust coordinate matching system, 1009(ab)
primary brain tumors, 867(ab)
primary progressive aphasia, 857(ab)
radionuclide bone scan and, detection of spinal metastases, 992(ab)
radionuclide studies and, osteomyelitis, 992(ab)
rapid registration and review, brain, 1067(ab)
scintigraphy and, bone marrow, staging of breast cancer, 914(ab)
SPECT liver volume measurement, 1066(ab)
standardization, cardiac tomographic imaging, 1434
subchrondral bone infractions, acute ligamentous knee injuries, 516
Tc-99m HMPAO and I-123 IMP, cerebral blood flow, SPECT, 1012(ab)
Tc-99m HMPAO SPECT and CT, diagnosis of dementia, 972(ab)
Tl-201 compared to Tc-99m MIBI, recurrent brain tumors, 867(ab)
Tl-201 SPECT and F-18 FDG PET, recurrent brain tumors, 867(ab)
Nuclear magnetic resonance spectroscopy, proton, stimulated auditory cortex, 974(ab)
Nuclear medicine
accuracy of Neuronet diagnosis, thyroid nodule, backpropagation simulator, 954(ab)
acupuncture message transmission, 409
Annual Meeting highlights, 12N(8)
artifacts in, 1068(ab)
certificate program, nuclear pharmacy training, 1073(ab)
computer-aided instruction, 1067(ab)
computer-based radiology teaching files, 1066(ab)
computer-based renal teaching file, 1073(ab)
computerized teaching file, 1066(ab)
computer system, efficient management, imaging and non-imaging information, 1006(ab)
departments, infection-control problems, blood reinfusion, 13N(4)
forum, 15N(5)
hardcopy images, high-resolution plain-paper laser printers, 947(ab)
imaging data, use of local area networks, intradepartmental distribution, 946(ab)
misadministration spurs statewide inspection, California nuclear medicine departments, 32N(3)
multifunctional image-containing database, 947(ab)
multi-media workstation, 947(ab)
one day in the routine, 463(le)
outpatient therapy, petition would ease strictures, 13N(7)
practice of, 14N(8)
regional dose distribution to hands, staff formulating/dispensing/administering radiopharmaceuticals, 1065(ab)
role in systematic imaging evaluation, suspected osteomyelitis, 1063(ab)
therapeutic applications, 31N(3)
threatened reactor worker strike, 19N(9)
transfer of images, interfile file format, 1007(ab)
use of Internet, computer communications to world community, 1067(ab)
workstation for all digital department, 947(ab)
Nuclear probes
cardiology, 448
miniature cadmium telluride detector, ventricular function, coronary artery bypass grafting, 441
Nuclear Regulatory Commission (NRC)
"below regulatory commission" consensus failure, 25N(1)
below regulatory concern, 18N(3)
compatibility, agreement states still chafing, 27N(3)
costs of dual regulation, 29N(10)
licensing fees, 30N(9)
medical quality management rule, 18N(3)
medical use of isotopes, 30N(9)
new commissioner, 18N(3)
nuclear physician's case against QM rule, 37N(5)
override of OMB disapproval, quality management rule, 32N(10)
probe of Medical Uses staff, 30N(9)
quality management rule, 23N(4), 34N(9)
radiation protection, 33N(9)
sending teams to study risk, medical misadministration, 26N(4)
user fees, 18N(3)
withdrawal of training criteria, 33N(12)

O

Oak Ridge National Laboratory, calutrons, 15N(6)
Occupational Safety and Health Administration

(OSHA), blood-borne pathogens, 26N(3)
Octreoscan, In-111 labeled somatostatin analog, kit develoment, cancer detection, 1025(ab)
Octreoscan-111, two diasteromers, cancer imaging, 900(ab)
Olfactory system, investigation with FDG-PET, 858(ab)
Oncogene, -encoded molecules, radiolabeled antibodies, tumor imaging and therapy, 2160
Oncology, Annual Meeting highlights, 11N(8)
Opiates, effect of nitrous oxide, C-11 carfentanil PET, 883(ab)
Orphan drug, coalition, 33N(9)
Osteoma, osteoid, radionuclide imaging, radiography and computed tomography, 269
Osteomyelitis
cellulitis and, dual bone and WBC scan imaging, planar and SPECT imaging, 839(ab)
chronic, site of fracture or surgery, lower extremity, 902(ab)
comparison of MRI and radionuclide studies, 992(ab)
infectious diabetic foot complications, In-111 human nonspecific immunoglobulin G, 1330
suspected, role of nuclear medicine, systematic imaging evaluation, 1063(ab)
Osteoporosis
better prediction, risk factor assessment, multiple regression analysis, 869(ab)
bone mineral content and density, healthy twelve-year-old white females, 1143
bone mineral density and spine fracture, cyclic oral phosphate, etidronate, 1
optimization of follow-up measurements, bone mass, 1406
Osteosarcoma
lower limb, stress fractures, 1699
primary, thyroid, 1399
quantitative tumor scintigraphy, time to metastasis, 1542
Ovarian neoplasms
-associated antigen, characteristics, chimeric monoclonal antibody MOv18, 2000
dosimetric evaluation of immunoscintigraphy, In-111 monoclonal antibody fragments, 1113
early detection of recurrences, Tc-99m monoclonal antibody, CA 125, 904(ab)
management with Tc-99m monoclonal antibodies, 904(ab)
novel HAMA radioimmunoassay, 852(ab)
radioimmunoimaging, recognition of CA125, human/mouse chimeric monoclonal antibody, 1001(ab)
Ovary, radiation dose, radionuclide hysterosalpingography, Tc-99m pertechnetate, 282
Oxygen-15
arrival delay of tracers, intravascular radioactivity, brain, 909(ab)
PET, intrasubject and intersubject averaging, 1009(ab)
Oxygen-15 butanol, PET, cortical areas in brain, visual imagery in reading, 908(ab)
Oxygen-15 water
bolus, signal-to-noise improvements, 3D PET, 1010(ab)
myocardial tissue fraction, rapid imaging technique, 994(ab)
PET
cerebral language area, 2D brain surface map, 857(ab)
event-related potentials, auditory cognitive task, 1016(ab)
left ventricular time-activity curve, 1669
partition coefficient, regional cerebral blood flow, 911(ab)
somatosensory stimulation, thalamic lesions, 858(ab)
Rb-82 and, myocardial perfusion, PET, 884(ab)
Oxygen-18 water
purification, photochemical combustion, 982(ab)
simple procedural change, F-18 FDG synthesis, 1027(ab)
target for production of F-18, 932(ab)

P

Paget's disease, bone scintigraphy, intravenous pamidronate, 1589
Pain
bone
metastases, therapeutic doses of Sr-89, 937(ab)
Re-186 HEDP treatment, 859(ab)
low back
180° SPECT of the spine, 950(ab)
zygapophyseal joint injection, SPECT and planar bone scintigraphy, 868(ab)
lower extremity, bone scintigraphy, preschool children, 351
palliation, multidose Sm-153 EDTMP, metastatic bone disease, 992(ab)
Palladium-109, chelates and their bioconjugates, 987(ab)
Palsy
progressive supranuclear, cerebral perfusion, 704
supranuclear, dopamine D2 receptors, I-123 ILIS SPECT, 1019(ab)
Pamidronate, intravenous, bone scintigraphy, Paget's disease, 1589
Pancreas, new imaging agent I-123 ERC 9, 841(ab)
Pancreatic lipase, site specific/stable radioiodination, I-131 1,2-Pal-3-IPPA, urine analysis, 1028(ab)
Paraplegia, impotence, treatment choice, nuclear penogram, 1035(ab)
Parathyroid
imaging, 1807
imaging with Tc-99m sestamibi, 313
localization of enlargement, Tc-99m MIBI and Tl-201 scintigraphy, ultrasound and CT, 895(ab)
pathology, simultaneous dual-isotope SPECT, 131
scintigraphy, subtraction algorithm, 996(ab)
Parathyroidectomy, influence on bone mineral content, 869(ab)
Parkinson's disease
delayed SPECT and regional cerebral blood flow, I-123 IMP, 1015(ab)
dementia and laterality of disease onset, regional cerebral blood flow, 1012(ab)
differential diagnosis by I-123 IBZM SPECT, 917(ab)
differentiation of syndromes, dopamine D2 receptor imaging, I-123 IBZM SPECT, 917(ab)
discordant twins, PET, 1013(ab)
dopamine D2 receptor imaging, I-123 IBZM SPECT, 917(ab)
dopamine fiber loss, C-11 CFT, 946(ab)
I-123 IBZM SPECT, 1018(ab)
loss of 6-[F-18]fluoro-L-dihydroxyphenylalanine metabolites, striatum, 916(ab)
MPTP-primate model, glucose metabolism, 965(ab)
multiple systemic atrophy, selective metabolic involvement, 1014(ab)
striato-nigral degeneration, dopamine D1 and D2 receptor imaging, PET, 917(ab)
Pathogens, blood-borne, 26N(3)
Paul Aebersold Award, Mathew Thakur, 34N(5)
Pediatric patients: *see also* Infants, Neonates
alternating hemiplegia, Tc-99m HMPAO SPECT, 1021(ab)
asymptomatic siblings, vesicoureteral reflux, cyclic voiding cystography, 873(ab)
brain tumors, Tc-99m MIBI/Tl-201 SPECT, 844(ab)
cardiac function in neonates and children, arterial switch operation, PET, 977(ab)
cerebral blood flow and predetermined ROIs, Xe-133 SPECT, 977(ab)
cerebral palsy, quantitative perfusion-defect indexes, Tc-99m HMPAO SPECT, 977(ab)
changes in regional cerebral blood flow, brain maturation, 696
children and adolescents, radionuclide cystography, vesicoureteral reflux, 1022(ab)
developmental cognitive disorders, F-18 FDG PET, 973(ab)
febrile urinary tract infections, Tc-99m DMSA scanning, 976(ab)
first nuclear medicine symposium, 40N(9)
glomerular filtration rate measurement, adequacy of one blood sample, 873(ab)
HIV-1-infected, seropositive mothers, FDG PET, 976(ab)
newborn period and early infancy, myocardial SPECT, fan-beam collimators, 930(ab)
obstructive uropathy diagnosis, normalized diuretic renogram parameters, 923(ab)
opsoclonus-myoclonus, location of neuroblastoma, MIBG usage, 930(ab)
preschool children, bone scintigraphy, lower extremity pain of unknown origin, 351
radioimmunotherapy for neuroblastoma, tumor dosimetry, I-124 3F9 PET, 2020
single plasma GFR, 173(le)
skeletal screening, traumatic brain injury, 873(ab)
symptomatic infants and children, radionuclide evaluation, Ebstein's deformity, 930(ab)
ureteral status, kidney washout, Tc-99m DTPA diuresis renography, 73
urinary tract infection, 872(ab)
Pelvis, radioiodine uptake, rectal wall teratoma, thyroidectomy for papillary carcinoma, 1848
Penis
blood flow, tumescence, dual-radioisotopic technique, 41
corporal venous leak, Tc-99m red blood cells, 49
nuclear penogram, treatment choice, impotent paraplegics, 1035(ab)
Peptides
attachment of monofunctional DTPA analogs, 988(ab)
imaging and therapy of tumors, 35N(5)
molecules with messages, annual meeting highlights, 10N(8)
Percutaneous transluminal coronary angioplasty (PTCA), early thallium imaging, tomographic evaluation, adenosine-induced coronary hyperemia, 2086
Perfusion, index of, mean transit time, 1004(ab)
Perfusion tracers, transmural uptake, infarct-specific tracers, 229
Peripheral vascular disease, functional imaging, 1797
pH, non-invasive assessment, fluorinated polymeric molecular probes, magnetic resonance spectroscopy, 974(ab)
Phagocytes, microautoradiographic study of F-18 FDG, mouse tumor tissue, 840(ab)

Phantom, influence of perfusion defect size, Tl-201 activity, tomographic defect severity, 995(ab)
L-Phenylalanine, delayed infusion, F-18 DOPA uptake in brain, 1383
Pheochromocytoma
C-11 HED PET, 1125
I-131 MIBG approval, 33N(9)
I-131 MIBG imaging, 833(ab)
intraoperative detection, I-125 MIBG, 1020(ab)
Phosphate, cyclic oral, etidronate and, bone mineral density, 1
Phosphatidylinositol, turnover, membrane trapping, C-11 1,2-diacylglycerols, 413
Phosphines, methylene bridged phosphineoxide-phosphine, versatile chelating agent, Re-188, 979(ab)
Phosphinimines, functionalized, small molecule neutral-lipophilic Tc-99m agents, 851(ab)
Phosphorus, -nitrogen backbone ligands, formulation, new radiopharmaceuticals, 1072(ab)
Phosphorus hydrazides
chelating agents, bifunctional frameworks, Tc-99m and Re-188, 910(ab)
multifunctional, new Tc-99m radiopharmaceuticals, 1032(ab)
Photodiodes, room temperature, high-rate/high-resolution PET module, crystal identification, 862(ab)
Physician Payment Review Commission (PPRC)
access to care, 24N(3)
Medicare volume performance standard, 24N(3)
report to Congress, 36N(9)
statement on Medicare, 24N(3)
Planar imaging
Alderson phantom, nuclear quantitation, tumor size and I-131 amount, 925(ab)
bone scintigraphy and SPECT, zygapophyseal joint injection, chronic low back pain, 868(ab)
dual bone and WBC scan imaging, osteomyelitis, cellulitis, 839(ab)
gated, detection, coronary artery disease, 866(ab)
myocardial perfusion, Tc-99m, Tl-201 and coronary angiography, 1783
scintigraphic views of monoclonal antibodies, biodistribution, radiation absorbed dose, 925(ab)
scintigraphy and SPECT, rotating slit collimator, 1005(ab)
Tc-99m ECD, global cerebral blood flow, Rhesus monkeys, 979(ab)
thallium, areas of reverse redistribution, viability with PET, 886(ab)
vs. SPECT, low back pain, 868(ab)
Plasma
algorithm for estimating slope, PATLAK analysis, dynamic PET data, 944(ab)
concentrations, body dimensions, single-sample clearance determinants, 629(le)
D-dimer concentration, suspected pulmonary embolus, 978(ab)
extracellular fluid volume measurements and, reproducibility, critically ill patients, 1468
human, quantitation, I-123 IBZM, 871(ab)
Plasmapheresis, radioimmunotherapy of micrometastases, mathematical modeling, dosimetry, 2167, 941(ab)
Plasminogen activator, tissue, Tc-99m inhibition, thrombosis scintigraphy, 1029(ab)
Platelet
-binding laminin peptide, direct Tc-99m labeling, 1031(ab)
-fibrin deposition on coronary stents, anticoagulation, minipig model, 845(ab)
radioindium-labeled autologous, MIRD dose estimate No. 15, 777
Pneumocystis, pneumonia, pulmonary disposition, gallium-67, 512
Pneumocystis carinii
accuracy of early gallium imaging, pulmonary infection, immunocompromised patients, 957(ab)
Tc-99m DTPA aerosol and Ga-67 scanning, 81
Pneumonitis, drug-induced, diffuse pulmonary uptake, In-111 leukocytes, 1175
Poland, radionuclide production threatened, 20N(7)
Poly-lysine, amino-dextran and, In-111 labeled monoclonal antibody, 988(ab)
Polyvinyl alcohol sponge, embolization of hepatic arteriovenous malformations, hereditary hemorrhagic telangiectasia, 260
Positive expiratory pressure, effectiveness of PEP mask, Tc-99m DTPA aerosol ventilation, cystic fibrosis, 835(ab)
Positron emission tomography
F-18 FMISO, noninvasive detection, hypoxic myocardium, 2202
myocardial blood flow, deoxyglucose uptake, myocyte viability, 1353
regional cardiac adenosine, 2138
Positron emission tomography (PET)
acetazolamide Tc-99m HMPAO SPECT and, cerebrovascular disease, 877(ab)
analysis of Kanji-Kana reading process, 827(ab)
anatomy-oriented 3-D ROI definition system, 1006(ab)
approval of drug master file, 33N(9)
arterial input function determination, hepatic and renal studies, use of abdominal aorta, 613
benperidol analogs, D2 receptor-specific PET tracers, 848(ab)
brain, automated stereotactic transformation, 1007(ab)
brain functional and structural deficits, young alcoholics, 1070(ab)
C-11 acetate
compared with F-18 fluorodeoxyglucose, recovery after revascularization, 855(ab)
oxidative metabolism, infarcted and periinfarcted myocardium, 953(ab)
C-11 carazolol, evaluation in pigs, 885(ab)
C-11 carfentanil, effect of nitrous oxide, endogenous opiate system, 883(ab)
C-11 CGP 12177, mechanisms of down-regulation, idiopathic cardiomyopathy, 896(ab)
C-11 cocaine, distribution and kinetics, human body, 521
C-11 flumazenil
benzodiazepine receptor binding, alcohol-dependent men, 1016(ab)
benzodiazepine receptors, human brain homogenates, 1011(ab)
C-11 HED, localization of pheochromocytoma, 1125
C-11 labeled compounds, contribution, labeled carbon dioxide, 581
C-11 methionine, effective method, imaging of head and neck cancer, 691
2-C-11 methyl-amino-2-methyl-3-phenyl-1-propanol, serotonin uptake sites, 861(ab)
C-11 NMSP, D2 dopamine receptor densities, 848(ab)
C-11 SAH, myocardial energy balance, 2144
C-11 tetrabenazine, brain biodistribution, monoaminergic neurons, 870(ab)
C-11 tetrabenazine and C-11 methoxy derivative, α-dihydrotetrabenazine, monoamine terminals, 983(ab)
C-11 thymidine, kinetic modeling, DNA synthesis, 1009(ab)
L-1-C-11 tyrosine and F-18 FDG, radiation-induced inhibition, tumor growth, 373
cardiac
attenuation scans, three-dimensional registration, 881(ab)
polar map displays, myocardial blood flow, 1628
position paper, 23N(4)
cardiac function in neonates and children, arterial switch operation, 977(ab)
cardiac volumes, delineation of myocardium, 933(ab)
central cholinergic nerve terminals, 1011(ab)
cerebral blood flow
brain perfusion Tc-99m ECD SPECT, 966(ab)
regional variation in statistical maps, 1008(ab)
cerebral glucose metabolism, striatal F-DOPA uptake, patients with chorea, 1015(ab)
cerebral metabolism
epilepsy, effect of disease duration, 1018(ab)
standardized approach, controlled behavioral conditions, 1011(ab)
clinical
bloody future, 620
debate continues, 1587(le)
science behind it, 1586(le)
clinical applications in cancer, 330
clinical neurological, interactive computer-based atlas, 1071(ab)
combined with radioimmunoscintigraphy, F-18 monoclonal antibody fragments, 1535
Cu-64 antibodies, 1685
Cu-64 radiopharmaceuticals, scintillating fiber detector module, small animals, 1010(ab)
decline of L-6-[F-18]fluorodopa rate constant K_1, *vs.* aging, 964(ab)
-defined targets for stereotaxic brain biopsy, 868(ab)
design features and performance, animal research, 595
discordant twins with Parkinson's disease, 1013(ab)
dopamine D1 and D2 receptor imaging, striatonigral degeneration, Parkinson's disease, 917(ab)
dual-labeling agents, dopamine D-2 receptors, 890(ab)
dual-tracer, lumped constant imaging, 944(ab)
dynamic, 1-aminocyclobutane[C-11]carboxylic acid, 2-compartment model, brain tumors, 922(ab)
dynamic studies of the heart, temporal sampling, kinetic model parameters, 881(ab)
ECG gated, C-11 monoxide, "background" question, 938(ab)
enhanced fluorodeoxyglucose uptake, metabolic design, combination therapy, 1981
evaluation of neural-network classifier, normal and Alzheimer's disease subjects, 1459
examination of visual mental imagery, 908(ab)
extent and severity of ischemic myocardium at risk, predictor of prognosis following thrombolytic therapy, 837(ab)
F-18, bone blood flow and influx rate, 937(ab)
F-18 antimyosin monoclonal antibody fragments, preliminary investigations, canine myocardial infarct model, 575
F-18 biotin, tumor localization, 1026(ab)
F-18 BMY 14802, synthesis and resolution, baboons, 830(ab)

F-18 BT-SCH, synthesis and *in vivo* evaluation, dopamine D1 ligand, 829(ab)
F-18 deoxyglucose, mediastinal lymph node mapping, 828(ab)
F-18 FDG
accuracy in dementia diagnosis, 967(ab)
Bayesian regression, metabolic rate of glucose utilization, 944(ab)
brain, registered atlas, 1071(ab)
brain tumor therapy, 1071(ab)
cerebral glucose metabolic rates, 30- and 45-minute acquisitions, 2103
chest imaging, 975(ab)
cranial and spinal neuromas, 1931
decreased cerebral glucose metabolism, Cushing's disease, 834(ab)
design of combination therapy, hexadecylphosphocholine and deoxyglucose, 1019(ab)
developmental cognitive disorders, 973(ab)
differential diagnosis, solitary pulmonary nodule, 836(ab)
differentiation of infectious from malignant CNS lesions, AIDS, 838(ab)
3-D semiquantitative method, intractable temporal lobe epilepsy, 970(ab)
evaluation of liver tumors, 333
fully quantitative neurological studies, without arterial blood sampling, 922(ab)
glucose loading or insulin clamp methods, myocardium, 1263
HIV-1-infected children, seropositive mothers, 976(ab)
increased uptake as prognostic indicator, myocardial infarction, 886(ab)
insulin clamp, myocardial glucose utilization, 1255, 1263
investigation of olfactory system, 858(ab)
late-life depression, 1013(ab)
left premotor cortex specialization, finger movements, 857(ab)
low grade and anaplastic astrocytomas, brain imaging, 966(ab)
lymphoma, 532
malignant lymphoma, proliferative activity, 325
malignant melanoma, 975(ab)
mediastinum, lung cancer, 828(ab)
method for correcting myocardium to blood pool spillover, 882(ab)
MIHA, myocardial viability, 953(ab)
MRI data and, atypical dementia and Alzheimer's disease, 965(ab)
multiple systemic atrophy, selective metabolic involvement, 1014(ab)
myocardial viability, coronary artery disease, 886(ab)
parietal lobe epilepsy, 1017(ab)
post-treatment evaluation, genitourinary malignancies, 829(ab)
preoperative chemotherapy, locoregionally advanced breast cancer, 828(ab)
pre-operative staging, colorectal carcinoma, 975(ab)
presurgical localization, epileptogenic zones, 928(ab)
prognostic implications, temporal lobe surgery, 929(ab)
quantitation, tumor glucose metabolism, 339
quantitative dynamic and whole body, breast cancer, 828(ab)
radiation-induced response, head and neck carcinoma, 829(ab)
recurrent brain tumors, 867(ab)
residual or recurrent musculoskeletal sarcoma, 992(ab)
temporal lobe metabolism, refractory epilepsy, 928(ab)
treatment planning and monitoring, lung tumors, 975(ab)
TSH stimulation of thyroid cancer, T4 replacement therapy, 894(ab)
F-18 FDOPA, nigrostriatal function, ratio method and graphical analyses, 945(ab)
F-18 fleroxacin, pharmacokinetics in rabbits, 924(ab)
F-18 fluconazole, pharmacokinetics, humans, 924(ab)
F-18 fluoride ion, skeletal kinetics, 633
F-18 fluoro analog of tamoxifen, estrogen receptors, radiosynthesis, 985(ab)
F-18 fluorocarazolol
β-adrenergic radiotracer, 984(ab)
ligand, β-adrenergic receptors, 983(ab)
6-F-18 fluoro-L-dopa kinetics, carbidopa administration, 1472
F-18 fluoromisonidazole, hypoxia, human gliomas, 2133
F-18 FMISO, quantification, tumor oxygenation status, 1010(ab)
F-18 monoclonal antibody fragments, 934(ab)
F-18 NMSP, benzamide analogs and, 985(ab)
fast maximum-likelihood reconstruction, 1710
flumazenil as a ligand, quantification, benzodiazepine receptors, 883(ab)
fluorinated SCH 38548 derivatives, dopamine D1 receptors, 829(ab)
forum, 15N(5)
functional brain scans, evidence in criminal court, 18N(6)
GABAergic modulation of endogenous dopamine, acetylcholine release, 847(ab)
Ga-68 platelets, 931(ab)
heart and brain, use of linear programming, glucose utilization and receptor binding, 944(ab)
hepatic FDG uptake kinetics, impact of glucose ingestion, 945(ab)
high count rate cardiac, spatially dependent dead-time losses, 2226
high-rate, high-resolution module, room temperature photodiodes, crystal identification, 862(ab)
high resolution image reconstruction, restoration, detector response, 872(ab)
I-124 3F9, tumor dosimetry, radioimmunotherapy in a child with neuroblastoma, 2020
I-124 monoclonal antibodies, c-*erb*B-2 protein overexpression, breast cancer, 2154
image reconstruction, artifacts, 1069(ab)
image reconstruction for volume imaging, axial extent, 871(ab)
improved quantitation of small objects, restoration and correction algorithms, 872(ab)
inexpensive high resolution detector, photomultiplier quadrant sharing, 1011(ab)
intracoronary Doppler probes and, concordant quantification, flow reserve, 836(ab)
ischemic segments, accelerated clearance, C-11 acetate, 856(ab)
labeled carbon dioxide, transient metabolite, 585
ligand, cerebral dopamine D-2 receptors, 847(ab)
ligand-receptor modeling, multi-injection approach, 943(ab)
Macintosh programs, 1069(ab)
maximum-likelihood reconstruction, clinically important characteristics, 1678
measurement of receptor concentration, instrumental errors, heart, 882(ab)
model sequences, factor analysis, dynamic structures, 1011(ab)
MPTP-primate model of Parkinson's disease, glucose metabolism, 965(ab)
MR brain images and, accuracy of surface fit registration, 921(ab)
MRI and
fully automated and robust coordinate matching system, 1009(ab)
primary brain tumors, 867(ab)
multi-energy maximum-likelihood reconstruction algorithms, 831(ab)
myocardial, region-of-interest strategy, 1243
myocardial perfusion, correction for patient motion, automated region definition, 882(ab)
N-13 ammonia
adenosine stress, myocardial perfusion images, 825(ab)
defect size and severity, 875(ab)
left ventricular mass and infarct size, explanted human hearts for validation, 826(ab)
methods for quantification, myocardial blood flow, 881(ab)
regional perfusion reserve, coronary artery disease, 826(ab)
N-13 ammonia stress perfusion, objective computerized quantitative method, heart, 1009(ab)
neurological indications, approval by Blues, 40N(11)
new generation, performance evaluation, 861(ab)
nonpeptide substance P analog, 860(ab)
O-15, intrasubject and intersubject averaging, 1009(ab)
O-15 butanol, cortical areas in brain, visual imagery in reading, 908(ab)
O-15 water
cerebral language area, 2D brain surface map, 857(ab)
event-related potentials, auditory cognitive task, 1016(ab)
left ventricular time-activity curve, 1669
partition coefficient, regional cerebral blood flow, 911(ab)
somatosensory stimulation, thalamic lesions, 858(ab)
octahedral gallium chelate, monoclonal antibodies, immunoscintigraphy, 1366
offering of little additional value, compared with SPECT, 1586(le)
parameter optimization programs, 1069(ab)
parametric Dopa-decarboxylase imaging, 879(ab)
pathophysiological evaluation, progressive aphasia, 1016(ab)
PATLAK analysis, algorithm, estimation of slope, 944(ab)
primary progressive aphasia, 857(ab)
probes for cocaine receptors, non-human primate model, 946(ab)
protein flux measurements, pulmonary blood flow, 1661
radiolabeled cocaine analogs, receptor imaging agent, 1025(ab)
Rb-82, *vs.* Tl-201 SPECT, myocardial perfusion, 1064(ab)
Rb-82 *vs.* F-18 FDG, hibernating myocardium, irreversible perfusion defects, 1065(ab)
real time-weighted integration, rapid calculation, functional images, 1008(ab)
reoriented cardiac, issues in quantitation, 1235
resolution, quantification, visual interpretation of FDG brain tumor studies, 872(ab)
retrospective post-therapy evaluation, cardiac function, coronary artery disease, 885(ab)

scanner gantry and bed, on-line repositioning, alignment with prior studies, 921(ab)
sentence comprehension, grammatical and semantic components, 1012(ab)
septum-less volume imaging scanner, count rate performance, 861(ab)
sinogram noise, quantitative assessment, reprojection, 1008(ab)
spatial low frequency pattern analysis, normals and schizophrenics, 287
SPECT and, F-18 FDG and Tl-201, myocardial viability, 1064(ab)
staff formulating/dispensing/administering radiopharmaceuticals, regional dose distribution, hands, 1065(ab)
standardization, cardiac tomographic imaging, 1434
standardized tests of performance, 1429(le)
static cardiac, automated three-dimensional analysis, 1008(ab)
Tc-94m radionuclide purity requirements, pharmacokinetic studies, 850(ab)
Tc-99m sestamibi, defect size and severity, 875(ab)
temporal lobe epilepsy, mesial temporal origin, 1014(ab)
three-dimensional
MRI image registration, simple device, 1008(ab)
scanners with retractable septa, scatter correction, 879(ab)
signal-to-noise improvements, bolus O-15 water activity, 1010(ab)
three-dimensional functional brain images, automated method, rotational correction, 1579
T-18 labeled ligands, benzodiazepine receptor studies, 883(ab)
tracers, industry split over approval, 24N(9)
trans-C-11 McN-5652, serotonin uptake sites, 860(ab)
transmission and emission scans, myocardial imaging, 1209, 1214
transmission processing, accuracy, attenuation correction, 862(ab)
triazolam and cental type benzodiazepine receptors, baboons, 973(ab)
tritium-3-colchicine, *in vivo* identification, tumor multidrug resistance, 1373
two-dimensional restoration filter, quantitation of amygdala, 921(ab)
volume imaging, attenuation correction, 862(ab)
vs. SPECT, Annual Meeting highlights, 13N(8)
whole-body
attenuation correction, 862(ab)
methods and performance characteristics, 1191
whole-body imaging, 1069(ab)
Postcholecystectomy, noninvasive test, Sphincter of Oddi dysfunction, 1216
Pregnancy, testing for, QM program, 30N(9)
Progestins, Tc-99m and Re-186 labeled, synthesis and receptor binding, 558
Propylene amine oxime, derivatives, glutathione-mediated decomposition, ligand structure, 988(ab)
Prostate-specific antigen, serial measurements, radiotherapy, localized cancer, 853(ab)
Prostatic neoplasms, F-18 androgens, potential imaging agents, 724
Protamine, In-111 DTPA-heparin, radiolabeling, pharmacokinetics, 1028(ab)
Protein
flux measurements, pulmonary blood flow, PET, 1661
intestinal loss, In-111 transferrin, inflammatory bowel disease, 919(ab)
Proteins
radiolabeled, biodistribution and kinetics, focal infection, 388
targeted, diagnostic imaging, 394
Proto-oncogenes
c-*erb*B2 overexpression, I-124 monoclonal antibodies and PET, breast cancer, 2154
c-kit, scintigraphic detection, monoclonal F(ab′)$_2$, 893(ab)
oncogene-encoded molecules, radiolabeled antibodies, tumor imaging and therapy, 2160
Psychiatry
functional brain SPECT, powerful clinical method, 1888
lithium carbonate therapy, hyperthyroidism, 996(ab)
PTCA: *see* Angioplasty, percutaneous transluminal coronary
Pulmonary embolism
atelectasis, infrequent chest X-ray finding, 849(ab)
computer-assisted diagnosis, ventilation-perfusion lung scanning, 1003(ab)
enhanced V/Q mismatch sign, 1072(ab)
likelihood, number of segmental mismatches, ventilation-perfusion lung scans, 849(ab)
low probability V/Q scans, routine ventilation imaging, 1022(ab)
suspected, D-dimer plasma concentration, 978(ab)
Putrescine, experience, value of, 1720
Pyeloplasty, pre- and post-, functional assessment, diuretic renogram, 977(ab)
Pyrrolidinyl acetamide, derivatives, labeling with F-18, 830(ab)

Q

Quality Management Rule, override of OMB disapproval, NRC, 32N(10)

R

Radiation
-induced alterations, location in cell, methionine or thymidine, 841(ab)
-induced inhibition of tumor growth, L-[1-^{11}C] tyrosine and F-18 FDG, PET, 373
-induced response, FDG PET, head and neck carcinoma, 829(ab)
injury after interstitial injection, iodocholesterol, 1722(le)
local and systemic effects, bone metabolism, quantitative SPECT, 1774
perceptions of risk, 20N(7)
protection, 33N(9)
implications, nonuniformity of dose, 384
safety
for beginners, 167
post-I-131 thyroid cancer therapy, 1402
synovectomy
Ho-166 hydroxyapatite, 937(ab)
radiolabeling, hydroxyapatite particles, 980(ab)
Radiation dose
absorbed, Tc-99m teboroxime, humans, 88
biodistribution and, planar scintigraphic views, radiolabeled monoclonal antibodies, 925(ab)
calculation, bone-to-marrow interface, Monte Carlo modeling, 623
calculation at bone-to-marrow interface, 1915(le)
distribution in thyroid follicle, revised method, 926(ab)
dynamic urinary bladder model, MIRD pamphlet No. 14, 783
estimates for chimeric monoclonal cT84.88, In-111 labeling, 953(ab)
I-131 QSPECT of phantom, transfer of CT vols, manual alignment, 925(ab)
ovaries, radionuclide hysterosalpingography, Tc-99m pertechnetate, 282
Radiation dosimetry, In-111 anti-CEA-F(ab′)$_2$ fragments, tissue distribution, rats, 1654
Radioactive waste
agreement states still chafing, NRC compatibility, 27N(3)
low-level: *see* Low-Level Radioactive Waste
monitored retrievable storage, 27N(1)
Radioactive Waste Act, hearing by Supreme Court, 37N(5)
Radioactivity, intravascular, arrival delay of O-15 tracers, brain, 909(ab)
Radioaerosols, pulmonary radioaerosol clearance, appropriate background subtraction, 836(ab)
Radioangioscintigraphy, renal post-transplanted patients, 991(ab)
Radiochemistry
microwave fields, C-11 alkylations, 1026(ab)
pharmacokinetics and, In-111 BAD-Lym-1, 1030(ab)
Radiocontrast, -induced acute renal failure, real time monitoring, 948(ab)
Radiofluorination, heterogeneous nucleophilic, thermally stable ion exchange resin, 984(ab)
Radiography
computed, dual-isotope autoradiography, 1005(ab)
neuro-SPECT imaging, immature third ventricle teratoma, 435
osteoid osteoma, 269
Radioimmunoassay, novel HAMA, ovarian cancer patients, 852(ab)
Radioimmunodetection
cancer identification, 803
lung cancer, monoclonal antibody HB4C5, 958(ab)
Radioimmunoimaging
alkylamine conjugation chemistry, labeling of antibodies, 986(ab)
second Sino-American nuclear medicine conference, 16N(4)
Radioimmunoscintigraphy
combined with PET, F-18 monoclonal antibody fragments, 1535
I-131 monoclonal antibody, renal cell carcinoma, 913(ab)
pretargeted immunoscintigraphy, hapten valency, murine tumor uptake, 2006
three-step monoclonal antibody pretargeting technique, uveal melanoma, 959(ab)
Radioimmunotherapy
antibody pretargeting, three-step approach, 880(ab)
biotin conjugates, anti-pan-carcinoma NR-LU-10 monoclonal antibodies, 880(ab)
cancer, 1110
child with neuroblastoma, tumor dosimetry, I-124 3F9 PET, 2020
chimeric antibody chCE7, neuroblastoma xenografts, 231
efficacy, 5-iododeoxyuridine, human tumors growing in nude mice, 1530
efficacy of immunophoresis, reduction of myelosuppression, 863(ab)
event loss estimation, 1005(ab)
I-131, bone marrow radiation absorbed dose estimation, leukemia, 941(ab)
I-131 anti-pan B-cell antibodies, B-cell lymphoma, 863(ab)

I-131 B1 and BC8 antibodies, trace and therapeutic amounts, 864(ab)
I-131 CC49 SPECT, CT and, advanced colorectal cancer, 1002(ab)
I-131 monoclonal antibody, bone marrow suppression, recombinant G-CSF, 933(ab)
I-131 pan-B-cell monoclonal antibody, B-cell lymphoma, 893(ab)
intraperitoneal, postural effects, monoclonal antibodies, 959(ab)
metastatic breast cancer, 862(ab)
metastatic gastrointestinal cancer, 863(ab)
micrometastases
continuing evolution, 2180
plasmapheresis, mathematical modeling, 941(ab)
monoclonal antibody, MIRDOSE dosimetry software protocol, 926(ab)
plasmapheresis, micrometastases, dosimetry, 2167
potential of CH2 domain deletion mutant, NR-LU-10, monoclonal antibody and F(ab′)$_2$, 1028
prospects and problems, anti-antibody, 958(ab)
reactor-produced Sc-47, 900(ab)
Re-186 monoclonal antibodies, Phase I trials, 1099
repeated low-dose, I-131 LL2 monoclonal antibody, lymphoma, 863(ab)
Re-186 TNT-1 and TNT-1-F(ab′)$_2$ monoclonal antibodies, 987(ab)
second generation high-affinity anti-CEA monoclonal antibody, 904(ab)
toxicity of total body irradiation, non-Hodgkin's lymphoma, 960(ab)
Radioindium, -labeled autologous platelets, MIRD dose estimate No. 15, 777
Radioiodination
B72.3/CC49/CC83 monoclonal antibodies, pharmacokinetics, 960(ab)
corticotropin-releasing factor, CRF-receptor imaging, 996(ab)
E2020 analogs, mapping, *sigma* receptors, 890(ab)
ETAC reagent, cross-linking antibody Fab′ fragments, 943(ab)
I-131 1,2-Pal-3-IPPA, pancreatic lipase, urine analysis, 1028(ab)
3-iodophenylisothiocyanate, coupling to monoclonal antibodies, 1029(ab)
new simple iodination method, 982(ab)
2-nitroimidazole derivatives, viable hypoxic tissue, SPECT, 891(ab)
novel candidate for SPECT imaging, sigma receptors, 981(ab)
Radioiodine, pelvic uptake, rectal wall teratoma, thyroidectomy for papillary carcinoma, 1848
Radioiodine-131, therapy for well-differentiated thyroid cancer, 1132
Radioisotopes
lung scanning, anatomy of, 676
medical use of, NRC Medical Use Division, 30N(9)
production and research, questions about future of DOE, 13N(6)
threatened reactor worker strike, 19N(9)
Unites States supply of, Congressional subcommittee, 16N(10)
Radioligands
alternate syntheses, I-125 ioxipride and I-125 epidepride, 982(ab)
C-11 NNC 722, dopamine uptake system, 931(ab)
radioiodinated 2β-carboxymethoxy-3β-(4-chlorophenyl)-8-(3E- and 3Z-iodopropen-2-yl)nortropanes, mapping of cocaine receptor sites, SPECT, 890(ab)
Radionuclides
arthrography and roentgenological contrast, total hip prosthesis loosening, 950(ab)
bone scan, MRI imaging, detection of spinal metastases, 992(ab)
cardiac volumes, correction for Compton scatter, buildup factor, 1642
common bile duct clearance, endoscopic nasobiliary drainage tube, gallbladder stone, 997(ab)
cystography, vesicoureteral reflux, children and adolescents, 1022(ab)
dual, Tc-99m and I-123, quantitative brain SPECT, 972(ab)
evaluation of Ebstein's deformity, symptomatic infants and children, 930(ab)
four methods, left ventricular volume determination, 763
hysterosalpingography, Tc-99m pertechnetate, radiation dose to ovaries, 282
image quantification, scatter correction technique, 888(ab)
production threatened in Poland, 20N(7)
stress tests, efficacy, referral bias, 2074
studies and MRI comparison, osteomyelitis, 992(ab)
validation of techniques in an animal model, ratio, hepatic arterial-to-portal venous blood flow, 239
Radiopharmaceuticals
absorbed dose calculations, rapidly growing tumors, 277
bis(dithiocarbamato)nitrido Tc(V), subcellular distribution, male rats, 850(ab)
chromatofocusing studies, monoclonal Fab′, 2148
development by National Lab and Biotech Firm, 44N(11)
formulation, phosphorus-nitrogen backbone ligands, 1072(ab)
Ga-68, myocardium, 931(ab)
government relations update, 15N(3)
Hevesy Nuclear Medicine Pioneer Award, Michael J. Welch, 16N(7)
incidence of adverse reactions, 1025(ab)
industry seeks speedier reviews, 19N(2)
industry split over approval, PET tracers, 24N(9)
In-111-labeled, quantitative autoradiographic study, heterogeneous activity distribution, 1825
I.V. administration, prevention of contamination, 1027(ab)
kits, reconstitution and fractionation, 1915(le)
preparation of I-125 PAB, malignant melanoma, 889(ab)
radiotoxicity, I-123/I-125/I-131-labeled compounds, mouse, 2196
rapid clearance, simulation, dynamic SPECT, 1200
second Sino-American nuclear medicine conference, 16N(4)
single kit, radiolabeling human polyclonal IgG, Tc-99m or In-111, 1024(ab)
staff formulating/dispensing/administering, regional dose distribution to hands, 1065(ab)
Tc- and Re-labeled progestins, 558
Tc-99m
multifunctional phosphorus hydrazides, 1032(ab)
perfusion agents, 22N(1)
uptake and dose heterogeneity, quantitative autoradiography, 1833
Radiopharmacy, how magic is the bullet, what will it do?, 549
Radiosynthesis, imaging estrogen receptors with PET, F-18 fluoro analog, tamoxifen, 985(ab)
Radiotherapy
computers and instrumentation, SNM Mid-Winter Meeting, 23N(1)
regional, Re-186 cell binding agent, 899(ab)
regional bone formation and, 1780
serial measurements, prostate-specific antigen, localized cancer, 853(ab)
Sr-89, metastatic prostatic carcinoma, 1316
Radiotoxicity, lymphocyte labeling, Tc-99m HMPAO, micronucleus assay, 1167
Radiotracers
monocationic, Tc-99m N_2S_2, synthesis and evaluation, 990(ab)
rapid washout from the heart, single-headed gamma camera SPECT system, 1146
targeted proteins for diagnostic imaging, 394
Reactor, -produced Sc-47, evaluation for radioimmunotherapy, 900(ab)
Reading, visual imagery, cortical areas in brain, PET study with O-15 butanol, 908(ab)
Receiver operating characteristics (ROC)
analysis for optimizing quantitative results, esophageal scintigraphy, 832(ab)
anatomy of ROC curve, 1068(ab)
Receptors
β-adrenergic
F-18 fluorocarazolol PET, 984(ab)
F-18 fluorocarazolol synthesis, 983(ab)
angiotensin II, ligand distribution, imaging potential, 900(ab)
benzodiazepine
activity-related plasticity, adult mouse brain, 883(ab)
binding of iomazenil, dynamic SPECT, 911(ab)
C-11 flumazenil binding, chronic alcohol-dependent men, 1016(ab)
C-11 flumazenil PET, human brain homogenates, 1011(ab)
F-18 labeled ligands, PET, 883(ab)
flumazenil as a ligand, PET, 883(ab)
hypometabolic parietal cortex, Alzheimer's disease, 887(ab)
interaction with traizolam, PET, 973(ab)
occupancy, SPECT, 887(ab)
visualization, C-11 RO 15-4513, 860(ab)
cocaine
mapping with radioligands, SPECT, 890(ab)
PET imaging probes, non-human primate model, 946(ab)
radiolabeled analogs, PET, 1025(ab)
corticotropin-releasing factor, radioiodination, potential tracer, 996(ab)
dopamine
density measured by C-11 raclopride and NMSP, same living human brain, 847(ab)
effects of age, SPECT and IBZM, 897(ab)
dopamine D1, fluorinated SCH 38548 derivatives, PET radiotracers, 829(ab)
dopamine D2
alternate syntheses, I-125 ioxipride and I-125 epidepride, 982(ab)
chemical family of ligand, 981(ab)
density, C-11 NMSP PET, 848(ab)
dual-labeling agents, PET and SPECT, 890(ab)
dynamic SPECT and whole body imaging, I-123 IBZM, 896(ab)
I-123 IBZM SPECT, 1964
I-123 IBZM SPECT, haloperidol, 898(ab)

I-123 IBZM SPECT, Parkinson's disease, 917(ab)
I-123 IBZM SPECT, Parkinson syndromes, 917(ab)
I-123 IBZM SPECT, unilateral Parkinson's disease, 1016(ab)
I-123 IBZM SPECT, Wilson's disease, 897(ab)
I-123 2′-ISP SPECT, 897(ab)
in vivo SPECT with iodine-iodolisuride, supranuclear palsy, 1481
PET tracers, benperidol analogs, 848(ab)
preclinical study, I-123 IBF SPECT, 870(ab)
preparation, F-18 NCQ 616 and C-11 FLB 457, 860(ab)
radioiodinated high-affinity ligands, 848(ab)
specific and non-specific binding of C-11 YM-09151-2, age dependency, 897(ab)
superior PET ligand, 847(ab)
supranuclear palsy, I-123 ILIS SPECT, 1019(ab)
dopamine D1 and D2, striato-nigral degeneration, Parkinson's disease and PET, 917(ab)
glucose utilization and, use of linear programming, PET studies of heart and brain, 944(ab)
hepatic, biochemistry, Ga-68 DF-NGA, 1160
histamine H1
blocking drugs, distribution of C-11 pyrilamine, 968(ab)
C-11 pyrilamine and C-11 doxepin, heart, 885(ab)
5-HT_3, potential tracer for imaging, 830(ab)
ligand-, PET, multi-injection approach, 943(ab)
measurement of concentration in the heart, instrumental errors, PET, 882(ab)
muscarinic, synthesis and biodistribution, C-11 2α-tropanyl benzilate, 423
muscarinic acetylcholine, I-125 QNB, rat brain, 883(ab)
muscarinic cholinergic
decreased binding of I-123 IDEX, temporal lobe epilepsy, 928(ab)
tracer kinetic analysis, C-11 NMPB, 882(ab)
opiate kappa, synthesis, F-18 N-(2-(pyrrolidinyl)-1-phenylethyl)acetamide analog, 830(ab)
serotonin, mapping, C-11 methylketanserin, 1026(ab)
serotonin S_2, I-125 altanserine SPECT, 1023(ab)
sigma
mapping of, radioiodinated E2020 analogs, 890(ab)
novel candidate for SPECT imaging, radioiodination, 981(ab)
somatostatin
I-123 TOCT and In-111 DOCT somatostatin analogues, neoplasms, 914(ab)
scintigraphy, In-111-DTPA-D-Phe-1-octreotide, 652

Reconstruction
accelerated, ordered subsets, 960(ab)
algorithm, singular value decomposition, attenuation in SPECT, 831(ab)
Bayesian, registered anatomical images as priors, SPECT, 963(ab)
cardiac SPECT, truncated projections, 831(ab)
cone beam, algorithm, displaced center-of-rotation, 891(ab)
3D ML-EM, improved signal-to-noise, 961(ab)
fan beam convolution, variable focal length collimators, 891(ab)
fast iterative method, basis, functional regions, 831(ab)
fast maximum-likelihood, 1710
high resolution PET image, restoration, detector response, 872(ab)
image, filtered back-projection, iterative linear algorithms, 871(ab)
improved resolution, SPECT, simulation results, 851(ab)
iterative
algorithm, SPECT grey matter imaging, 1225
quantification, human basal ganglia, 878(ab)
maximum-likelihood
clinically important characteristics, 1678
improved brain SPECT, 964(ab)
PET images, artifacts, 1069(ab)
quantitative method, single-orbit cone beam SPECT, 892(ab)
quantitative performance of maximum likelihood, image wide resolution convergence, 871(ab)
three-dimensional iterative, SPECT, 879(ab)
volume-imaging PET, function of axial extent, 871(ab)

Red blood cells
human, reduction of teboroxime extraction, rabbit heart, 864(ab)
serial measurements of cardiac volumes, count-based methods, 1324
UltraTag RBC kit, anticoagulants, reagent volume, 989(ab)

Reflux
duodenogastric, significance, diagnosis of acute cholecystitis, 898(ab)
gastroesophageal, abnormal esophageal motility, angina-like chest pain, 955(ab)
vesicoureteral
cyclic voiding cystography, asymptomatic siblings, 873(ab)
radionuclide cystography, children and adolescents, 1022(ab)

Regional wall motion
choice of stress for diagnostic perfusion, MIBI-SPECT, stress echocardiography, 825(ab)
regional metabolic abnormality, relation to perfusion, myocardial infarction, 659
thrombolytic therapy, Tc-99m sestamibi defect size, 927(ab)

Regions of interest (ROI)
anatomy-oriented 3-D ROI definition system, 1006(ab)
maximum likelihood-expectation maximization reconstruction, SPECT, 451

Rejection
cardiac allograft, I-123 anti-ICAM-1 imaging, rats, 1000(ab)
cardiac transplantation, antimyosin agents, primates, 1994

Renography
captopril
captopril-stimulated PRA, bilateral renal artery stenosis, 907(ab)
cortical residual activity, renal artery stenosis, 906(ab)
segmental branch renal artery stenosis, 266
diuresis, gravity-assisted drainage view, 1022(ab)
diuretic
functional assessment, pre- and post-pyeloplasty, 977(ab)
natural history, infantile hydronephrosis, 2098
DTPA, triple radiopharmaceutical renal study, renovascular hypertension, 1034(ab)
volume expanded diuretic, postnatal assessment, suspected uretero-pelvic junction obstruction, 2094
"well tempered" diuretic, hydronephrosis or hydroureteronephrosis, asymptomatic neonate, 2047

Reperfusion, infarct-related arterial patency, serial tomographic imaging, Tc-99m sestamibi, 2080
Resins, thermally stable ion exchange, heterogeneous nucleophilic radiofluorination, 984(ab)
Resource Based Relative Value Scale (RBRVS), PPRC report to Congress, 36N(9)
Respiration, effect of cocaine, Tc-99m D,L-HMPAO, rat brain slices, 964(ab)
Restenosis, fibrin deposition, coronary artery injury, 845(ab)
Rhenium-186
anti-P185HER2 monoclonal antibody, animal tumor model, 934(ab)
cell binding agent, regional radiotherapy, 899(ab)
comparison of bone-seeking agents, mechanistic implications, 899(ab)
direct *vs.* chelate labeled NR-LU-10 monoclonal antibody, tumored nude mice, 910(ab)
immunoconjugates, effective stabilization, 979(ab)
labeling the diaminedithiol ligand system, 1032(ab)
pharmacokinetics after Re-186-HEDP, bone metastases, 646
Tc-99m complexes and
structural requirements, rapid tubular transport, 900(ab)
unsymmetrical BAT ligand, 989(ab)
TNT-1 and TNT-1-F(ab′)$_2$ monoclonal antibodies, radioimmunotherapy, 987(ab)
Rhenium-186 etidronate, radiochemical and chemical stability of injection, radiolysis effects, 1024(ab)
Rhenium-186 HEDP, treatment of bone pain, 859(ab)
Rhenium-186 IgG, metabolic studies, normal and tumor-bearing mice, 979(ab)
Rhenium-186 monoclonal antibodies, radioimmunotherapy, Phase I trials, 1099
Rhenium-186 progestin, Tc-99m and, synthesis and receptor binding, 558
Rhenium-188
I-131 Mu-9 IgG and, therapeutic potential, single and fractionated doses, 1000(ab)
methylene bridged phosphineoxide-phosphine, versatile chelating agent, 979(ab)
Tc-99m and, bifunctional frameworks, phosphorus hydrazide chelates, 910(ab)
Rhenium-188 antibody, generation by direct labeling methods, 909(ab)
Rhenium-188 Rc(V)-DMSA, facile synthesis, triphenylphosphine reduction, perrhenate at room temperature, 1024(ab)
Rheumatic fever
carditis, importance, scintigraphic diagnosis, 995(ab)
Tc-99m radionuclide angiography, thrombosis detection, left atrial appendage, 365
Rotor's disease, scintigraphic aspect, Tc-99m mebrofenin, 1550
Rubidium-82
O-15 water and, myocardial perfusion, PET, 884(ab)
PET
vs. F-18 FDG, hibernating myocardium, 1065(ab)
vs. Tl-201 SPECT, myocardial perfusion, 1064(ab)

S

Samarium-153
comparison of bone-seeking agents, mechanistic

implications, 899(ab)
Cu-67 immunoconjugates, tumor therapy, 942(ab)
intra-arterial microspheres, pre-operative sterilization, kidney cancers, 1024(ab)
Samarium-153 EDTMP
escalating dose schedule, metastatic bone cancer, 1451
multidose, pain palliation, metastatic bone disease, 992(ab)
Sarcoidosis
acute, In-111 leukocyte and Ga-67 imaging, 2027
assessment of disease activity, Ga-67 citrate scanning, 751
uveitis, Ga-67 citrate scanning, 1851
Sarcoma
Ewing's and osteogenic, scintigraphic differentiation, gallium and bone scintigraphy, 1063(ab)
Kaposi's, Tc-99m DTPA aerosol, Ga-67 scanning, 81
musculoskeletal, F-18 FDG PET, 992(ab)
soft-tissue, metastasis, gallium imaging, 1594
soft tissue and bone, Tl-201 scan patterns, 843(ab)
Scandium-47, reactor-produced, evaluation for radioimmunotherapy, 900(ab)
Scatter
acceptance testing and quality assurance, WAM module, 1005(ab)
attenuation and depth-dependent resolution, 180° myocardial SPECT, 842(ab)
camera-induced, collimator penetration, I-131 imaging, 889(ab)
component, SPECT projections, 842(ab)
Compton
deconvolution-fitting, energy and spatial regularization, 842(ab)
prediction process and cubic spline, SPECT, 888(ab)
radionuclide cardiac volumes, buildup factor, 1642
correction
attenuation and, SPECT imaging, 2232
3D PET studies, scanners with retractable septa, 879(ab)
dual photopeak window, uniformity, 962(ab)
dual-photopeak window method, 605
energy spectra, neural network, 963(ab)
four methods, Monte Carlo-simulated source distributions, 962(ab)
radionuclide image quantification, 888(ab)
semiquantification, I-123 IBZM SPECT, 972(ab)
spectral imaging, standard acquisition energy window, 888(ab)
whole-body SPECT, 1007(ab)
SCH 38548, fluorinated derivatives, PET radiotracers, dopamine D-1 receptors, 829(ab)
Schizophrenia
depression and, Tc-99m HMPAO SPECT, 972(ab)
mapping of *sigma* receptors, radioiodinated E2020 analogs, 890(ab)
spatial low frequency pattern analysis, positron emission tomography, 287
Schwannoma, cranial and spinal neuroma, PET-fluorodeoxyglucose, 1931
Scientific exhibits, prizes, 19N(2)
Scintigraphy
adenosine thallium, high cardiac risk, patients referred for vascular surgery, 952(ab)
adenosine Tl-201, lung thallium uptake, 1600
adrenocortical, unilateral incidentally discovered adrenal or juxtaadrenal masses, 996(ab)
appearance of Alzheimer's disease, Tc-99m HMPAO SPECT, 181
assessment of MIBG uptake, globally denervated human and canine hearts, 1444
bile extravasation, presence of ascites, hepatic transplantation, 115
biliary, grading of hyperperfusion, rim sign, 898(ab)
bolus transport and contraction parameters, multiple-swallow investigations, 1291
bone
I-131 MIBG and, detection of neuroblastoma, 1735
intravenous pamidronate, Paget's disease, 1589
lower extremity pain of unknown origin, preschool children, 351
Tc-99m MDP abdominal uptake, continuous ambulatory dialysis, 2052
captopril-enhanced, renal artery stenosis, en-bloc pediatric renal transplant, 263
cardiac blood-pool, Tc-99m liposomes, 984(ab)
detection of overexpressed c-kit protooncogene, monoclonal $F(ab')_2$ fragments, 893(ab)
diabetes, gastric motility disturbances, 832(ab)
differentiation of osteogenic sarcoma, Ewing's sarcoma, gallium and bone scintigraphy, 1063(ab)
diuretic MAG_3 renal, routine protocol, congenital and acquired renal disorders, 1035(ab)
dobutamine stress thallium, usefulness and safety, 951(ab)
esophageal
achalasia and achalasia-like disorders, 590
reproducibility, normal ranges, 2106
ROC-analysis, 832(ab)
F-18 FDG, chemotherapeutic impact, malignant lymphoma, 858(ab)
gastric emptying of liquids, 956(ab)
hemodynamic-scintigraphic study, myocardial ischemia, adenosine infusion, 952(ab)
hepatobiliary
bile lakes, liver transplant infarcts, 997(ab)
hepatic transport function, 998(ab)
intrahepatic *vs.* extrahepatic cholestasis, 1186
high-resolution, postnatal maturation, myocardial sympathetic nerves, 935(ab)
I-123 iodoamphetamine, Budd-Chiari syndrome, 744
I-123 MIBG and I-123 TOCT, metastatic carcinoid tumors, 1121
I-131 MIBG
diagnostic value, kindred with MEN-II, 1065(ab)
pitfalls, diagnosis of neuroblastoma, 930(ab)
importance of diagnosis, carditis in rheumatic fever, 995(ab)
In-111 antimyosin, significance, uncomplicated valvular replacement, 895(ab)
In-111 antimyosin monoclonal antibody, time course, myocardial infarction, 1501
In-111 labeled human nonspecific IgG, evaluation, inflammatory bowel disease, 919(ab)
In-111 pentatreotide, gastro-entero-pancreatic endocrine tumors, 976(ab)
In-111 somatostatin analogue, visualization, malignant lymphoma, 903(ab)
leukocyte, diagnosis of mycotic aneurysm, 1486
location and size of defects, myocardial perfusion, fatal infarction, 251
marrow changes, hormonal changes, 1427(le)
MIBG, location of neuroblastoma, opsoclonus-myoclonus, 930(ab)
MRI and, bone marrow, staging of breast cancer, 914(ab)
parathyroid, subtraction algorithm, 996(ab)
phase analysis, consequences, ventricular tachycardia, 994(ab)
planar, SPECT and, rotating slit collimator, 1005(ab)
planar bone
SPECT, low back pain, 868(ab)
zygapophyseal joint injection, chronic low back pain, 868(ab)
plastic detectors, high-resolution I-125 imaging, rat brain blood flow, 1003(ab)
presurgical HMPAO, patients with medically refractory seizures, 967(ab)
pulsed Doppler and per-jejunum, portal venous blood flow, liver cirrhosis, 997(ab)
quantitative tumor, time to metastasis, dogs with osteosarcoma, 1542
radiolabeled amyloid P-component, 913(ab)
renal
captopril, renal artery stenosis, 2045
captopril, unexpected pressor responses, 906(ab)
prognostic value with captopril, renovascular hypertension, 2040
Rotor's disease, Tc-99m mebrofenin, 1550
sestamibi, radioisotopic assessment, myocardial viability, 1925
somatostatin analog, carcinoid tumors, 914(ab)
somatostatin receptor, In-111-DTPA-D-Phe-1-octreotide, 652
sphincter of Oddi dysfunction, 1223
subchrondral bone infractions, acute ligamentous knee injuries, 516
Tc-99m antifibrin, acute deep venous thrombosis, 848(ab)
Tc-99m antigranulocyte Fab′ fragments, compared to In-111 oxine/Tc-99m HMPAO leukocytes, infectious diseases, 903(ab)
Tc-99m EHIDA hepatobiliary, diagnostic criteria for biliary atresia, neonatal jaundice, 899(ab)
Tc-99m HMPAO cerebral cortical activity, 117
Tc-99m HMPAO cerebral perfusion, timely brain death declaration, 2209
Tc-99m MAG_3, captopril, renal artery stenosis, 990(ab)
Tc-99m MIBI, myocardial viability, thallous chloride injection, 906(ab)
Tc-99m TBI, detection of metastases, thyroid carcinoma, 914(ab)
thallium
incremental diagnostic value and impact, 1727
incremental value, cost consciousness, 1732
thrombosis, Tc-99m inhibited recombinant t-PA, 1029(ab)
Tl-201
localization, parathyroid enlargement, 895(ab)
viable myocardium, chronic coronary artery disease, 505
tomographic myocardial perfusion, integration of wall kinetic and perfusion data, 933(ab)
torsion in triorchidism, 1854
two-phase scrotal, classification of varioceles, 1034(ab)
ventilation-perfusion, intermediate likelihood-ratio results, 849(b)
white blood cell, monoclonal antibodies, septic loosening of endoprostheses, 840(ab)
Sclerosis, systemic, left ventricular diastolic function, 68
Scrotum, two-phase scintigraphy, classification of varioceles, 1034(ab)
Seizures
medically refractory, presurgical HMPAO scin-

tigraphy, 967(ab)
simple and partial, foci localization, Tc-99m HMPAO SPECT, 971(ab)
Self-referral, bans on, 36N(9)
Senescence, accelerated mouse, altered tritiated nicotine accumulation, 1023(ab)
Sepsis
cellular hypoxia, marker F-18 fluoromisonidazole, 924(ab)
loosening of endoprostheses, WBC scintigraphy with monoclonal antibodies, 840(ab)
spread of infectious complications, odontogenic abscess, Tc-99m HMPAO-labeled WBC scan, 254
Serotonin
improved preparation, I-123 LSD or I-125 LSD, 982(ab)
presynaptic, synthesis and evaluation, I-125 5-I-6-NQP, 890(ab)
transporter, MIBG uptake, 935(ab)
uptake sites
trans-C-11 McN-5652, 860(ab)
2-[C-11]methyl-amino-2-methyl-3-phenyl-1-propanol PET, 861(ab)
Shock, cardiogenic, acute onset, normal coronary arteries, 1558
Shunt
left-to-right, quantitation, recirculation subtraction, 1917(le)
portal systemic, fraction quantification, I-123 HIDPM, 997(ab)
Sincalide, continuous infusion, calculation, gallbladder ejection fraction, 537
Single photon emission computed tomography (SPECT)
180°, spine, patients with LBP, 950(ab)
acquisition, effects, differential tracer washout, 1251(le)
adrenal, without dexamethasone suppression, primary aldosteronism, 834(ab)
anatomy-oriented 3-D ROI definition system, 1006(ab)
attenuation correction
dual-energy X-ray CT, 901(ab)
iterative methods, 962(ab)
basal ganglia uptake, monkey brain phantom, 963(ab)
Bayesian reconstruction, registered anatomical images as priors, 963(ab)
benzodiazepine receptor occupancy, relation to benzodiazepine medication, 887(ab)
blood flow in stroke, clinical prognosis, 878(ab)
brain
attenuation effect, 961(ab)
blood flow, interventional neuroradiology, 826(ab)
cerebral angioplasty, delayed ischemia due to vasospasm, 1789
dual radionuclide data acquisition, Tc-99m and I-123, 972(ab)
extracorporeal membrane oxygenation, neonates, 1943
maximum-likelihood reconstruction, 964(ab)
multimedia multimodality interactive computer tutorial, 1071(ab)
rapid registration, 1005(ab)
transcranial Doppler, acute ischemic stroke therapy, 968(ab)
brain perfusion
cocaine abuse, AIDS dementia complex, 1312, 887(ab)
differential diagnosis, dementia, 1017(ab)
regional cerebral blood flow, PET comparison, 966(ab)
cardiac
cardiofocal collimator, 852(ab)
defect detection, cone beam geometry, 961(ab)
defect detection, restoration filters, 842(ab)
emission and transmission noise propagation, non-uniform attenuation correction, 902(ab)
reconstructions, truncated projections, 831(ab)
volume, delineation of myocardium, 933(ab)
cerebral blood flow and MRI, differential diagnosis, dementia, 1014(ab)
cerebral perfusion, relative error-estimation, regional analysis, 969(ab)
cerebral perfusion abnormalities, Alzheimer's disease, 973(ab)
clinical, promotion of, 38N(9)
cocaine receptor site mapping, radioligands, 890(ab)
collimation, spatially variant focusing, 891(ab)
compared to PET, 1586(le)
comparison of single/dual/triple-head, 1070(ab)
Compton scatter correction method, prediction process, cubic spline, 888(ab)
computer-directed coregistration, multislice functional and anatomic images, external fiducials, 961(ab)
cone-beam, sampling considerations, 891(ab)
continuous imaging protocol, Tc-99m tebo and Tl-201, 1304
Cramer-Rao bound analysis of effects, attenuation, feature size and activity estimation, 962(ab)
current role, imaging of subdural hematoma, 248
delayed, I-123 IMP, dementia, 1015(ab)
diagnostic accuracy, Alzheimer's disease, 1019(ab)
dual bone and WBC scan imaging, osteomyelitis, cellulitis, 839(ab)
dual-detector, cone beam tomography, 892(ab)
dual isotope, brain, headtome set 031, 1017(ab)
dual isotope immunoscintigraphy, improved demarcation of tumors, occult colorectal carcinoma, 1000(ab)
dual-labeling agents, dopamine D-2 receptors, 890(ab)
dual radionuclide, feasibility with I-123 and Tc-99m, 851(ab)
dynamic
detection and correction of motion, 911(ab)
iomazenil binding to human benzodiazepine receptor, 911(ab)
kinetic modeling, teboroxime, 878(ab)
simulation, radiopharmaceuticals with rapid clearance, 1200
whole body imaging, I-123 IBZM and dopamine D2 receptors, 896(ab)
equitable reimbursement, 36N(9)
fast maximum-likelihood reconstruction, 1710
four scatter correction methods, Monte Carlo-simulated source distributions, 962(ab)
functional brain, powerful clinical method, 1888
functional brain scans, evidence in criminal court, 18N(6)
fusion with CT/MRI images, radiolabeled monoclonal antibodies, 960(ab)
Ga-67 citrate, biopsy-confirmed residual Hodgkin's disease, mediastinum, 345
gamma camera, image truncation, cone beam CT, 901(ab)
gated, Tc-99m sestamibi, fixed defects as infarct or artifact, 927(ab)
gated blood-pool imaging
parametric display, 3-D biventricular function, 952(ab)
potential added clinical value, 910(ab)
gated or non-gated Cardiolite, quantitative evaluation, myocardial perfusion abnormalities, 927(ab)
gated Tc-99m sestamibi, left ventricular ejection fractions, 927(ab)
generalized Gibbs prior, maximum *a posteriori*-EM SPECT reconstruction, 832(ab)
grey matter imaging, compensation, iterative reconstruction algorithm, 1225
high-resolution three-head, dual energy acquisition, liver tumor imaging, 976(ab)
hippocampal blood flow, diagnosis, Alzheimer's disease, 940(ab)
I-125 altanserine, potential ligand, serotonin S_2 receptors, 1023(ab)
I-123 CIT, monoamine transporter sites, nonhuman primate brain, 945(ab)
I-123 IBF, preclinical study, D2 dopamine receptor, 870(ab)
I-123 IBZM
differential diagnosis of Parkinsonism, 917(ab)
dopamine D2 receptors, 1964
dopamine D2 receptors, effects of age, 897(ab)
dopamine D2 receptors, haloperidol, 898(ab)
dopamine D2 receptors, Parkinson's disease, 917(ab)
dopamine D2 receptors, Parkinson syndromes, 917(ab)
dopamine D2 receptors, Wilson's disease, 897(ab)
dopamine D2 receptors, unilateral Parkinson's disease, 1016(ab)
Parkinson's disease, multi-system atrophy and dystonia, 1018(ab)
semiquantification, scatter correction, 972(ab)
I-123 IBZM and Tc-99m HMPAO, subjects with and at risk for Huntington's disease, 970(ab)
I-123 ILIS, dopamine D2 receptors, supranuclear palsy, 1019(ab)
I-123 IMP
cerebral blood flow, no arterial sampling, 969(ab)
cerebral perfusion, progressive supranuclear palsy, 704
nondemented old patients, Down's syndrome, 967(ab)
partition coefficient, regional cerebral blood flow, 911(ab)
I-123 IPPA, myocardial involvement, systemic myopathies, 995(ab)
I-123 2′-ISP, D-2 dopamine receptors, 897(ab)
I-131 CC49 monoclonal antibody, radioimmunotherapy and CT, advanced colorectal cancer, 1002(ab)
imaging and quantitation, spatial factors, 1069(ab)
imaging in small animals, 852(ab)
improved colonic transit procedure, easily prepared marker, 833(ab)
improved reconstructed resolution, simulation results, 851(ab)
in vivo imaging of D2 receptor, iodine-iodolisuride, supranuclear palsy, 1481
liver volume measurement, autopsy and NMR imaging, 1066(ab)
maximum likelihood-expectation maximization reconstruction, ROC analysis, 451
maximum-likelihood important characteristics, clinically important characteristics, 1678
McSPECT prototype, cylindrical brain SPECT system, 852(ab)
measured attenuation map, attenuation correction, simple method, 843(ab)

MIBI, choice of stress for diagnostic perfusion, wall motion imaging, 825(ab)
moyamoya disease, before and after external-to-internal carotid artery bypass, 1692
multi-energy maximum-likelihood reconstruction algorithms, 831(ab)
multi-head camera, sensitivity, resolution and image quality, 1859
multiple gated, myocardial thickening, phase analysis, 926(ab)
myocardial
computer-aided diagnosis, coronary artery disease, 272
fan-beam collimators, newborn period and early infancy, 930(ab)
180° myocardial, scatter, attenuation and depth-dependent resolution, 842(ab)
myocardial perfusion, Tc-99m MIBI radionuclide angiography, dipyridamole, 846(ab)
neuro-SPECT and radiographic imaging, immature third ventricle teratoma, 435
N-isopropyl[I-123]IMP, regional cerebral blood flow, 1741
N-isopropyl[I-123]p-iodoamphetamine, regional cerebral blood flow, 965(ab)
perfusion imaging, autopsy-diagnosed dementia, 939(ab)
PET and, F-18 FDG and Tl-201, myocardial viability, 1064(ab)
planar bone scintigraphy and, zygapophyseal joint injection, chronic low back pain, 868(ab)
planar scintigraphy and, rotating slit collimator, 1005(ab)
projections based on analytical scatter functions, estimate, scatter component, 842(ab)
project underway, 44N(11)
prototype emission-transmission CT imaging system, 1881
qualitative approach to HIV dementia, 1018(ab)
quantification, attenuation and scatter correction, cardiac imaging, 2232
quantitative
I-131, transfer of CT vols, 925(ab)
local and systemic effects of radiation, bone metabolism, 1774
quantitative stress-redistribution Tl-201, prone imaging, validation, 1509
quantitative *vs.* visual analysis, Tl-201 defect reversibility and severity, 905(ab)
radial slices, myocardial perfusion studies, 1070(ab)
radioiodinated high-affinity dopamine D2 receptor ligands, *in vivo* comparison, 848(ab)
radioiodinated 2-nitroimidazole derivatives, viable hypoxic tissue, 891(ab)
radioiodination of sigma receptors, 981(ab)
rapidly cleared tracers, 1206
rapid registration and review, brain, 1067(ab)
reimbursement, 19N(3)
sequential high resolution, intracranial arteriovenous malformations, Tc-99m RBC and Tc-99m HMPAO, 839(ab)
simultaneous acquisitions, rCBF and glucose metabolism, 965(ab)
simultaneous dual-isotope, parathyroid pathology, 131
simultaneous emission/transmission, scanning line source, attenuation correction, 901(ab)
simultaneous rest Tl-201/stress Tc-99m sestamibi, myocardial perfusion, 854(ab)
single-headed gamma camera system, rapid radiotracer washout, heart, 1146
single-orbit cone beam, quantitative reconstruction method, 892(ab)
standardization, cardiac tomographic imaging, 1434
Tc-99m and I-123, validation by phantom studies, brain, 2030
Tc-99m CEROTEC, interictal localization, epileptic foci, 966(ab)
Tc-99m DMSA
three-head rotating gamma camera, renal scan, 1021(ab)
triple-head imaging, urinary tract infection, 991(ab)
Tc-99m DTPA and Tc-99m desferoxamine aerosols, lung ventilation, 835(ab)
Tc-99m ECD, kinetic behavior, compartment analysis and dynamic SPECT, 909(ab)
Tc-99m exametazine, unilateral voluntary hand movement, regional cerebral uptake, 1623
Tc-99m HMPAO
acetazolamide, cerebrovascular disease, 877(ab)
acetazolamide, vascular response and diaschisis, 967(ab)
acute aphasia, 970(ab)
alternating hemiplegia, childhood, 1021(ab)
Barre-Liou syndrome, cervical manipulation, 972(ab)
bilateral and symmetrical anomalies, brain, 485
brain, 1875
carbon dioxide reactivity, cerebrum and cerebellum, 1014(ab)
cerebral blood flow, brain tumors and strokes, 971(ab)
cerebral blood flow, chronic subdural hematoma, 246
cerebral blood flow, choreo-athetoid syndrome, 838(ab)
cerebrovascular reserve capacity, carotid artery stenosis, 971(ab)
compared to MR/CT, diagnosis of dementia, 972(ab)
crossed cerebellar diaschisis, cerebral infarction, 877(ab)
3-D semiquantitative method, intractable temporal lobe epilepsy, 970(ab)
feasibility, cortical activation study, 1015(ab)
independent aura/ictal/interictal cerebral perfusion, 438
kinetic behavior, brain, 135
linearization algorithm, cerebral blood flow, 912(ab)
localization, epileptic foci, 971(ab)
neurofocal imaging, brain, 1070(ab)
perfusion change after thrombolytic therapy, ischemic stroke, 877(ab)
presurgical evaluation, temporal lobe epilepsy, 929(ab)
quantitative perfusion-defect indexes, children with cerebral palsy, 977(ab)
regional cerebral blood flow, Down's syndrome, 1013(ab)
regional cerebral blood flow, Wisconsin card sorting test, 967(ab)
schizophrenia and depression, 972(ab)
scintigraphic appearance, Alzheimer's disease, 181, 312
sensitivity and specificity, dementia, 1013(ab)
status epilepticus, 928(ab)
Tc-99m HMPAO and I-123 IMP, cerebral blood flow, 1012(ab)
Tc-99m HMPAO and Tc-99m ECD, kinetics, brain tumors, 969(ab)
Tc-99m MIBI
resting and exercise myocardial imaging, children, 929(ab)
stability, perfusion defect size, 876(ab)
Tc-99m monoclonal antibody 174H.64, staging head and neck cancer, 912(ab)
Tc-99m PPN.1011, clinical evaluation, myocardium, 875(ab)
Tc-99m sestamibi
dobutamine, coronary artery disease, 866(ab)
F-18 FDG glucose PET, malignancy, 858(ab)
myocardial viability, 886(ab)
right ventricular ischemia, inferior myocardial infarction, 876(ab)
same day, myocardium, 876(ab)
spontaneous chest pain, coronary intervention, 875(ab)
Tc-99m TEBO
delay of image acquisition, myocardium, 952(ab)
preprocessing masking technique, 854(ab)
three-detector, simultaneous transmission and emission, 901(ab)
three-dimensional
cerebral blood flow, obsessive-compulsive disorder, 838(ab)
iterative reconstruction, 879(ab)
myocardial perfusion, Tc-99m sestamibi stress perfusion, 926(ab)
three-headed, transmission data acquisition, 901(ab)
Tl-201
attenuation correction, 1574
brain tumor recurrence, 867(ab)
distinction, high-grade from low-grade gliomas, 868(ab)
effect of patient motion, 1566
exercise-redistribution, myocardial viability after infarction, 906(ab)
F-18 FDG PET and MRI, recurrent brain tumors, 867(ab)
influence of perfusion defect size, tomographic defect severity, 995(ab)
meningioma, prediction of histological type, 971(ab)
myasthenia gravis, 1020(ab)
myocardial viability, coronary artery disease, 886(ab)
of theoretical derivations, empirical evidence, 1578
recurrent primary brain tumors, 1071(ab)
re-evaluation for brain tumor, 844(ab)
reinjection studies, collateralization, 915(ab)
sensitivity to patient motion, 1571
teboroxime resting washout, coronary disease, 876(ab)
vs. Rb-82 PET, myocardial perfusion, 1064(ab)
Tl-201 and Tc-99m phytate, liver tumor imaging, high-resolution three-head imaging, 918(ab)
Tl-201 and Tc-99m sestamibi
heart transplantation, coronary arteriopathy, 951(ab)
myocardial viability, 905(ab)
Tl-201 myocardial, major upward creep of heart, COPD, 1846
triple-headed DMSA, comparison with ultrasonography, 922(ab)
triple-head high-resolution
diagnosis, femoral head avascular necrosis, 936(ab)
diagnosis, hepatic hemangioma, 918(ab)
vs. PET, Annual Meeting highlights, 13N(8)
vs. planar bone scintigraphy, low back pain, 868(ab)
whole-body, method for scatter correction,

1007(ab)
Xe-133
cerebral blood flow and predetermined ROIs, children, 977(ab)
surgical outcome, temporal lobe epilepsy, 1018(ab)
Skeleton
axial, bone mineral density, acromegaly, 1608
bone mineral density, dual-energy X-ray absorptiometry, 1137
kinetics, evaluation, F-18 fluoride ion PET, 633
nonvisualization, bone scan, secondary to intravenous etidronate therapy, 748
screening in children, traumatic brain injury, 873(ab)
Sn(II) complexes, macromolecular, direct Tc-99m labeling with antibody, 1029(ab)
Sn(II)-DPEDO kit, Tc-99m labeled brain scanning, elimination of chiral centers, coordination sphere, 920(ab)
Sn-117m, comparison of bone-seeking agents, mechanistic implications, 899(ab)
Society of Nuclear Medicine (SNM)
ACNP and, medicare fee schedule, 18N(1)
actions of the Board of Trustees, 23N(4)
Annual Meeting highlights, molecules with messages, 10N(8)
Annual Meeting preview, 33N(5)
budget testimony, 13N(6)
court upheld nuclear quality management rule, 19N(7)
government relations update, 30N(9), 14N(12)
identifying nuclear medicine's practitioners, 26N(4)
licensing decision, California radioactive waste site, 40N(9)
Mid-Winter Meeting, computers and instrumentation, 23N(1)
new way to order medicine books, 33N(3)
Nuclear Medicine Week goes international, 33N(3)
standardization, cardiac tomographic imaging, 1434
trustees favor central office move to nation's capitol, 27N(8)
Somatostatin, radiolabeled, thyroid and orbital accumulation, Graves' disease, 894(ab)
Somatostatin analogue, Tc-99m and In-111, preparation, preliminary evaluation, 851(ab)
Spasm, infantile, regional cerebral blood flow, 1018(ab)
Species differences, interspecies variation in biodistribution, Tc-99m CPI, 1357
Spheroids, multicellular tumor, radioiodinated MIBG, neuroblastoma micrometastases, 859(ab)
Sphincter of Oddi
dysfunction
noninvasive test, postcholecystectomy, 1216
scintigraphic evaluation, 1223
Spinal cord, injury, renal plasma flow, glomerular filtration rate, 1035(ab)
Spine
fracture, bone mineral density, cyclic oral phosphate and etidronate, 1
neuroma, PET-fluorodeoxyglucose, 1931
Spleen
-liver scan, fatty liver, masquerade as neoplasm, 258
radiolabeled granulocyte kinetics, systemic vasculitis, 491
Starling effect, reduced exercise capacity, cardiac transplantation, 939(ab)
Stenosis
carotid artery, cerebrovascular reserve capacity, thrombendarteriectomy, 971(ab)
coronary, adenosine, Tl-201 compared to Tc-99m teboroxime, 864(ab)
iliac artery, renal transplant hypertension, 1178
renal artery
captopril-stimulated PRA, 907(ab)
chronic rejection, renal kinetics in transplants, 923(ab)
cortical residual activity, captopril renography, 906(ab)
Tc-99m MAG_3 scintigraphy, captopril, 990(ab)
Stents, coronary, platelet-fibrin deposition, anticoagulation, 845(ab)
Stereotaxy, automated, transformation, functional brain PET images, 1007(ab)
Stomach
antral processing of solid meal, acute and chronic alcohol, 832(ab)
applications of amplitude images, interpretation, gastric bleed studies, 1006(ab)
Fourier approach to gastric motility, 956(ab)
gastric uptake of Ga-67 in AIDS, 643
Streptavidin
biotin and, localization of infection, 1810
imaging infection/inflammation, radiolabeled biotin, 924(ab)
labeled biotin and, tumor localization, substitute for antibody, 934(ab)
Striata, variation of axial recovery, tilt, solution of, 921(ab)
Striatum, loss of 6-[F-18]fluoro-L-dihydroxyphenylalanine metabolites, 916(ab)
Stroke
acute ischemic, transcranial Doppler, brain SPECT, 968(ab)
blood flow, clinical prognosis, SPECT, 878(ab)
brain tumors and, cerebral blood flow, HMPAO-SPECT and MRI technique, 971(ab)
cross cerebellar diaschisis, neurolite imaging, 968(ab)
functional brain SPECT, powerful clinical method, 1888
ischemic, perfusion change after thrombolytic therapy, Tc-99m HMPAO SPECT, 877(ab)
neurolite as an aid in diagnosis and localization, 878(ab)
Strontium-89
different therapeutic doses, metastatic bone pain, 937(ab)
low-dose infusion cisplatin and, hormone refractory prostate carcinoma metastatic to bone, 1437
radiotherapy, metastatic prostatic carcinoma, 1316
Substance P analog, nonpeptide, synthesis of, PET studies, 860(ab)
***N*-Succinimidyl 4-[F-18]fluorobenzoate,** labeling of monoclonal antibodies with F-18, 881(ab)
Sudden death, thallium scan, court litigation, 120
Supranuclear palsy, *in vivo* SPECT with iodine-iodolisuride, D2 receptor, 1481
Supreme Court, case against radioactive waste policy amendments act, 33N(3)
Surgery, *vs.* conservative management, antenatal hydronephrosis, impaired renal function, 873(ab)
Sympathetic nervous system
localization of pheochromocytoma, C-11 HED PET, 1125
MIBG heart and lung extraction fraction, first-pass analysis, 716
myocardial, postnatal maturation, high-resolution scintigraphy, 935(ab)
Synovectomy
radiation
Ho-166 hydroxyapatite, 937(ab)
radiolabeling, hydroxyapatite particles, 980(ab)
radionuclide, polymeric microspheres, neutron-activated holmium-166, 398

T

Tamoxifen, F-18 fluoro analog, radiosynthesis, estrogen receptors and PET, 985(ab)
Taste, dysfunction, thyroid cancer, I-131 treatment, 996(ab)
Teboroxime
extraction in rabbit heart, reduction by incubation with human RBC, 864(ab)
kinetic modeling, dynamic SPECT imaging, 878(ab)
myocardial perfusion imaging, adenosine, accuracy and optimal imaging time, 854(ab)
preprocessing masking technique, SPECT, 854(ab)
resting washout and stress thallium SPECT, coronary disease, 876(ab)
Technetium-94m, radionuclide purity requirements, pharmacokinetic studies, PET, 850(ab)
Technetium-96, comparison of bone-seeking agents, mechanistic implications, 899(ab)
Technetium-96 sestamibi, myocardial blood flow, co-injection technique, 1152
Technetium-99m
alkyl-hydroxyamamide complexes, 1033(ab)
anatomy of radioisotope lung scanning, 676
brain scanning agent, elimination of chiral centers, coordination sphere, 920(ab)
cationic complexes, myocardial tissue uptake, 1033(ab)
cell binding agent, 920(ab)
compared to N2S2 chelate labeled NR-LU-10 Fab′, tumored nude mice, 909(ab)
complexes and Re, structural requirements, rapid tubular transport, 900(ab)
direct labeling, platelet-binding laminin peptide, 1031(ab)
direct labeling of antibody, macromolecular Sn(II) complexes, 1029(ab)
dual-radioisotopic technique, tumescence, penile blood flow, 41
equilibrium imaging, Kr-81m, right ventricular determination, 932(ab)
evaluation of 12 biotin derivatives, 920(ab)
gated blood-pool imaging, ECG gated PET C-11 monoxide, "background" question, 938(ab)
human immunoglobulin, dendrimers as linker molecules, 986(ab)
hypodermically injected, study on radioactive pathways, 403
I-123 and
dual radionuclide data acquisition, quantitative brain SPECT, 972(ab)
feasibility, dual radionuclide SPECT imaging, 851(ab)
SPECT, brain, 2030
ImmunRAID-CEA, patient response, human anti-mouse antibody, 1002(ab)
inhibited recombinant tissue plasminogen activator, thrombosis scintigraphy, 1029(ab)
-labeled organic cations, synthesis, renal excretion, 2190
labeling of antimyosin Fab′, instant kit method, myocardial infarct model, 144
mapping of leukocytes, secondary ion mass spectrometry microscopy, 2162
myocardial imaging agent, kit development,

Technecard, 850(ab)
new radiopharmaceuticals, multifunctional phosphorus hydrazides, 1032(ab)
radionuclide angiography, thrombosis detection, left atrial appendage, 365
Re-188 and, bifunctional frameworks, phosphorus hydrazide chelates, 910(ab)
Re complexes and, unsymmetrical BAT ligand, 989(ab)
renal scan, diagnosis, bleeding mycotic iliac aneurysm, 1548
second binding site in IgG, relation to histidine groups, 1029(ab)
serial measurements of cardiac volumes, count-based methods, 1324
side chain modifications, bis(dithiocarbamato) nitrido technetium(V), myocardial uptake, 1034(ab)
small molecule neutral-lipophilic agents, functionalized phosphinimines, 851(ab)
targeted proteins, diagnostic imaging, 394
Tl-201 and, dual-isotope autoradiography, computed tomography, 1005(ab)
transmission source, Tl-201 cardiac SPECT, simultaneous acquisition of emission/transmission data, 2238
two new myocardial perfusion agents, 22N(1)
Xe-133 and, dual isotope imaging, energy weighted acquisition, 889(ab)

Technetium-99m D,L-HMPAO, uptake mechanism in cell cultures, dissociated postnatal rat cerebellum, 108

Technetium-99m antibody
direct and indirect, comparison in mice, 909(ab)
pharmacokinetic modeling, 958(ab)

Technetium-99m anti-CEA antibodies, technical limitations of immunoscintigraphy, 1001(ab)

Technetium-99m antifibrin, scintigraphy, acute deep venous thrombosis, 848(ab)

Technetium-99m antifibrin Fab', localization or pharmacokinetics, anticoagulation by heparin, acute venous thrombosis, 978(ab)

Technetium-99m anti-fibrin monoclonal antibody, accumulation in inflammatory focus, 1181

Technetium-99m antigranulocyte antibody
clinical usefulness, differential diagnosis, intracranial abscess, 957(ab)
suspected bone infections, 526

Technetium-99m antigranulocyte Fab' fragments, scintigraphy, compared to In-111 oxine/Tc-99m HMPAO leukocytes, infectious diseases, 903(ab)

Technetium-99m antigranulocyte monoclonal antibody, fever of unknown origin, 902(ab)

Technetium-99m antimyosin Fab', instant kit method, myocardial infarct model, 144

Technetium-99m avidin, kidney uptake, isoelectric point, 986(ab)

Technetium-99m bicisate: *see* Technetium-99m ECD

Technetium-99m Cerotec
brain scan, assessment, brain death, 970(ab)
SPECT, interictal localization, epileptic foci, 966(ab)

Technetium-99m colloid, Tc-99m monoclonal antibodies and, image subtraction analysis, liver lesions, 913(ab)

Technetium-99m complexes, properties that facilitate renal tubular transport, 920(ab)

Technetium-99m CPI
human pharmacokinetics and radiopharmacological studies, 1949
interspecies variation in biodistribution, 1357

Technetium-99m DACH, potential new cationic renal tubular agent, normal human volunteers, 923(ab)

Technetium-99m desferoxamine, Tc-99m DTPA aerosols and, SPECT lung ventilation, 835(ab)

Technetium-99m dexamethasone phosphate, imaging of inflammatory lesions, 1027(ab)

Technetium-99m dextran, lymphoscintigraphy, transverse rectus abdominus myocutaneous flap, autogenous breast reconstruction, 859(ab)

Technetium-99m DISIDA, utility of cholescintigraphy, laparoscopic cholecystectomy, 898(ab)

Technetium-99m DMSA
elimination of background and kidney-depth correction, compartment modeling, renal uptake rate, 1004(ab)
febrile urinary tract infections, 976(ab)
parenchymal renal lesion after ESWL, 990(ab)
pentavalent, small coordination complexes, tumor imaging, 469(le)
renal scans, variability, standardized rating scale, 922(ab)
replacement with Tc-99m MAG_3, exclusion, focal renal defect, 2090
SPECT
three-head rotating gamma camera, renal scan, 1021(ab)
triple-head imaging, urinary tract infection, 991(ab)
triple-headed SPECT, comparison with ultrasonography, 922(ab)

Technetium-99m DTPA
aerosol, MIRD dose estimate Report No. 16, 1717
aerosol and gallium-67 scanning, pulmonary complications, HIV infection, 81
aerosol clearance, effect of molecular size, 1022(ab)
bifunctional, macrocyclic ligands, serum stability studies with Y-88, 1031(ab)
diuresis renography, ureteral status, children, 72
effects of dipyridamole, renal function, 355
incidence of adverse reactions, 1025(ab)
monofunctional analogs, attachment to peptides and antibodies, 988(ab)
radiation dosimetry, human biodistribution studies, 33
renal uptake-plasma volume product, glomerular filtration rate, 1712
single-injection multi-sample renal clearance methods, optimum sample times, 948(ab)
Tc-99m desferoxamine aerosols and, SPECT lung ventilation, 835(ab)
ventilation, effectiveness of PEP mask, cystic fibrosis, 835(ab)

Technetium-99m DTPA-HSA, cerebrovascular response to acetazolamide, new method for monitoring, 969(ab)

Technetium-99m ECD
brain perfusion SPECT, cerebral blood flow, PET, 966(ab)
brain retention, effect of radiolabeled impurities, dosimetry, 989(ab)
kinetic behavior in human brain, compartment analysis and dynamic SPECT, compared to Tc-99m HMPAO, 909(ab)
planar imaging, global cerebral blood flow, monkeys, 979(ab)
SPECT, kinetics, brain tumors, 969(ab)
synthesis of isomers, brain, monkeys, 979(ab)
Tc-99m HMPAO and, intrasubject comparison, healthy human subjects, 480

Technetium-99m EHIDA, hepatobiliary scintigraphy, diagnostic criteria for biliary atresia, neonatal jaundice, 899(ab)

Technetium-99m erythrocytes, modification of labeling technique, effectiveness, 2222

Technetium-99m exametazine, regional cerebral uptake, unilateral voluntary hand movement, 1623

Technetium-99m fragment E_1, thrombus imaging, preparation, preliminary evaluation, 710

Technetium-99m 2GAM, renal imaging, evaluation in humans, 923(ab)

Technetium-99m glucarate, Tl-201 and, acute myocardial infarction, rats, 1988

Technetium-99m glucoheptonate white blood cells, inflammatory bowel disease, 998(ab)

Technetium-99m HDP, incidence of adverse reactions, 1025(ab)

Technetium-99m HIDA, hepatic clearance of derivatives, hyperbilirubinemic states, 1551

Technetium-99m HIG
assessment of infectious conditions, musculoskeletal system, 839(ab)
bone scans and, joint inflammation, rheumatoid arthritis, 840(ab)
detection of bone and joint inflammation, 839(ab)
one-step labeling kit, imaging of inflammation and tumors, 1028(ab)

Technetium-99m HMPAO
angiography of the brain, quantitative approach, 877(ab)
brain perfusion SPECT, acute aphasia, 970(ab)
brain scans, high-resolution SPECT, neurofocal imaging, 1070(ab)
brain SPECT
bilateral and symmetrical anomalies, 485
cerebral angioplasty, delayed ischemia due to vasospasm, 1789
cerebral blood flow, choreo-athetoid syndrome, 838(ab)
r-CBF variability, 826(ab)
regional cerebral blood flow, Down's syndrome, 1013(ab)
cerebral cortical activity, scintigraphy, 117
cerebral perfusion, internal carotid artery occlusion, 969(ab)
cerebral perfusion scintigraphy, timely brain death declaration, 2209
comparative study of TcGH and TcHMPAO, diagnosis of brain death, 1016(ab)
compartment analysis and dynamic SPECT, kinetic behavior, Tc-99m ECD, 909(ab)
differential diagnosis of dementia, 939(ab)
I-123 IMP and
dual-isotope brain imaging, normal volunteers, 827(ab)
regional cerebral blood flow, drug abuse, 1015(ab)
regional cerebral blood flow, SPECT and MRI, 1012(ab)
independent aura/ictal/interictal cerebral perfusion, 438
intraarterial carotid artery injection, recurrent glioma, 966(ab)
isomers D,L and effect of cocaine, uptake and respiration, rat brain slices, 964(ab)
isomers D and L, biological evaluation, 1032(ab)
kinetic behavior in human brain, cerebral blood flow, dynamic SPECT, 135
-labeled WBC scan, spread of infectious complications, odontogenic abscess, 254
lymphocyte labeling, radiotoxicity study, micron-

ucleus assay, 1167
presurgical scintigraphy, patients with medically refractory seizures, 967(ab)
SPECT
acetazolamide, cerebrovascular disease, 877(ab)
acetazolamide effect, vascular response and diaschisis, 967(ab)
alternating hemiplegia, childhood, 1021(ab)
attenuation correction, brain, 1875
Barre-Liou syndrome, cervical manipulation, 972(ab)
brain blood flow, interventional neuroradiology, 826(ab)
carbon dioxide reactivity, cerebrum and cerebellum, 1014(ab)
cerebral blood flow, brain tumors and strokes, 971(ab)
cerebral blood flow, chronic subdural hematoma, 246
cerebrovascular reserve capacity, carotid artery stenosis, 971(ab)
cocaine abuse, AIDS dementia complex, 1312
crossed cerebellar diaschisis, cerebral infarction, 877(ab)
3-D semiquantitative method, intractable temporal lobe epilepsy, 970(ab)
feasibility of cortical activation study, subtraction method, 1015(ab)
kinetics, brain tumors, 969(ab)
linearization algorithm, cerebral blood flow, 912(ab)
localization, epileptic foci, 971(ab)
perfusion change after thrombolytic therapy, ischemic stroke, 877(ab)
presurgical evaluation, temporal lobe epilepsy, 929(ab)
quantitative perfusion-defect indexes, children with cerebral palsy, 977(ab)
regional cerebral blood flow, Wisconsin card sorting test, 967(ab)
remote history, traumatic brain injury, 52
schizophrenia and depression, 972(ab)
scintigraphic appearance, Alzheimer's disease, 181, 312
sensitivity and specificity, dementia, 1013(ab)
status epilepticus, 928(ab)
subjects with and at risk for Huntington's disease, 970(ab)
SPECT compared to MR/CT, diagnosis of dementia, 972(ab)
Tc-99m ECD and, intrasubject comparison, healthy human subjects, 480
Tc-99m RBC and, sequential high resolution SPECT, intracranial arteriovenous malformations, 839(ab)
Technetium-99m HMPAO leukocytes, Tc-99m antigranulocyte Fab′ fragments, scintigraphy, 903(ab)
Technetium-99m HMPAO lymphocytes, fast diagnosis of abdominal infections, 1253(le)
Technetium-99m hydrazino nicotinamide, conjugated chemotactic peptides, imaging focal sites of infection, 910(ab)
Technetium-99m hydroxyamic acids, tumor imaging agents, 988(ab)
Technetium-99m IDA, quantitative cholescintigraphy, differentiation, congenital gallbladder abnormality, 431
Technetium-99m L,L-EC, renal imaging agent, 551
Technetium-99m LDL, binding to parenchymal and non-parenchymal cells, normal and estradiol-stimulated rat liver, 1028(ab)
Technetium-99m leukocytes
clinical experience with Tc-99m nanocolloid, 999(ab)
diagnosis of sternal wound infection, 59
In-111 oxine and, simultaneous imaging, community hospital, 902(ab)
Technetium-99m liposomes
cardiac blood-pool scintigraphy, 984(ab)
newly developed labeling procedure, successful infection detection, rats, 1027(ab)
Technetium-99m MAG_3
clearance
camera-based method, gamma variate fit, 991(ab)
optimized camera based method, 948(ab)
preliminary "normal" values, infants, 1021(ab)
prospective validation, single sample technique, 1620
diuretic renal scintigraphy, routine protocol, congenital and acquired renal disorders, 1035(ab)
evaluation of new ligands, renal function agents, 988(ab)
hepatobiliary excretion, 990(ab)
kits, prolonging useful life, 991(ab)
modified amide bonds, 1032(ab)
potential renal imaging agents, 919(ab)
radiation dosimetry, human biodistribution studies, 33
renal scans, hepatic activity, 992(ab)
replacement of Tc-99m DMSA, exclusion, focal renal defect, 2090
scintigraphy, captopril, renal artery stenosis, 990(ab)
simplified ERPF determination, 1034(ab)
single-injection multi-sample renal clearance methods
comparison, 948(ab)
optimum sample times, 948(ab)
technescan, labeling conditions and QC, 1033(ab)
vs. I-131 hippurate, functional and anatomic evaluation, renal transplants, 1035(ab)
Technetium-99m MDP
accumulation of F-18 FDG, bone fracture, 869(ab)
compared to Tc-99m MIBI uptake, benign and malignant bone lesions, 319
diffuse abdominal uptake, continuous ambulatory dialysis, bone scintigraphy, 2052
extraosseous uptake, pathophysiologic approach, 1063(ab)
gallium and, scintigraphic differentiation, osteogenic and Ewing's sarcoma, 1063(ab)
I-131 MIBG and bone scintigraphy, detection of neuroblastoma, 1735
skeletal nonvisualization, bone scan, intravenous etidronate therapy, 748
Technetium-99m mebrofenin, scintigraphic aspect, Rotor's disease, 1550
Technetium-99m medronate, uptake in hepatic necrosis, Budd-Chiari syndrome, 1390
Technetium-99m mertiatide, atlas of renal transplant imaging studies, 1073(ab)
Technetium-99m MIBI
compared to Tl-201 scintigraphy with reinjection, viable myocardium, chronic coronary artery disease, 505
radionuclide angiography, SPECT myocardial perfusion, dipyridamole, 846(ab)
rest-redistribution Tl-201, chronic coronary artery disease, 905(ab)
scintigraphy, myocardial viability, thallous chloride injection, 906(ab)
SPECT
resting and exercise myocardial imaging, children, 929(ab)
stability, perfusion defect size, 876(ab)
subcellular distribution and analysis, perfused rat hearts, 1516
Tl-201
follow-up, differentiated thyroid carcinoma, 844(ab)
and MRI, recurrent brain tumors, 867(ab)
Tl-201 chloride and, uptake, primary thyroid lymphoma, 1396
Tl-201 scintigraphy and, localization, parathyroid enlargement, 895(ab)
Tl-201 SPECT and, childhood brain tumors, 844(ab)
uptake in benign and malignant bone lesions, compared to Tc-99m MDP, 319
use in peripheral vascular disease, 629(le)
Technetium-99m monoclonal antibody
CA 125, early detection, ovarian cancer recurrences, 904(ab)
F023C5 anti-CEA IgG1, gastrointestinal tumor targeting, role of CEA content, 892(ab)
174H.64, SPECT, staging of head and neck cancer, 912(ab)
HPLC, recovery and calibration, 1030(ab)
management of colorectal and ovarian cancer, 904(ab)
Tc-99m colloid image subtraction analysis and, liver lesions, 913(ab)
Technetium-99m N_2S_2, monocationic radiotracers, synthesis and evaluation, 990(ab)
Technetium-99m nanocolloid, clinical experience, 999(ab)
Technetium-99m NGA, evaluation of local reduced mass, functioning hepatocytes, chronic liver diseases, 998(ab)
Technetium-99m nitrido dithiocarbamate, myocardial imaging agents, improved synthesis, 989(ab)
Technetium-99m 2-nitroimidazole, imaging regional hypoxia, occlusion of LAD coronary artery, rabbit myocardium, 865(ab)
Technetium-99m P53, myocardial imaging agent, structural characterization, 850(ab)
Technetium-99m pertechnetate
pulmonary mean transit times, teboroxime, 846(ab)
radionuclide hysterosalpingography, radiation dose to ovaries, 282
thyroid scanning, 1722(le)
Technetium-99m phytate
high-resolution three-head SPECT, dual energy acquisition, liver tumor imaging, 976(ab)
Tl-201 and, liver tumor imaging, high-resolution three-head SPECT, 918(ab)
Technetium-99m phytate sucralfate, new procedure, advanced ulcer avid agent, 1033(ab)
Technetium-99m polyclonal IgG
carbohydrate modification, sites of bacterial infection, 1378
single radiopharmaceutical kit, 1024(ab)
Technetium-99m PPN.1011, SPECT, clinical evaluation, myocardium, 875(ab)
Technetium-99m progestin, Re-186 and, synthesis and receptor binding, 558
Technetium-99m Q12, myocardial blood flow in canine heart, 993(ab)
Technetium-99m red blood cells
gastrointestinal bleeding studies, early negative images, 202
penile corporal venous leak, 49
preparation with UltraTag RBC kit, evaluation, heparin and anticoagulant citrate dextrose, 306(le)

Tc-99m HMPAO and, sequential high resolution SPECT, intracranial arteriovenous malformations, 839(ab)

Technetium-99m sestamibi
acute Adriamycin cardiotoxicity, chick heart cells, 864(ab)
cardiac perfusion abnormalities, Kawasaki syndrome, 929(ab)
comparison of rest-redistribution Tl-201 uptake, coronary artery disease, 905(ab)
defect size, thrombolytic therapy, regional wall motion, 927(ab)
detection of coronary artery disease, 1091
dobutamine and exercise, coronary artery disease, 951(ab)
gated SPECT, characterization of fixed defects, infarct or artifact, 927(ab)
localization of parathyroid adenoma
hyperparathyroidism, 1801
primary hyperparathyroidism, 894(ab)
lung uptake, correlation with LV ejection fraction, 846(ab)
multiple gated SPECT, myocardial thickening, phase analysis, 926(ab)
myocardial distribution, nontransmural infarction, 223
myocardial imaging, comparison, same-day protocols, 186
myocardial reperfusion imaging, acute chest pain, non-diagnostic EKG, 876(ab)
myocardial SPECT imaging
comparison, short and standard data acquisition, 855(ab)
early and delayed imaging, 855(ab)
parathyroid imaging, 313
perfusion and regional contraction, peak left ventricular ejection fraction, coronary artery disease, 847(ab)
PET, defect size and severity, 875(ab)
planar, blinded evaluation, myocardial perfusion studies, 668
retention characteristics, canine myocardium, 865(ab)
same-day acquisition protocol, 468(le)
scintigraphy, radioisotopic assessment, myocardial viability, 1925
serial tomographic imaging, infarct-related arterial patency, reperfusion therapy, 2080
SPECT
dobutamine, coronary artery disease, 866(ab)
F-18 FDG glucose PET, malignancy, 858(ab)
myocardial viability, 886(ab)
right ventricular ischemia, inferior myocardial infarction, 876(ab)
same day, myocardium, 876(ab)
spontaneous chest pain, coronary intervention, 875(ab)
Tl-201 and, myocardial viability, 905(ab)
stress perfusion, myocardial function and viability, 3-D SPECT, 926(ab)
stress/rest Tl-201 SPECT, myocardial perfusion, 854(ab)
Tl-201 and
heart transplantation, coronary arteriopathy, 951(ab)
imaging, myocardial infarction, 865(ab)
quantitative dual isotope autoradiography, uptake in rabbits, 993(ab)
rest/exercise imaging, defect reversibility, 855(ab)
uptake kinetics, rat heart endothelial and fibroblast-like cells, 102
viable myocardium, 815
uptake by recurrent Hurthle cell carcinoma, thyroid, 1393
vial breakage with microwave oven, 176(le)

Technetium-99m somatostatin analogue, In-111 somatostatin analogue and, preparation, preliminary evaluation, 851(ab)

Technetium-99m sulphur colloid, dosimetry, cellular level, Kupffer cells, 380

Technetium-99m T691, preclinical studies, regional cerebral perfusion, 1836

Technetium-99m TBI, scintigraphy, detection of metastases, thyroid carcinoma, 914(ab)

Technetium-99m TBIDA, hot spots on liver scan, focal nodular hyperplasia, 918(ab)

Technetium-99m teboroxime
absorbed radiation dose to humans, 88
detection of coronary artery disease, 1091
myocardial blood flow, co-injection technique, 1152
myocardial extraction, interaction with blood, 94
myocardial SPECT imaging, delay of image acquisition, exercise-induced perfusion defects, 952(ab)
planar myocardial perfusion imaging, Tl-201 and coronary angiography, 1783
retention characteristics, canine myocardium, 865(ab)
Tl-201 and
continuous SPECT imaging protocol, 1304
coronary stenosis, vasodilation with adenosine, 864(ab)

Technetium-99m tetrofosmin
biokinetics, myocardial perfusion, one-day imaging, 874(ab)
clinical efficacy, myocardial imaging agent, 874(ab)
comparison of defect size, peak exercise, 874(ab)
effect of coronary blood flow on uptake, rabbit heart, 846(ab)
myocardial imaging
coronary heart disease, 875(ab)
perfusion and blood flow, 993(ab)
structural characterization, myocardial imaging agent, 850(ab)

Technetium-99m (V)-DMSA, facile synthesis of Re-188-labeled Rc(V)-DMSA, triphenylphosphine reduction, perrhenate at room temperature, 1024(ab)

Technetium-99m (V)-thiocyanate, gastric empyting and intragastric distribution, oil, presence of liquid or solid meal, 1283

Technetium-PnAO-nitroimidazole complex, chemistry of, localization in hypoxic tissue, 919(ab)

Technology, coming reform of health care system, 24N(4)

Telangiectasia, hereditary hemorrhagic, embolization, hepatic arteriovenous malformations, 260

Tenascin, detection of breast tumors, labeled BC-2 monoclonal antibody, 999(ab)

Teratoma
immature third ventricle, radiographic and neuro-SPECT imaging, 435
rectal wall, pelvic radioiodine uptake, thyroidectomy for papillary carcinoma, 1848

Testes
macro- and microscopic biodistribution, In-111, rats, 954(ab)
radiotoxicity, I-123/I-125/I-131-labeled compounds, mouse, 2196

1,4,7,10-Tetraazacyclododecane, simple synthesis and activation, immunoconjugation, 942(ab)

Thakur, Mathew, Aebersold Award, 34N(5)

Thallium-201
accumulation by epidermoid inclusion cyst, 1857
adenosine scintigraphy, high cardiac risk, patients referred for vascular surgery, 952(ab)
after brain surgery and irradiation, quantification using an animal model, 964(ab)
brain SPECT, re-evaluation for brain tumor, 844(ab)
cardiac SPECT imaging, Tc-99m transmission source, simultaneous acquisition of emission/transmission data, 2238
-chloride uptake, hypermetabolic bone marrow, granulocyte stimulating factor, 2014
comparison of digital and analog film display, 1003(ab)
CT/MRI/angiography in bone and soft tissue sarcoma, 843(ab)
defect reversibility and severity, quantitative *vs.* visual analysis, 905(ab)
delayed post-reinjection, detection of viable myocardium, 1064(ab)
dipyridamole
improvement of image quality, walking exercise, 2061
predictive value, myocardial bridging, 1905
dipyridamole imaging, dose comparisons, coronary artery disease, 866(ab)
dobutamine, scintigraphy, usefulness and safety, 951(ab)
early imaging after PTCA, 866(ab)
tomographic evaluation, adenosine-induced coronary hyperemia, 2086
exercise myocardial SPECT, major upward creep of heart, COPD, 1846
exercise-redistribution SPECT, myocardial viability after infarction, 906(ab)
exercise whole-body thallium perfusion imaging, peripheral vascular disease, 1797
high-resolution three-head SPECT, dual energy acquisition, liver tumor imaging, 976(ab)
I-123 branched fatty acid analogue and, assessment, ischemic but viable myocardium, 885(ab)
importance of delayed scanning, 463(le)
influence of perfusion defect size, tomographic defect severity, 995(ab)
injection, myocardial viability, Tc-99m scintigraphy, 906(ab)
lack of redistribution, dipyridamole imaging, postoperative and long-term outcome, 951(ab)
myocardial blood flow, co-injection technique, 1152
optimal imaging time as a tumor agent, lymphoma, 844(ab)
planar myocardial perfusion imaging
detection, coronary artery disease, 1091
Tc-99m tebo, 1783
quantitative stress-redistribution SPECT, prone imaging, validation, 1509
redistribution, FDG PET, increased FDG uptake after myocardial infarction, 886(ab)
redistribution model, 915(ab)
reinjection
enhanced detection of ischemia, quantitative reversibility maps, 916(ab)
interval between reinjection and imaging, post-MI patients, 915(ab)
patients without previous myocardial infarction, 916(ab)
rest-redistribution
chronic coronary artery disease, relation to Tc-99m MIBI, 905(ab)
resting sestamibi uptake, coronary artery dis-

ease, 905(ab)
rest/stress Tc-99m sestamibi SPECT, myocardial perfusion, 854(ab)
retention characteristics, canine myocardium, 865(ab)
reversible perfusion defects, incomplete right bundle branch block, normal coronary angiogram, 1556
scan
contribution, differentiated thyroid carcinoma, 955(ab)
interpretation, court litigation, 120
patterns, bone and soft tissue sarcoma, 843(ab)
scintigraphy
adenosine, lung thallium uptake, 1600
incremental diagnostic value and impact, 1727
incremental value, cost consciousness, 1732
localization, parathyroid enlargement, 895(ab)
scintigraphy with reinjection, viable myocardium, chronic coronary artery disease, 505
SPECT
attenuation correction, 1574
brain tumor recurrence, 867(ab)
distinction, high-grade from low-grade gliomas, 868(ab)
heart transplantation, coronary arteriopathy, 951(ab)
meningioma, prediction of histological type, 971(ab)
myasthenia gravis, 1020(ab)
myocardial viability, coronary artery disease, 886(ab)
of theoretical derivations, empirical evidence, 1578
recurrent primary brain tumors, 1071(ab)
reinjection studies, collateralization, 915(ab)
sensitivity to patient motion, 1571
teboroxime resting washout, coronary disease, 876(ab)
vs. Rb-82 PET, myocardial perfusion, 1064(ab)
SPECT and F-18 FDG PET, MRI, recurrent supratentorial and infratentorial brain tumors, 867(ab)
stress test, ECG response and perfusion images, 1723(le)
Tc-99m and, dual-isotope autoradiography, computed tomography, 1005(ab)
Tc-99m glucarate and, acute myocardial infarction, rats, 1988
Tc-99m MIBI and
follow-up, differentiated thyroid carcinoma, 844(ab)
MRI, recurrent brain tumors, 867(ab)
Tc-99m MIBI SPECT and, childhood brain tumors, 844(ab)
Tc-99m phytate and, liver tumor imaging, high-resolution three-head SPECT, 918(ab)
Tc-99m sestamibi and
imaging, myocardial infarction, 865(ab)
quantitative dual isotope autoradiography, uptake in rabbits, 993(ab)
rest/exercise imaging, defect reversibility, 855(ab)
uptake kinetics, rat heart endothelial and fibroblast-like cells, 102
viable myocardium, 815
Tc-99m sestamibi SPECT and, myocardial viability, 905(ab)
Tc-99m teboroxime and
continuous SPECT imaging protocol, 1304
coronary stenosis, vasodilation with adenosine, 864(ab)
tomographic perfusion imaging, effect of patient motion, 1566
tomography, pharmacologic stress and, extent and location of CAD, 2067
transient exercise *vs.* dipyridamole-induced left ventricular cavitary dilatation, 951(ab)
uptake after reinjection, regional ventricular function, myocardial perfusion, 915(ab)
uptake pattern in bone lesions, differentiation, benign from malignant processes, 869(ab)
Thallium-201 chloride, Tc-99m MIBI and, uptake, primary thyroid lymphoma, 1396
Thrombendarteriectomy, carotid artery stenosis, cerebrovascular reserve capacity, 971(ab)
Thrombocytopenia, hepatic sequestration of In-111 platelets, GM-CSF, 923(ab)
Thrombogenicity, comparative, cellulose-acetate hemodialyzer, 956(ab)
Thrombolytic therapy
late infarct size and ejection fraction, acute myocardial infarction, 939(ab)
perfusion change, ischemic stroke, Tc-99m HMPAO SPECT, 877(ab)
predictor of prognosis, PET, ischemic myocardium at risk, 837(ab)
Thrombosis
acute deep venous, Tc-99m antifibrin scintigraphy, 848(ab)
acute venous, anticoagulation by heparin, Tc-99m antifibrin Fab′ localization, 978(ab)
detection in left atrial appendage, Tc-99m radionuclide angiography, 365
imaging, Tc-99m frament E_1, preliminary evaluation, 710
scintigraphy, Tc-99m inhibited recombinant t-PA, 1029(ab)
thallium scan, court litigation, 120
Thymidine, methionine or, location in cell, radiation-induced alterations, 841(ab)
Thyroglobulin, measurement, I-131 whole-body scan, thyroid carcinoma, 172(le)
Thyroid
autonomous nodule, treatment, percutaneous ethanol injection, 954(ab)
follicle, radiation dose distribution, revised method, 926(ab)
nodule, accuracy of neuronet diagnosis, backpropagation simulator, 954(ab)
orbital radiolabeled somatostatin accumulation, Graves' disease, Graves' ophthalmopathy, 894(ab)
post-I-131 cancer therapy, radiation safety considerations, 1402
primary osteosarcoma, 1399
radioactive uptake, potential effects, contrast material iodides, 237
scanning with Tc-99m pertechnetate, 1722(le)
uptake neck phantoms, 304(le)
well-differentiated neoplasms, radioiodine-131 therapy, 1132
Thyroidectomy, papillary carcinoma, pelvic radioiodine uptake, rectal wall teratoma, 1848
Thyroid neoplasms
differentiated, clinical meaning, circulating antithyroglobulin antibodies, 1478
I-131 contamination, 2110
I-131 therapy, quantitative dosimetric approach, 894(ab)
surprise findings, Chernobyl, 23N(11)
taste dysfunction, I-131 treatment, 996(ab)
TSH stimulation, sequential FDG PET studies, before and after T4 thyroid replacement therapy, 894(ab)
well-differentiated, chest X-rays and bone scans, I-131 scans, 894(ab)
Title VII, appropriations, 26N(3)
Tomography, cone beam, dual-detector SPECT system, 892(ab)
Tracers, new developments, 16N(8)
Tracheobronchitis, necrotizing, In-111 white blood cell scan, 1704
Transferrin
hepatic Ga-67 concentration and, Ga-67 distribution, 1701
IgG and $F(ab')_2$ conjugates, preparation, characterization, 986(ab)
Transplantation
cardiac, reduced exercise capacity, Starling effect, 939(ab)
distribution in cells of In-111 hepatocytes, 918(ab)
lung, scintigraphy in follow-up, 835(ab)
renal
atlas of imaging studies, Tc-99m mertiatide, 1073(ab)
functional and anatomic evaluation, Tc-99m MAG_3 *vs.* I-131 hippurate, 1035(ab)
hypertension, iliac artery stenosis, 1178
renal kinetics, chronic rejection, renal artery stenosis, 923(ab)
single lung, quantitative exercise-rest ventilation-perfusion imaging, 835(ab)
Triazolam, interaction with central type benzodiazepine receptors, PET, baboons, 973(ab)
Trionix, lawsuit of ADAC Laboratories, gamma camera technology, 18N(2)
Triorchidism, scintigraphy of torsion, 1854
Tritium-3-colchicine, tumor multidrug resistance, *in vivo* identification, 1373
Tuberculosis, extrapulmonary, Ga-67 scan, computed tomography, 2118
Tumescence, evaluation of penile blood flow, dual-radioisotopic technique, 41
Tumor-associated antigens, similarity and co-expression, recognition, different monoclonal antibodies, 853(ab)
Tumors
quantitative scintigraphy and time to metastasis, dogs with osteosarcoma, 1542
rapidly growing, absorbed dose calculations, 277
solid
5-iododeoxyuridine, efficacy of radioimmunotherapy, 1530
localization with streptavidin and labeled biotin, substitute for antibody, 934(ab)
radiolabeled monoclonal antibody heterogeneous distribution, binding site barrier, 893(ab)
Tyramine cellobiose, radioiodinated monomeric antibody P-67, improved tumor retention, 987(ab)

U

Ulcer, avid agent, new procedure, 1033(ab)
Ultrasonography
cerebrovascular reserve capacity, carotid artery stenosis, thrombendarteriectomy, 971(ab)
compared to triple-headed DMSA SPECT, 922(ab)
intracoronary probes and PET, concordant quantification, flow reserve, 836(ab)
Tc-99m MIBI and Tl-201 scintigraphy, localization, parathyroid enlargement, 895(ab)
transcranial, brain SPECT, acute ischemic stroke therapy, 968(ab)
Ureter
function, assessment of hydronephrosis, 78
kidney washout, Tc-99m DTPA diuresis renography, children, 73
Uretero-pelvic junction

natural history of infantile hydronephrosis, diuretic renography, 2098
suspicion of obstruction, postnatal assessment, volume expanded diuretic renography, 2094
Urinary bladder, dynamic model for radiation dose calculation, MIRD pamphlet No. 14, 783
Urinary tract
febrile infections, Tc-99m DMSA scanning, children, 976(ab)
infection, triple-head imaging, Tc-99m DMSA SPECT, 991(ab)
infection in childhood, 872(ab)
Urokinase, lung scan, pulmonary arteriogram improvement, 849(ab)
U.S. Court of Appeals, upheld nuclear quality management rule, 19N(7)
Uveitis, sarcoid, Ga-67 citrate scanning, 1851

V

Varioceles, classification by two-phase scrotal scintigraphy, 1034(ab)
Vascular disease, peripheral, use of Tc-99m MIBI, 629(le)
Vasculitis, systemic, radiolabeled granulocyte kinetics, 491
Vasospasm, delayed ischemia, cerebral angioplasty, brain SPECT, 1789
Ventilation
enhanced V/Q mismatch sign, pulmonary embolism, 1072(ab)
go with the flow—but how far?, 1939
lung, Tc-99m DTPA and Tc-99m desferoxamine aerosols, SPECT, 835(ab)
necrotizing tracheobronchitis, In-111 white blood cell scan, 1704
perfusion scans, severe diffuse obstructive airway disease, single-breath Xe-133, 1072(ab)
regional, volume and, separation by Kr-81m, 1935
routine imaging, PE evaluation, low probability V/Q scans, 1022(ab)
V/Q frequency distribution, pulmonary diseases, 1023(ab)
Ventilation-perfusion
exercise-rest, single lung transplant, 835(ab)
lung scanning, computer-assisted diagnosis, pulmonary embolism, 1003(ab)
lung scans, number of segmental mismatches, likelihood of pulmonary embolism, 849(ab)
scintigraphy, intermediate likelihood-ratio results, 849(ab)
Ventricular function
biventricular, parametric display, gated blood-pool SPECT, 952(ab)
left
count-based ratio method and volume, first-pass radionuclide angiography, 2124
diastole, systemic sclerosis, 68
during exercise, coronary jeopardy score, 938(ab)
ejection fraction, gated Tc-99m sestamibi SPECT, 927(ab)
perfusion and performance, single radiopharmaceutical and one camera, 1411
regions of interest, simulated annealing, 932(ab)
severely impaired ejection fraction, cardiac peak power, 938(ab)
time-activity curve, O-15 water PET, 1669
volume determination, radionuclide methods, 763
miniature cadmium telluride detector, coronary artery bypass grafting, 441
myocardial perfusion and, simultaneous assessment, total coronary artery occlusion, 825(ab)
nuclear probes in cardiology, 448
right, volume determination, Kr-81m multiple-gated imaging and Tc-99m equilibrium imaging, 932(ab)
thallium uptake after reinjection, myocardial perfusion, 915(ab)
Ventriculography, radionuclide, rest and exercise, active acromegaly, 834(ab)
Vesamicol, F-18 labeled acyclic analogues, potential cholinergic neuron markers, 983(ab)
VEST, continuous, miniature cadmium telluride detector, coronary artery bypass grafting, 1914(le)

W

WAM module, acceptance testing and quality assurance, 1005(ab)
Water, contraction/relaxation of actomyosin, T2 relaxation behavior, 974(ab)
Welch, Michael J., Hevesy Nuclear Medicine Pioneer Award, 16N(7)
White blood cells
dual bone and WBC scan imaging, osteomyelitis and cellulitis, planar and SPECT imaging, 839(ab)
monoclonal antibodies, 34N(5)
scintigraphy with monoclonal antibodies, septic loosening, endoprostheses, 840(ab)
Wilson's disease, dopamine D2 receptors, I-123 IBZM, 897(ab)
Wound healing, hematopoietic neoplasia, soft-shell clam, 998(ab)

X

Xenografts
human epidermoid carcinoma, biodistribution, In-111 B3 monoclonal antibody, 842(ab)
neuroblastoma
distribution of I-125 MIBG, electron microscopic autoradiography, 1021(ab)
radioimmunolocalization, chimeric antibody chCE7, 231
scintigraphic detection, overexpressed c-kit protooncogene, monoclonal $F(ab')_2$ fragments, 893(ab)
Xenon, dual-radioisotopic technique, tumescence, penile blood flow, 41
Xenon-127, economic advantages over Xe-133, 305(le)
Xenon-133
method to evaluate PE, low probability V/Q scans, routine ventilation scans, 1022(ab)
single-breath, severe diffuse obstructive airway disease, 1072(ab)
SPECT
cerebral blood flow and predetermined ROIs, children, 977(ab)
surgical outcome, temporal lobe epilepsy, 1018(ab)
Tc-99m and, dual isotope imaging, energy weighted acquisition, 889(ab)
X-ray
chest
atelectasis, pulmonary embolism, 849(ab)
bone and I-131 scans, well-differentiated thyroid cancer, 894(ab)

Y

Young Investigators Symposium, Computer and Instrumentation Council as sponsor, 32N(10)
Yttrium-88, bifunctional DTPA and macrocyclic ligands, serum stability studies, 1031(ab)
Yttrium-88 immunoconjugates, biodistribution, chelate rigidity and denticity, 1030(ab)
Yttrium-90
attachment to antibody via popular chelators, liver homogenates, 1030(ab)
microsphere therapy, three-dimensional tumor dosimetry, 735